Sample ID,Structure,Sample Name,Drug Name,NCGC Unique ID,Primary Mechanism of Action,Gene Symbol
NCGC00346607-01,CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C,Curcumol,,QRMPRVXWPCLVNI,mitochondrial modulator,
NCGC00095537-06,OCC(O)C(O)C(O)CO,ARABITOL(D),,HEBKCHPVOIAQTA,sugar alcohol,
NCGC00263217-01,O=C(NC1=CC2=C(C=C1)N=C(NC(=O)C3=CC=CC=C3)S2)C4C5CC6CC(C5)CC4C6,NVP231,,UDTWNDBVRLDPNE,Ceramide kinase inhibitor,CERS1
NCGC00263184-01,OC(=O)CCC1CCC(CC1)(C2=CC(=CC=C2F)F)[S+]([O-])(=O)C3=CC=C(Cl)C=C3,MK-0752,,GWXSGTHYRGRKNP,g-Secretase Inhibitor,NOTCH1
NCGC00094358-17,CC/1=C(\C=C\C(C)=C\C=C\C(C)=C/C(O)=O)C(C)(C)CCC1,ISOTRETINON,,SHGAZHPCJJPHSC,Retinoid RAR Agonists,RARB
NCGC00022567-08,NC1=NC(=NC2=C1N=C[N]2[C@H]3C[C@H](O)[C@@H](CO)O3)Cl,Cladribine,,PTOAARAWEBMLNO,Adenosine Deaminase Inhibitor,ADA
NCGC00262641-02,CC1=CC=C(C=C1)[S+]([O-])(=O)OCC(=O)NC2=CC=C(C(O)=O)C(=C2)O,NSC 74859 (S3I-201),,YGLOOZMZDMUGDT,STAT-3 Inhibitor,STAT3
NCGC00090782-07,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@H](O)CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C,Nelfinavir mesylate,,QAGYKUNXZHXKMR,HIV Protease Inhibitors,
NCGC00242480-01,CC(C)(C)C1=CC(=C(NC(=O)C/2=C/NC3=C(C=CC=C3)C2=O)C=C1O)C(C)(C)C,Ivacaftor;VX-770?,,PURKAOJPTOLRMP,CFTR Channel Activator,CFTR
NCGC00346972-01,CC1=CC(=CC(=C1)OCC2=CC=C(CN3CCC[C@@H]3CO)C=C2)C[S+]([O-])(=O)C4=CC=CC=C4,PF-543,,NPUXORBZRBIOMQ,Sphingosine Kinase 1 (SphK1) Inhibitors,SPHK1
NCGC00159455-04,COC1=CC2=NC=NC(=C2C=C1OCCCN3CCOCC3)NC4=CC=C(F)C(=C4)Cl,Gefitinib;Iressa/ZD-1839,ZD-1839;Iressa;ZD1839;ZD 1839;N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide;(3-Chloro-4-fluorophenyl)[7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl]amine;gefitinibum;CIPLUS_700352;gefitinib;4-(3-CHLORO-4-FLUOROPHENYLAMINO)-7-METHOXY-6-(3-(4-MORPHOLINYL)PROPOXY)QUINAZOLINE;Gefitinib;GEFITINIB;,XGALLCVXEZPNRQ,EGFR (HER1; erbB1) inhibitor,EGFR
NCGC00015121-16,CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2,PHENOXYBENZAMINE HYDROCHLORIDE,,QZVCTJOXCFMACW,adrenergenic receptor antagaonist,
NCGC00021146-06,C1=CC=C4C(=C1)NC(=O)N(CCN3CCC(C(=O)C2=CC=C(F)C=C2)CC3)C4=O,Ketanserin,"R 41,46;R-41,468;KETANSERIN;R-41468;KETANSERIN TARTRATE;NCGC00024865-03;CIPLUS_711598;Ketanserin tartrate salt;Ketanserin tartrate hydrate;NCGC00024865-04;KETANSERIN TARTATE;R 4146;NCGC00024865-01;NCGC00024865-02;2,4(1H,3H)-Quinazolinedione, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-;3-(2-(4-(p-Fluorobenzoyl)-1-piperidinyl)ethyl)-2,4(1H,3H)-quinazolinedione L-tartrate;NCGC00024865-05;3-(2-(4-(4-FLUOROBENZOYL)-1-PIPERIDINYL)ETHYL)-2,4(1H,3H)QUINAZOLINEDIONE;ketanserinum;CIPLUS_190847;3-(2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl)-2,4(1H,3H)-quinazolinedione tartrate salt;R 41468 tartrate salt;R4146;Ketanserin;3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione;ketanserine;WHO NO. 5087;Ketanserin tartrate;Ketanserinum;ketanserin;R 41468;Ketanserina;Ketanserine;R41,46;NCGC00017140-01;2,4(1H,3H)-Quinazolinedione, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-,(R-(R*,R*))-2,3-dihydroxybutanedioate (1:1);NCGC00016200-01;LS-140148;NCGC00094444-01;LS-140149;NCGC_Prestw-392;",FPCCSQOGAWCVBH,5-HT2A Antagonists?,HTR2A
NCGC00017245-12,OC1=CC2=C3C(=C1O)OC(=O)C4=CC(=C(O)C(=C34)OC2=O)O,ELLAGIC ACID,,AFSDNFLWKVMVRB,Aldose Reductase Inhibitor,AKR1B1
NCGC00015771-12,CN(C)CCOC(C1=CC=CC=C1)C2=C(C)C=CC=C2,ORPHENADRINE CITRATE,,QVYRGXJJSLMXQH,Muscarinic Antagonists,
NCGC00094201-01,C[C@H](CC1=CC=C(O)C(=C1)O)[C@@H](C)CC2=CC(=C(O)C=C2)O,Nordihydroguaiaretic acid from Larrea divaricata (creosote bush),"NCGC00089785-03;1,2-BENZENEDIOL, 4,4'-(2,3-DIMETHYL-1,4-BUTANEDIYL)BIS-, (R*,S*)-;SP-134101;CIPLUS_153652;NORDIHYDROGUAIARETIC ACID;LS-136429;butane, 1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethyl-;4,4'-(2,3 Dimethyl-1,4-butanediyl)bis(1,2-benzenediol);ACTINEX;CIPLUS_213635;4,4'-(2,3-Dimethyltetramethylene)dipyrocatechol;Nordihydroguaiaretic Acid;1,4-Bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane;MASOPROCOL;Masoprocolum;NDGA;masoprocol;LS-174190;MESO-4,4'-(2,3-DIMETHYLTETRAMETHYLENE)DIPYROCATECHOL;Masoprocol;NCGC00094201-02;NCGC00094201-01;masoprocolum;Dihydronorguaiaretic Acid;meso-Nordihydroguaiaretic Acid;NORDIHYDROGUARETIC ACID;Nordihydroguaiaretic acid;NCGC00015741-01;1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-;Nordihydroguaiaretic acid from Larrea divaricata (creosote bush);Actinex;MESO-NORDIHYDROGUAIARETIC ACID;Nordihydroguaiaretic Acid, (R*,S*)-Isomer;",HCZKYJDFEPMADG,5-Lipoxygenase Inhibitor,ALOX5
NCGC00095118-05,C[S+]([O-])(=O)C1=CC=C(C=C1)C/2=C(/C(=O)OC2)C3=CC=CC=C3,ROFECOXIB,,RZJQGNCSTQAWON,Cyclooxygenase-2 Inhibitor,PTGS2
NCGC00263205-01,CC1(C)CNC2=C1C=CC(=C2)NC(=O)C3=CC=CN=C3NCC4=CC=NC=C4,Motesanib;AMG-706,,RAHBGWKEPAQNFF,"VEGFR-1,2,3 Inhibitor",FLT1
NCGC00346463-01,CNC(=O)C1=C(OC2=CC(=C(C=C12)C3CC3)N(CCO)[S+](C)([O-])=O)C4=CC=C(F)C=C4,Nesbuvir,,KGLWAGUVODXRDF,RNA-Directed RNA Polymerase Inhibitor,
NCGC00014650-03,CO[C@@H]1/C=C/C=C(C)/CC2=CC(=C(Cl)C(=C2)OC)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]3(C)O[C@@H]3[C@H](C)[C@@H]4C[C@@]1(O)NC(=O)O4,Ansamitocin P3,,OPQNCARIZFLNLF,Tubulin polymerization inhibitor,TUBB
NCGC00163329-04,COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=C(Cl)C=CC=C3,CLOPIDOGREL SULFATE,,GKTWGGQPFAXNFI,P2Y12 (P2T) Antagonists,P2RY12
NCGC00167513-03,COC1=CC2=C(NC3=CC=C(Br)C=C3F)N=CN=C2C=C1OCC4CCN(C)CC4,Vandetanib;AZD-6474;CH-331;Caprelsa;ZD-6474;Zactima,,UHTHHESEBZOYNR,EGFR (HER1; erbB1) Inhibitor,EGFR
NCGC00346490-01,NCC(=O)NC1=CC=C(C=C1)[N]2N=C(C=C2C3=CC4=C(C=C3)C5=C(C=CC=C5)C=C4)C(F)(F)F,OSU-03012,,YULUCECVQOCQFQ,Phosphoinositide Dependent Kinase (PDK) 1 Inhibitors,PDPK1
NCGC00346649-01,CC[N]1N=NC2=C1N=C(N=C2N3CCOCC3)C4=CC=C(NC(=O)NC5=CC=C(C=C5)C(=O)N6CCN(C)CC6)C=C4,PKI-402,,ZAXFYGBKZSQBIV,PI3K Inhibitor,PIK3CA
NCGC00167466-03,ClCCN(N=O)C(=O)NC1CCCCC1,Lomustine (CeeNU),,GQYIWUVLTXOXAJ,DNA Alkylating Agent,
NCGC00346547-01,CCCCCCCCCCCCC1=CC=C(C=C1)[S+]([O-])(=O)NC2=NN=CS2,PHT-427,,FFBZXUCNBWAAEE,Phosphoinositide Dependent Kinase (PDK) 1 Inhibitors,PDPK1
NCGC00347280-01,NC1=C(C#N)C(=CC(=N1)C2=C(OCC3CC3)C=CC=C2O)C4CCNCC4,IKK-2 Inhibitor VIII,,DYVFBWXIOCLHPP,IKK-2 (IKK-beta) Inhibitor,IKBKB
NCGC00016388-03,COC1=C(OC)C2=C(C=C1)[C@@H](OC2=O)[C@@H]3N(C)CCC4=C3C(=C5OCOC5=C4)OC,NOSCAPINE HYDROCHLORIDE,,AKNNEGZIBPJZJG,Tubulin polymerization inhibitors,TUBB
NCGC00346560-01,CC/1=C/N([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O,"Telbivudine (Sebivo, Tyzeka)",,IQFYYKKMVGJFEH,DNA Polymerase Inhibitors,
NCGC00263115-01,CC(C)(N)C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=C3C=CC=C4)[S+](C)([O-])=O,Ibutamoren mesilate;L-163191/MK-0677,,PQNWMTXPSNLKMV,Growth Hormone Secretagogue,GH1
NCGC00345822-01,CN(C)CC(C)(C)CNC1=N[N]2C(=NN=C2C3=CC=CC=C3)C=C1C4CCC4,Akt-I-1         (Akt-I-1),,FKCXKEHHZXEWGP,AKT Inhibitor,AKT1
NCGC00263271-02,COC1=CC=CC(=C1/C2=N/CC3=C(N=C(NC4=CC(=C(C=C4)C(O)=O)OC)N=C3)C5=CC=C(Cl)C=C25)F,MLN8237 (Alisertib),,ZLHFILGSQDJULK,Aurora-A inhibitor,AURKA
NCGC00346518-01,CC(O)C1C2C(C)\C(=C(/N2C1=O)C(O)=O)SC3CNC(C3)C(=O)N(C)C,Meropenem,,DMJNNHOOLUXYBV,Carbapenem Antibiotic,
NCGC00163470-09,CO[C@@H]1C[C@@H](CC[C@H]1O)/C=C(C)/[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]4(O)O[C@H]([C@H](C[C@@H](C)C\C(=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC)[C@H](C[C@H]4C)OC,TACROLIMUS,,QJJXYPPXXYFBGM,Macrolide Antibiotic,
NCGC00163485-03,,Wortmannin,,,PI3K Inhibitor,PIK3CA
NCGC00346096-02,CC/1=C(/C(CC(=O)N1)C2=CC=C(C=C2)C(F)(F)F)C(=O)NC3=C(F)C=C4[NH]N=CC4=C3,GSK429286A,,OLIIUAHHAZEXEX,"ROCK 1, ROCK 2 Inhibitor",ROCK1
NCGC00229512-04,COC1=C(C=C(SC2=CN=C(NC(=O)C3=CC=C(CNC(C)C(C)(C)C)C=C3)S2)C(=C1)C)C(=O)N4CCN(CC4)C(C)=O,BMS-509744,,ZHXNIYGJAOPMSO,ITK inhibitor,ITK
NCGC00346493-01,O=C(NC1CC1)NC2=C[NH]N=C2C3=NC4=CC(=CC=C4[NH]3)CN5CCOCC5,AT9283,,LOLPPWBBNUVNQZ,Aurora-A/B Inhibitor,AURKA
NCGC00346489-01,CC1COC2(CCN(CC2)C/3=N/C(=O)C4=CC(=CC(=C4S3)[N+]([O-])=O)C(F)(F)F)O1,BTZ043 racemate,,GTUIRORNXIOHQR,tuberculosis pathway inhibitor,
NCGC00160514-03,COC\1=C(/OC)C(=O)\C(=C(C)/C1=O)CCCCCCCCCCO,IDEBENONE,,JGPMMRGNQUBGND,Free Radical Scavenger,
NCGC00015848-04,NC1CC1C2=CC=CC=C2,trans-2-Phenylcyclopropylamine hydrochloride,,AELCINSCMGFISI,MAO-A/B Inhibitor,MAOA
NCGC00346594-01,CC1(C)C[C@H](C2CC[C@]3(C)\C(=C/C[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O,Oleanolic Acid (Caryophyllin),,AOWMBRPPHGNFDX,Secretory Phospholipase A2 (sPLA2) Inhibitors,PLA2G5
NCGC00181303-02,N[C@@H]1[C@H]([C@@H]([C@@H](O[C@@H]1O[C@H]2[C@H]([C@H](O[C@H]([C@H]4O)[C@@H]([C@H](C[C@H]4N)N)O[C@H]([C@@H]3N)O[C@@H]([C@H]([C@@H]3O)O)CN)O[C@@H]2CO)O)CN)O)O.O=S(O)(O)=O.O=S(O)(O)=O.O=S(O)(O)=O,Neomycin sulfate,"Proctosedyl suppository;CIPLUS_207582;CIPLUS_3885417;Neomycine;METHYLPREDNISOLONE SODIUM SUCCINATE;neomycin C;nivemycin;CIPLUS_203775;Sofratulle;CIPLUS_769520;DEXAMETHASONE SODIUM PHOSPHATE;METHYLPREDNISOLONE;Sulfate, Fradiomyci;Proctosedyl;NEO-HYDELTRASOL;framycetine;Neomycin Palmitate;NEOMYCIN B, SULFATE (SALT);Framycetinum;neomycinum;Fradiomycin sulfate;Neomycin solution;D-Streptamine, O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(O-2,6-glucopyranosyl-(1-4)-O-(O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-2-deoxy-;(1R,2R,3S,4R,6S)-4,6-DIAMINO-2-((3-O-(2,6-DIAMINO-2,6-DIDEOXY-.BETA.-L-IDOPYRANOSYL)-.BETA.-D-RIBOFURANOSYL)OXY)-3-HYDROXYCYCLOHEXYL 2,6-DIAMINO-2,6-DIDEOXY-.ALPHA.-D-GLUCOPYRANOSIDE;Sulfate, Neomyci;LS-178601;LS-178600;LS-178603;Sulfate, Neomycin;D-STREPTAMINE, O-2,6-DIAMINO-2,6-DIDEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-(O-2,6-DIAMINO-2,6-DIDEOXY-.BETA.-L-IDOPYRANOSYL-(1->3)-.BETA.-D-RIBOFURANOSYL-(1->5))-2-DEOXY-, SULFATE (SALT);Neomycin B trisulfate  hydrate;Framycetine;NCGC_Prestw-158;Neomycin sulfate;NCGC00016581-01;CIPLUS_774369;neomycin C monohydrochloride;CIPLUS_207321;Proctosedyl ointment;LS-96091;LS-96096;NEOMYCIN SULFATE  (CREAM);NEOMYCIN B;LS-96095;NEOMYCIN B SULFATE;NEOMYCIN SULFATE;.ALPHA.-D-GLUCOPYRANOSIDE, (1R,2R,3S,4R,6S)-4,6-DIAMINO-2-((3-O-(2,6-DIAMINO-2,6-DIDEOXY-.BETA.-L-IDOPYRANOSYL)-.BETA.-D-RIBOFURANOSYL)OXY)-3-HYDROXYCYCLOHEXYL 2,6-DIAMINO-2,6-DIDEOXY-;NCGC00095265-01;NCGC00095265-02;D-Streptamine, O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-2-deoxy-;framygen;Neomycin Sulfate;NEO-DELTA-CORTEF;Neomycin palmitate;NEOMYCIN;Framycetin Sulfate;CIPLUS_158283;neomycine;NEO-CORT-DOME;LS-147017;NEO-SYNALAR;CIPLUS_3853417;Mycifradin;FRAMYCETIN;Neomycinum;PROCTOSEDYL;FRAMYCETIN SULFATE;CIPLUS_743120;Framicetina;NEOMYCIN PALMITATE;framycetinum;Fradiomycin Sulfate;framycort;CORDRAN-N;HS_993;Neomycin C;Neomycin B;Neomycin A;HYDROCORTISONE ACETATE;Neomycin B hydrochloride;LS-178596;LS-178597;LS-178595;LS-178519;LS-178593;NEOMYCIN SULFATE  (OINTMENT);Neomycin;NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE;LS-178598;LS-178599;Sulfate, Framyceti;Neomycin B Sulfate;Neomycin B, monohydrochloride;Soframycin;Framycetin;Antibiotic 10676;Pregn-4-ene-3,20-dione, 21--(acetyloxy)-11,17-dihydroxy-, (11beta)-, mixt. with O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-beta-D-ribofuranosyl-(1-5))-2-deoxy-D-streptamine;Palmitate, Neomyci;NEO-MEDROL ACETATE;CIPLUS_786808;CIPLUS_151525;",PGBHMTALBVVCIT,30S Ribosomal Protein Inhibitors,
NCGC00166088-05,NC\1=N\C(=O)N(\C=N1)[C@H]2C[C@H](O)[C@@H](CO)O2,,,XAUDJQYHKZQPEU,DNA Methyltransferase (DNMT) Inhibitor,DNMT1
NCGC00263173-03,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=CC(=CC(=C34)[NH]2)F,"Rucaparib (AG-014699 , PF-01367338)",,HMABYWSNWIZPAG,PARP-1/PARP-2 Inhibitor,PARP1
NCGC00346710-01,CC(C)(OCC1=N[N](CC2=CC=CC=C2)C3=C1C=CC=C3)C(O)=O,Bindarit,,MTHORRSSURHQPZ,non-steroidal antiinflammatory,
NCGC00016488-03,C(NC1=C2NC=NC2=NC=N1)C3=CC=CO3,,Kinetin solution;6-Furfurylaminopurine (Kinetin);6 Furfurylaminopurin;Kinetin hydrochloride;KINETIN;NCGC_Prestw-659;6-Furfuryladenine;NCGC00094553-02;NCGC00094553-03;6-Furfurylaminopurine;NCGC00094553-01;6 Furfuryladenin;Kinetin;CIPLUS_203650;N6-Furfuryladenine;NCGC00016488-01;,QANMHLXAZMSUEX,plant hormone,
NCGC00185090-03,CC(=O)NC1=C(C2=C(CNC2)S1)C3=NC4=C(S3)C=CC=C4,NCGC00185090-04,,MODNMLYGANOZDZ,APE1 inhibitor,APE1
NCGC00018139-08,CC(C)OC1=CC=C2C(=C1)O\C=C(/C2=O)C3=CC=CC=C3,Ipriflavone,,SFBODOKJTYAUCM,Treatment of Osteoporosis,
NCGC00091268-11,CN(C)[C@H]\1[C@@H]2[C@@H](O)[C@H]3\C(=C(O)/[C@]2(O)C(=O)\C(=C1O)C(N)=O)C(=O)C4=C(C=CC=C4O)[C@@]3(C)O,OXYTETRACYCLINE,,IWVCMVBTMGNXQD,Tetracycline Antibiotic,
NCGC00024594-01,CCCCC(NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1)C=O,Calpeptin,"Carbamic acid, (1-(((1-formylpentyl)amino)carbonyl)-3-methylbutyl)-, phenylmethyl ester, (S-(R*,R*))-;CIPLUS_215618;benzylcarbonyl-Leu-nLeu-H;N-CBZ-Leu-nLeu-al;LS-172355;calpeptin;NCGC00163432-01;Calpeptin;NCGC00024594-01;",PGGUOGKHUUUWAF,Proteasome Inhibitor,PSMD1
NCGC00346726-01,OC[C@H]1O[C@@H]2[C@@H](OC\3=N\C(=N)\C=C/[N@@]23)[C@@H]1O,Cyclocytidine HCl,,BBDAGFIXKZCXAH,antiviral,
NCGC00165783-02,CC1=C(C)C2=C(C=C1)C(=O)C3=C(O2)C(=CC=C3)CC(O)=O,DMXAA (ASA404),,XGOYIMQSIKSOBS,Interferon Inducer,
NCGC00250383-01,CC1=CSC(=N1)NC(=O)C2=C(N)C3=C(S2)N=C4CCCC4=C3C(F)(F)F,Irestatin 9389,,PPKYBLJPUZGDGQ,IRE1alpha/XBP-1 inhibitor,ERN1
NCGC00345846-01,CC1=C(NC2=CC=CC(=C2)[S+]([O-])(=O)NC(C)(C)C)N=C(NC3=CC=C(CN4CCOCC4)C=C3)N=C1,TG-46,,NNJLBENMZUBXHU,Jak2 inhibitor,JAK2
NCGC00182868-02,O=C(NCCCCC1CCN(CC1)C(=O)C2=CC=CC=C2)\C=C\C3=CN=CC=C3,Daporinad;APO-866;FK-866,,KPBNHDGDUADAGP,NMPRTase Inhibitor,NAMPT
NCGC00242506-02,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)B(O)O,Bortezomib,,GXJABQQUPOEUTA,Proteasome Inhibitor,PSMD1
NCGC00160527-05,CCOC1=CC(=C(Cl)C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(F)C=C3)N,Mosapride citrate,,YPELFRMCRYSPKZ,5-HT4 Antagonists,HTR4
NCGC00164613-03,CC(=C/C1=CC=CC=C1)\C=C2/SC(=S)N(CC(O)=O)C2=O,Epalrestat,,CHNUOJQWGUIOLD,Aldose Reductase Inhibitor,AKR1B1
NCGC00263017-01,COC1=C(OC)C=C2C(=NC(=NC2=C1)C3=CC=C(C=C3)N4CCN(C)CC4)NCCN5CCOCC5,CPG-52364,,TUOZJWZCVIRDKO,"TLR 7, 8 and 9 antagonist",TLR7
NCGC00347954-01,CNC1CCC(CC1)N(CC2=CC=CC(=C2)C3=CC=NC=C3)C(=O)C4=C(Cl)C5=CC=CC=C5S4,,,VFSUUTYAEQOIMW,Hedgehog agonist,SHH
NCGC00345855-01,[O-][S+]1(=O)CCN(CC1)CC2=CC=C(C=C2)C3=CC=CC4=NC(=N[N]34)NC(=O)C5CC5,GPLG0634,,LFKRLUYNGIVHKD,Jak1 Inhibitor,JAK1
NCGC00346874-01,C[C@](CC1=C[NH]C2=CC=CC=C12)(NC(=O)OC3C4CC5CC(C4)CC3C5)C(=O)NC[C@H](NC(=O)CCC(O)=O)C6=CC=CC=C6,CI 988,,FVQSSYMRZKLFDR,CCK2 (CCKB/Gastrin) Antagonists,
NCGC00015149-15,CCCCNC1=CC(=CC(=C1OC2=CC=CC=C2)[S+](N)([O-])=O)C(O)=O,BUMETANIDE,,GXZSSBJRQQVGBT,Loop Diuretics,
NCGC00016879-07,CC(C)NC(=O)N[S+]([O-])(=O)C1=C(NC2=CC(=CC=C2)C)C=CN=C1,Torsemide (Demadex),,VJWSBMXKTXHWQQ,Loop Diuretics,
NCGC00182851-01,[C@@]42([C@H]([C@@H]1CCC=3[C@@]([C@H]1C(C2)=O)(\C=C/C(C=3)=O)C)C[C@@H]([C@@]4(C(=O)CO)O)C)C,Meprednisone,"meprednisonum;Betapar;CIPLUS_157972;meprednisone;Meprednisone;(16.BETA.)-17,21-DIHYDROXY-16-METHYLPREGNA-1,4-DIENE-3,11,20-TRIONE;Meprednisona;MEPREDNISONE;Meprendisone;Meprednisonum;16-methylprednisone;Bitanisone;PREGNA-1,4-DIENE-3,11,20-TRIONE, 17,21-DIHYDROXY-16-METHYL-, (16.BETA.)-;LS-118513;",PIDANAQULIKBQS,Glucocorticoid steroid,
NCGC00182045-02,OC[C@H]1O[C@H](C[C@@H]1O)[N]2C=NC3=C2\N=C/NC[C@H]3O,Pentostatin;CI-825;CL-67310465;Coforin;NSC-218321;Nipent;Oncopent;PD-81565;YK-176,,FPVKHBSQESCIEP,Adenosine Deaminase Inhibitor,ADA
NCGC00346740-01,CCOC1=C(OCCNC(C)CC2=CC=C(OC)C(=C2)[S+](N)([O-])=O)C=CC=C1,Tamsulosin hydrochloride,,WQZOWNCWWCPWHL,alpha1-Adrenoceptor Antagonists,ADRA1A
NCGC00015036-08,NC12CC3CC(CC(C3)C1)C2,,AMANTaDINE,DKNWSYNQZKUICI,Dopamine Receptor Agonist,DRD1
NCGC00242491-02,BrC1=CC=CC=C1NC(=O)NC2=C3N=N[NH]C3=C(C=C2)C#N,SB 265610,,SEDUMQWZEOMXSO,CXCR2 Antagonist,CXCR2
NCGC00346695-01,CN(C[C@@H]1COCCO1)[S+]([O-])(=O)NC2=CC3=C(C=C2)\C=C/C4=C(C=C(C=N4)C5=C[N](C)N=C5)C3=O,MK-2461,,CNIPSLYLSVCVKY,VEGFR-1 (Flt-1) Inhibitors,FLT1
NCGC00346431-01,CN(CC#C)C/C1=C/C2=CC=CC=C2OC3=CC=CC=C13,CGP 3466B maleate;omigapil,,QLMMOGWZCFQAPU,Glyceraldehyde 3-phosphate Dehydrogenase (GAPDH) Inhibitors,GAPDH
NCGC00346538-01,C[C@@H]1C/C=C/C=C/C=C/C=C/[C@H](C[C@@H]2O[C@](O)(C[C@@H](O)C[C@@H]3O[C@H]3/C=C/C(=O)O1)C[C@H](O)[C@H]2C(O)=O)O[C@@H]4O[C@H](C)[C@@H](O)[C@H](N)[C@@H]4O,Natamycin (Pimaricin),,NCXMLFZGDNKEPB,Antifungal Agent,
NCGC00015159-06,C2CC2COCCC1=CC=C(OCC(O)CNC(C)C)C=C1,Betaxolol,"SL-75.212-10;LS-122006;LS-122005;LS-178489;CIPLUS_739710;NCGC00093669-01;NCGC00015159-01;LS-178203;betaxololum;HS_187;2-PROPANOL, 1-(4-(2-(CYCLOPROPYLMETHOXY)ETHYL)PHENOXY)-3-((1-METHYLETHYL)AMINO)-, (2S)-, HYDROCHLORIDE;(S)-BETAXOLOL HYDROCHLORIDE;NCGC_Prestw-382;betaxolol;Betaxololum;betoptic;Betaxolol;LS-172312;AL-1577A;CIPLUS_685261;2-PROPANOL, 1-(4-(2-(CYCLOPROPYLMETHOXY)ETHYL)PHENOXY)-3-((1-METHYLETHYL)AMINO)-, (2S)-;PILOCARPINE HYDROCHLORIDE;(2S)-1-(4-(2-(CYCLOPROPYLMETHOXY)ETHYL)PHENOXY)-3-(ISOPROPYLAMINO)PROPAN-2-OL;CIPLUS_184767;Betaxolol Hydrochloride;HS_774;BETAXOLOL HYDROCHLORIDE;CIPLUS_728134;CIPLUS_196933;ALO-1401-02;Betaxolo Hydrochloride;2-PROPANOL, 1-(4-(2-(CYCLOPROPYLMETHOXY)ETHYL)PHENOXY)-3-((1-METHYLETHYL)AMINO)-, HYDROCHLORIDE, (S)-;Betoptic;WHO NO. 4530;LEVOBETAXOLOL;Levobetaxolol Hydrochloride;NCGC00024863-01;LS-178569;NCGC00024863-04;NCGC00016904-01;LEVOBETAXOLOL HYDROCHLORIDE;NCGC00024863-03;Kerlone;levobetaxolol;2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-;CHLORTHALIDONE;Levobetaxolol hydrochloride;SL 75212;Betaxolol hydrochloride;BETAXOLOL;levobetaxololum;Levobetaxolol;1-(4-(2-(CYCLOPROPYLMETHOXY)ETHYL)PHENOXY)-3-((1-METHYLETHYL)AMINO)-2-PROPANOL HYDROCHLORIDE, DL-;",NWIUTZDMDHAVTP,beta1-Adrenoceptor Antagonists,ADRB1
NCGC00346512-01,CN\1C(=O)/C(=C(\N=C1N2CCCC[S+]2([O-])=O)C(=O)NCC3=CC=C(F)C=C3)O,BMS-707035,,QGVZPVNRMGXYBR,HIV Integrase Inhibitors,
NCGC00345810-01,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2CCC(O)NC2=O,Tetrahydrouridine,,UCKYOOZPSJFJIZ,Cytidine Deaminase Inhibitors,CDA
NCGC00242504-01,C[C@@H]1C[C@H]2[C@@H]3\C=C(C)/C4=C/C5=C(C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O)C=N[N]5C6=CC=CC=C6,Cortivazol,,ABBZCJLJVANSLA,Glucocorticoid Receptor (GR) Agonist,
NCGC00181098-01,NC1=NC(OC)=C(N=CN2[C@H]3[C@H]([C@@H]([C@@H](CO)O3)O)O)C2=N1,Nelarabine,nelarabinum;Nelzarabine;CIPLUS_728663;O(6)-methylguanosine;506U78UH;NELARABINE;2-AMINO-9-B-ARABINOFURANOSYL-6-METHOXY-9H-PURINE;O6-methylguanosine;NELZARABINE;6'-O-methylguanosine;CIPLUS_673513;Nelarabine;LS-172477;nelzarabine;,IXOXBSCIXZEQEQ,Antimetabolite,
NCGC00253646-01,COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1,Agomelatine,,YJYPHIXNFHFHND,5-HT2C Antagonists,HTR2C
NCGC00263157-01,CCOC\1=C(/C(=O)NC2=CC=C(OC3=C(Cl)C(=NC=C3)N)C(=C2)F)C(=O)N(\C=C1)C4=CC=C(F)C=C4,BMS-777607,,VNBRGSXVFBYQNN,HGFR (MET; c-Met) Inhibitor,MET
NCGC00167430-03,ClC1=CC=C(C(C[N]2C=CN=C2)OCC3=C(Cl)SC=C3)C(=C1)Cl,TIOCONAZOLE,,QXHHHPZILQDDPS,Antifungal Agent,
NCGC00160165-01,CC(=O)C1=C(O)C(C)=C(O)C2=C1OC3=CC(=O)C(C(C)=O)=C(O)C23C,,"USNIC ACID;CIPLUS_747159;CIPLUS_699271;usnic acid;(+)-Usnic acid from Usnea dasypoga;usniacin;CIPLUS_3744949;(+)-Usnic acid Usnea dasypoga;2,6-Diacetyl-7,9-dihydroxy-8,9b-dimethyldibenzofuran-1,3(2H,9bH)-dione;(+)-Usniacin;CIPLUS_173383;2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyl-1,3(2H,9bH)-dibenzofurandione;CIPLUS_179437;NCGC00094823-01;CIPLUS_166726;(+)-Usnic acid;USNIC ACID, (+);Usnic acid;LS-61059;NCGC00142542-02;NCGC00160165-01;",ICTZCAHDGHPRQR,adrenergenic receptor antagaonist,
NCGC00250398-01,CN(C)C1CCN(CC1)C(=O)C2=CC=C(NC(=O)NC3=NC(=NC(=N3)N4CCOCC4)N5CCOCC5)C=C2,PF-05212384;PKI-587,,CYXYNDAHNRFPMP,mTOR inhibitor,MTOR
NCGC00346580-01,CC[C@]12\C=C/CN3CC[C@]4([C@@H](N(C)C5=CC(=C(C=C45)[C@]6(C[C@H]7C[C@H](CN(C7)CC8=C6[NH]C9=C8C=CC=C9)C(C)(F)F)C(=O)OC)OC)[C@](O)([C@@H]1OC(C)=O)C(=O)OC)[C@H]23,Vinflunine Tartrate,,NMDYYWFGPIMTKO,Tubulin polymerization inhibitor,TUBB
NCGC00091823-05,CC1=CC(=C2C(=O)C3=C(O)C=CC=C3C(=O)C2=C1)O,CHRYSOPHANOL,,LQGUBLBATBMXHT,VEGFR-1/2 Inhibitor,FLT1
NCGC00242484-02,COC(=O)NC1=CC=C(C=C1)C2=NC3=C(C=N[N]3C4CCN(CC4)C(=O)OC)C(=N2)N5CCOCC5,WYE-354,,IMXHGCRIEAKIBU,mTORC1/2 inhibitor,MTOR
NCGC00263196-01,CC(C)(C)C1=CC(=C(NC(=O)NC2=CC3=C([NH]N=C3)C=C2)S1)C(O)=O,S6K-18,,BSRFCMMJUFQEOX,p70 ribosomal S6 kinase (S6K1) inhibitor,RPS6KB1
NCGC00183434-03,CC(C)(C)[C@H](NC(=O)C1=CC(=C(N)C=C1)Cl)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(O)=O)C#N,,,KENKPOUHXLJLEY,Caspase 1 Inhibitors,CASP1
NCGC00179250-04,CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C3C=C(Cl)C=C(Cl)C3=C1)C(F)(F)F,Halofantrine,,FOHHNHSLJDZUGQ,antimalarial agents,
NCGC00179034-08,NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1,"4,4 -(Pentane-1,5-diylbis(oxy))dibenzimidamide",,XDRYMKDFEDOLFX,PRL Phosphatase Inhibitors,
NCGC00250377-01,O=C1\C=C(OC2=C(C=CC=C12)C3=CC=CC4=C3SC5=C4C=CC=C5)\N6CCOCC6,NU-7441,,JAMULYFATHSZJM,DNA-Dependent Protein Kinase (DNA-PK) Inhibitor,PRKDC
NCGC00346444-01,C[S+]([O-])(=O)C1=CC=C(C=C1)C2=CN=C(N)C(=N2)C(=O)NC3=CC=CC=C3,VE-821   ,,GEXYTIAHHADEFM,ATR Kinase Inhibitors,ATR
NCGC00166076-06,OC[C@H]1O[C@@H](OC2=CC=C(O)C=C2)[C@H](O)[C@@H](O)[C@@H]1O,ARBUTIN,,BJRNKVDFDLYUGJ,Free Radical Scavenger,
NCGC00229704-01,O=C2C1=C(N=C(C)N2)C=CC(CN(C)C3=CC=C(C(N[C@H](C(O)=O)CCC(O)=O)=O)S3)=C1,Raltitrexed,Raltitrexed,IVTVGDXNLFLDRM,thymidylate synthase inhibitor,TYMS
NCGC00167506-03,CC[C@@H]1/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)/C(C)=C/[C@@H]4CC[C@H](Cl)[C@@H](C4)OC,Pimecrolimus,,KASDHRXLYQOAKZ,Macrolide Antibiotic,
NCGC00263208-01,CC(C)C1=CC=CC=C1CC2=CC(=C(O)C(=C2O)O)C(=O)NC3=CC=C(C=C3)[S+]([O-])(=O)C4=C(C=CC=C4)C(C)(C)C,TW-37,,WBSVTBWVLLDTMU,Bcl-xL inhibitor/Mcl-1 inhibitor,BCL2L1
NCGC00346656-01,CCC1=C2N=C(C=C(NCC3=CC=C[N+](=C3)[O-])[N]2N=C1)N4CCCC[C@H]4CCO,Dinaciclib (SCH727965),,PIMQWRZWLQKKBJ,CDK1/2/5/9 inhibitor,CDK1
NCGC00025060-16,CN(CC1=NC2=C(N)N=C(N)N=C2N=C1)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O,Abitrexate (Methotrexate),,FBOZXECLQNJBKD,Dihydrofolate Reductase (DHFR) Inhibitors,DHFR
NCGC00015257-06,CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1,Clofibrate,"Aluminium clofibrate;CLOFIBRATE;Athromidin;Clofibratum;Clofibrato;NCGC00093755-01;Atromid-S;Miscleron;NCGC00093755-07;Ethyl Chlorophenoxyisobutyrate;NCGC00093755-08;NCGC00093755-05;NCGC00093755-06;Clofibrate (2-2-methyl-propionic acid ethyl ester);Ethyl 2-(4-chlorophenoxy)isobutyrate;Miskleron;clofibrat;Chlorophenoxyisobutyrate, Ethy;ETHYL CLOFIBRATE;ETHYL 2-(P-CHLOROPHENOXY)-2-METHYLPROPIONATE;Atromid;CIPLUS_155815;CLOFIBRATE CALCIUM;Ethyl 2-(4-chlorophenoxy)-2-methylpropionate;clofibratum;LS-7282;Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, ethyl ester;Clofibrate;Ethyl 2-(4-chlorophenoxy)-2-methylpropanoate;Atromid S;NCGC00015257-01;clofibrate;2-(4-Chlorophenoxy)-2-methylpropionic acid ethyl ester;Clofibric Acid, Ethyl Ester;",KNHUKKLJHYUCFP,PPARalpha Agonist,PPARA
NCGC00091032-08,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3\C=C(Cl)/C4=C/C(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O,Cyproterone acetate,,UWFYSQMTEOIJJG,Androgen Receptor Antagonist,AR
NCGC00095245-01,CCC(=O)OC1CCC2C3CCC/4=C/C(=O)CC[C@@]4(C)C3CC[C@]12C,TESTOSTERONE PROPIONATE,"NCGC00095245-01;NCGC00095245-02;LS-148823;Testex;Testaform;CIPLUS_701930;17beta-Propionyloxy-4-androsten-3-one;Ferring Brand of Testosterone Propionate;4-Androsten-17beta-ol-3-one 17-propionate;NCGC00016254-01;Agovirin;Androst-4-en-3-one, 17-(1-oxopropoxy)-(17-beta)-;CIPLUS_148843;Androst-4-en-3-one, 17-(1-oxopropoxy)-, (17beta)-;ANDROST-4-EN-3-ONE, 17-(1-OXOPROPOXY)-, (17.BETA.)-;propionat Eifelfango, Testostero;synovex-H;Eifelfango Brand of Testosterone Propionate;17beta-Hydroxy-4-androsten-3-one 17-propionate;Testosterone Propionate;(17.BETA.)-3-OXOANDROST-4-EN-17-YL PROPIONATE;NCGC_Prestw-401;TESTOSTERONE PROPIONATE;Virormone;Testosteron propionat Eifelfango;Testosterone propionate;",PDMMFKSKQVNJMI,Androgen Receptor Agonist,AR
NCGC00346639-01,COC(=O)\C=C\C(=O)OC,Dimethyl Fumarate,,LDCRTTXIJACKKU,NFkappaB-inducing kinase Inhibitor,NFKB1
NCGC00159422-02,CC(S)C(=O)NCC(O)=O,Tiopronin,"Glycine, N-(2-mercaptopropionyl)-;Thiopronine;tioproninum;tiopronine;CIPLUS_159333;Meprin (detoxicant);N-(2-Mercaptopropionyl)glycine;LS-72720;CIPLUS_783647;CIPLUS_660729;N-(2-MERCAPTOPROPIONYL)GLYCINE;Tiopronine;CIPLUS_660811;Dextiopronin;Tiopronino;Tiopronin;CIPLUS_660812;TIOPRONIN;Tiopronin (n-2-mercaptopropionyl glycine);Tioproninum;dextioproninum;Glycine, N-(2-mercapto-1-oxopropyl)-;THIOLA;Thiola;",YTGJWQPHMWSCST,Copper Chelator,
NCGC00346482-01,[O-][S+](=O)(CCSSCC[S+]([O-])(=O)O[Na])O[Na],Dimesna,,VNAGYFARZFGOFG,chemoprotective agent,
NCGC00242056-02,COC1=CC2=C(C=C1OC)[N](C=N2)C3=CC(=C(S3)C#N)OCC4=C(C=CC=C4)[S+](C)([O-])=O,IKK-3 Inhibitor IX,,LDTAHRLHGHFHKP,IKK-3 Inhibitor,IKBKB
NCGC00016360-05,OC1=CC=C(OCC2=CC=CC=C2)C=C1,MONOBENZONE,,VYQNWZOUAUKGHI,topical medical depigmentation treatment,
NCGC00164629-03,COC1=C(O)C(=CC(=C1)CC=C)C(=O)NCCO,Alibendol,,UMJHTFHIQDEGKB,"treatments of indigestin, nausea",
NCGC00159336-05,CC1(C)[C@@H](N2[C@@H](CC2=O)[S+]1([O-])=O)C(O)=O,Sulbactam,,UPSQWEOSSAAAHC,beta-Lactamase Inhibitor,
NCGC00346889-01,CN(CCO)C(=O)C1=C[N]2C=C(C)N=C2C(=C1)N[C@@H]3CCOC4=CC=CC(=C34)C,PF 3716556,,YBHKBMJREUZHOV,H+/K+-ATPase Inhibitor,
NCGC00346499-01,C[C@](O)(COC1=CC=C(C=C1)C#N)C(=O)NC2=CC=C(C#N)C(=C2)C(F)(F)F,Ostarine (MK-2866),,JNGVJMBLXIUVRD,Selective Androgen Receptor Modulators (SARM)?,AR
NCGC00015163-08,NC(CO)C(=O)NNCC1=C(O)C(=C(O)C=C1)O,BENSERAZIDE HYDROCHLORIDE,,BNQDCRGUHNALGH,DOPA decarboxylase inhibitor,DDC
NCGC00182055-02,CC(=O)O.Oc1ccc(cc1)c5c(C)c2cc(O)ccc2n5Cc3ccc(cc3)OCCN4CCCCCC4,Bazedoxifene;TSE-424/WAY-140424,BAZEDOXIFENE ACETATE;Bazedoxifeno;bazedoxifene acetate;Bazedoxifene  Acetate;Bazedoxifene Acetate;Bazedoxifene;WAY-140424;CIPLUS_731651;Bazedoxifene acetate;CIPLUS_787914;,UCJGJABZCDBEDK,Selective Estrogen Receptor Modulators (SERM),ER
NCGC00346725-01,CNC(=O)C1=CC=C(C=C1F)N2C(=S)N(C(=O)C23CCC3)C4=CN=C(C#N)C(=C4)C(F)(F)F,ARN-509,,HJBWBFZLDZWPHF,Androgen Receptor Antagonists,AR
NCGC00179244-04,CCN[C@H]1C[C@H](C)[S+]([O-])(=O)C2=C1C=C(S2)[S+](N)([O-])=O,Dorzolamide HCL,,UFCODOWYHPCGCL,Carbonic Anhydrase Type II Inhibitors,CA2
NCGC00345805-01,O=C(NC1=NN=C(O1)C2=CC=CO2)C3=CC(=NC4=CC=CC=C34)C5=CC=CC=C5,STX-0119   ,,MNPXTRXFUMGQLK,STAT-3 Inhibitor,STAT3
NCGC00345839-01,CC[S+]([O-])(=O)N1CC(CC#N)(C1)[N]2C=C(C=N2)C3=NC=NC4=C3C=C[NH]4,"Baricitinib phosphate salt  (INCB-28050,    LY3009104)",,KGHHTVPQWVRJGG,Jak2 inhibitor,JAK2
NCGC00016371-05,N[S+]([O-])(=O)C1=CC(=C(Cl)C(=C1)[S+](N)([O-])=O)Cl,Dichlorphenamide (Diclofenamide),,BSXUYTXOUOKRQV,Carbonic Anhydrase Type Inhibitor,CA1
NCGC00160515-03,C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@@H]2CO)O[C@H]3[C@H](O)[C@@H](O)C(O)O[C@@H]3CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]4\C=C(CO)/[C@@H](O)[C@H](O)[C@H]4O,ACARBOSE,,XUFXOAAUWZOOIT,alpha-Glucosidase Inhibitors,GAA
NCGC00178698-04,CCOC(=O)\C1=C\[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,OSELTAMIVIR PHOSPHATE,,VSZGPKBBMSAYNT,Neuraminidase (Sialidase) Inhibitors,
NCGC00263221-01,CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCC1=CC=CC=C1)C(=O)N[C@@H](C(=O)OCC)C2=CC=CC=C2,Ezatiostat,,GWEJFLVSOGNLSS,Glutathione-s-transferase P1 (GSTP1) Inhibitor,GSTP1
NCGC00345817-01,CNC(=O)[C@H](CC/1=C/N=C\2/C=C\C\C=C12)NC(=O)[C@H](CC(C)C)CC(=O)NO,GM-6001,,SVPQWSUSBRNQBI,MMP Inhibitor,MMP1
NCGC00346934-01,CC(C)(C)C(=O)OC1=CC=C(C=C1)[S+]([O-])(=O)NC2=CC=CC=C2C(=O)NCC(O)=O,Sivelestat,,JIODRNUYULYNKE,Leukocyte Elastase Inhibitor,ELA2
NCGC00181785-01,O=C1NC(CN2CCO[C@@H]([C@@H]2C3=CC=C(C=C3)F)O[C@@H](C4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4)C)=NN1,Aprepitant;L-754030 /MK-0869/ONO-7436,"aprepitantum;MK-0869;5-((2-(1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY)-3-(4-FLUOROPHENYL)-4-MORPHOLINYL)METHYL)-1,2-DIHYDRO-3-OXO-3H-1,2,4-TRIAZOL, 2R-(2AR*,3A);Merck brand of aprepitant;CIPLUS_728707;MK 0869;MK-869;MK 869;L-754030-000Z;HS_534;(2R)-(1R)-3,5-bis(trifluoromethylphenyl)ethoxy)-(3S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazole)methyl-morpholine;aprepitant;APREPITANT;Emend;Aprepitant;",ATALOFNDEOCMKK,Tachykinin NK1 Antagonist,TACR1
NCGC00095899-04,CN(C)CCC1=C[NH]C2=CC=C(C[N]3C=NC=N3)C=C12,Rizatriptan Benzoate (Maxalt),,ULFRLSNUDGIQQP,5-HT1B Agonist,HTR1B
NCGC00095109-06,COC1=CC=C(C=C1)C(CN(C)C)C2(O)CCCCC2,VENLAFAXINE,,PNVNVHUZROJLTJ,5-HT Reuptake Inhibitor,HTR1A
NCGC00345784-01,CN(C)C[C@@H](NC(=O)N1CC2=C([NH]N=C2NC3=C4SC=CC4=NC(=N3)C)C1(C)C)C5=CC=CC=C5,PF-3758309,,AYCPARAPKDAOEN,p21-Activated Kinase 4 (PAK4) Inhibitors,PAK4
NCGC00263565-02,CC[C@]12CC[C@H]3[C@@H](CCC/4=C/C(=O)CC[C@H]34)[C@@H]1\C=C/[C@@]2(O)C#C,Gestodene,,SIGSPDASOTUPFS,Progestogen hormone,PGR
NCGC00346730-01,COC([C@H](OC1=NC(=CC(=N1)C)C)C(O)=O)(C2=CC=CC=C2)C3=CC=CC=C3,Ambrisentan,,OUJTZYPIHDYQMC,Endothelin ETA Receptor Antagonist,EDNRA
NCGC00015242-12,N[S+]([O-])(=O)C1=C(Cl)C=C2\N=C/N[S+]([O-])(=O)C2=C1,CHLOROTHIAZIDE,,GEAKDLJXQWCJSJ,hypertension treatment,
NCGC00163318-03,CC1=C(NC(=O)C2=CC=CC(=C2)NC(=O)NC3=CC=CC(=C3)C(=O)NC4=CC(=CC=C4C)C(=O)NC5=CC=C(C6=C5C(=CC(=C6)[S+](O)([O-])=O)[S+](O)([O-])=O)[S+](O)([O-])=O)C=C(C=C1)C(=O)NC7=CC=C(C8=CC(=CC(=C78)[S+](O)([O-])=O)[S+](O)([O-])=O)[S+](O)([O-])=O,,SURAMIN,GTCRKBMTGCSJTB,Fibroblast Growth Factor (FGF) Inhibitors,FGF2
NCGC00179642-04,ClC1=CC(=C(C=C1)C(C[N]2C=CN=C2)OCC3=C(Cl)C=CC=C3Cl)Cl,Isoconazole nitrate (Travogen),,MPIPASJGOJYODL,Antifungal Agent,
NCGC00018258-09,ClC1=CC=C(COC(C[N]2C=CN=C2)C3=CC=C(Cl)C=C3Cl)C=C1,ECONAZOLE NITRATE,,LEZWWPYKPKIXLL,Antifungal Agent,
NCGC00015500-10,OC2(CCN(CCCC(C3=CC=C(F)C=C3)=O)CC2)C1=CC=C(Cl)C=C1,Haloperidol,"NCGC00023875-08;HALOPERIDOL HCL;1-Butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-;NCGC00023875-07;N-n-butyl haloperidol iodide;NCGC00023875-06;NCGC00023875-05;4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone;RED.HALOPERIDOL;Vesadol;NCGC00023875-04;CIPLUS_148665;NCGC00023875-02;PROPANOIC ACID, 2-HYDROXY-, COMPD. WITH 4-(4-(4-CHLOROPHENYL)-4-HYDROXY-1-PIPERIDINYL)-1-(4-FLUOROPHENYL)-1-BUTANONE, UNDEFINED STOICHIOMETRY;4'-Fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone;NCGC00015500-01;Haldol;HALOPERIDOL;LS-48311;haloperidolum;HALOPERIDOL LACTATE;Haloperidol;CIPLUS_769572;HS_686;NCGC_Prestw-115;haloperidol reductase;NCGC00016234-01;4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone;Haloperidol Lact;haloperidol;Haloperidol hydrochloride;Haloperidol metabolite II;1-BUTANONE, 4-(4-(4-CHLOROPHENYL)-4-HYDROXY-1-PIPERIDINYL)-1-(4-FLUOROPHENYL)-;HS_685;HALOPERIDOL DECANOATE;HS_684;4-[4-(4-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone;4-(4-(P-CHLOROPHENYL)-4-HYDROXYPIPERIDINO)-4-FLUOROBUTYROPHENONE;Haloperidolum;CIPLUS_743122;4-(4-CHLOROPHENYL)-1-(4-(4-FLUOROPHENYL)-4-OXOBUTYL)-4-PIPERIDINE;Haloperidol Dec;NCGC00023875-09;4-(4-(4-CHLOROPHENYL)-4-HYDROXYPIPERIDIN-1-YL)-1-(4-FLUOROPHENYL)BUTAN-1-ONE;1H-Azepinium, 1-(4-amino-4-oxo-3,3-diphenylbutyl)hexahydro-1-methyl-, iodide, mixt. with 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone;",LNEPOXFFQSENCJ,Dopamine D2 Antagonist,DRD2
NCGC00092288-01,CC1=CC=C2\N=C/3N(CC[C@@]3(O)C(=O)C2=C1)C4=CC=CC=C4,,"NCGC00092288-02;1-Phenyl-1,2,3,4-tetrahydro-4-hydroxypyrrolo[2.3-b]-7-methylquinolin-4-one;NCGC00025281-05;NCGC00025281-04;(-)-Blebbistatin;NCGC00025281-01;(R)-(+)-Blebbistatin;Blebbistatin;(?)-Blebbistatin;",LZAXPYOBKSJSEX,myosin II ATPase inhibitor,MYH2
NCGC00346629-01,C[C@@H]1CCO[C@H]2CN\3/C=C(/C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)\C(=C3C(=O)N12)O,S/GSK1349572 (GSK1349572),,RHWKPHLQXYSBKR,HIV Integrase Inhibitors,
NCGC00346835-01,OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12,2-Iminobiotin,,WWVANQJRLPIHNS,Inducible Nitric Oxide Synthase (NOS-2) Inhibitors,NOS2
NCGC00015444-04,ClC1=C(O)C(O)=CC2=C1CCNCC2C3=CC=C(O)C=C3,Fenoldopam,"6-Chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol monohydrobromide;fenoldopamum;SK&F-82526-J;Fenoldopam mesilate;LS-176582;6-CHLORO-1-(4-HYDROXYPHENYL)-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE-7,8-DIOL;NCGC00093942-01;SKF-82526;WHO NO. 4673;1H-3-BENZAZEPINE-7,8-DIOL, 6-CHLORO-2,3,4,5-TETRAHYDRO-1-(4-HYDROXYPHENYL)-;Corlopam;SKF82526;NCGC00015444-01;Fenoldopam;FENOLDOPAM;FENOLDOPAM MESYLATE;Fenoldopam Mesylate;fenoldopam;SK&F-82526;Fenoldopam monohydrobromide;CORLOPAM;LS-27994;LS-27993;SK&F82526;SK&F 82526;Fenoldopam hydrochloride;SK&F8252;NCGC00025246-03;NCGC00025246-02;SKF-82526J;NCGC00025246-01;6-CHLORO-2,3,4,5-TETRAHYDRO-1-(P-HYDROXYPHENYL)-1H-3-BENZAZEPINE-7,8-DIOL METHANESULFONATE;SK&F-82526J;SK&F 8252;CIPLUS_3751177;Fenoldopam Hydrobromide;SKF8252;Fenoldopam bromide;Fenoldopam mesylate;SKF 82526;CIPLUS_188304;CIPLUS_188303;SKF 8252;1H-3-Benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-;Hydrobromide, Fenoldopa;",TVURRHSHRRELCG,Dopamine D1 Agonist,DRD1
NCGC00025059-04,CC(C)C1NC(=O)C(NC(=O)C2=C3\N=C\4/C(=C(C)\C(=O)\C(=C4C(=O)NC5C(C)OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C6CCCN6C(=O)C(NC5=O)C(C)C)N)OC3=C(C)C=C2)C(C)OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C7CCCN7C1=O,Actinomycin D,,RJURFGZVJUQBHK,DNA-Directed RNA Polymerase Inhibitor,PRKDC
NCGC00021305-08,CO[C@@H]1C[C@@H](CC[C@H]1O)C[C@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(C)/[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC,Rapamycin,,QFJCIRLUMZQUOT,mTOR inhibitor,MTOR
NCGC00241104-01,CC(C)(C)c4cc(NC(=O)Nc3ccc(OCCN1CCOCC1)c2ccccc23)n(n4)c5ccc(C)cc5,Doramapimod;BIBR-796?,,MVCOAUNKQVWQHZ,p38 MAPK Inhibitor,MAPK14
NCGC00263180-01,CN1C(=O)C(=C/2N(C(=O)N(C3CC3)C(=O)C2=C1/NC4=CC=C(I)C=C4F)C5=CC=CC(=C5)NC(C)=O)\C,Trametinib;GSK-1120212B/JTP-74057,,LIRYPHYGHXZJBZ,Mek 1/2 inhibitor,MAP2K1
NCGC00346679-01,O=C(NC1CCOCC1)C2=CC=C(C=C2)C3=NC=CC(=C3)C4=C[NH]N=C4C5=NC=CC=C5,GW788388,,SAGZIBJAQGBRQA,TGF-bR1 (ALK5) Inhibitor,
NCGC00346579-01,CC1=C(C=CC=C1)N2\C(=N/C3=C(C(=CC=C3)C)C2=O)C[N]4N=CC5=C4N=CN=C5N,PIK-293,,KQDBVHKNIYROHU,PI3K Inhibitor,PIK3CA
NCGC00015478-08,OC1=C(Br)C=C(C=C1Br)\C=C2/C(=O)NC3=C2C=C(I)C=C3,,,LMXYVLFTZRPNRV,Raf Kinase Inhibitors,BRAF
NCGC00178529-03,C[C@H]1COC2=C3N1\C=C(C(O)=O)/C(=O)C3=CC(=C2N4CCN(C)CC4)F,Levofloxacin (Levaquin),,GSDSWSVVBLHKDQ,DNA Topoisomerase IV Inhibitors,TOP2B
NCGC00346947-01,FC1=CC=C(CN2\C=C/C=C(/C(=O)N[C@@H](COC3=CC4=C(NC(=O)N4)C=C3)C5=CC=CC=C5)C2=O)C=C1F,PDK1 inhibitor,,GCWCGSPBENFEPE,Phosphoinositide Dependent Kinase (PDK) 1 Inhibitors,PDPK1
NCGC00346475-01,CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1CC2=C([NH]C3=C2C=CC(=C3)F)C4=C(C[C@@H]5C[C@H](O)CN5C(=O)[C@H](CC)NC(=O)[C@H](C)NC)C6=C([NH]4)C=C(F)C=C6,Birinapant,,PKWRMUKBEYJEIX,IAP Inhibitor,XIAP
NCGC00017354-06,CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O,SPECTINOMYCIN HYDROCHLORIDE,,UNFWWIHTNXNPBV,Antibiotic,
NCGC00346887-01,[O-][S+](=O)(NCC1=CC=C(C=C1)C(=O)NNC(=O)C2=CC=CC=C2)C3=CC(=C(F)C=C3)Cl,TCN 201,,VFWGDGFMXIEDBM,NMDA Antagonist,GRIN2A
NCGC00065890-07,CC1=CC=NC2=C1NC(=O)C3=CC=CN=C3N2C4CC4,Nevirapine (Viramune),,NQDJXKOVJZTUJA,Reverse Transcriptase Inhibitor,TERT
NCGC00165898-02,FC1=C(C=C(Cl)C=C1)C2=NC3=NC=CN=C3C(=N2)NC4=CC=NC=C4,SD-208,,BERLXWPRSBJFHO,TGF-bR1 (ALK5) Inhibitor,
NCGC00253438-01,CC[C@H]1N(C2CCCC2)C3=NC(=NC=C3N(C)C1=O)NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5,BI-2536,,XQVVPGYIWAGRNI,Polo-like Kinase-1 (Plk-1) Inhibitor,PLK1
NCGC00165768-02,NC(=O)C1=CC2=C([NH]C(=N2)C3=CC=C(OC4=CC=C(Cl)C=C4)C=C3)C=C1,,,UXGJAOIJSROTTN,Checkpoint Kinase 2 (Chk2) Inhibitors,CHEK2
NCGC00346676-01,CN1CCN(CC1)C2=CC=C(C=C2)C3=NC4=C(N5CCN(CC5)CC6=NOC(=C6)C)C(=CN=C4[NH]3)Br,CCT137690,,GFLQCBTXTRCREJ,Aurora-A/B/C Kinase Inhibitor,AURKA
NCGC00343768-01,CC1=NC=C(NC(=O)NC2=C(OC[C@@H]3CNCCO3)C=C(C)C(=C2)Br)N=C1,,,SYYBDNPGDKKJDU,Chk1 Inhibitor,CHEK1
NCGC00263218-02,C\C(O)=C(C#N)\C(=O)NC1=CC=C(C=C1)C(F)(F)F,Teriflunomide;A-771726/HMR-1726,,UTNUDOFZCWSZMS,"MMP-2, 9 Inhibitor",MMP2
NCGC00249611-03,CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(=C1)Cl)B(O)O,MLN2238,,MXAYKZJJDUDWDS,Proteasome Inhibitor,PSMD1
NCGC00344622-02,CC(C)N(CCCNC(=O)NC1=CC=C(C=C1)C(C)(C)C)C[C@H]2O[C@H]([C@H](O)[C@@H]2O)[N]3C=C(Br)C4=C3N=CN=C4N,,,IQCKJUKAQJINMK,DOT1L Inhibitor,
NCGC00016831-04,COC1=CC(=C(C(=O)CCCN2CCCC2)C(=C1)OC)OC,BUFLOMEDIL HYDROCHLORIDE,,OWYLAEYXIQKAOL,vasodilator,
NCGC00096081-03,CC\1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)/CCCC2(C)C)C(C)(C)CCC1,beta-CAROTENE,,OENHQHLEOONYIE,Vitamin/Supplement,
NCGC00188943-04,OC(=O)C/1=C/C(=O)NC(=O)N1,Orotic acid (6-Carboxyuracil),,PXQPEWDEAKTCGB,metabolite,
NCGC00159459-02,C2(C)=C(OC)C(CC=C(C)CCC(=O)OCCN1CCOCC1)=C(O)C3=C2COC3=O,Mycophenolate mofetil,"Mycophenolate mofetil hydrochloride;mycophenolic acid morpholinoethyl ester;RS 61443;Mycophenolate Mofetil;Mycophenolate Mofetil Hydrochloride;mycophenolate mofetil hydrochloride;MYCOPHENOLATE MOFETIL HYDROCHLORIDE;RS-61443;Cellcept;CIPLUS_196921;mycophenolate mofetil;CIPLUS_739758;2-(4-MORPHOLINO)ETHYL (E)-6-(1,3-DIHYDRO-4-HYDROXY-6-METHOXY-7-METHYL)-3-OXO-5-ISOBENZOFURANYL)-4-METHYL-4-HEXENOATE;HS_286;LS-172327;Mycophenolate mofetil;LS-172272;MYCOPHENOLATE MOFETIL;CIPLUS_660816;",RTGDFNSFWBGLEC,Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors,IMPDH1
NCGC00263186-02,CN1CCC(CC1)CNC2=N[N]3C(=NC=C3C4=CC=CC(=C4)OC(F)(F)F)C=C2,SGI-1776 free base,,MHXGEROHKGDZGO,Pim-1/Flt3 Inhibitor,PIM1
NCGC00015675-03,C\C1=C(\C=C(\C#N)C(=O)N1)C2=CC=NC=C2,Milrinone,"PRIMACOR;1,6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile;PROPANOIC ACID, 2-HYDROXY-, COMPD. WITH 1,6-DIHYDRO-2-METHYL-6-OXO(3,4'-BIPYRIDINE)-5-CARBONITRILE (1:1);Milrinone;CIPLUS_191828;MILRINONE LACTATE;HS_949;LS-44610;WIN-47,203;NCGC00025189-03;MILRINONE;1,6-DIHYDRO-2-METHYL-6-OXO(3,4'-BIPYRIDINE)-5-CARBONITRILE;NCGC00164390-01;milrinone;ym 018;milrinonum;NCGC_Prestw-1065;(3,4'-Bipyridine)-5-carbonitrile, 6-dihydro-2-methyl-6-oxo-;1,6-Dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile;NCGC00015675-02;NCGC00015675-01;CIPLUS_749790;Primacor;NCGC00025189-02;Milrinone Lact;NCGC00025189-01;",PZRHRDRVRGEVNW,Phosphodiesterase III (PDE3) Inhibitor,PDE3A
NCGC00015673-08,[O-][N+]1=C(N)N=C(N2CCCCC2)C=C1N,Minoxidil,"Loniten;Regaine;CIPLUS_755237;Minoxidil;6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide;NCGC00015673-02;minoxidilum;MINOXIDIL;LS-135040;U 10858;2,6-DIAMINO-4-PIPERIDINOPYRIMIDINE 1-OXIDE;Pfizer Brand of Minoxidil;Rogaine;NCGC_Prestw-20;6-(1-Piperidinyl)pyrimidine-2,4-diamine 3-oxide;6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine;ROGAINE;2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide;Riup;CIPLUS_170351;CIPLUS_179263;minoxidil;Minoxidil Pfizer Bran;HS_956;NCGC00024666-04;NCGC00015673-01;Minoxidilum;NCGC00024666-05;NCGC00024666-06;NCGC00024666-07;NCGC00024666-01;NCGC00024666-02;NCGC00024666-03;",ZFMITUMMTDLWHR,K(ATP) Channel Activators,
NCGC00263200-01,CC1=NC(=NC(=C1)NC2=CC(=CC=N2)NC(=O)C3=C(Cl)C=CC=C3Cl)N,RO495,,LNGDQKGREFSTHB,Tyk 2 inhibitor,TYK2
NCGC00347949-01,COC1=CC=C(CCC(=O)NC2=NC3=CC=C(Cl)C=C3S2)C=C1OC,,,LXFKEVQQSKQXPR,Wnt Signaling Inhibitor,WNT5A
NCGC00346612-01,N[C@]1(C[S+]([O-])(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O,LY2140023 (LY404039),,PKSYHGURNZLSKW,mgluR2/3 Agonists,GRM2
NCGC00242503-01,COC1=C(C(=CC=C1)OC)C2=CC(=N[N]2C3=C4C=CC(=CC4=NC=C3)Cl)C(=O)NC5(C6CC7CC(C6)CC5C7)C(O)=O,Meclinertant;Reminertant;SR-48692,,DYLJVOXRWLXDIG,Carboxypeptidase A Inhibitor,CPA1
NCGC00345826-01,C1CCN(CC1)CCOC2=CC(=CC=C2)C3=N[NH]C4=CC=C(C=C34)C5=N[NH]C=N5,CC-401,,XDJCLCLBSGGNKS,JNK Inhibitor,MAPK8
NCGC00015096-11,CCCCC1=C(C(=O)C2=CC(=C(OCCN(CC)CC)C(=C2)I)I)C3=C(O1)C=CC=C3,Amiodarone,AMIODARONE,IYIKLHRQXLHMJQ,Muscarinic M3 Receptor Ligand,
NCGC00345844-01,CC(C)(C)NC(=O)NC1=CC=CC(=C1)NC2=NC(=C(F)C=N2)NC(C)(C)CO,Bayer-18        ,,DYNMZYFOSRSMAC,Tyk 2 inhibitor,TYK2
NCGC00179308-05,CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)\C4=C\C(=O)\C=C/[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF,"Fluticasone propionate (Flonase, Veramyst)",,WMWTYOKRWGGJOA,Corticosteroid,
NCGC00184997-01,Cc1nnc(o1)C(=O)NC(C)(C)C3=NC(C(=O)NCc2ccc(F)cc2)=C(O)C(=O)N3C,Raltegravir,RALTEGRAVIR POTASSIUM;,CZFFBEXEKNGXKS,HIV Integrase Inhibitors,
NCGC00022037-06,C[C@H]1C[C@@H]2[C@H](CC[C@@]3(C)[C@H]2CC[C@]3(OC(C)=O)C(C)=O)[C@@]\4(C)CCC(=O)\C=C14,Medroxyprogesterone acetate,,PSGAAPLEWMOORI,Progesterone Receptor Agonist,PGR
NCGC00346558-01,C[C@@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC3=CC=CC=C3OCC(F)(F)F,Silodosin (Rapaflo),,PNCPYILNMDWPEY,alpha1-Adrenoceptor Antagonists,ADRA1A
NCGC00346658-01,CC1(COC1)COC2=CC3=C(C=C2)[N](C=N3)C4=NC5=C(C=CC=C5C=C4)N6CCC(N)CC6,Crenolanib (CP-868596),,DYNHJHQFHQTFTP,PDGFR beta inhibitor,PDGFRB
NCGC00346942-01,COC1=C(OC)C=C2C(=NC=NC2=C1)NC3=CC(=C(O)C(=C3)Br)Br,WHI-P97,,YVCXQRVVNQMZEI,EGFR (HER1; erbB1) Inhibitor,EGFR
NCGC00241101-02,CCOC1=CC2=C(C=C1NC(=O)\C=C\CN(C)C)C(=C(C=N2)C#N)NC3=CC=C(OCC4=CC=CC=N4)C(=C3)Cl,Neratinib (HKI-272),,JWNPDZNEKVCWMY,EGFR (HER1; erbB1) inhibitor,EGFR
NCGC00344391-02,CN(C1CCC2=C(C1)C3=CC=CC=C3[N]2CC(O)=O)[S+]([O-])(=O)C4=CC=C(F)C=C4,TM-30089,,VFBOFHRHJGPKQR,prostaglandin D2 CRTH2 inhibitor,PTGDR2
NCGC00017312-03,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2\C=C/C(=O)NC2=O,Uridine,,DRTQHJPVMGBUCF,Anti-anxiety drug,
NCGC00015989-16,O=C1CCC(N2C(=O)C3=C(C=CC=C3)C2=O)C(=O)N1,THALIDOMIDE,,UEJJHQNACJXSKW,TNF-alpha Production Inhibitors,TNF
NCGC00142599-02,CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C\C=C/4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,Stigmasterol (Stigmasterin),,HCXVJBMSMIARIN,Steroid hormone,
NCGC00263532-03,CN(C)CC\C=C/1C2=C(COC3=CC=C(CC(O)=O)C=C13)C=CC=C2,Olopatadine hydrochloride (Opatanol),,JBIMVDZLSHOPLA,Mediator Release Inhibitors,
NCGC00015977-02,OC(=O)C1CCCN(CCC=C(C2=CC=CC=C2)C3=CC=CC=C3)C1,SKF 89976A hydrochloride,"SK&F 89976-A, hydrochloride, (R)-isomer;1-(4,4-Diphenyl-3-butenyl)-3-piperidinecarboxylic acid hydrochloride;SK&F 89976-A, hydrochloride, (S)-isomer;SK&F 89976-A;NCGC00094414-01;SK&F 89976-A, hydrochloride;SK&F 89976-A, (R)-isomer;NCGC00015977-01;SKF 89976A;N-(4,4-diphenyl-3-butenyl)nipecotic acid;LS-114699;LS-178258;LS-178414;CIPLUS_669297;NCGC00024987-01;LS-177862;LS-177863;LS-177864;SKF 89976A hydrochloride;SKF-89976A;NCGC00024987-03;NCGC00024987-02;SK&F 89976-A, (+-)-isomer;",TXQKSMSLZVKQBI,GAT-1 Inhibitor,SLC6A1
NCGC00346574-01,CCC[C@H](NC1=C(C)C=NC(=N1)C2=CC(=C(NC(=O)NCC)C=C2)OC)C3=CC=CN=C3,CYT997,,MTJHLONVHHPNSI,Tubulin depolymerization inhibitor,TUBB
NCGC00249685-02,CN1CCN(CC1)C2=CC3=C([NH]C(=N3)C/4=C(\N)C5=C(F)C=CC=C5NC4=O)C=C2,Dovitinib;CHIR-258/NVP-TKI258/TKI-258,,PIQCTGMSNWUMAF,FGFR inhibitor,
NCGC00346635-01,CNC(=O)NC1=CC=C(C=C1)C2=NC3=C(C=N[N]3C4CCC5(CC4)OCCO5)C(=N2)N6CC7CCC(C6)O7,WYE-125132,,QLHHRYZMBGPBJG,mTORC1/2 inhibitor,MTOR
NCGC00160398-04,NC(=N)NC1=CC=C(C=C1)C(=O)OC2=CC=C3C=C(C=CC3=C2)C(N)=N,,NAFAMOSTAT MESILATE,MQQNFDZXWVTQEH,Tryptase Inhibitors,TPSAB1
NCGC00091112-08,CN(C)C1=CC=C(C=C1)C(C2=CC=C(C=C2)N(C)C)=C/3\C=C/C(/C=C3)=[N+](C)C,GENTIAN VIOLET,,LGLFFNDHMLKUMI,TNFR1 (p55/CD120a) Modulator,
NCGC00346670-01,COC1=CC2=NC=CC(=C2C=C1)OC3=CN=C(NC(=O)C/4=C(C)/N(CC(C)(C)O)N(C4=O)C5=CC=CC=C5)C=C3,AMG458,,GLBZSOQDAOLMGC,HGFR (MET; c-Met) Inhibitor,MET
NCGC00346625-01,FC1=CC=C(C=C1)C2=CC=C(O2)\C=C/3SC(=O)NC3=O,CAY10505,,UFBTYTGRUBUUIL,PI3K gamma Inhibitor,PIK3CG
NCGC00346450-01,CN1\N=C(N)/C2=C[N]([C@@H]3O[C@H](CO[P](O)(O)=O)[C@@H](O)[C@H]3O)C4=C2C1=NC=N4,Tricyclic Nucleoside Monophosphate (TCN-P),,URLYINUFLXOMHP,PKB/Akt Inhibitor,AKT1
NCGC00346622-01,COC1=C(OC)C(=CC(=C1)NC2=NC=C(F)C(=N2)NC3=CC=C4OC(C)(C)C(=O)N(CO[P](O)(O)=O)C4=N3)OC,R788 (Fostamatinib),,GKDRMWXFWHEQQT,Syk Kinase inhibitor,SYK
NCGC00249388-01,CC1=CC=CC(=N1)C2=N[N]3CCCC3=C2C4=CC=NC5=CC(=CC=C45)C(N)=O,LY2157299,,PBLNPFVCOVYAKI,TGF-bR1 (ALK5) and TGFbR2 inhibitor,
NCGC00346526-01,CCC1=CC=CC(=C1NC(=O)N2CC3=C(C2)C(=N[NH]3)NC(=O)C4=CC=C(C=C4)N5CCN(C)CC5)CC,PHA-680632,,OBWNXGOQPLDDPS,Aurora-A/B/c Inhibitor,AURKA
NCGC00346964-01,CC(C)[N]1C=NC2=C(NC3=CC=CC(=C3)NC(=O)C=C)N=C(NC4CCC(CC4)N(C)C)N=C12,HMSL10084,,DGEBYERMQBTMHV,FLT3,FLT3
NCGC00091835-09,CN(CCCl)CCCl,MECHLORETHAMINE,,HAWPXGHAZFHHAD,DNA Alkylating Agent,
NCGC00183876-01,OC(/C=C/C(O)=O)=O.C[C@@H](OC[P](OCOC(OC(C)C)=O)(OCOC(OC(C)C)=O)=O)CN1C(N=CN=C2N)=C2N=C1,Tenfovir disoproxil fumarate,TENOFOVIR DISOPROXIL FUMARATE;Bis(isopropyloxycarbonyloxy)methyl [(R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl-phosphonate--fumaric acid (1:1);Tenofovir disoproxil fumarate;tenofovir disoproxil fumarate;Gilead brand of tenofovir disoproxil fumarate;Viread;Tenofovir Disoproxil Fumarate;tenofovir disoproxil;CIPLUS_696535;CIPLUS_700852;Tenofovir disoproxil fumarate(TDF);LS-173814;,JFVZFKDSXNQEJW,Reverse Transcriptase Inhibitor,TERT
NCGC00161398-01,CN1C=C(\C=C2/C(=O)NC3=CC=CN=C23)C4=C1C=CC=C4,GW 441756,"GW441756 hydrochloride;NCGC00165797-01;GW 441756;NCGC00161398-01;1,3-Dihydro-3-[(1-methyl-1H-indol-3-yl)methylene]-2H-pyrrolo[3,2-b]pyridin-2-one hydrochloride;",NXNQLECPAXXYTR,Tropomyosin Related Kinase A (TrkA) inhibitor,NTRK1
NCGC00263280-01,CC(C)C[C@@H]1NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@H](CC2=C[NH]C3=C2C=CC=C3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@](C)(CCCCCC\C=C/CCC[C@](C)(NC(=O)[C@H](CC(C)C)NC1=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(N)=O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)CCNC(C)=O)[C@H](C)O,Ac-SAH-p53-8 ,,ZXDJSIREXBJLTD,HDM2/HDMX inhibitor,HSPA2
NCGC00178840-06,CC1=C(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C([O-])=O)C(=NO1)C4=C(Cl)C=CC=C4,Cloxacillin sodium,,LQOLIRLGBULYKD,beta-lactam antibiotic,
NCGC00091011-09,OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,Chloramphenicol (Chloromycetin),,WIIZWVCIJKGZOK,Antibiotic,
NCGC00263130-01,CCCCN1C(=O)N(CC2=C(F)C=CC=C2)C(=O)C3=C1[NH]C(=N3)CC4=CC=C(NC(C)=O)C=C4,cPEPCK inhibitor ,,JHSHXKJSPVHPCJ,cPEPCK inhibitor,PCK1
NCGC00271534-03,CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(O)=O,Nateglinide (Starlix),,OELFLUMRDSZNSF,Insulin Secretagogues,
NCGC00163107-06,ClC1=CC=C(C=C1)C2=C(\C=N\OCC3=CC(=C(Cl)C=C3)Cl)[N]4C=CSC4=N2,CITCO,,ZQWBOKJVVYNKTL,Constitutive androstane receptor agonist,NR1I3
NCGC00263132-02,C[N]1C=C(C=N1)C2=C3\C=N/NC(=O)C4=C3C(=CC(=C4)NC(=O)[C@H](N)C5CCCCC5)[NH]2,PF-477736,,NDEXUOWTGYUVGA,Chk1 Inhibitor,CHEK1
NCGC00345803-01,CC[C@H](CC#N)OC(=O)N[C@@H](C)C1=CC=CC(=C1)NC(=O)NC2=CC=C(C3=CN=CO3)C(=C2)OC,AVN-944,,GYCPCOJTCINIFZ,Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors,IMPDH1
NCGC00183044-01,O=C(C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@]([H])1C[C@@]([H])2CC4=C3C(O)=CC=C4N(C)C)[C@@]1(O)C(O)=C2C3=O,Minocycline,,ZZZRUAITSXLWBH,Tetracycline Antibiotic,
NCGC00346435-01,NC(=O)C1=CC=CC2=C[N](N=C12)C3=CC=C(C=C3)[C@@H]4CCCNC4,MK-4827,,PCHKPVIQAHNQLW,PARP-1/PARP-2 Inhibitor,PARP1
NCGC00246966-03,COC(=O)NC1=NC2=CC(=CC=C2[NH]1)C(=O)C3=CC=C(F)C=C3,Flubendazole (Flutelmium),,CPEUVMUXAHMANV,antiparasitic agent,
NCGC00016641-01,CN[C@@H]1[C@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]2[C@@H](O[C@H](C)[C@@]2(O)C=O)O[C@@H]3[C@@H](O)[C@@H](O)[C@@H](NC(N)=N)[C@@H](O)[C@H]3NC(N)=N,Streptomycin sulfate,"PENICILLIN-STREPTOMYCIN;CIPLUS_779854;agrimycin-100;HS_1297;LS-1247;Streptomycin;D-Streptamine, O-2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl-(1-2)-O-5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl-(1-4)-N,N'-bis(aminoiminomethyl)-;Streptomycin A;agrimycin 100;NCGC00094785-01;Streptomycin sulfate;NCGC00094785-02;STREPTOMYCIN TRIHYDROCHLORIDE;panstrilline;CIPLUS_695713;Estreptomicina;LS-147053;Streptomycin sesquisulfate;STREPTOMYCIN SULFATE;streptomycinum;Streptomycin sulfate salt;STREPTOMYCIN HYDROCHLORIDE;CIPLUS_148847;as-15;STREPTOMYCIN;streptomycine;Streptomycin Sulfate;CIPLUS_756770;NCGC00016641-01;NCGC_Prestw-321;CIPLUS_779640;NSC 14083;STREPTOMYCIN SESQUISULFATE;CIPLUS_778596;CIPLUS_768515;CIPLUS_162550;panstrilline sulfate (2:3);CIPLUS_778528;CIPLUS_775021;CIPLUS_774301;CIPLUS_775022;",UCSJYZPVAKXKNQ,30S Ribosomal Protein Inhibitors,
NCGC00188865-02,C[N]1N=C2C=C(C=CC2=C1C)N(C)C3=NC(=NC=C3)NC4=CC=C(C)C(=C4)[S+](N)([O-])=O,Pazopanib;GSK-786034/Votrient/Armala,,XPUJIFWTVXGLRJ,multi-kinase,CERS1
NCGC00346468-01,CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC/4=C/C(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO,17 alpha-propionate,,GPNHMOZDMYNCPO,Androgen Receptor Antagonist,AR
NCGC00263182-02,NC1=C(NC(=O)C2=CC=C(CNC3=NC(=CC=N3)C4=CC=CN=C4)C=C2)C=CC=C1,Mocetinostat (MGCD0103),,HRNLUBSXIHFDHP,Histone Deacetylase (HDAC) 1 Inhibitor,HDAC1
NCGC00016991-06,CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC,PROPARACAINE HYDROCHLORIDE,,KCLANYCVBBTKTO,Sodium channel inhibitor,
NCGC00346520-01,CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@H](O)[C@@H]1/C=C/C(O)CCC2=CC=CC=C2,Bimatoprost,,AQOKCDNYWBIDND,prostaglandin,
NCGC00344508-01,COC1=CC(=CC=C1)[C@@H](C)NCCCC2=CC=CC=C2Cl,NPS R568,,ZVQUCWXZCKWZBP,Calcium-Sensing Receptor (CaSR) Agonists,CASR
NCGC00250378-01,CCCCN1CCC(CC1)CNC(=O)C2=C3OCCC[N]3C4=CC=CC=C24,Piboserod hydrochloride;SB-207266A,,KVCSJPATKXABRQ,5-HT4 Antagonists,HTR4
NCGC00015823-18,CN1\C(=C(\O)C2=C(C=CC=C2)[S+]1([O-])=O)C(=O)NC3=CC=CC=N3,PIROXICAM,,IAPMPNKHZPZVQU,Cyclooxygenase Inhibitor,PTGS1
NCGC00346504-01,NC(=O)[C@@H](CCC(F)(F)F)N(CC1=C(F)C=C(C=C1)C2=NOC=N2)[S+]([O-])(=O)C3=CC=C(Cl)C=C3,BMS-708163 (Avagacestat),,SBTQVSZTFFUILD,g-Secretase Inhibitor,NOTCH1
NCGC00346592-01,COC1=CC=C(C=C1)C/2=C(OC3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)/C(=O)C4=C(O2)C(=C(OC5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C=C4O)CC=C(C)C,Icariin,,TZJALUIVHRYQQB,Phosphodiesterase V (PDE5) inhibitor,PDE5A
NCGC00162094-04,C[C@H]1CC2C3CCC/4=C/C(=O)/C=C\[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,BETAMETHASONE,,UREBDLICKHMUKA,Glucocorticoid steroid,
NCGC00160531-01,[H][C@@](O)(CCN1C(C(C)C)=C(C(=O)NC2=CC=CC=C2)C(=C1C3=CC=C(F)C=C3)C4=CC=CC=C4)C[C@@]([H])(O)CC([O-])=O,,"ATORVASTATIN CALCIUM;CI-981;Atorvastatin Sodium;CIPLUS_205162;CIPLUS_205163;ATORVASTATIN;ATORVASTATIN CALCIUM HYDRATE;pd 134298-38a;HS_829;Atorvastatin calcium hydrate;CIPLUS_197066;Atorvastatin Calcium Hydrate;2-(4-FLUOROPHENYL)-5-(1-METHYETHYL)-3-PHENYL-4-(PHENYLAMINOCARBONYL)-1-((3,5-DIHYDROXY)HEPTANOIC ACID)-1H-PYRROLE CALCIUM,L-;Atorvastatin calcium;LS-136975;NCGC00095067-02;NCGC00095067-01;LS-136974;atorvastatin calcium;Atorvastatin Calcium;LIPITOR (ATORVASTATIN CALCIUM) TABLETS;CI 981;LS-172139;atorvastatinum;atovarstatine;Atorvastatin Calcium (Lipitor);atorvastatin, calcium salt;[R-(R*, R*)]-2-(4-fluorophenyl)-(beta), (delta)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1) trihydrate;atorvastatin;Lipitor;Atorvastatin;Atorvastatin Calcium Anhydride;",XUKUURHRXDUEBC,HMG-CoA Reductase Inhibitor,HMGCR
NCGC00263122-01,C1CC2=C(C1)C(=N[NH]2)C3=N[NH]N=N3,MK-0354,,LTQYSJKGRPGMPO,Nicotinic Acid Receptor Partial Agonist,NIACR1
NCGC00015672-01,OC1=CC(=C(C=C1)\C2=C(O)\C(=O)C3=C(O2)C=C(O)C=C3O)O,Morin,"2',3,4',5,7-Pentahydroxyflavone;Morin hydrate;morin;NCGC00015672-01;3,5,7,2',4'-pentahydroxyflavone;2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one;MORIN;NCGC00164326-01;LS-69029;2',3,4',5,7-pentahydroxyflavone;NCGC00022214-03;NCGC00022214-04;NCGC00022214-05;CIPLUS_197378;morin hydrate;NCGC00022214-07;Morin;",YXOLAZRVSSWPPT,Cytochrome P450 CYP1A2 Inhibitor,CYP1A2
NCGC00015766-08,OC1=C(C(C)(C)C)C=C(C)C(CC2=NCCN2)=C1C,Oxymetazoline,"Phenol, 3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-6-(1,1-dimethylethyl)-2,4-dimethyl-;oxymetazolinum;NCGC00094218-01;oxymetazoline;Afrin;3-[(4,5-Dihydro-;CIPLUS_158470;3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol hydrochloride;OXYMETAZOLINE HYDROCHLORIDE;2-(3-Hydroxy-2,6-dimethyl-4-t-butylbenzyl)-2-imidazoline hydrochloride;NCGC00094218-02;NCGC00094218-03;LS-104146;LS-104147;Phenol, 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-, hydrochloride;CIPLUS_208338;Oxymetazoline hydrochloride;NCGC00015766-02;NCGC00015766-01;nasivin hydrochloride;NCGC00022345-06;Oxymetazoline;NCGC00022345-05;NCGC00022345-04;HS_35;NCGC00022345-02;NCGC_Prestw-224;Phenol, 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-;Oximetazolina;oxymeta zoline;Afrazine;OXYMETAZOLINE;Oxymetazolinum;",WYWIFABBXFUGLM,alpha1A/2A-Adrenoceptor Agonists,ADRA1A
NCGC00016241-11,N[S+]([O-])(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O,FUROSEMIDE,,AEWUPPZRKSYATO,Loop Diuretics,
NCGC00159356-02,O=C\1CC[C@H]5C(=C/1)/CC[C@@H]2[C@@H]5CC[C@]3(C)[C@H](CC[C@@H]23)OC(=O)CCc4ccccc4,Nandrolone phenpropionate,"Nandroloni phenylpropionas;ESTR-4-EN-3-ONE, 17-(1-OXO-3-PHENYLPROPOXY)-, (17.BETA.);nortestosterone phenylpropionate;CIPLUS_149019;LS-64857;Nandrolone Phenpropionate;Nandrolone decanoate;Durabolin;NANDROLONE PHENPROPIONATE;LS-171982;norandrolone phenylpropionate;Nandrolone phenpropionate;NANDROLONE PHENYLPROPIONATE;Durabolin-50;Nerobolyl;nandrolone phenpropionate;19-nortestosterone phenylpropionate;Nandrolone Phenylpropionate;nandrolone phenpropionate, (17alpha)-isomer;17 beta-hydroxyestr-4-en-3-one hydrocinnamate;Nerobolil;Fenobolin;NSC-23162E;17.BETA.-HYDROXYESTR-4-EN-3-ONE HYDROCINNAMATE;Nandrolone phenylpropionate;",UBWXUGDQUBIEIZ,Steroid hormone,
NCGC00015321-04,C2(O)=C(O)C=CC(CCNC(C)CCC1=CC=C(O)C=C1)=C2,Dobutamine,"NCGC00015321-01;LS-171786;DOBUTREX;1,2-BENZENEDIOL, 4-(2-((3-(4-HYDROXYPHENYL)-1-METHYLPROPYL)AMINO)ETHYL)-, (+/-)-, (S-(R*,R*))-2,3-DIHYDROXYBUTANEDIOATE (1:1) (SALT);(?)-4-[2-[[3-(4-Hydroxyphenyl)-1-methylpropyl]amino]ethyl]-1,2-benzenediol hydrochloride;LS-176194;LS-176193;CIPLUS_178257;NCGC00016857-01;(+/-)-3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenethylamine hydrochloride;LS-172468;LEVDOBUTAMINE;Dobutamine Phosphate (1:1) Salt, (-)-Isomer;Dobutamine, Phosphate (1:1) Salt (+)-Isomer;Dobutamine, (-)-Isomer;Dobutamine HCl;Dobutamine hydrochloride;LS-176579;Dobutrex;CIPLUS_783677;CIPLUS_207303;LS-172467;LS-29983;CIPLUS_682448;NCGC_Prestw-352;DOBUTAMINE;Dobutamine (+)-Isomer;Dobutamine Tartrate (1:1), (R-(R*,R*))-Isomer;Dobutamine tartrate;cpd w/o isomeric designation;NCGC00093799-01;levdobutamine;DOBUTAMINE HYDROCHLORIDE;Dobutamine Tartrate;NCGC00024629-01;Dobutamina;LS-171928;NCGC00024629-02;NCGC00024629-03;Dobutaminum;Dobutamine;1,2-Benzenediol, 4-(2-((3-(4-hydroxyphenyl)-1-methylpropyl)amino)ethyl)-, (+-)-;NCGC00095018-02;NCGC00095018-01;(+/-)-4-(2-((3-(P-HYDROXYPHENYL)-1-METHYLPROPYL)AMINO)ETHYL)PYROCATECHOL D-TARTRATE (1:1) (SALT);DOBUTAMINE TARTRATE;LS-175120;Dobutamine Hydrochloride;levdobutaminum;LY 174008;",JRWZLRBJNMZMFE,beta1-Adrenoceptor Antagonists,ADRB1
NCGC00167746-01,COC1=C(Cl)C=C(NC(=O)NC2=NOC(=C2)C)C(=C1)OC,,"PNU120596;PNU-120596;1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea;NCGC00167746-01;PNU 120596;N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea;",CEIIEALEIHQDBX,Nicotinic alpha7 Positive Allosteric Modulators,CHRNA7
NCGC00346485-01,NC1=NC=NC2=C1C(=C[N]2C3CC(C3)CN4CCCC4)C5=CC(=CC=C5)OCC6=CC=CC=C6,NVP-ADW742,,LSFLAQVDISHMNB,IGF-1R Inhibitor,IGFR1
NCGC00022858-07,OC(COC1=C2C(=O)\C=C(/OC2=CC=C1)C([O-])=O)COC3=C4C(=O)\C=C(/OC4=CC=C3)C([O-])=O,CROMOLYN SODIUM,,IMZMKUWMOSJXDT,Mediator Release Inhibitors,
NCGC00015479-20,OC1=CC=C(C=C1)\C2=C\OC3=C(C(=CC(=C3)O)O)C2=O,GENISTEIN,,TZBJGXHYKVUXJN,DNA Topoisomerase II Inhibitors,TOP2A
NCGC00346461-01,NC1=C2C(=C[N](C3CC(C3)CN4CCC4)C2=NC=N1)C5=CC(=CC=C5)OCC6=CC=CC=C6,NVP-AEW541,,AECDBHGVIIRMOI,IGF-1R Inhibitor,IGFR1
NCGC00167768-02,COC1=C(OC)C=C2C(=CC=NC2=C1)OC3=CC=C(NC(=O)NC4=CC=C(F)C=C4F)C(=C3)F,Ki8751,,LFKQSJNCVRGFCC,VEGFR-2 inhibitor,FLT1
NCGC00015245-07,CC(C[N+](C)(C)C)OC(N)=O,,CARBAMYL-BETA-METHYLCHOLINE Cl,NZUPCNDJBJXXRF,Muscarinic receptor Agonists,
NCGC00162423-04,CO[C@@H]([C@@H]1CC2=C(C(=C3C(=C(C)C(=CC3=C2)C[C@H]4C[C@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@@H](O)[C@@H](C)O4)O)O)C(=O)[C@H]1O[C@@H]6C[C@H](O[C@@H]7C[C@H](O[C@@H]8C[C@](O)(CO)[C@@H](O)[C@H](C)O8)[C@@H](O)[C@H](C)O7)[C@@H](O)[C@H](C)O6)C(=O)[C@@H](O)[C@@H](C)O,Mithramycin A,,YYLMAPWKLCSQNP,Alcohol Dehydrogenase Inhibitor,ADH1A
NCGC00345795-01,NC1(CCN(CC1)C2=C3C=C[NH]C3=NC=N2)C(=O)N[C@@H](CCO)C4=CC=C(Cl)C=C4,AZD-5363,,JDUBGYFRJFOXQC,PKB/Akt Inhibitor,AKT1
NCGC00241342-02,ClC1=CC(=CC(=C1)CNC2=C(C=NC=N2)C3=CC4=C(OCO4)C=C3)Cl,,,JQSJAVBMIMDUFO,Clk Inhibitor,CLK1
NCGC00346543-01,CNC(=O)C1=CC=C\2C(=C1)NC(=O)C2=C(\NC3=CC(=CC=C3)CN(C)C)C4=CC=CC=C4,BIX 02188,,BQNHHYZMVCQLJG,Mek 5 Inhibitor,MAP2K5
NCGC00018185-07,COC1=CC=C(\C=C\C(=O)NC2=CC=CC=C2C(O)=O)C=C1OC,,"3,4-DAA;BRL-9952AA;tranilast hydrate;SB-252218;WHO NO. 5070;tranilastum;N-(3',4'-dimethoxycinnamoyl)anthranilic acid;NCGC00015995-01;Rizaben;CIPLUS_181716;N-(3,4-dimethoxycinnamoyl)anthranilic acid;N-5';2-((3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic acid;TRANILAST;L-645,284;2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid;LS-171947;N 5';MK-341;Tranilast;tranilast;tranilast sodium salt;NCGC00021458-04;NCGC00021458-05;Tranilastum;NCGC00021458-02;LS-172907;(E)-2-((3-(3,4-DIMETHOXYPHENYL)-1-OXO-2-PROPENYL)AMINO)BENZOIC ACID;LS-37150;",NZHGWWWHIYHZNX,TNF-alpha Production Inhibitor,TNF
NCGC00167785-02,OC1=C(C=CC=C1CC=C)/C=N/NC(=O)CN2CCN(CC2)CC3=CC=CC=C3,PAC-1,,YQNRVGJCPCNMKT,Procaspase 3 Activator,CASP3
NCGC00346492-01,CC1=CC=C(C=C1)[S+]([O-])(=O)NC2=NC3=CC=CC=C3N=C2NC4=CC5=NSN=C5C=C4,XL147,,QAUOFULMCMFYJP,PI3K Inhibitor,PIK3CA
NCGC00346893-01,CC1OC(OC/2=C(/OC3=C(C(=CC(=C3)O)O)C2=O)C4=CC=C(O)C=C4)C(O)C(OC(C)=O)C1OC(C)=O,SL 0101-1,,SXOZSDJHGMAEGZ,MAPKAP-K1 (RSK; p90Rsk) Inhibitor,RPS6KA1
NCGC00346437-01,CN[C@@H]1CN(C[C@H]1OC)C2=NC3=C(C=C2)C(=O)C(=C\N3C4=NC=CS4)/C(O)=O,Voreloxin Hydrochloride,,XZAFZXJXZHRNAQ,DNA Topoisomerase II Inhibitors,TOP2A
NCGC00346477-01,C[C@H](NC(=O)C(=O)NC1=CC=CC=C1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COC2=C(F)C(=CC(=C2F)F)F,,,SCVHJVCATBPIHN,Caspase Inhibitors,CASP1
NCGC00242501-01,CC1=CC(=C(C)[N]1C2=CC=CC=C2)\C=C3\SC4=NC5=C(C=CC=C5)[N]4C3=O,ITX3,,SJMYMKPBODEZSH,Triple Functional Domain Protein (TRIO) Inhibitor,TRIO
NCGC00346508-01,NC1=NC2=NC(=C(N=C2C(=N1)N)C3=CC(=CC=C3)O)C4=CC=CC(=C4)O,TG100-115,,UJIAQDJKSXQLIT,PI3K Inhibitor,PIK3CA
NCGC00178499-03,NC1=NC(=CS1)\C(=N\O)C(=O)N[C@H]2[C@H]3SC\C(=C(/N3C2=O)C(O)=O)C=C,Cefdinir (Omnicef),,RTXOFQZKPXMALH,Cephalosporin antibiotic,
NCGC00167558-01,FC(C=C(C2=C3F)C(C(C(O)=O)=CN2CCF)=O)=C3N(CC1)CCN1C,Fleroxacin,"Ro 23-6240;Fleroxacin;Megalocin;Megalone;CIPLUS_192010;fleroxacine;3-Quinolinecarboxylic acid, 6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-;Ro 23 624;Quinodis;6,8-DIFLUORO-1-(2-FLUOROETHYL)-1,4-DIHYDRO-7-(4-METHYL-1-PIPERAZINYL)-4-OXO-3-QUINOLINECARBOXYLIC ACID;RO-23-6240;fleroxacinum;6,8-Difluoro-1-(2-fluoroethyl)1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid;FLEROXACIN;AM 83;Gr??nenthal Brand of Fleroxacin;AM83;6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methylpiperazino)-4-oxo-3-quinolinecarboxylic acid;LS-141577;Ro 23624;AM-833;fleroxacin N-oxide;",XBJBPGROQZJDOJ,Quinoline Antibiotic,
NCGC00179501-04,COC1=C(O)C=C(C=C1)[C@@H]2CC(=O)C3=C(O2)C=C(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)C=C3O,Hesperidin,,QUQPHWDTPGMPEX,Free Radical Scavenger,
NCGC00015962-02,OC1=CC=C(C=C1)C2=NC(=C([NH]2)C3=CC=C(F)C=C3)C4=CC=NC=C4,SB 202190,SB 202190;NCGC00015962-01;SB-202190;NCGC00025089-03;NCGC00025089-02;CIPLUS_753358;NCGC00025089-05;NCGC00025089-04;4-[4-(4-Fluorphenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol;NCGC00025089-01;4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole;4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole;,QHKYPYXTTXKZST,p38 MAPK Inhibitor,MAPK14
NCGC00250392-01,CC(C)CN1C(=O)N(C)C(=O)C2=C1SC(=C2C(=O)N3C[C@H](O)CO3)CC4=C(C)[NH]N=C4C,AR-C155858,,ISIVOJWVBJIOFM,MCT1 inhibitor,SLC16A1
NCGC00347067-01,N[S+]([O-])(=O)C1=CC=C(NC/2=C/C(=O)C3=CC=CC=C3C2=O)C=C1,,,UOOBTJHNCAWIEN,microphthalmia-associated transcription factor (MITF) Inhibitor,
NCGC00346954-01,OC1=CC=C(C(=C1)O)C2=CC=C(C=C2)C3=N[NH]C(=C3)NC4=CC=CC(=C4)CNC5CC5,TCS 2312,,JMEXWOPTERDPHI,Chk1 Inhibitor,CHEK1
NCGC00017248-10,CCCCCCCCCCCC/1=C(O)/C(=O)/C=C(O)\C1=O,Embelin,,IRSFLDGTOHBADP,X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors,XIAP
NCGC00093656-03,OC[C@H]1O[C@H](C[C@@H]1O)N2/C=C(/C=C/Br)C(=O)NC2=O,(E)-5-(2-Bromovinyl)-2'-deoxyuridine,,ODZBBRURCPAEIQ,Reverse Transcriptase Inhibitor,TERT
NCGC00016332-03,CC1=CC/2=C(C=C1C)N(C[C@@H](O)[C@@H](O)[C@@H](O)CO)C/3=N/C(=O)NC(=O)C3=N2,RIBOFLAVIN,,AUNGANRZJHBGPY,Vitamin,
NCGC00015610-18,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F,Leflunomide;HWA-486/RS-34821,,VHOGYURTWQBHIL,Jak inhibitor,JAK1
NCGC00016889-05,CN1\C(=C(\O)C2=C(C=CS2)[S+]1([O-])=O)C(=O)NC3=CC=CC=N3,TENOXICAM,,MHLVRGMNJBUIRL,non-steroidal antiinflammatory,
NCGC00015147-09,N\C(NCC1=CC=CC=C1)=N/C(=O)C2=NC(=C(N)N=C2N)Cl,Benzamil,,KXDROGADUISDGY,Epithelial Sodium Channels (ENaC) Blockers,SCNN1D
NCGC00018153-09,C\C=C(C1=CC=C(O)C=C1)\C(=C\C)C2=CC=C(O)C=C2,DIENESTROL,,NFDFQCUYFHCNBW,Estrogen Receptor (ER) Agonist,ESR1
NCGC00014911-01,CC(C)(O)\C=C/C(=O)[C@](C)(O)[C@H]1[C@H](O)C[C@]2(C)[C@@H]3C\C=C4/[C@@H](/C=C(/O)C(=O)C4(C)C)[C@]3(C)C(=O)C[C@@]12C,,cucurbitacin I;elatericin B;CIPLUS_215764;,NISPVUDLMHQFRQ,Jak2 inhibitor,JAK2
NCGC00181767-01,C2(O)=C(O)C=C(C(=O)C1=CC=C(C)C=C1)C=C2N(=O)=O,Tolcapone,"3,4-dihydroxy-4'-methyl-5-nitrobenzophenone;TOLCAPONE;Tasmar;3,4-dihydroxy-5'-methyl-5-nitrobenzophenone;Ro-40-7592;tolcapone;Ro 40-7592;ro 40-7592;Tolcapone;HS_1338;CIPLUS_213593;Roche brand of tolcapone;3,4-DIHYDROXY-4'-METHYL-5-NITROBENZOPHENONE;LS-91226;tolcaponum;RO-40-7592;",MIQPIUSUKVNLNT,catechol-O-methyltransferase (COMT),COMT
NCGC00346743-01,O.Cl.CCN(CC)CC1=CC2=C(C=C1)C=C(COC(=O)NC3=CC=C(C=C3)C(=O)NO)C=C2,ITF2357 (Givinostat),,YALNUENQHAQXEA,Histone Deacetylase (HDAC) Inhibitor,HDAC1
NCGC00015466-04,NCC1(CCCCC1)CC(O)=O,Gabapentin hydrochloride,HS_632;NCGC00016891-01;CI-945;LS-7194;Gabapentine;Gabapentin;Gabapentinum;Go 3450;1-(Aminomethyl)-cyclohexaneacetic acid;NCGC00095184-01;NCGC00095184-02;NCGC00015466-01;CIPLUS_3746646;Gabapentino;CIPLUS_183654;Gabapentin hydrochloride;1-(AMINOMETHYL)CYCLOHEXANEACETIC ACID;Neurontin;NCGC_Prestw-861;1-(aminomethyl)cyclohexaneacetic acid;(1-aminomethyl-1-cycloheptyl)acetic acid;gabapentin;GABAPENTIN;NCGC00021545-05;gabapentine;gabapentin ISTD;NCGC00021545-04;NCGC00021545-02;HS_996;3-methylgabapentin;gabapentinum;3-methyl gabapentin;,UGJMXCAKCUNAIE,Calcium Channels (Voltage-Gated) alpha2/delta-1/2 Subunit Ligand,
NCGC00250411-01,OC(=O)[C@H](C1CCCC1)C2=CC=C(OCC3=NC4=CC=CC=C4C=C3)C=C2,Veliflapon;BAY-X 1004,,ZEYYDOLCHFETHQ,5-lipoxygenase-activating (FLAP) inhibitor,ALOX5AP
NCGC00345798-01,CC[N]1C(=CC2=C3[N](C)C=NC3=C(NC4=N[N](C)C(=C4)C)N=C12)C(=O)N(C5CC5)C6CC6,BMS-911543,,JCINBYQJBYJGDM,Jak2 inhibitor,JAK2
NCGC00346554-01,COC1=CC2=C(C=C1)C=C(C=C2)C3=C(N=C([NH]3)C4=CC=C(C=C4)[S+](C)[O-])C5=CC=NC=C5,Tie2 kinase inhibitor,,SINQIEAULQKUPD,Tie-2 kinase inhibitor,TEK
NCGC00015924-13,CNCC(O)C1=CC=C(O)C=C1,OXEDRINE,,YRCWQPVGYLYSOX,alpha1-Adrenoceptor Agonists,ADRA1A
NCGC00346550-01,CC1=C(N=C(NC(=O)C2(CC2)C3=CC4=C(OC(F)(F)O4)C=C3)C=C1)C5=CC=CC(=C5)C(O)=O,VX-809,,UFSKUSARDNFIRC,CFTR Channel Modulator,CFTR
NCGC00247878-01,CCNC(=O)C1=NOC(=C1C2=CC=C(CN3CCOCC3)C=C2)C4=C(O)C=C(O)C(=C4)C(C)C,NVP-AUY922;AUY-922/VER-52296,,NDAZATDQFDPQBD,Heat Shock Protein 90 (hsp90) Inhibitor,HSP90AB1
NCGC00345084-01,ClC1=CC=C(CNC(=O)C[C@@H]2C\C=C/CCC(=O)O[C@@H](CNC2=O)C3=CC=CC=C3)C=C1,Robotnikinin,,DRDSZZCLAHXSAE,Hedgehog antagonist,SHH
NCGC00023193-04,F[C@@]([C@](C=C4)(C)C3=CC4=O)2[C@@H](O)C[C@]([C@](C5)([H])[C@@]([H])2CC3)(C)[C@@]1([C@](CO)=O)[C@@H]5OC(C)(C)O1,Triamcinolone acetonide,"NCGC00094800-01;NCGC00094800-02;CL-22353;Acetonide, Triamcinolon;Triamcinolone Acetonide;Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)-;SQ-9727;Azmacort;A, Kenacor;Triamcinolone acetonide acetate;Tricort4;Kenalog;CIPLUS_149383;Pevisone;Cinonide;LS-1692;Tricort 4;Triamcinolone acetonide;9A-FLUORO-11B,16A,17A,21-TETRAHYDROXYPREGNA-1,4-DIENE-3,20-DIONE 16,17-ACETONIDE;HS_1404;TRIAMCINOLONE ACETONIDE;Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)-, mixt. with 1-(2-((4-chlorophenyl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole mononitrate;Monacort;Kenacort A;CIPLUS_769193;flutone;Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)-, mixt. with 5,7-dichloro-8-quinolinol;Kenalog 40;9alpha-Fluoro-16alpha-hydroxyprednisolone 16alpha,17alpha-acetonide;Tricort-40;9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-acetonide;40, Kenalo;CIPLUS_769545;",YNDXUCZADRHECN,Glucocorticoid steroid,
NCGC00096077-05,CN1CCN(CC1)C/2=N/C3=CC=CC=C3NC4=C2C=C(C)S4,OLANZAPINE,,KVWDHTXUZHCGIO,Dopamine D2 Antagonist,DRD2
NCGC00344625-02,OC(=O)CNC(=O)\C1=C(/O)C2=CC=CC=C2N(CC3=CC=CC=C3)C1=O,,,CAOSCCRYLYQBES,Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors,HIF1A
NCGC00163492-04,C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O,Cerulenin,,GVEZIHKRYBHEFX,Fatty acid synthase inhibitor,FAS
NCGC00183878-01,O=C(O)C(C)c1cc2CC(=O)c3ccccc3Sc2cc1,Zaltoprofen,"CN 100;Zaltoprofenum;Zaltoprofen;CIPLUS_691922;CIPLUS_3889078;CN-100;Peon;10,11-dihydro-alpha-methyl-10-oxodibenzo(b,f)thiepin-2-acetic acid;zaltoprofenum;Zaltoprofeno;LS-61331;zaltoprofene;ZALTOPROFEN;Zaltoprofene;",MUXFZBHBYYYLTH,Cyclooxygenase Inhibitor,PTGS1
NCGC00024956-02,COC1=CC2=NC=NC(=C2C=C1OC)NC3=CC=CC(=C3)Br,,,LSPANGZZENHZNJ,EGFR (HER1; erbB1) Inhibitor,EGFR
NCGC00263176-01,NC1=C(Cl)C(=CC=N1)OC2=C(F)C=C(NC(=O)\C3=C\N\C=C(C3=O)\C4=CC=C(F)C=C4)C=C2,BMS-794833,,PDYXPCKITKHFOZ,VEGFR-2 Inhibitor,KDR
NCGC00094810-06,CC(=O)CC(C1=CC=CC=C1)C/2=C(O)/C3=CC=CC=C3OC2=O,WARFARIN,,PJVWKTKQMONHTI,"Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitor",VKORC1
NCGC00024415-39,COC1=CC=CC2=C1C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C(=O)CO)C(=C3C2=O)O,Doxorubicin;Adriamycin,DOXORUBICIN HCL,AOJJSUZBOXZQNB,DNA Topoisomerase II Inhibitors,TOP2A
NCGC00346938-01,CCOC1=CC2=C(C(=C1OCC)F)C(=N)N(CC(=O)C3=CC(=C(OC)C(=C3)C(C)(C)C)N4CCOCC4)C2,E5555,,QWKAUGRRIXBIPO,Thrombin Inhibitors,
NCGC00164624-03,CC(C)(C)C(=O)OCO[P](=O)(COCC[N]1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C,"Adefovir Dipivoxil (Preveon, Hepsera)",,WOZSCQDILHKSGG,DNA Polymerase Inhibitors,
NCGC00263211-01,CCOC1=CC=C(NC2=NC(=CS2)C3=C(C)N=C4C=CC=C[N]34)C=C1,JK 184,,ROYXIPOUVGDTAO,Alcohol dehydrogenase 7 inhibitor,ADH7
NCGC00263125-01,COC1=CC=C(COC2=C(OC)C=C3C(=C2)OC(=O)C4=C3C=CC(=C4)C(C)O)C=C1,SG-00529;Palomid-529,,YEAHTLOYHVWAKW,mTORC1/2 inhibitor,FGF2
NCGC00179511-04,CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC2=CC=CC=C2,Racecadotril (Acetorphan),,ODUOJXZPIYUATO,"Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors",
NCGC00189075-01,FC1=C(F)C=CC(C(NOC[C@H](O)CO)=O)=C1NC2=CC=C(I)C=C2F,PD-0325901;PD-325901,PD-0325901,SUDAHWBOROXANE,MEK inhibitor,MAP2K1
NCGC00095709-06,CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C,TANSHINONE IIA,,HYXITZLLTYIPOF,TNF-alpha Production Inhibitors,TNF
NCGC00346686-01,O=C1NC(=O)[C@H]([C@@H]1C2=C[NH]C3=C2C=CC=C3)C4=C[N]5CCCC6=CC=CC4=C56,ARQ 197 (Tivantinib),,UCEQXRCJXIVODC,HGFR (MET; c-Met) Inhibitor,MET
NCGC00346956-01,CNC(=O)C1=CC=C(NC2=CC(=C3C=C[NH]C3=N2)NC4=C(C=CC=C4)[S+]([O-])(=O)C(C)C)N=C1,HMSL10015,,CVHWGWOPQUQFLD,Bcr-Abl inhibitor,ABL1
NCGC00167403-03,C[N]1N=C(C)C=C1NC2=NC=C3CN(C(=O)N(C)C3=N2)C4=C(C)C=CC(=C4)NC(=O)C5=CC=CC(=C5)C(F)(F)F,Pluripotin,,NBZFRTJWEIHFPF,Dual RASGAP/Erk inhibitor,RASAL1
NCGC00093356-08,NC\1=N\C(=O)N(\C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O,Cytarabine,,UHDGCWIWMRVCDJ,DNA Polymerase Inhibitors,
NCGC00167496-02,CN(C)C1=CC2=C(C=C1)N=C3C=CC(=CC3=[S+]2)N(C)C,,"Methylene Blue Hydrate;Chromosmon;3,7-bis(Dimethylamino)phenazathionium chloride;Phenothiazin-5-ium, 3,7-bis(dimethylamino)-, chloride;Urolene Blue;CIPLUS_682274;L+ ffler's alkaline methylene blue stain solution;chlorure de methylthioninium;Methylthioninium Chloride;Methylene Blue - potassium hydroxide solution;Methylene Blue N;Blue N, Methylen;Methylene Blue zinc chloride double salt monohydrate;Blue, Swis;Methylene blue hydrate;CIPLUS_148989;AB02540576-01;Ehrlich's reagent III;Cloruro de metiltioninio;Methylene blue;METHYLTHIONINIUM CHLORIDE;Phenothiazin-5-ium, 3,7-bis(dimethylamino)-, chloride, trihydrate;Methylene Blue solution alkaline according to L+ ffler;Yamamoto Methylene Blue B;Azure II;Methylene Blue zinc chloride double salt;Blue, Methylen;methylthioninii chloridum;Chlorure de methylthioninium;LS-268;Methylene Blue solution;Basic Blue 9;Methylene Blue;Taylor's Blue;1,9-Dimethyl-Methylene Blue;Tetramethylthionine chloride;Methylene blue trihydrate;Methylthioninii chloridum;LS-1619;METHYLENE BLUE;Methylene Blue hydrate;3,7-bis(dimethylamino)phenothiazin-5-ium chloride trihydrate;N, Methylene Blu;CIPLUS_657740;",RBTBFTRPCNLSDE,antimalarial agents,
NCGC00263113-01,CNC(=O)N1\N=C(\C2=CC=C(N)C=C2)C3=CC4=C(OCO4)C=C3CC1C,GYKI-53655;LY-300168,,SMGACXZFVXKEAX,AMPA receptor antagonist,
NCGC00186030-03,O=C1NC(=O)C(/S1)=C/C2=CC=C3N=CC=NC3=C2,AS-605240,,SQWZFLMPDUSYGV,PI3K gamma Inhibitor,PIK3CG
NCGC00188382-04,CC(NCC1=CC=C2N(CC(C)(C)O)\C(NC2=C1)=N\C(=O)C3=CC=C(S3)C4=C[NH]N=C4)C(C)(C)C,NCGC00188382-01,,MUAICZWSFWUFNA,ITK inhibitor,ITK
NCGC00016438-05,CNNCC1=CC=C(C=C1)C(=O)NC(C)C,Procarbazine hydrochloride (Matulane),,CPTBDICYNRMXFX,DNA Alkylating Agent,
NCGC00024995-10,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)C2[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C6=CC=CC=C6)C7=CC=CC=C7)\C(=C1/C5(C)C)C,PACLITAXEL,,RCINICONZNJXQF,Tubulin depolymerization inhibitor,TUBB
NCGC00249684-01,NC(=O)N(C1=NC(=C(C=C1)C(N)=O)C2=C(F)C=C(F)C=C2)C3=C(F)C=CC=C3F,VX-702;KVK-702,,FYSRKRZDBHOFAY,p38 MAPK Inhibitor,MAPK14
NCGC00263167-02,CC(C)(C)C1=CN=C(CSC2=CN=C(NC(=O)C3CCNCC3)S2)O1,SNS-032 (BMS-387032),,OUSFTKFNBAZUKL,"CDK2,7,9 Inhibitor",CDK2
NCGC00347904-01,[O-][N+](=O)C1=CC(=CC=C1)C2=CC=C(OCC(CCC3=CC=NC=C3)N4C(=O)CSC4=O)C=C2,AZ 11645373,,VQEHBLGYANQWEA,P2X7 Receptor Antagonist,P2RX7
NCGC00025176-01,CCOC(=O)C1=CN=C[N]1[C@H](C)C2=CC=CC=C2,Etomidate,"LS-78232;etomidate;1H-Imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (R)-;Amidate;1H-Imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (+-)-;R 2649;ethnor;CIPLUS_3887320;Ethomidate;R16659;R-26490;ETOMIDATE SULFATE;HS_569;CIPLUS_177855;etomidatum;ETHYL 1-(1-PHENYLETHYL)IMIDAZOLE-5-CARBOXYLATE, D-;Radenarkon;ABSELE;NCGC00025176-01;Hypnomidate;Etomidate;ETOMIDATE;CIPLUS_778814;Etomidato;hypnomidate;CIPLUS_775429;NCGC_Prestw-1041;Etomidatum;R2649;CIPLUS_766535;NCGC00016817-01;",NPUKDXXFDDZOKR,GABAA Receptor Modulator,GABRA1
NCGC00346621-01,NC1(CCN(CC1)C2=C3C=C[NH]C3=NC=N2)CC4=CC=C(Cl)C=C4,CCT128930,,RZIDZIGAXXNODG,PKB/Akt Inhibitor,AKT1
NCGC00345024-01,O=C/1NC(=O)C(=C1C2=CN=C3C=CC=C[N]23)/C4=C[N]5CCN(CC6=C5C4=CC=C6)C(=O)N7CCOCC7,,,INJUVNWOFHYUIN,GSK-3 inhibitor,GSK3B
NCGC00242249-02,CN(C)CCOC1=CC=C(C=C1)C2=NC(=C([NH]2)C3=CC4=C(C=C3)\C(CC4)=N\O)C5=CC=NC=C5,SB590885,,MLSAQOINCGAULQ,Raf kinase B Inhibitor,BRAF
NCGC00187983-01,O=C(NCC1=CC=CC=C1)C2=CSC(=N2)NC3=CC=NC=N3,,,DOBKQCZBPPCLEG,ROCK Inhibitor,ROCK1
NCGC00263967-03,O.O.O.[Na+].NCCCC(O)([P](O)(O)=O)[P](O)(O)=O,Alendronate (Fosamax),,OGSPWJRAVKPPFI,Protein Tyrosine Phosphatase (PTP) Inhibitors,PTP4A1
NCGC00241102-02,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)[N]3C4=C(C=CC=C4)C5=C3C6=C(C7=CC=CC=C7[N]26)C8=C5CNC8=O)N(C)C(=O)C9=CC=CC=C9,PKC 412,,BMGQWWVMWDBQGC,PKC/flt3 inhibitor,PRKCA
NCGC00016623-06,NC(=N)NC(=N)N1CCOCC1,Moroxydine,,KJHOZAZQWVKILO,antiinfluenza drug,
NCGC00167490-02,CCCCN(CCCC)CC(O)C1=C2C3=CC=C(Cl)C=C3C(=C/C4=CC=C(Cl)C=C4)/C2=CC(=C1)Cl,Lumefantrine,,DYLGFOYVTXJFJP,antimalarial agents,
NCGC00345813-01,COC1=CC=C(C=C1)/C2=C(O)/C(=O)C3=C(O)C=C(O)C(=C3O2)CC=C(C)C,Icaritin,,TUUXBSASAQJECY,flavone,
NCGC00263121-01,CCCCCCCC1=CC=C(CCC2=CC=CC(=C2C(O)=O)O)C=C1,MG-149,,WBHQYBZRTAEHRR,Histone acetyltransferase inhibitor,HAT1
NCGC00161825-02,OC(=O)CC1=CC=CC(=C1)OCCCN(CC(C2=CC=CC=C2)C3=CC=CC=C3)CC4=CC=CC(=C4Cl)C(F)(F)F,GSK-3965;GW-3965?,,NAXSRXHZFIBFMI,ABCA1 Expression Enhancer,ABCA1
NCGC00016258-07,C\C1=C\C(=O)C2=C(C=CC=C2)C1=O,MENADIONE,,MJVAVZPDRWSRRC,Cell Division Cycle CDC25 Phosphatase Inhibitor,CDC25
NCGC00163553-02,CN1C2N(CCC3=C2[NH]C4=C3C=CC=C4)C(=O)C5=C1C=CC=C5,Evodiamine (Isoevodiamine),,TXDUTHBFYKGSAH,Alkaloid,
NCGC00246971-03,OC[C@H]1O[C@@H](OC2=CC(=CC(=C2)/C=C/C3=CC=C(O)C=C3)O)[C@H](O)[C@@H](O)[C@@H]1O,Polydatin(Piceid),,HSTZMXCBWJGKHG,ICAM1 Expression Inhibitors,
,,,,,VCAM1 Expression Inhibitors,ICAM1
NCGC00178913-04,CC/1=C(\O)C(=O)\C=C2/C1=C/C=C3\[C@@]2(C)CC[C@@]4(C)[C@@H]5C[C@@](C)(CC[C@]5(C)CC[C@]34C)C(O)=O,Celastrol,,KQJSQWZMSAGSHN,Heat Shock Protein 90 (hsp90) Inhibitor,HSP90AB1
NCGC00346711-01,C[C@]\12CC[C@H](O)CC1=C/CC3C2CC[C@@]\4(C)C3C\C=C4[N]5C=NC6=C5C=CC=C6,Galeterone (TOK-001),,PAFKTGFSEFKSQG,Selective Androgen Receptor Modulators (SARM)?,AR
NCGC00346506-01,NC/1=N/[C@]2(COC[C@H]2CS1)C3=CC(=CC=C3F)NC(=O)C4=NC=C(F)C=C4,LY2886721,,NIDRNVHMMDAAIK,beta-Secretase 1/2 (BACE1/2) Inhibitors,BACE1
NCGC00345539-02,OCCN(CCC1=C[NH]C2=C1C=CC=C2)CC3=CC=C(\C=C\C(=O)NO)C=C3,"LAQ824 (NVP-LAQ824, Dacinostat)",,BWDQBBCUWLSASG,HDAC Inhibitor,HDAC1
NCGC00025357-01,O=C(NCCO[N+]([O-])=O)c1cccnc1,Nicorandil,"LS-130673;CIPLUS_3749723;NCGC00025357-02;NCGC00025357-01;CIPLUS_186802;3-Pyridinecarboxamide, N-(2-(Nitroxy)ethyl)-;Sigmart;Nicorandilum;NICORANDIL;SG-75;nicorandil;Nicorandil;nicorandilum;N-(2-HYDROXYETHYL)NICOTINAMIDE NITRATE;",LBHIOVVIQHSOQN,K(ATP) Channel Activators,
NCGC00344512-01,COC1=CC=CC2=C1[C@]34CCN(CC5CC5)[C@H](C2)[C@@]3(CCC(=O)C4)OC,Cyprodime,,INUCRGMCKDQKNA,Opioid receptor antagonist,
NCGC00346600-01,C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5C/C=C6/C[C@H](CC[C@]6(C)[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O,Dioscin (Collettiside III),,VNONINPVFQTJOC,peroxiredoxins (PRDX) 1/6,PRDX1
NCGC00263193-01,COC1=CC(=CC=C1NC(=O)NC(C)C2=NC=CS2)OC3=CC=NC4=CC(=C(OC)C=C34)OC,KI-20227,,SHPFDGWALWEPGS,CSF1R (c-FMS) Inhibitor,CSF1R
NCGC00025323-01,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O,Ubenimex;NK-421,"NK-421;ubenimexum;N-[(2S,3R)-3-Amino-2-hydroxy-4-phenylbutyryl]-L-leucine hydrochloride;Ubenimex;N-((2S,3R)-3-AMINO-2-HYDROXY-4-PHENYLBUTANOYL)-LEUCINE;NCGC00015167-02;NCGC00162164-01;(3-amino-2-hydroxy-4-phenylbutanoyl)-L-leucine;([2S,3R]-3-Amino-2-hydroxy-4-phenylbutanoyl)-L-leucine;NCGC00093881-01;bestatin, (D-Leu)-(R-(R*,R*))-isomer;ubenimex;BESTATIN;UBENIMEX;bestatin, (L-Leu)-(S-(R*,R*))-isomer;LS-87810;([2R,3R]-3-Amino-2-hydroxy-4-phenylbutanoyl)-L-leucine;LS-176149;CIPLUS_214436;LS-176147;LS-176148;LS-176145;LS-176146;LS-176144;bestatin, (D-Leu)-(R-(R*,S*))-isomer;bestatin, (D-Leu)-(S-(R*,S*))-isomer;NCGC00025323-03;NCGC00093685-01;NCGC00025323-02;NCGC00025323-01;N-[(2S,3R)-3-Amino-2-hydroxy-4-phenylbutyryl]-L-leucine;Bestatin hydrochloride;NCGC00015167-01;bestatin;Epibestatin hydrochloride;Bestatin;nk 421;bestatin, (L-Leu)-(R-(R*,S*))-isomer;([2R,3R]-3-Amino-2-hydroxy-4-phenylbutanoyl)-L-leucine hydrochloride;bestatin, (L-Leu)-(R-(R*,R*))-isomer;",VGGGPCQERPFHOB,Leukotriene A4 Hydrolase Inhibitor,LTA4H
NCGC00263107-01,CC[C@@H](C)[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)C2=CC=NO2)C(=O)N3CCC4(CC3)CCC5=C4C=CC=C5,GB 83,,ZXMXAOYWSLZLQM,PAR2 Antagonist,PAR2
NCGC00263083-01,CCC(CC)C(C)C1(CCCCC1)C(=O)NC2=C(SC(=O)C(C)C)C=CC=C2,Dalcetrapib,,AMHOWMHYRSJEFV,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,CETP
NCGC00163474-05,C[C@@H]1CN[C@H]2[C@@H](C)[C@@]\3(CC[C@H]\4[C@@H]5C/C=C6/C[C@@H](O)CC[C@]6(C)[C@H]5CC4=C3C)O[C@@H]2C1,Cyclopamine,,QASFUMOKHFSJGL,Smo Receptor Antagonist,SMO
NCGC00164622-04,C[C@@H](C1=NC=NC=C1F)[C@](O)(C[N]2C=NC=N2)C3=CC=C(F)C=C3F,Voriconazole,,BCEHBSKCWLPMDN,Lanosterol 14alpha-demethylase Inhibitors,CYP51A1
NCGC00185741-01,NC(CC1=C(N)C(C(C2=CC=CC=C2)=O)=CC=C1)=O,Nepafenac,,QEFAQIPZVLVERP,Cyclooxygenase-2 Inhibitor,PTGS2
NCGC00015004-11,ClC1=CC\2=C(OC3=C(C=CC=C3)\N=C2N4CCNCC4)C=C1,,AMOXAPINE,QWGDMFLQWFTERH,5-HT2A Antagonists?,HTR2A
NCGC00241113-01,CC1=C(CCC(O)=O)C(=C([NH]1)\C=C\2C(=O)NC3=CC=CC=C23)C,,,NHFDRBXTEDBWCZ,VEGFR-2 Inhibitor,FLT1
NCGC00024976-04,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)[N]2C=NC3=C2N=C(NCCC4=CC=C(CCC(O)=O)C=C4)N=C3N,CGS 21680 HCl,,PAOANWZGLPPROA,Adenosine A2 Antagonist,ADORA2
NCGC00250375-02,C[C@]1(O)CC(C1)C2=NC(=C3[N]2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6,Linsitinib;OSI-906/ASP-7487,,PKCDDUHJAFVJJB,IGF-1R Inhibitors,IGFR1
NCGC00345830-01,CN1C(=O)C(=C\C2=C1N=C(NC3=CC=CC(=C3)C(O)=O)N=C2)/C4=C(Cl)C=CC=C4Cl,PD173955-Analogue 1,,RBURTLAMOSHNGX,cSRC inhibitor,SRC
NCGC00016101-09,CC1=CC(=CC(=C1C\C2=N\CCN2)C)C(C)(C)C,XYLOMETAZOLINE HYDROCHLORIDE,,HUCJFAOMUPXHDK,alpha2A/B/C-Adrenoceptor Agonists,ADRA2A
NCGC00346498-01,CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]3C[C@H](CN3C1=O)OC(=O)N4CC5=C(C4)C(=CC=C5)F)C(=O)N[S+]([O-])(=O)C6CC6,Danoprevir,,SNMGQXHJQOQNLC,HCV Protease Inhibitor,
NCGC00167519-04,OC(=O)CC[N]1C2=C(C[C@@H](CC2)N[S+]([O-])(=O)C3=CC=C(F)C=C3)C4=CC=CC=C14,Ramatroban,,YITXQYNJJXYNAS,prostaglandin D2 CRTH2 inhibitor,PTGDR2
NCGC00346957-01,COC1=C(NC2=NC(=C(Cl)C(=N2)N)NC3=C(C=CC=C3)[S+]([O-])(=O)C(C)C)C=CC(=C1)N4CCC(CC4)C(N)=O,HMSL10016,,SZYMZPYKPCRFDE,EGFR (HER1; erbB1) Inhibitor,EGFR
NCGC00263156-02,COC(=O)C1=CC=C\2C(=C1)NC(=O)C2=C(\NC3=CC=C(C=C3)N(C)C(=O)CN4CCN(C)CC4)C5=CC=CC=C5,BIBF1120 (Vargatef),,XZXHXSATPCNXJR,VEGFR-1/2/3 Inhibitor,FLT1
NCGC00346572-01,CC(C)C1=CC(=C(CC(=O)N[S+]([O-])(=O)OC2=C(C=CC=C2C(C)C)C(C)C)C(=C1)C(C)C)C(C)C,Avasimibe (CI-1011),,TTWBTKWXGCWCDH,Cyp2C9 Inhibitor,CYP2C9
NCGC00025109-01,CN(C)C1=CC=CC(=C1)C(=O)NC2=CC(=C(C)C=C2)NC(=O)C3=CC=C(O)C=C3,ZM 336372,NCGC00025109-03;N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide;ZM336372;ZM-336372;ZM 336372;NCGC00025109-02;NCGC00025109-01;,PYEFPDQFAZNXLI,Raf Kinase Inhibitors,BRAF
NCGC00346462-01,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2\C=C/C(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC3=CC=CC=C3,PSI-7977,,TTZHDVOVKQGIBA,RNA-Directed RNA Polymerase Inhibitor,
NCGC00345843-01,CC\1=C(C(=O)N(\C=C1)C2=CC=C(C=C2)C3=NC=CO3)/C4=CC5=CN=C(N)N=C5C=C4,AMG-25  ,,IGFSMGCBFTXTJK,KIT inhibitor,KIT
NCGC00025029-05,NC(/SC1=CC=CC=C1N)=C(C#N)\C(C#N)=C(N)\SC2=CC=CC=C2N,U0126-EtOH,,DVEXZJFMOKTQEZ,Mek 1/2 inhibitor,MAP2K1
NCGC00167491-02,NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1,Lenalidomide;CC-5013;ENMD-0997;Revlimid,,GOTYRUGSSMKFNF,TNF-alpha Production Inhibitor,TNF
NCGC00093976-06,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]2C[C@@](O)(CC3=C(O)C4=C(C(=C23)O)C(=O)C5=C(C=CC=C5)C4=O)C(C)=O,,,XDXDZDZNSLXDNA,DNA Topoisomerase II Inhibitors,TOP2A
NCGC00346890-01,C[N+](C)([O-])CCNC1=CC=C(NCC[N+](C)(C)[O-])C2=C1C(=O)C3=C(C(=CC=C3O)O)C2=O,Banoxantrone dihydrochloride,,YZBAXVICWUUHGG,DNA Topoisomerase II Inhibitors,TOP2A
NCGC00241111-02,FC1=CC=C(SC/2=N/N3\C=N/C(=O)/C(=C3/C=C2)C4=C(Cl)C=CC=C4Cl)C(=C1)F,VX-745,,VEPKQEUBKLEPRA,p38 MAPK Inhibitor,MAPK14
NCGC00250408-01,COC1=C(N[S+]([O-])(=O)C2=C(F)C=C(F)C=C2)C=C(C=N1)C3=CC=C4N=CC=C(C5=CN=NC=C5)C4=C3,GSK 2126458;2126458/GSK-458,,PDQIXVPYENBUGM,PI3Kalpha/beta/delta/gamma Inhibitor,PIK3CA
NCGC00250405-01,COC1=C(CO)C=C(C=C1)C2=CC=C3C(=N2)N=C(N=C3N4CCOC[C@@H]4C)N5CCOC[C@@H]5C,AZD-8055,,KVLFRAWTRWDEDF,mTORC1/2 Inhibitor,MTOR
NCGC00250380-01,CN1\C=N/C2=CC=C(NC3=CC(=CC=C3C)NC(=O)C4=CC(=CC=C4)C(C)(C)C#N)C=C2C1=O,AZ-628,,ZGBGPEDJXCYQPH,Raf kinase B/C Inhibitor,BRAF
NCGC00159508-05,[O-]C(=O)C1=C(C(=C(Cl)C(=C1Cl)Cl)Cl)C/2=C/3\C=C(I)/C(=O)/C(=C3OC4=C2C=C(I)C(=C4I)[O-])I,Rose Bengal disodium,,VDNLFJGJEQUWRB,Free radical formation,
NCGC00015442-16,F\C1=C\NC(=O)NC1=O,FLUOROURACIL,,GHASVSINZRGABV,Pyrimidine Antagonists,
NCGC00023212-07,C\C1=C\N(C(=O)NC1=O)[C@H]2\C=C/[C@@H](CO)O2,Stavudine,"2',3'-didehydro-3'-deoxythymidine;Estavudina;BMY 2785;Stavudine;Stavudine, Monosodium Salt;2',3'-Didehydro-3'-deoxythymidine;Zerit;NCGC00023212-08;NCGC00023212-09;NCGC00023212-05;BMY-27857;LS-1160;HS_1529;stavudinum;STAVUDINE;Bristol-Myers Squibb Brand of Stavudine;Thymidine, 2',3'-didehydro-3'-deoxy-;3'-DEXOYTHYMIDINE-2'-ENE;Estavudina (INN-Spanish);AB08007115-01;2',3'-Anhydrothymidine;Stavudine (2',3'-Didehydro-3'-Deoxythymidine);Stavudinum;2',3'-Didehydro-2',3'-dideoxythmidine;Sanilvudine;stavudine;CIPLUS_161328;stavudine (d4T);1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine;Dideoxydidehydrothymidine;D4T (2',3'-Didehydro-3'-deoxythymidine);Bristol-Myers Brand of Stavudine;2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE;LS-172902;NCGC00015325-01;AB02509573-01;BMY2785;2',3' Didehydro 3' deoxythymidin;",XNKLLVCARDGLGL,Reverse Transcriptase Inhibitor,TERT
NCGC00024728-01,CC(OC1=CC=C(O)C=C1)([P](O)(O)=O)[P](O)(O)=O,"L-690,330","L690330;Phosphonic acid, (1-(4-hydroxyphenoxy)ethylidene)bis-;L 690330;1-(4-hydroxyphenoxy)ethylenebisphosphonic acid;L-690,330;CIPLUS_708787;NCGC00024728-01;L-690330;1-(p-hydroxyphenoxy)ethylenebisphosphonate;",JKOCAAWWDVHWKB,inositol monophophatase inhibitor,INPPL1
NCGC00092276-06,C[C@@H](N)C1CC[C@@H](CC1)C(=O)NC2=CC=NC=C2,Y-27632,,IYOZTVGMEWJPKR,"ROCK 1, ROCK 2 Inhibitor",ROCK1
NCGC00183036-02,CC/1=C(/N2[C@H](SC1)[C@H](NC(=O)[C@H](N)\C3=C\C\C=C/C3)C2=O)C(O)=O,Cephradine (Velosef),,RDLPVSKMFDYCOR,Cephalosporin antibiotic,
NCGC00164615-03,CC1SC/2=C(C(O)=O)/C(=O)C3=CC(=C(C=C3N12)N4CCN(CC4)C\C5=C(C)\OC(=O)O5)F,Prulifloxacin,,PWNMXPDKBYZCOO,Antibacterial,
NCGC00346549-01,ClC1=CC=C(C=C1)C2(CCNCC2)C3=CC=C(C=C3)C4=C[NH]N=C4,AT7867,,LZMOSYUFVYJEPY,Akt1/2/3 Inhibitor,AKT1
NCGC00016364-03,CN(C)CC[C@H](C1=CC=C(Cl)C=C1)C2=CC=CC=N2,CHLORPHENIRAMINE (S) MALEATE,,SOYKEARSMXGVTM,Histamine H1 Receptor Antagonists,HRH1
NCGC00346553-01,CC(C)C1=C2N=C(NCCCCCCN)C=C(NCC3=CC=CC=C3)[N]2N=C1,BS-181 HCl,,DNYBIOICMDTDAP,CDK7 Inhibitor,CDK7
NCGC00346524-01,CO[C@H]1CCC(O[C@@H]1C)O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]4O[C@@](O)(CO)[C@H](C)C[C@@H]4C)[C@@H]2C)[C@]5(C)CC[C@]6(C[C@H](O)[C@@H](C)[C@H](O6)[C@@H](C)/C=C(C)/C(=O)[C@H](C)C[C@H](C)C(=O)O[Na])O5,Nanchangmycin,,XMAIRYYXDCNFKP,Polyether Antibiotic,
NCGC00095164-05,CCCC1=CC(=CC=N1)C(N)=S,PROTIONAMIDE,,VRDIULHPQTYCLN,tuberculosis treatment,
NCGC00092361-06,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O,Prostaglandin E2,,XEYBRNLFEZDVAW,prostaglandin,
NCGC00161602-05,C[C@@H]1[C@H]\2[C@H](O)[C@H]3[C@H](N(C)C)\C(=C(C(N)=O)/C(=O)[C@@]3(O)\C(=C2C(=O)C4=C(O)C=CC=C14)O)O,DOXYCYCLINE HYDROCHLORIDE,,JBIWCJUYHHGXTC,Matrix Metalloproteinase Inhibitors,MMP1
NCGC00016777-07,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(O)C(=C2)C(C)(C)C)C(C)(C)C,PROBUCOL,,FYPMFJGVHOHGLL,ABCA Modulator?,
NCGC00016978-05,CCOC1=C(C=CC(=C1)CC(=O)N[C@@H](CC(C)C)C2=C(C=CC=C2)N3CCCCC3)C(O)=O,Repaglinide,,FAEKWTJYAYMJKF,Insulin Secretagogues,
NCGC00093985-10,CC1NC2=CC(=C(C=C2C(=O)N1C3=C(C)C=CC=C3)[S+](N)([O-])=O)Cl,METOLAZONE,,PFIJIICFSMRWEO,Carbonic Anhydrase Type VII Inhibitor,CA7
NCGC00091104-05,COC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CC(O)=O,ASPARTAME,,IAOZJIPTCAWIRG,synthetic sugar substitute,
NCGC00346822-01,OC1=CC=C(C=C1)C/2=C/C3=C(OC2)C=C(O)C=C3,Phenoxodiol,,ZZUBHVMHNVYXRR,Sphingosine Kinase 1 (SphK1) Inhibitors,SPHK1
NCGC00167487-01,O=S(=O)(C[C@](C)(O)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F)c2ccc(F)cc2,Bicalutamide,"4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide;CIPLUS_193420;ICI 176334;ICI-176,334;ICI-176334;AstraZeneca brand of bicalutamide;0   Casodex;Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+-)-;Cosudex;BICALUTAMIDE;Casodex;Bicalutamide (Casodex);HS_262;(2RS)-4'-CYANO-3-(4-FLUOROPHENYL-SULPHONYL)-2-HYDROXY-2-METHYL-3'-(TRIFLUOROMETHYL)PROPIONANILIDE;bicalutamide;Astra brand of bicalutamide;NCGC00164635-01;Bicalutamide;bicalutamidum;Zeneca brand of bicalutamide;LS-119125;",CMPOAZJLBGOPQD,Androgen Receptor Antagonist,AR
NCGC00164550-01,O=S(CC(NC\C=C/COC2=NC=CC(CN3CCCCC3)=C2)=O)CC1=CC=CO1,Lafutidine,lafutidine;N-(4-(4-piperidinylmethyl)pyridyl-2-oxy)-(Z)-butenyl-2-(furfurylsulfinyl)acetamide;Lafutidine;FRG 8813;Protecadin;NCGC00164550-01;lafutidinum;LAFUTIDINE;FRG-8813;LS-9648;N-(4-(4-piperidinylmethyl)pyridyl-2-oxy)butenyl-2-(furfurylsulfinyl)acetamide;CIPLUS_207982;n-(4-(4-piperidinylmethyl)pyridyl-2-oxy)butenyl-2-(furfurylsulfinyl)acetamide;,KMZQAVXSMUKBPD,Histamine H2 Receptor Antagonists,HRH2
NCGC00025341-01,COC(=O)C\1=C(C)\N\C(=C(/C1C2=CC=CC3=NON=C23)C(=O)OC(C)C)C,Isradipine,"PN 200-110;isradipinum;Isradipine, (R)-Isomer;AW-200-110 N;Isaradipine;CIPLUS_741035;Isradipine, (+-)-Isomer;Isradipine;PN 20503;ISOPROPYL 4-(2,1,3-BENZOXADIAZOL-4-YL)-1,4-DIHYDRO-5-METHOXYCARBONYL-2,6-DIMETHYL-3-PYRIDINECARBOXYLATE;NCGC00016931-01;LS-177809;PN-200-110;NCGC00025341-01;Isradipine, (S)-Isomer;ISRADIPINE;LS-177810;CIPLUS_191160;4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester;PN 205 03;PN-205-034;PN-205-033;LS-131190;LS-177211;PN 205-034;PN 205-033;CIPLUS_736058;DynaCirc;PN20503;3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester;NCGC_Prestw-1021;isradipine;Dynacirc;Lomir;",HMJIYCCIJYRONP,Calcium Channel Blocker,
NCGC00263210-01,CCOC1=C(OCC)C(=CC(=C1)C(=O)NC2=CC(=C(Cl)C=C2)C3=NC4=C([NH]3)C=CC=C4)OCC,SANT-2,,VQOJFGFKIVFMDH,Smoothened (Smo) Receptor Antagonist,SMO
NCGC00347279-01,C1CO[C@@H](C1)CNC2=NC=NC3=C2C(=C(O3)C4=CC=CC=C4)C5=CC=CC=C5,AIM-100,,XNFHHOXCDUAYSR,ACK1/TNK2 Inhibitor,TNK2
NCGC00017376-10,COC1=CC=C2C[C@@H]3N(C)CCC4=C3C(=C(OC)C(=C4)OC)OC5=C(OC)C=C6CCN(C)[C@@H](CC7=CC=C(OC1=C2)C=C7)C6=C5,Tetrandrine (Fanchinine),,WVTKBKWTSCPRNU,Calcium Channel Blocker,
NCGC00247877-01,COC1=C(C)C=NC(=C1C)C[N]2C=NC3=C(Cl)N=C(N)N=C23,CNF-2024;BIIB-021,,QULDDKSCVCJTPV,Heat Shock Protein 90 (hsp90) Inhibitor,HSP90AB1
NCGC00347943-01,OC(=O)CCNC1=NC(=NC(=C1)N2CCC3=CC=CC=C3CC2)C4=NC=CC=C4,,,AVZCPICCWKMZDT,H3K27 Histone Demethylases UTX and JMJD3 Inhibitor,
NCGC00015332-04,COC1=CC=C(C=C1)C2SC3=C(C=CC=C3)N(CCN(C)C)C(=O)C2OC(C)=O,,"L-cis-DILTIAZEM;NCGC00016818-01;d-cis-Diltiazem;Aldizem;LS-40510;CIPLUS_746434;LS-40513;CRD-401;NCGC00024309-06;NCGC00024309-02;Hydrochloride, Diltiaze;NCGC00024309-04;CIS-3-(ACETYLOXY)-5-(2-(DIMETHYLAMINO)ETHYL)-2,3-DIHYDRO-2-(4-METHOXYPHENYL)-1,5-BENZOTHIAZEPIN-4(5H)-ONE, D-;NCGC00024309-05;DILTIAZEM HYDROCHLORIDE;diltiazemum;NCGC00163133-01;NCGC00163133-02;Diltiazemum;Cardil;TIAZAC;NCGC00095200-01;Diltiazem malate;(+)-cis-Diltiazem hydrochloride;NCGC00095200-02;NCGC_Prestw-134;Tiamate;8   Diltiazem Hcl;CIPLUS_3741740;Diltiazem;DILTIAZEM MALATE;CIPLUS_205107;Dilacor XR;Diltiazem Hydrochloride;(2S,3S)-(+)-cis-3-Acetoxy-5-(2-dimethylaminoethyl)-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one hydrochloride;CIPLUS_180243;DILTIAZEM;CIPLUS_775262;HS_466;Cardizem;HS_469;CRD 40;CRD40;NCGC00093768-01;CIPLUS_668872;LS-173219;CIPLUS_788008;NCGC00015332-01;Dilren;Malate, Diltiaze;HS_253;Diltiazem hydrochloride;diltiazem;1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)-;TIAMATE;Diltiazem Malate;Dilzem;",HSUGRBWQSSZJOP,L-type Ca2+ channel blocker,
NCGC00091057-06,COC1=C(O)C=CC(=C1)[C@H]2OC3=C(O[C@@H]2CO)C=CC(=C3)[C@H]4OC5=C(C(=CC(=C5)O)O)C(=O)[C@@H]4O,Silibinin (Silybin),,SEBFKMXJBCUCAI,P-Glycoprotein (MDR-1) Inhibitor,
NCGC00091253-07,COC1=CC(=C(C=O)C=C1OC)OC,ASARYLALDEHYDE,,IAJBQAYHSQIQRE,Cyclooxygenase-2 Inhibitor,PTGS2
NCGC00346953-01,N#CC(C1=NC2=CC=CC=C2S1)C3=CC=NC(=N3)NCCC4=CC=CN=C4,JNK Inhibitor V,,RCYPVQCPYKNSTG,JNK Inhibitor,MAPK8
NCGC00181111-01,O=C(C3=CC=C(C(O)=O)C=C3)NC1=CC2=C(C(C)(C)CCC(C)2C)C=C1,Tamibarotene,"Tamibarotene;CIPLUS_685490;tamibarotenum;TAMIBAROTENE;Am80;Benzoic acid, 4-(((5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino)carbonyl)-;AM-80;4-((5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl)benzoic acid;Amnoid;tamibarotene;Am 80;",MUTNCGKQJGXKEM,Retinoid RAR Agonists?,RARB
NCGC00161630-02,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=CC=C3\C(=C(NC(=O)C4=CC=C([O-])C(=C4)CC=C(C)C)/C(=O)OC3=C2C)O)OC1(C)C,Novobiocin sodium (Albamycin),,YJQPYGGHQPGBLI,Heat Shock Protein 90 (hsp90) Inhibitor,HSP90AB1
NCGC00344588-01,COC1=CC2=C(C=C1C3=C(C)ON=C3C)N=CC4=C2N([C@H](C)C5=CC=CC=N5)C(=O)N4,I-BET151 (GSK1210151A) ,,VUVUVNZRUGEAHB,"Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitor",BRD4
NCGC00164576-03,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)COC3=C(C)C=CC=C3C)CC4=CC=CC=C4,Lopinavir;ABT-738,,KJHKTHWMRKYKJE,HIV Protease Inhibitors,
NCGC00025091-04,COC1=CC=C2[C@H]3CC[C@]4(C)[C@H](CC[C@H]4[C@@H]3CCC2=C1)NCCCCCCN5C(=O)\C=C/C5=O,U-73122??,,LUFAORPFSVMJIW,Phospholipase C Inhibitor,PLCG1
NCGC00345085-01,CC(C)[C@@H]1N(C)C2=C3C(=C[NH]C3=CC=C2)C[C@@H](CO)NC1=O,(-)-Indolactam V,,LUZOFMGZMUZSSK,lineage-specific differentiation enhancer,
NCGC00016868-11,COC1=CC2=C(C=C1)[N](C(=C2CC(=O)OCC(O)=O)C)C(=O)C3=CC=C(Cl)C=C3,ACEMETACIN,,FSQKKOOTNAMONP,Cyclooxygenase-1/2/3 Inhibitor,PTGS1
NCGC00024999-02,CC[C@H](NC(C)C)[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2,Procaterol,"PROCATEROL;Procaterolum;procaterol;LS-176276;LS-176277;Procaterol Monohydrochloride, (R*,R*)-(-)-Isomer;CIPLUS_183546;LS-176278;LS-176279;Procaterol Monohydrochloride, (R*,R*)-(+)-Isomer;Procaterol, (R*,S*)-(-)-Isomer;LS-178229;Procaterol hydrochloride;2(1H)-Quinolinone, 8-hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-, (R*,S*)-(+-)-;Pro-Air;CIPLUS_726646;Procterol Hcl;NCGC00024999-01;NCGC00024999-02;LS-176037;Procaterol Hydrochloride;LS-176100;Procaterol;LS-176280;procaterolum;Procaterol Hydrochloride (replaced);Procaterol Monohydrochloride, (R*,R*)-(+-)-Isomer;Meptin;Procaterol Monohydrochloride;LS-142798;LS-142797;erythro-8-Hydroxy-5-[1-hydroxy-2-(isopropylamino)butyl]-2(1H)-quinolinone;PROCATEROL HYDROCHLORIDE;CIPLUS_677393;Procaterol, (R*,R*)-(+-)-Isomer;LS-176377;CIPLUS_189741;Procaterol Monohydrochloride, (R*,S*)-(+)-Isomer;Procaterol hydrochloride hemihydrate;Procaterol Monohydrochloride, (R*,S*)-(-)-Isomer;",FKNXQNWAXFXVNW,beta2-Adrenoceptor Agonists,ADRB2
NCGC00167524-03,CCC(C)(C)C1=CC=C(CC(C)CN2C[C@H](C)O[C@H](C)C2)C=C1,Amorolfine Hydrochloride,,MQHLMHIZUIDKOO,Antifungal Agent,
NCGC00013724-01,O=C([C@@H]([C@]4=CC=CC=C4)CO)O[C@@H]2C[C@@H]3[C@H]1O[C@H]1[C@@H]([N@+](C)3C)C2,Scopolamine methylbromide,METHSCOPOLAMINE BROMIDE;CIPLUS_3848045;CIPLUS_775135;Methscopolamine bromide;CIPLUS_165133;Skopolate;Hyoscine methyl nitrate;(-)-Scopolamine methyl bromide;PAMINE;NCGC00094377-01;NCGC00094389-01;LS-157838;NCGC00016203-01;METHSCOPOLAMINE NITRATE;Hyoscine methyl bromide;N-Methylscopolamine;HYOSCINE METHONITRATE;LS-157841;CIPLUS_152257;Pamine;LS-157840;Daipin;NCGC00162342-01;NCGC00162342-02;CIPLUS_213391;N-Methylscopolamine Methylsulfate;(-)-Scopolamine methyl nitrate;N-METHYLSCOPOLAMINE METHYLSULFATE;NCGC00015973-01;NCGC00094723-01;methylscopolamine methyl sulfate;NCGC00094723-02;N-Methylscopolamine methylsulfate;,LZCOQTDXKCNBEE,Muscarinic Antagonists,
NCGC00021925-04,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC/4=C/C(=O)/C=C\[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,Prednisolone acetate (Omnipred),,LRJOMUJRLNCICJ,Glucocorticoid steroid,
NCGC00346837-01,[O-][N+](=O)C1=CC=C(OC(=O)N2CCN(CC2)CC3=CC=CC(=C3)OC4=CC=CC=C4)C=C1,JZL-195,,QNYRAEKLMNDRFY,Monoacylglycerol lipase (MAGL) inhibitor,MGLL
NCGC00263521-02,CC(=O)OCC(=O)[C@@]12\N=C(C)/O[C@@H]1C[C@H]3[C@@H]4CCC/5=C/C(=O)/C=C\[C@]5(C)[C@H]4[C@@H](O)C[C@]23C,Deflazacort (Calcort),,FBHSPRKOSMHSIF,Corticosteroid,
NCGC00346527-01,CC1=NC(=C(O)C2=C1C=C(OC3=CC=CC=C3)C=C2)C(=O)NCC(O)=O,FG-4592,,YOZBGTLTNGAVFU,Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors,HIF1A
NCGC00164601-03,COC1=NC(=CC=C1)N(C)C(=S)OC2=CC=C3CCCCC3=C2,Liranaftate,,VPHPQNGOVQYUMG,Fungal Squalene Monooxygenase Inhibitor,
NCGC00183128-01,O=C1[C@@]([C@](CC5)(C)[C@]4([H])C([C@H]5O[C@@H]3[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H]([C@](O)=O)O7)[C@@H](O)[C@H](O)[C@@H]([C@@](O)=O)O3)(C)C)([H])[C@](CC4)(C)[C@@]2(C)C([C@]([C@@]6(C)CC2)([H])C[C@@](CC6)(C)[C@@](O)=O)=C1,Glycyrrhizin,"CIPLUS_751995;CIPLUS_158305;GLYCYRRHIZINATE DIPOTASSIUM;Glycyron;CIPLUS_743360;alpha-D-glucopyranosiduronic acid, (3 beta,20 beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-beta-D-glucopyranuronosyl-;stronger neominophagen C;CIPLUS_3887476;6   Ammonium Glycyrrhizinate;GLYCYRRHIZINIC ACID;Diammonium glycyrrhizinate;Monoammonium glycyrrhizinate;CIPLUS_732445;CIPLUS_704836;uralsaponin A;Glycyrrhizinate Dipotassium;GLYCYRRHIZIN, AMMONIATED;CIPLUS_748154;18??-Diammonium Glycyrrhizinate;alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-beta-D-glucopyranuronosyl-, mixt. with L-cysteine, glycine and DL-methionine;NCGC00095778-01;CIPLUS_735908;3-hydroxy-11 oxoolean-12-en-30-oic acid-3-O-glucuronopyranosyl-(1-2)glucuronopyranoside;Glycyrrhizinate, Dipotassiu;Glycyrrhizic acid monoammonium salt;CIPLUS_730518;Acid, Glycyrrhizi;Glycyrrhizic acid ammonium salt;Diammonium Glycyrrhizinate;GLYCYRRHETINIC ACID GLYCOSIDE;AMMONIUM GLYCYRRHIZATE;MONOAMMONIUM GLYCYRRHIZINATE;CIPLUS_198565;GLYCYRRHIZIN;CIPLUS_753388;Glycyrrhizin;Glycyrrhizic acid;Glycyrrhizinate dipotassium;DIAMMONIUM GLYCYRRHIZINATE;Glycyrrhizinic Acid;Zinc Glycyrrhizate;Glycyrrhizate, Zin;3-O-(2-O-beta-D-Glucopyranuronosyl-alpha-D-glucopyranuronosyl)-18beta-glycyrrhetinic acid ammonium salt;Acid, Glycyrrhizini;Neubormitin;beta-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-beta-D-glucopyranuronosyl-;Glycyruhinic acid;GLYCYRRHIZIC ACID;AMMONIUM GLYCYRRHIZINATE;Dipotassium Glycyrrhizinate;LS-72973;Glycyrrhizic Acid;",LPLVUJXQOOQHMX,Thrombin Inhibitors,
NCGC00015049-18,OC1=CC=C(C=C1)\C2=C\C(=O)C3=C(O2)C=C(O)C=C3O,APIGENIN,,KZNIFHPLKGYRTM,Cyp2C9 Inhibitor,CYP2C9
NCGC00263097-01,COC1=CC2=C(C=C1OCCCN3CCCC3)N=CN=C2OC4=C(F)C5=C([NH]C(=C5)C)C=C4,Cediranib,,XXJWYDDUDKYVKI,VEGFR-1/2/3 inhibitor,FLT1
NCGC00165863-02,CCN(CC)CCCCNC1=NC=C2C=C(C(=NC2=N1)NC(=O)NC(C)(C)C)C3=CC(=CC(=C3)OC)OC,PD-173074;PD-0173074??,,DXCUKNQANPLTEJ,FGFR 1/3 inhibitor,
NCGC00263147-01,CC1=N[NH]C2=CC=C(C=C12)C3=CC(=CN=C3)OC[C@@H](N)CC4=CC=CC=C4,A-674563,,BPNUQXPIQBZCMR,Akt1/PKA Inhibitor,AKT1
NCGC00263181-01,CC[N]1C(=NC2=C(N=CC(=C12)OC[C@H]3CCCNC3)C#CC(C)(C)O)C4=NON=C4N,GSK-690693,,KGPGFQWBCSZGEL,Akt1/2/3 Inhibitor,AKT1
NCGC00346532-01,CC1CCC(CC1)C(=O)N(C2CCC(O)CC2)C3=C(SC(=C3)C#CC(C)(C)C)C(O)=O,VX-222,,WPMJNLCLKAKMLA,RNA-Directed RNA Polymerase Inhibitor,
NCGC00161923-04,COC1=C(OC)C(=CC(=C1)[C@H]2[C@H]3[C@H](COC3=O)[C@@H](O)C4=C2C=C5OCOC5=C4)OC,Picropodophyllotoxin,,YJGVMLPVUAXIQN,IGF-1R Inhibitors,IGFR1
NCGC00163451-03,C[N]1C2=C(C=CC=C2)C3=C4C(=O)NCC4=C5C6=C(C=CC=C6)[N](CCC#N)C5=C13,Go 6976,,VWVYILCFSYNJHF,PKC inhibitor,PRKCA
NCGC00167831-01,CCC1=C2CN3C(=O)\C4=C(/C=C3/C2=NC5=CC=C(O)C=C15)[C@@](O)(CC)C(=O)OC4,,"7-Ethyl-10-hydroxycamptothecine;NCGC00167831-01;7-Ethyl-10-hydroxycamptothecin(SN-38);(4S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)dione;SN-38;Irrinotecan;7-ETHYL-10-HYDROXYCAMPTOTHECIN;7-ethyl-10-hydroxycamptothecin;4,11-DIETHYL-4,9-DIHYDROXY-1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)-QUINOLINE-3,14(4H,12H)-DIONE;7-ethyl-10-hydroxycamptothecin glucuronide;CAMPTOTHECIN, 7-ETHYL-10-HYDROXY-;SN-38 glucuronide;CIPLUS_682291;SN 38;",FJHBVJOVLFPMQE,DNA Topoisomerase I Inhibitors,TOP1
NCGC00345821-01,C[N]1N=CC(=C1C(=O)NC2=C(F)C=CC(=C2)NC3=CC4=C(C=C3)C(=N[NH]4)\C=C\C5=CC=CC=N5)C,AG13958,,LLMBCXVXEQNNJB,VEGFR-2 (FLK-1/KDR) Inhibitors,FLT1
NCGC00346728-01,CC[C@H](C)[C@H](N)C/1=N/CC(S1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC([O-])=O)C(=O)N[C@@H]([C@H](C)CC)C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC([O-])=O)NC(=O)[C@H](CC3=C[NH]C=N3)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC2=O)[C@H](C)CC,Bacitracin zinc,,MNJKVJAYSVAQLU,Peptide Antibiotic,
NCGC00159418-02,O=C(N1)N(C2OCCC2)C=C(F)C1=O,Tegafur,"S1-tegafur-oxonate combination;1-UFT protocol;Franroze;S-1 cpd;FTORAFUR;LS-155181;CIPLUS_726411;1-UFT;2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-;tegafurum;CIPLUS_682169;Uftoral;Ftorafur;CIPLUS_735510;BMS 247616;S-1 compound;5-FLUORO-1-(TETRAHYDRO-2-FURYL)-URACIL;TEGAFUR;CIPLUS_682553;Tegafurum;UFT protocol;5-Fluoro-1-(tetrahydro-2-furyl)uracil;LS-158685;Tegafur;BMS247616;CIPLUS_171248;UFTORAL;CIPLUS_676259;Tegafur-Uracil;S-1 (combination);tegafur;Atillon;Tegafur (Ftorafur);1 UFT;S1-fluoropyrimidine oxoonate combination;TS-1 cpd;S 1 (combination);",WFWLQNSHRPWKFK,Pyrimidine Antagonists,
NCGC00345851-01,CC1=C(CN2CCN(CC2)[S+](C)([O-])=O)SC3=C1N=C(N=C3N4CCOCC4)C5=CN=C(N)N=C5,GNE 477,,JZMWLEPQSLXFKZ,PI3K Inhibitor,PIK3CA
NCGC00346458-01,C[C@@H](NC(=O)C1=C(Cl)C(=NC=N1)N)C2=NC=C(S2)C(=O)NC3=NC=C(Cl)C(=C3)C(F)(F)F,MLN-2480,,VWMJHAFYPMOMGF,Raf Kinase Inhibitors,BRAF
NCGC00263092-01,CC1(C)SCCN([C@H]1C(=O)NO)[S+]([O-])(=O)C2=CC=C(OCC#CCO)C=C2,Apratastat,,BZHWKODEVHFEOJ,TNF-alpha-Converting Enzyme Inhibitor,TNF
NCGC00181152-01,N[Pt](OCC1=O)(O1)N,Nedaplatin,"Aqupla;NSC 375101D;nedaplatinum;Nedaplatin;NEDAPLATIN;CIPLUS_214377;LS-117704;CGDP-II;(glycolato-O,O')diammineplatinum II;NSC-375101D;cis-diammine(glycolato)platinum II;nedaplatin;nedaplatine;254-S;",GRHLMSBCOPRFNA,DNA Alkylating Agent,
NCGC00167532-01,FC(C=C(C3=C4OC)C(C(C(O)=O)=CN3C2CC2)=O)=C4N1CCCC(C1)NC,Balofloxacin,"3-Chloro-2,6-dinitro-4-(trifluoromethyl)aniline;Balofloxacin;Q-35;3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)-1-piperidinyl)-4-oxo-;balofloxacinum;1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methylaminopiperidine-1-yl)-4-oxoquinoline-3-carboxylic acid;BALOFLOXACIN;CIPLUS_208011;Balofloxacin Hydrate;balofloxacin;Q 35;",MGQLHRYJBWGORO,Antibacterial,
NCGC00263209-02,COC1=CC=C(C=C1)C2CC(=N/N2C3=CC=C(C=C3)[S+](N)([O-])=O)\C4=CC=CC=C4,,,QJTFMKKRRRGSLH,Cdc42 GTPase inhibitor,CDC42
NCGC00016305-10,NC1=CC=C(C=C1)[S+]([O-])(=O)NC2=NC=CC=N2,Sulfadiazine,,JNSIGQZDHNFJIB,Antibiotic,
NCGC00346516-01,CO/N=C(/C(=O)N[C@H]1[C@H]2SC\C(=C(/N2C1=O)C(O)=O)CN3\C=C/C(=N)N3CCO)C4=CSC(=N4)N,Cefoselis sulfate,,ZINFAXPQMLDEEJ,Antibiotic,
NCGC00345789-01,CC1(C)CCC(=C(\C1)C2=CC=C(Cl)C=C2)/CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)N[S+]([O-])(=O)C5=CC=C(NCC6CCOCC6)C(=C5)[N+]([O-])=O)OC7=CN=C8[NH]C=CC8=C7,ABT-199,,CWBPQMKQMRMOFK,Bcl-2 Inhibitor,BCL2
NCGC00163415-03,CC/1=C\CC[C@@]2(C)O[C@@H]2[C@H]3OC(=O)C(=C)[C@@H]3CC1,PARTHENOLIDE,,KTEXNACQROZXEV,NF-kappaB Activation Modulator,NFKB1
NCGC00015233-04,ClC1=CC=C(C=C1)C(C2=CC=C(Cl)C=C2)[N+]3=C[N](CC(OCC4=C(Cl)C=C(Cl)C=C4)C5=C(Cl)C=C(Cl)C=C5)C=C3,Calmidazolium chloride,,CTKNMSVWMRRCPW,Calmodulin-Dependent Protein Kinase II Inhibitors,CAMKK2
NCGC00015100-14,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,ALTRETAMINE,,UUVWYPNAQBNQJQ,Antineoplastic Agent,
NCGC00174736-02,CC(=O)OC[C@@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)N2\C=C/C(=O)NC2=O,Uridine triacetate,,AUFUWRKPQLGTGF,Pyrimidine Antagonists,
NCGC00246968-02,CCCC1=NC(=C([N]1CC2=CC=C(C=C2)C3=CC=CC=C3C4=N[NH]N=N4)C(O)=O)C(C)(C)O,Olmesartan,,VTRAEEWXHOVJFV,Angiotensin AT1 Antagonist,AGT
NCGC00253760-02,CCC[S+]([O-])C1=CC=C2[NH]C(=NC2=C1)NC(=O)OC,Albendazole Oxide (Ricobendazole),,VXTGHWHFYNYFFV,antiparasitic agent,
NCGC00167535-01,O=P(O)(O)CO[C@H](C)CN2C1=C(N=C2)C(N)=NC=N1,Tenofovir,"9-(2-phosphonylmethoxypropyl)adenine, (S)-isomer;tenofovir?disoproxil?fumarate;tenofovir;9-((R)-2-PHOSPHONOMETHOXY-PROPYL)ADENINE MONOHYDRATE;TENOFOVIR;GS-1278;9-(2-phosphonylmethoxypropyl)adenine, (+-)-isomer;(((R)-2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY)METHYL)PHOSPHONIC ACID, MONOHYDRATE;efavirenz?+?emtricitabine?+?tenofovir;(R)-((2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY)METHYL)PHOSPHONIC ACID MONOHYDRATE;Tenofovir;LS-172029;Tenofovir disoproxil;Tenofovir(PMPA);CIPLUS_206929;9-PMPA;CIPLUS_10557245;LS-173296;LS-173297;(R)-2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methylphosphonic acid;9-(2-phosphonylmethoxypropyl)adenine, (R)-isomer;LS-172481;CIPLUS_699321;tenofovirum;emtricitabine?+?tenofovir;",SGOIRFVFHAKUTI,Reverse Transcriptase Inhibitor,TERT
NCGC00242596-01,O=C(N[C@@H](CCC(O)=O)[C@@](O)=O)C1=CC=C(C(CC#C)CC3=NC2=C(N)N=C(N)N=C2N=C3)C=C1,Pralatrexate,,OGSBUKJUDHAQEA,Dihydrofolate Reductase (DHFR) Inhibitors,DHFR
NCGC00181013-01,O=C5C=CN=C(N5)N(C)C(CC4)CCN4C1=NC(C=CC=C3)=C3N1CC2=CC=C(F)C=C2,Mizolastine,Zolistan;Mizolen;Zolim;Sanofi Synthelabo brand of mizolastine;mizolastine;Schwarz brand of mizolastine;Galderma brand of mizolastine;Mizolastinum;SL-85.0324;MIZOLASTINE;2-((1-(1-(P-FLUOROBENZYL)-2-BENZIMIDAZOLYL)-4-PIPERIDYL)METHYLAMINO)-4(3H)-PYRIMIDINONE;Allphar brand of mizolastine;SL 85.0324;Mistamine;LS-135935;CIPLUS_207953;Mizolastine;mizolastinum;Mistalin;Novag brand of mizolastine;Mizolastina;Mizollen;,PVLJETXTTWAYEW,Histamine H1 Receptor Antagonists,HRH1
NCGC00345782-01,ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1,CHS-828,,BOIPLTNGIAPDBY,IKK Inhibitor,IKBKB
NCGC00253562-02,CN(C)CC[C@H](CSC1=CC=CC=C1)NC2=C(C=C(C=C2)[S+]([O-])(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=C(C=CC=C5)C6=CC=C(Cl)C=C6)[N+]([O-])=O,ABT-737,,UQAKVLLFWLYJRC,Bcl-xL inhibitor,BCL2L1
NCGC00263150-01,CC(=O)NC1=CC=C(OC[C@](C)(O)C(=O)NC2=CC(=C(C=C2)[N+]([O-])=O)C(F)(F)F)C=C1,Andarine,,YVXVTLGIDOACBJ,Selective Androgen Receptor Modulators (SARM)?,AR
NCGC00346675-01,CN[C@@H](C)C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)CC(C)C,AT-406,,LSXUTRRVVSPWDZ,cIAP1/2 and XIAP inhibitor,XIAP
NCGC00263564-02,C[C@@H]\1CC(=O)N\N=C1C2=CC=C(NN=C(C#N)C#N)C=C2,Levosimendan,,WHXMKTBCFHIYNQ,K(ATP) Channel Activators,
NCGC00346602-01,CCN1C[C@@]2(CC[C@H](OC)[C@@]34[C@@H]2C[C@@H]([C@@H]13)[C@@]5(O)C[C@H](OC)[C@H]6C[C@@H]4[C@]5(O)[C@H]6OC)OC(=O)C7=C(NC(C)=O)C=CC=C7,Lappaconite Hydrobromide,,NWBWCXBPKTTZNQ,Antiinflammatory alkaloid,
NCGC00181771-01,O=S(C)(=O)Nc1ccc(cc1)C(O)CCCN(CC)CCCCCCC.O=C(O)/C=C/C(=O)O.CCN(CCCCCCC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1,Ibutilide fumarate,"CIPLUS_685160;CIPLUS_731244;CIPLUS_197003;ibutilidum;Ibutilidum;ibutilide, fumarate salt (2:1), (+)-isomer;LS-172765;Ibutilida;ibutilide;LS-90123;LS-90124;LS-172966;Ibutilide;U-82209E;ibutilide, (+-)-isomer;Ibutilide Fumarate;Ibutilide fumarate;Corvert;U-70,226E;IBUTILIDE FUMARATE;IBUTILIDE;ibutilide fumarate;N-(4-(4-(ETHYLHEPTYLAMINO)-1-HYDROXYBUTYL)PHENYL)METHANESULFONAMIDE (E)-2-BUTENEDIOATE (2:1 SALT);",LJJSIWUWLRVCBP,K(ATP) Channel Blockers,
NCGC00346722-01,FC1=CC=C(C=C1)C(=O)N2CCC[C@@H](C2)C3=NC(=NO3)C4=CC=C(F)C=C4,ADX-47273,,VXQCCZHCFBHTTD,mgluR5 Antagonists,GRM5
NCGC00015882-09,NC1=NC2=C(C=C(C=C2)OC(F)(F)F)S1,Riluzole;PK-26124/RP-54274/Rilute,2-Amino-6-(trifluoromethoxy)-benzothiazole;NCGC00023141-05;NCGC00023141-06;Riluzole hydrochloride;NCGC_Prestw-167;NCGC00023141-02;Rilutek;NCGC00023141-04;2-Amino-6-trifluoromethoxybenzothiazole;amino-2 trifluoromethoxy-6 benzothiazole (french);Riluzol;Riluzolum;PK-26124;NCGC00015882-02;2-AMINO-6-(TRIFLUOROMETHOXY)BENZOTHIAZOLE;RP-54274;CIPLUS_158927;Riluzole;Prestwick-03A08;2-Amino-6-(trifluoromethoxy)benzothiazole;NCGC00015882-01;RILUZOLE;2 Amino 6 trifluoromethoxybenzothiazol;LS-40688;riluzole;riluzolum;,FTALBRSUTCGOEG,Glutamate Release Inhibitor,GRM1
NCGC00247029-02,OC[C@H]1OC(O)C[C@@H](O)[C@@H]1O,2-Deoxyglucose,,PMMURAAUARKVCB,sugar,
NCGC00346668-01,CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C,Pramiracetam,,ZULJGOSFKWFVRX,neuroprotective drug,
NCGC00347953-01,O=C(NC1=CC2=C([NH]C=C2)C=N1)C3=CC=CC=C3,,,HWJRIFZDXJKJJN,Oct4 Activator,
NCGC00167328-02,CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C,E-64-d,,SRVFFFJZQVENJC,Calpain Inhibitor,CAPN1
NCGC00346696-01,CC1=CC(=C(N=C1)C2=CC(=NC=C2Cl)N3CCN(CC3)C(=O)CC[S+](C)([O-])=O)C,PF-5274857,,BBVNTTZIOTWDSV,Smoothened (Smo) receptor agonist,SMO
NCGC00022848-06,OCC(=O)[C@@]2(O)CC[C@H]3[C@@H]4CC\C1=C\C(=O)CC[C@]1(C)[C@H]4[C@@H](O)C[C@]23C,Hydrocortisone,"Hydrocortisone and antiinfectives;Hydrocortisone solution;Hydrocortisone Valerate;Acticort;HCTRPCX;(11.BETA.)-11,17,21-TRIHYDROXYPREGN-4-ENE-3,20-DIONE;Hydrocortisone Caproate;CIPROFLOXACIN HYDROCHLORIDE;hydrocortisone acetate (0.25%-0.5%);Hydrocortisone hemisuccinate monohydrate;VOSOL HC;HYDROCORTISONE (0.5-1%);CHLORAMPHENICOL / HYDROCORTISONE;HYDROCORTISONE;HYDROCORTISONE AS THE ACETATE / LIGNOCAINE AS LIGNOCAINE HYDROCHLORIDE / NEOMYCIN AS THE SULFATE;BACITRACIN ZINC / FRAMYCETIN SULFATE / HYDROCORTISONE ACETATE / POLYMYXIN B SULFATE;hydrocortisone;Kendall's compound F;hydrocortisonum;Cortisol;Hydrocortisone Tebutate;CIPLUS_686238;CIPLUS_751406;Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-, mixt. with dibenzoyl peroxide and 8-quinolinol sulfate (1:1) (salt) monopotassium salt;hycortol;CIPLUS_749943;Hydrocortisone-Water Soluble;CORTISOL;Hydrocortisone and antiseptics;NCGC00016215-01;4-Pregnene-11beta,17alpha,21-triol-3,20-dione;Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-, mixt. with 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-1H-imidazole mononitrate;11-Epicortisol;hydrocortisone acetate  (0.25-5.0%);CIPLUS_148533;CIPLUS_773183;LS-178496;LS-174854;CIPLUS_769560;Hydrocortisone Probutate;Hydrocortisonum;BAY O 9867;Hydrocortisone;CHLORAMPHENICOL / HYDROCORTISONE ACETATE;Hydrodexan;Daktacort;Cortifair;Reichstein's substance M;Canesten HC;hydrocortisone-receptor complex;CIPLUS_752076;Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-;Hidrocortisona;NCGC00095243-01;NCGC00095243-02;17-Hydroxycorticosterone;CIPLUS_709621;HYDROCORTISONE (0.25-5%);Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer;hydrocortisone (0.5-1%);receptor, hydrocortisone;hydrocortisone receptors;Calmurid-HC;NCGC_Prestw-447;Epicortisol;LS-176065;cortisol receptors;Hydrocortisone butyrate and antiseptics;HYDROCORTISONE / NEOMYCIN SULFATE;Alphaderm;11beta,17alpha,21-Trihydroxypregn-4-ene-3,20-dione;Hydrocortisone and antibiotics;HYDROCORTISONE 21-RETINOATE;Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-, mixt. with 1-((2-chlorophenyl)diphenylmethyl)-1H-imidazole;cpd w/o stereochem designation;HYDROCORTISONE / LIGNOCAINE HYDROCHLORIDE / NEOMYCIN SULFATE;HS_710;HYDROCORTISONE SODIUM SUCCINATE;11 Epicortiso;Hydrocortisone Base;NCGC00022848-03;hydrocortisone receptor;NCGC00022848-08;NCGC00022848-09;LS-178511;HYDROCORTISONE ACETATE;PREGN-4-ENE-3,20-DIONE, 11,17,21-TRIHYDROXY-, (11.BETA.)-;hydrocortisone alcohol;Hydrocortisone, (11 alpha)-Isomer;quinoderm hydrocortisone;LS-178466;CHLORHEXIDINE GLUCONATE / HYDROCORTISONE ACETATE / LIGNOCAINE HYDROCHLORIDE / PHENOXYETHANOL;Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-, mixt. with 1-carboxy-N,N,N-trimethylmethanaminium hydroxide inner salt, 2-hydroxypropanoic acid and urea;UREA;Hydrocortisone base;Hydrocortisone and mydriatics;CIPLUS_672786;NCGC00015507-01;Cyclodextrin-encapsulated hydrocortisone;SCH-21663;Hydrocortisone Buteprate;clotrimazole-hydrocortisone;LS-7439;hydrocortisone (0.25-5%);Cortril;",JYGXADMDTFJGBT,immunosuppressant,PTGS2
NCGC00274062-01,O[C@@H](COC1=CC=CC2=C1C=CC=N2)CN3CCN(CC3)C4C5=C(C=CC=C5)[C@H]6[C@@H](C7=C4C=CC=C7)C6(F)F,LY335979,,IHOVFYSQUDPMCN,P-Glycoprotein (MDR-1) Inhibitor,
NCGC00263108-01,CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\C4=CC=C(C=N4)C5=CC=CC(=C5)F,Vorapaxar;MK-5348/SCH-530348,,ZBGXUVOIWDMMJE,PAR1 Antagonist,PAR1
NCGC00167526-03,CN(C)C(=O)COC(=O)CC1=CC=C(OC(=O)C2=CC=C(NC(N)=N)C=C2)C=C1,Camostat mesylate,,XASIMHXSUQUHLV,Serine Protease Inhibitor,
NCGC00015420-09,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C=C(O)C=C3O)C2=O,Emodin,,RHMXXJGYXNZAPX,Casein Kinase II (CK2) Inhibitor,
NCGC00345461-02,CC1=N[NH]C(=C1)NC2=N[N]3C(=C(C)N=C3C(=C2)CN4CCOCC4)CC5=CC=C(Cl)C=C5F,LY2784544,,SQSZANZGUXWJEA,Jak2 inhibitor,JAK2
NCGC00274063-01,COC1=CC=C(C=C1)C2=NC3=CC(=CC=C3[NH]2)/C4=N/NC(=O)CC4C,Pimobendan(Vetmedin),,GLBJJMFZWDBELO,Phosphodiesterase III (PDE3) Inhibitor,PDE3A
NCGC00345022-02,OC(=O)CCCCCC(=O)NN=C1CCCC1,IDE 2,,CVYPYYPTFNVREL,lineage-specific differentiation enhancer,
NCGC00164572-01,O=C(NN2CCCCC2)C1=NN(C3=CC=C(C=C3Cl)Cl)C(C4=CC=C(C=C4)Cl)=C1C,Rimonabant,"Rimonabant Base;SR 141716;SR-141716;5-(P-CHLOROPHENYL)-1-(2,4-DICHLOROPHENYL)-4-METHYL-N-PIPERIDOPYRAZOLE-3-CARBOXAMIDE;(N-(Piperidin-1-yl)-5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide;SR-141716A;Rimonabant HCL;SR141716;RIMONABANT;5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidino-1H-pyrazole-3-carboxamide;N-PIPERIDINO-5-(4-CHLOROPHENYL)-1-(2,4-DICHLOROPHENYL)-4-METHYLPYRAZOLE-3-CARBOXAMIDE;NCGC00164572-01;SR 141716A;rimonabantum;1H-PYRAZOLE-3-CARBOXAMIDE, 5-(4-CHLOROPHENYL)-1-(2,4-DICHLOROPHENYL)-4-METHYL-N-1-PIPERIDINYL-;rimonabant;CIPLUS_789414;CIPLUS_682303;Rimonabant(Nlt);N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride;5-(4-CHLOROPHENYL)-1-(2,4-DICHLOROPHENYL)-4-METHYL-N-PIPERIDIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE;SR-141716 FORM 2;SR141716A;Rimonabant;acomplia;",JZCPYUJPEARBJL,cannabinoid CB1 antagonist,CNR1
NCGC00345083-01,CO[C@@H]1C(C[C@H]2O[C@]1(C)[N]3C4=C(C=CC=C4)C5=C6C(=O)NC(=O)C6=C7C8=C(C=CC=C8)[N]2C7=C35)N(C)C(=O)C9=CC=CC=C9,Stauprimide,,MQCCJEYZKWZQHU,lineage-specific differentiation enhancer,
NCGC00345808-01,CN(CC(=O)N(CC1=CC=C(C=C1)C2CCCCC2)C3=CC=C(C(O)=O)C(=C3)O)[S+]([O-])(=O)C4=C(F)C(=C(F)C(=C4F)F)F,BP-1-102,,ZDFQPZFZDJMCEO,STAT-3 Inhibitor,STAT3
NCGC00345853-01,CN(C)CC(=O)N1CCC(CC1)C2=CC=C(NC(=O)C3=NC(=C[NH]3)C#N)C(=C2)\C4=C\CCCC4,JNJ-28312141,,GUBJNPWVIUFSTR,CSF1R (c-FMS) Inhibitor,CSF1R
NCGC00345850-01,N#CC(=C/1NC2=CC=CC=C2S1)\C3=NC(=NC=C3)OCC4=CC=C(CN5CCOCC5)C=C4,AS-602801  (Bentamapimod),,LRRWTQBREKZHNX,JNK Inhibitor,MAPK8
NCGC00345828-01,CC(C)(C)C1=NC2=C([NH]1)C3=CC=C(F)C=C3C4=C2\C=C/NC4=O,Merck -5 ,,VNDWQCSOSCCWIP,Jak inhibitor,JAK1
NCGC00242490-02,CCN(CC)CCOC1=CC=C(NC2=NC=C3\C=C(/C(=O)N(C)C3=N2)C4=C(Cl)C=CC=C4Cl)C=C1,PD-166285,,IFPPYSWJNWHOLQ,cSRC inhibitor,SRC
NCGC00164380-02,OC3=C2[C@@](CCC3=O)(C)[C@]1([H])[C@](CC2)([H])[C@@](CCC4=O)([H])[C@]4(C)CC1,4-Hydroxyandrostenedione,"NCGC00095102-02;4-Hydroxy-4-androstene-3,17-dione;NCGC00095102-01;NCGC00015070-01;4-OH Androstenedione;4-hydroxyandrost-4-ene-3,17-dione;formestane;NCGC00095102-03;NCGC00164380-01;Fromestane;CIPLUS_154577;CGP 32349;4-OHA;formestanum;CGP-32349;Formestane (4-Androsten-4-ol-3,17-dione);4-Hydroxyandrost-4-ene-3,17-dione;4-hydroxyandrostene-3,17-dione;4-Androsten-4-ol-3,17-dione;4-HYDROXYANDROSTENEDIONE;Lentaron;4-OH-A;LS-19455;4-hydroxy-4-androstene-3,17-dione;NCGC00093579-01;NCGC00093579-02;4-hydroxyandrostenedione;FORMESTANE;CGP 32 349;Novartis brand of formestane;Formestane;",ZMEULISFKSVRLQ,Aromatase Inhibitor,CYP19A1
NCGC00016610-08,CN(C(=S)OC1=CC=C2C=CC=CC2=C1)C3=CC(=CC=C3)C,TOLNAFTATE,,FUSNMLFNXJSCDI,Fungal Squalene Monooxygenase Inhibitor,
NCGC00181296-01,O=C(C(C)=C2C)C(C(CCCCCC(O)=O)C1=CC=CC=C1)=C(C)C2=O,"(+-)-7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid","CIPLUS_196846;Bronica;SERATRODAST;7-(3,5,6-TRIMETHYL-1,4-BENZOQUINON-2-YL)-7-PHENYLHEPTANOIC ACID, DL-;AA-2414;AA 2414;seratrodastum;A-73001;Benzeneheptanoic acid, zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-, (+-)-;ABT-001;seratrodast;aa-2414;7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid;Seratrodast;LS-30374;",ZBVKEHDGYSLCCC,Prostanoid TP Agonist,TBXA2R
NCGC00185736-01,C[C@H](O)[C@H](CC)N1N=CN(C1=O)c2ccc(cc2)N3CCN(CC3)c4ccc(cc4)OCC6C[C@@](Cn5cncn5)(OC6)c7ccc(F)cc7F,Posaconazole,,RAGOYPUPXAKGKH,Lanosterol 14alpha-demethylase Inhibitors,CYP51A1
NCGC00346720-01,NC/1=N/C(=O)C2=C(N1)[N](C=N2)[C@@H]3C[C@H](O)[C@@H](CO)C3=C,Entecavir hydrate,,QDGZDCVAUDNJFG,DNA Polymerase Inhibitors,
NCGC00018158-08,COC1=C(OC)C=C2C(=NC(=NC2=C1)N3CCN(CC3)C(=O)C4COC5=C(O4)C=CC=C5)N,DOXAZOSIN MESYLATE,,RUZYUOTYCVRMRZ,alpha1-Adrenoceptor Antagonists,ADRA1A
NCGC00015471-06,N\C1=N\C2=C(N=C[N]2COC(CO)CO)C(=O)N1,Ganciclovir,,IRSCQMHQWWYFCW,DNA Polymerase Inhibitors,
NCGC00346496-01,CN1CCN(CC1)C2=CC=C(NC3=NC=C(Cl)C(=N3)OC4=CC(=CC=C4)NC(=O)C=C)C=C2,WZ3146,,APHGZZPEOCCYNO,EGFR (HER1; erbB1) Inhibitor,EGFR
NCGC00241108-03,CNC(=O)C1=CC=CC=C1SC2=CC=C3C(=C2)[NH]N=C3\C=C\C4=CC=CC=N4,Axitinib;AG-013736;AG-13736;Inlyta,,RITAVMQDGBJQJZ,VEGFR-1/2/3 Inhibitor,FLT1
NCGC00346565-01,COC1=CC2=C(C=C1CC3=C(F)C(=CC=C3)Cl)C(=O)\C(=C/N2[C@H](CO)C(C)C)C(O)=O,Elvitegravir (GS-9137),,JUZYLCPPVHEVSV,HIV Integrase Inhibitors,
NCGC00346713-01,COC1=CC(=CC(=C1)OC)CCC2=CC(=N[NH]2)NC(=O)C3=CC=C(C=C3)N4C[C@@H](C)N[C@@H](C)C4,AZD4547,,VRQMAABPASPXMW,FGFR 3 Inhibitor,
NCGC00162073-05,[O-][S+](=O)(NCCNC\C=C\C1=CC=C(Br)C=C1)C2=CC=CC3=CN=CC=C23,,,YUIABEHRMZWVGY,PKB/Akt Inhibitor,AKT1
NCGC00346965-01,COC1=CC(=CC=C1NC2=NC=C3N(C(C)C)C(=O)CCN(C4CCCC4)C3=N2)C(=O)NC5CCN(C)CC5,HMSL10087,,VIJIVCXRKDRGGA,FLT4,FLT4
NCGC00092318-02,CCN(CC)CCCC(C)NC1=NC(=CC(=N1)C)NC2=CC3=C(N)C=C(C)N=C3C=C2,NSC 23766,,DEFBCZWQLILOJF,Rac1-GEF inhibitor,RAC1
NCGC00167518-03,CO[C@@H]1C[C@@H](CC[C@H]1OC(=O)C(C)(CO)CO)C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC,Temsirolimus (Torisel),,CBPNZQVSJQDFBE,mTOR inhibitor,MTOR
NCGC00263212-01,CCOC1=CC(=CC(=C1OCC(=O)OC)Cl)/C=C2\C(=N/N(C2=O)C3=CC=CC=C3)C,SJ-172550,,RKKFQJXGAQWHBZ,MDM4 (MDMX) Inhibitor,MDM4
NCGC00163567-03,OC1=CC=C(C=C1CC=C)C2=CC(=CC=C2O)CC=C,,,FVYXIJYOAGAUQK,NF-kappaB Activation Modulator,NFKB1
NCGC00163700-04,CC[C@]1(O)C[C@H]2CN(CCC3=C([NH]C4=C3C=CC=C4)[C@@](C2)(C(=O)OC)C5=CC6=C(C=C5OC)N(C=O)[C@H]7[C@](O)([C@H](OC(C)=O)[C@]8(CC)\C=C/C[N@@]9CC[C@]67[C@H]89)C(=O)OC)C1,,VINCRISTINE SULFATE,OGWKCGZFUXNPDA,Tubulin polymerization inhibitor,TUBB
NCGC00346648-01,CC[N]1C=C(C2=C3C=C([NH]C3=NC=C2)C4=CC=CC(=C4)CN(C)C)C(=N1)C5=CC=C(NC(=O)N(C)C)C=C5,GSK1070916,,QTBWCSQGBMPECM,Aurora-B/C Inhibitor,AURKB
NCGC00346517-01,CCCCCCCCCC(=O)N[C@@H](CC1=C[NH]C2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)C4=CC=CC=C4N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC3=O)[C@@H](C)CC(O)=O,Daptomycin,,DOAKLVKFURWEDJ,Lipopeptide Antibiotic,
NCGC00345823-01,CC(C)(N)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3)N=C2C4=CC=CC=C4,"Akt-I-1,2                 (Akt-I-1,2)",,CBJJSCYIXJYEAW,AKT1/2 Inhibitor,AKT1
NCGC00188346-01,Oc1cc2cc(nc2cc1)c4nn(c3ncnc(N)c34)C(C)C,PP242,pp242,MFAQYJIYDMLAIM,mTOR Inhibitor,MTOR
NCGC00346950-01,N[S+]([O-])(=O)C1=CC=C(NC2=NC3=C([NH]C=N3)C(=N2)OCC4CCCCC4)C=C1,NU6102,,IJMJHMZRTMZWLE,CDK 1 & 2 inhibitor,CDK1
NCGC00345833-01,CN(C)CCOC1=CC(=CC=C1NC(=O)C2COC3=CC=CC=C3O2)C4=C[NH]N=C4,SR3677,,OQWZIAVXCYIZNN,ROCK II Inhibitor,ROCK2
NCGC00181336-03,NC1=NC(=NC2=C1N=C[N]2[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)F,2-Fluoroadenosine,,HBUBKKRHXORPQB,Purine-Nucleoside Phosphorylase Inhibitors,PNP
NCGC00015365-18,OC1=CC=C(C=C1)\C2=C\OC3=C(C=CC(=C3)O)C2=O,DAIDZEIN,,ZQSIJRDFPHDXIC,Estrogen Receptor Modulator,ESR1
NCGC00263133-01,C[S+]([O-])(=O)C1=CC=CC(=C1)CNC2=C(C=NC(=N2)NC3=CC=C4NC(=O)CCC4=C3)C(F)(F)F,PF-573228,,DJLOYAWVGAKXJV,Focal Adhesion Kinase (FAK) Inhibitor,PTK2
NCGC00025234-01,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O,Alprostadil,"Alprostadil;CIPLUS_726983;ALPROSTADIL A-CYCLODEXTRIN;NCGC00025234-03;ALPROSTADIL;NCGC00025234-01;alprostadilum;MR-356;OC-3186;Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-;U 42170;13,14-dihydro-PGE2;PGE1 oligomer;Prink;pge-1;PROST-13-EN-1-OIC ACID, 11,15-DIHYDROXY-9-OXO-, (11A,13E,15S)-;MR-256;U-10,136;prost-5-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11alpha,15S)-;NCGC_Prestw-1018;Prostaglandine E;(1R,2R,3R)-3-HYDROXY-2-((E)-(3S)-3-HYDROXY-1-OCTENYL)-5-OXOCYCLOPENTANEHEPTANOIC ACID;CIPLUS_780954;CIPLUS_737951;HS_62;PGE1;Prostaglandin- E1-[5,6-3H(N)];U-42170;OC 3186;NCGC00016535-01;LS-58016;PROSTAGLANDIN E1;Befar;MR 356;Alprostadilum;MR 356, (5Z,13E,15S)-isomer;MR 256;Prostaglandin E1;Tandetron;13,14-dihydroprostaglandin E2;alprostadil;CIPLUS_156290;Alprostadil Alfadex;Alprostadil alfadex;CIPLUS_173149;PROSTAGLANDIN E1, SODIUM SALT;ALPROSTADIL ALFADEX;ALPROSTADIL SODIUM;(11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid;CIPLUS_3882243;",GMVPRGQOIOIIMI,prostaglandin,
NCGC00250393-01,CC(O)[C@H](NC(=O)[C@@H]1CSSC[C@H](CC(=O)[C@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CC=C(O)C=C3)C(=O)N[C@H](CC4=C[NH]C5=CC=CC=C45)C(=O)N[C@@H](CCCCN)C(=O)N1)C(N)=O,CAP-232,,AMCKRLCICPRLSG,Somatostatin srif2B (sst4) Agonist,SSTR4
NCGC00092329-01,OC(CN1CCC(CC1)CC2=CC=C(F)C=C2)C3=CC=C(Cl)C=C3,Eliprodil;SL-82.0715,"SL-820715;A-(4-CHLOROPHENYL)-4-(4-FLUOROPHENYLMETHYL)-1-PIPERIDINEETHANOL HYDROCHLORIDE;CIPLUS_196967;SL 82.0715;SL 82-0715;eliprodil;SL 820715;LS-172417;Eliprodil;ELIPRODIL HYDROCHLORIDE;CIPLUS_755593;1-Piperidineethanol, alpha-(4-chlorophenyl)-4-(4-fluorophenyl)-, (+-)-;eliprodilum;alpha-(4-Chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol;ELIPRODIL;NCGC00092329-02;(4-chlorophenyl)-4-((4-fluorophenyl)methyl)-1-piperidineethanol;NCGC00092329-03;",GGUSQTSTQSHJAH,NMDA Antagonist,GRIN2A
NCGC00015067-13,CC(=O)OC1=C(C=CC=C1)C(O)=O,ASPIRIN,,BSYNRYMUTXBXSQ,non-steroidal antiinflammatory,
NCGC00016710-04,CN1CCC[C@@H]1CCO[C@](C)(C2=CC=CC=C2)C3=CC=C(Cl)C=C3,CLEMASTINE,,YNNUSGIPVFPVBX,Histamine H1 Receptor Antagonists,HRH1
NCGC00017394-08,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C6=CC(=O)OC6)[C@H](O)[C@H](O)[C@H]1O,,"OUABAIN HYDRATE, (-)",LPMXVESGRSUGHW,Na+/K+-ATPase Inhibitors,NKAIN1
NCGC00347939-01,CCOC1=CC=CC=C1N/N=C2\C(=N/N(C2=O)C3=NC(=CS3)C4=CC=CC=C4)C,,,KOCVKGYKBLJEPK,BAX activator,BCL2
NCGC00015772-13,CC1COC2=C3N1\C=C(C(O)=O)/C(=O)C3=CC(=C2N4CCN(C)CC4)F,OFLOXACIN,,GSDSWSVVBLHKDQ,Antibiotic,
NCGC00165909-03,ClC1=CC=CC=C1C([N]2C=CC=N2)(C3=CC=CC=C3)C4=CC=CC=C4,TRAM-34,,KBFUQFVFYYBHBT,Intermediate Conductance Channel Blockers,
NCGC00344507-02,CC(N[C@H]1CCCC[C@@H]1NC(=O)C2=CC=C(Cl)C=C2)C3=CC=CC4=C3C=CC=C4,Calhex 231,,YTFUQWWKTIWYEY,Calcium-Sensing Receptor (CaSR) Agonists,CASR
NCGC00165816-02,CC(OC(=O)NC1=C(ON=C1C)C2=CC=C(CSCCC(O)=O)C=C2)C3=C(Cl)C=CC=C3,Ki16425,,LLIFMNUXGDHTRO,Lysophospholipid edg2 (LPA1)/edg7 (LPA3) Receptor Antagonists,LPAR1
NCGC00247866-04,O=C(NC1=NN=C(S1)C2=CC=NC=C2)NC3=CC(=C(C=C3)C4=C[NH]N=C4)C#N,NCGC00247866-02,,PNYZVACPJDKKEE,BLM inhibitor,BLM
NCGC00017344-06,OC1=CC2=C(C=C1)C(=O)\C(=C(O2)\C3=CC(=C(O)C=C3)O)O,Fisetin (Fustel),,XHEFDIBZLJXQHF,Histone Deacetylase/SIRT1 Activator,SIRT1
NCGC00164447-01,ClC1(C(C2=CC=C(C=C2)OC(C(=O)O)(C)C)C1)Cl,Ciprofibrate,"Modalim;NCGC00093652-01;NCGC00093652-02;Oroxadin;Ciprofibrato;Ciprofibratum;WIN 35833;NCGC00164447-01;NCGC00015202-01;Sanofi Synthelabo brand of ciprofibrate;ciprofibratum;2-(4-(2,2-dichlorocyclopropyl)phenoxy)2-methylpropanoic acid;Hyperlipen;NCGC_Prestw-1076;2-(P-(2,2-DICHLOROCYCLOPROPYL)-PHENOXY)-2-METHYLPROPIONIC ACID;CIPROFIBRATE;2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid;CIPLUS_181189;Win 35,833;ciprofibrate;LS-7279;Ciprofibrate;Lipanor;NCGC00016867-01;Sanofi Winthrop brand of ciprofibrate;",KPSRODZRAIWAKH,PPARalpha Agonist,PPARA
NCGC00015462-12,CC1=NC=C(N=C1)C(=O)NCCC2=CC=C(C=C2)[S+]([O-])(=O)NC(=O)NC3CCCCC3,,GLIPIZIDE,MKGWVFBAAZYWCF,K(ATP) Channel Blockers,
NCGC00162453-10,C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C,Trichostatin A (TSA),,RTKIYFITIVXBLE,HDAC1 Inhibitor,HDAC1
NCGC00189220-05,COC1=C(OCCCN2CCCC2)C=C3N=C(N=C(NC4CCN(CC4)C(C)C)C3=C1)C5CCCCC5,UNC-0638,,QOECJCJVIMVJGX,Histone-lysine N-methyltransferase EHMT2 Inhibitor,EHMT2
NCGC00015897-06,COC1=C(OCC(O)CN2CCN(CC2)CC(=O)NC3=C(C)C=CC=C3C)C=CC=C1,RANOLAZINE,,XKLMZUWKNUAPSZ,Sodium channel inhibitor,SCN9A
NCGC00168459-04,COC1=CC(=C(OC)C=C1)C2=NN=C3C=CC(=N[N]23)C4=CC(=C(OC)C=C4)O[C@@H]5CCOC5,NCGC00168459-01,,HQUIEUONYYTHEW,Phosphodiesterase IIII (PDE4) inhibitor,PDE4A
NCGC00346606-01,CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@H]4C(C)(C)[C@H](CC[C@@]45C[C@@]35CC[C@]12C)NC,Cyclovirobuxin D (Bebuxine),,GMNAPBAUIVITMI,acute myocardial ischemia drug,
NCGC00018172-08,CC1CC2=C(C=CC=C2)N1NC(=O)C3=CC=C(Cl)C(=C3)[S+](N)([O-])=O,INDAPAMIDE,,PESCKZFEUDWKKH,Carbonic Anhydrase Type VII Inhibitor,CA7
NCGC00025092-02,COC1(CCN(CCC2=C[NH]C3=CC=C(F)C=C23)CC1)C[S+]([O-])C4=CC=CC=C4,GR-159897,,BANYJBHWTOJQDU,Tachykinin NK2 Antagonist,TACR2
NCGC00023673-08,NC1=NC=NC2=C1N=C[N]2[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O,,ADENOSINE,OIRDTQYFTABQOQ,Adenosine Receptor Agonist,ADORA1
NCGC00162385-05,C\C1=C(\C=C(C#N)/C(=O)N1)C2=C[N]3C=CN=C3C=C2,Olprinone hydrochloride,,JPAWFIIYTJQOKW,Phosphodiesterase III (PDE3) Inhibitor,PDE3A
NCGC00263105-01,CC(C)OC(=O)/C1=C/N(CC(C)(C)C2=C1[NH]C3=CC=CC=C23)C(=O)C4=CC=C(F)C(=C4)F,Turofexorate isopropyl;FXR-450/WAY-362450/XL-335,,INASOKQDNHHMRE,Farnesoid X Receptor Agonist,
NCGC00263158-01,S=C(NCC1=CC2=C(OCO2)C=C1)N3CCN(CC3)C4=NC=NC5=C4OC6=C5C=CC=C6,Amuvatinib;MP-470/HPK-56,,FOFDIMHVKGYHRU,PDGFR alpha Inhibitor,PDGFRA
NCGC00159349-07,CC[C@]12CC[C@H]3[C@@H](CCC/4=C/C(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,Levonorgestrel (Levonelle),,WWYNJERNGUHSAO,Progestogen hormone,PGR
NCGC00015884-09,C1(NC(C3CC3)C2CC2)=NCCO1,Rilmenidine,"N-(Dicyclopropylmethyl)-4,5-dihydro-2-oxazolamine hemifumarate salt;rilmenidinum;RILMENIDINE;S-3341-3;S3341;Rilmenidine Dihydrogen Phosphate;Rilmenidine hemifumarate;Hyperium;Oxaminozoline;Biopharma brand of rilmenidine phosphate;NCGC00021689-02;Rilmenidine;CIPLUS_775732;NCGC00021689-05;NCGC00021689-04;NCGC_Prestw-982;NCGC00021689-06;NCGC00015884-01;NCGC00015884-02;2-(N-(dicyclopropylmethyl)amino)oxazoline phosphate salt;S-3341;2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro-;oxaminozoline;N-(Dicyclopropylmethyl)-4,5-dihydro-2-oxazolamine;S 3341;2-(N-(dicyclopropylmethyl)amino)oxazoline;rilmenidine phosphate;Rilmenidine hemifumarate salt;rilmenidine;LS-100036;CIPLUS_210842;Oxaminozoline hemifumarate salt;Rilmenidene hemifumarate salt;",CQXADFVORZEARL,Imidazoline I1 Receptor Agonists,NISCH
NCGC00016361-13,CC(=O)NC1=CC=C(O)C=C1,ACETAMINOPHEN,,RZVAJINKPMORJF,Cyclooxygenase-3 Inhibitor,PTGS1
NCGC00014925-07,CC[C@@]1(O)C(=O)OC\C2=C1\C=C3/N(CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C34)C2=O,Topotecan hydrochloride,,UCFGDBYHRUNTLO,DNA Topoisomerase I Inhibitors,TOP1
NCGC00178638-04,CC(C)[C@H](N)C(=O)OCCOC[N]1C=NC2=C1\N=C(N)/NC2=O,Valaciclovir HCl,,HDOVUKNUBWVHOX,DNA Polymerase Inhibitors,
NCGC00090759-02,N[Pt](N)(Cl)Cl,cis-Dichlorodiamine platinum,,DQLATGHUWYMOKM,DNA Alkylating Agent,
NCGC00263164-01,COC1=C(OC)C=C2C(=CC=NC2=C1)OC3=CC=C(NC(=O)C4(CC4)C(=O)NC5=CC=C(F)C=C5)C=C3,Cabozantinib;BMS-907351/XL-184,,ONIQOQHATWINJY,VEGFR-2 Inhibitor,KDR
NCGC00024196-06,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3\C=C(C)/C4=C/C(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O,Megestrol Acetate,,RQZAXGRLVPAYTJ,Progesterone Receptor Antagonist,PGR
NCGC00183039-01,O=C1O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)/C=C/C=C/CC/C=C/C=C/C=C/C=C/[C@H](O[C@H]3O[C@@H](C)[C@H](O)[C@@H](N)[C@H]3O)CC2[C@H]([C@](O)=O)[C@@H](O)C[C@@](O2)(O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)C1,Nystatin,LS-97612;Nystatin;NYLIDRIN HYDROCHLORIDE;Nystatin preparation;NCGC_Prestw-517;Nystatine;NCGC00094222-02;nystatine;Nilstat;NCGC00016579-01;LS-178591;Nystatin dihydrate;Mycostatin;Nystatin G;NCGC00094222-03;NYSTATIN;nystatinum;Nystatin A3;Nystatin A1;Nystatin A2;TRIAMCINOLONE ACETONIDE;CANDEX;Nistatina;Nystatinum;Stamicin;CIPLUS_158274;Fungicidin;Stamycin;,VQOXZBDYSJBXMA,Antifungal Agent,
NCGC00262598-01,COC1=CC=C(CC2C3=C(CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]4(C)CCC5=C(C=C(OC)C(=C5)OC)C4CC6=CC(=C(OC)C=C6)OC)C=C(OC)C(=C3)OC)C=C1OC.[O-][S](=O)(=O)C7=CC=CC=C7.[O-][S](=O)(=O)C8=CC=CC=C8,Atracurium besylate,,YXSLJKQTIDHPOT,neuromuscular blocker,
NCGC00185000-03,CN(C)C\C=C\C(=O)NC1=CC2=C(NC3=CC(=C(F)C=C3)Cl)N=CN=C2C=C1O[C@H]4CCOC4,Afatinib;BIBW-2992,,ULXXDDBFHOBEHA,EGFR (HER1; erbB1) inhibitor,EGFR
NCGC00250403-01,CC1=CC=C(F)C(=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=N[NH]C4=CC=C3)N,Linifanib;ABT-869/RG-3635,,MPVGZUGXCQEXTM,VEGFR-2 inhibitor,KDR
NCGC00015887-05,CC(NCCC1=CC=C(O)C=C1)C(O)C2=CC=C(O)C=C2,RITODRINE HYDROCHLORIDE,,IOVGROKTTNBUGK,beta2-Adrenoceptor Agonists,ADRB2
NCGC00238454-02,COC1=CC=C2/C3=N/CCN3\C(=N/C2=C1OC)NC(=O)C4=CC=CN=C4,PIK-90,,ZJAVHOMVDCMAMF,PI3K Inhibitor,PIK3CA
NCGC00025300-01,COC1=C(O)C=C2CCC3C(CC[C@]4(C)[C@@H](O)CCC34)C2=C1,2-Methoxyestradiol,"Panzem;CIPLUS_208498;(17 beta)-2-methoxyestra-1,3,5(10)-triene-3,17-diol;3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene;2-Methoxyestradiol;2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether;2-METHOXY-3,17B-ESTRADIOL;NCGC00094082-01;NCGC00094082-02;NCGC00025300-01;NCGC00015690-01;2-Hydroxyestradiol 2-methyl ether;2-methoxyestradiol;2-METHOXYESTRADIOL;2-methoxyestradiol-17 beta;1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether;2-methoxyestradiol, (17alpha)-isomer;",CQOQDQWUFQDJMK,Hypoxia Inducible Factor 1-alpha Inhibitor,HIF1A
NCGC00347908-01,COC1=C(OC)C=C(CC(=O)NC(N\C(NC2=CC=CC3=C2C=CC=C3)=N\C#N)C(C)(C)C)C=C1,A 740003,,JDAOXUVHEBTCNB,P2X7 Receptor Antagonist,P2RX7
NCGC00016706-05,CCCCC1=CC2=C([NH]C(=N2)NC(=O)OC)C=C1,,,YRWLZFXJFBZBEY,Tubulin depolymerization inhibitor,TUBB
NCGC00181129-05,CC1=NC(=CC(=N1)NC2=NC=C(S2)C(=O)NC3=C(Cl)C=CC=C3C)N4CCN(CCO)CC4,Dasatinib;BMS-354825;Sprycel,,ZBNZXTGUTAYRHI,Bcr-Abl inhibitor,ABL1
NCGC00185994-02,CCC1=CC=C(C=C1)\C=C/2SC(=S)NC2=O,10058-F4,,SVXDHPADAXBMFB,MYC Expression Inhibitors,MYC
NCGC00263187-01,CN1C(=O)/C(=C(NC2=CC=C(I)C=C2F)\C3=C1\N=C/N(C[C@@H](O)CO)C3=O)F,TAK-733,,RCLQNICOARASSR,MEK inhibitor,MAP2K1
NCGC00183285-04,CC1=C[N](C=N1)C2=CC(=CC(=C2)NC(=O)C3=CC(=C(C)C=C3)NC4=NC(=CC=N4)C5=CC=CN=C5)C(F)(F)F,Nilotinib;AMN-107?,,HHZIURLSWUIHRB,Bcr-Abl Kinase Inhibitor,ABL1
NCGC00183682-01,CCOC1OC(=O)C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)C3=CC(Cl)=C(N)C=C3)C(C)(C)C,,,SJDDOCKBXFJEJB,Caspase 1 (IL-1beta Converting Enzyme) Inhibitors,CASP1
NCGC00346577-01,FC(F)(F)C1=CN=C([NH]1)C2=CC(=CC=N2)OC3=CC4=C([NH]C(=N4)NC5=CC=C(C=C5)C(F)(F)F)C=C3,Raf265 derivative,,UDNNLEQKNPVZON,Raf kinase B/C inhibitor,BRAF
NCGC00168784-01,FC1(F)[C@@H](O[C@H](CO)[C@H]1O)N(C=CC(N)=N2)C2=O.Cl,Gemcitabine;Gemzar;Inno-D07001,"Gemcitabine Hcl;LS-59068;gemcitabinum;GEMCITABINE;LS-59069;CIPLUS_197001;LS-171889;gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer;gemcitabine;Gemcitabine;2'-deoxy-2',2'-difluorocytidine;GEMCITABINE HCL;Gemcitabina;GEMZAR;Gemcitabine hydrochloride;GEMCITABINE HYDROCHLORIDE;CIPLUS_207103;CIPLUS_207104;gemcitabine, (D-threo-pentafuranosyl)-isomer;gemcitabine, (beta-D-threo-pentafuranosyl)-isomer;Gemzar;LS-171890;Gemcitabinum;LS-171894;LY-188,011;Gemcitabine Hydrochloride;GEMCITABINE HCI;2'-DEOXY-2',2'-DIFLUOROCYTIDINE HYDROCHLORIDE;",SDUQYLNIPVEERB,ribonucleotide reductase inhibitor,RRM2
NCGC00347947-01,CCOC(=O)\C1=C(/C)N\C2=C(C1C3=CC=C(C=C3)C4=CC=CC=C4)\C(=O)CC(C)(C)C2,,,ULFUJLFTRWWLPO,TGF-b Inhibitor,
NCGC00346714-01,CC(C)NC[C@@H](C(=O)N1CCN(CC1)C2=C3[C@H](C)C[C@@H](O)C3=NC=N2)C4=CC=C(Cl)C=C4,GDC-0068,,GRZXWCHAXNAUHY,PKB/Akt Inhibitor,AKT1
NCGC00242481-02,NC(=O)NC1=C(SC(=C1)C2=CC(=CC=C2)F)C(=O)N[C@H]3CCCNC3,AZD-7762,,IAYGCINLNONXHY,Chk1/2 Inhibitor,CHEK1
NCGC00346587-01,COC1=C(O)C2=C(C=C1O)C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]23,Bergenin (Cuscutin),,YWJXCIXBAKGUKZ,Protein Tyrosine Phosphatase (PTP) Inhibitors,PTP4A1
NCGC00178319-07,C[S+]([O-])(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl,Thiamphenicol (Thiophenicol),,SPIWJGRFUSFKBK,Antibiotic,
NCGC00347282-01,CN(C)[S+]([O-])(=O)N1CCN(CC1)C2=CC=C(OCC3=N[N](C)C(=C3C4=C5[N](CC6=CC=CN=C6)C(=C(CCCOC7=CC=CC8=C7C=CC=C8)C5=CC=C4)C(O)=O)C)C=C2,VU0483487-1,,CNMHULGZUHYIAQ,Mcl Inhibitor,MCL1
NCGC00263086-01,CC(C)CCN1C(C)C(=N)N(C)C2=C1N=C(NC3=CC(=C(O)C(=C3)F)F)N=C2,BI-D1870,,YIJVPONGUZTUBW,MAPKAP-K1 (RSK; p90Rsk) Inhibitor,RPS6KA1
NCGC00017323-07,CN(C)[C@H]\1[C@@H]2C[C@H]3C(=C(O)\[C@]2(O)C(=O)\C(=C1O)C(N)=O)/C(=O)C4=C(O)C=CC=C4[C@@]3(C)O,TETRACYCLINE HYDROCHLORIDE,,OFVLGDICTFRJMM,30S Ribosomal Protein Inhibitors,
NCGC00167805-02,CC(=O)OCCN1C(=O)C2=C(C)N=C3C=CC(=CC3=C2C1=O)[S+]([O-])(=O)N4CCOCC4,Ivachtin,,MWXJJTMEUGWKKY,Caspase 3 inhibitor,CASP3
NCGC00016672-04,CN(C)CCN(CC1=CC=C(Cl)C=C1)C2=CC=CC=N2,Chloropyramine hydrochloride,,ICKFFNBDFNZJSX,Histamine H1 Receptor Antagonists,HRH1
NCGC00346537-01,CC(C)(C)C[N]1C(=NC2=C1N=C(C=C2)C3=C(N=C([NH]3)C(C)(C)C)C4=CC=C(F)C=C4)N,LY2228820,,XPPBBJCBDOEXDN,p38 MAPK Inhibitor,MAPK14
NCGC00250401-01,CN1CC[C@H]([C@@H](O)C1)C2=C(O)C=C(O)C3=C2O\C(=C/C3=O)C4=CC=CC=C4Cl,Flavopiridol;Alvocidib;HL-275;HMR-1275;L86-8275;MDL-107826A;NSC-649890,,BIIVYFLTOXDAOV,CDK1/2/4/6/7/9 Inhibitor,CDK1
NCGC00346931-01,CNC(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=CC=C(C=C3OC)N4CCOCC4,NVP-TAE226,,UYJNQQDJUOUFQJ,Focal Adhesion Kinase (FAK) Inhibitor,PTK2
NCGC00094872-08,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N3CCCCC3,PIPERINE,,MXXWOMGUGJBKIW,MAO-A/B Inhibitor,MAOA
NCGC00186464-02,COCCCOC1=CC(=CC=C1OC)C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C,ALISKIREN HEMIFUMARATE,,UXOWGYHJODZGMF,Renin Inhibitor,
NCGC00159515-02,O=C1N(C3=NC=C(Cl)C=C3)[C@@H](OC(N4CCN(C)CC4)=O)C2=NC=CN=C12,Eszopiclone,"Zopiclone;(5S)-6-(CHLOROPYRIDIN-2-YL)-7-OXO-6,7-DIHYDRO-5H-PYRROLO[3,4-B] PYRAZIN-5-YL 4-METHYL- PIPERAZINE-1-CARBOXYLATE, (+)-;Eszopiclone;(5S)-6-(5-CHLORO-2-PYRIDINYL)-6,7-DIHYDRO-7-OXO-5H-PYRROLO(3,4-B)PYRAZIN-5-YL 4-METHYL-1-PIPERAZINECARBOXYLATE;Estorra;eszopiclonum;NCGC00016108-01;Zopiclona;CIPLUS_734464;IMOVANE;zopiclone, racemic;zopiclone;ZOPICLONE;CIPLUS_180420;ESZOPICLONE;Imovane;4-Methyl-1-piperazinecarboxylic acid 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester;(+)-(5S)-6(chloropyridine-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)-pyrazin-5-yl-4-methyl-piperazine-1-carboxylate;IL-27,267;Amoban;NCGC00024993-03;zopiclonum;NCGC00024993-04;NCGC00024993-01;eszopiclone;RP-27267;Zopiclonum;6-(5-CHLORO-2-PYRIDYL)-7-((4-METHYL-1-PIPERAZINYL)CARBONYLOXY)-6,7-DIHYDRO-5H-PYRROLO(3,4-B)PYRAZIN-5-ONE;1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester;LS-110937;WY-43,037;(S)-ZOPICLONE;",GBBSUAFBMRNDJC,GABAA Receptor Modulator,GABRA1
NCGC00016256-16,CCC1=C(C(=NC(=N1)N)N)C2=CC=C(Cl)C=C2,Pyrimethamine,,WKSAUQYGYAYLPV,Dihydrofolate Reductase (DHFR) Inhibitors,DHFR
NCGC00347174-02,C[N]1N=C(COC2=CC=C(C=C2)N3CCN(CC3)C(C)=O)C(=C1C)C4=C5[N](CC6=CC=CN=C6)C(=C(CCCOC7=CC=CC8=C7C=CC=C8)C5=CC=C4)C(O)=O,VU0482089-2,,VKKQBUSCPZGZBT,Mcl Inhibitor,MCL1
NCGC00095112-04,COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C,AVOBENZONE,,XNEFYCZVKIDDMS,UVA ray absorber,
NCGC00093347-06,COC1=CC=C2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCC2=C1,Mestranol,,IMSSROKUHAOUJS,Estrogen Receptor (ER) Agonist,ESR1
NCGC00345802-01,ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C2=CC=CC=C2)C3=CC=CC=C3,ACY-1215,,QGZYDVAGYRLSKP,Histone Deacetylase (HDAC) 6 Inhibitor,HDAC6
NCGC00163540-03,COC1=CC=C(C=C1O)C/2=C/C(=O)C3=C(O2)C=C(O)C=C3O,DIOSMETIN,,MBNGWHIJMBWFHU,Lipid Lowering Agents,
NCGC00344509-01,CC1=CC=C(C(=C1)C)C(C)(O)C2=NC3=CC=CC=C3S2,AC-265347,,IGSZVEPQZANNAB,Calcium-Sensing Receptor (CaSR) Agonists,CASR
NCGC00346729-01,[O-]C(=O)[C@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)CC3=CC=CC=C3,Mitiglinide calcium,,WPGGHFDDFPHPOB,Insulin Secretagogues,
NCGC00095133-04,CC(=O)OCC(CC[N]1C=NC2=CN=C(N)N=C12)COC(C)=O,FAMCICLOVIR,,GGXKWVWZWMLJEH,antiviral,
NCGC00346674-01,CC(C)C1=C(O)C=C(O)C(=C1)C(=O)N2CC3=C(C2)C=C(CN4CCN(C)CC4)C=C3,AT13387,,IFRGXKKQHBVPCQ,Heat Shock Protein 90 (hsp90) Inhibitor,HSP90AB1
NCGC00091544-08,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(=C4)O)[C@@H]1CC[C@@H]2O,beta-Estradiol,"ESTRADIOL ENANTHATE H-3;Estradiol Receptor alpha;E2-BSA;ESTROGENS;estradiol sulfate;tetraPhPor estradiol;ESTRADIOL 3-PHOSPHATE DISODIUM;ETHINYL ESTRADIOL .BETA.-CYCLODEXTRIN CLATHRATE;Polyestradioli phosphas;NCGC00015422-01;CIPLUS_158146;(17b)-Estra-1,3,5(10)-triene-3,17-diol;ESTRADIOL MUSTARD;17beta-Estradiol;1,3,5(10)-Estratriene-3,17alpha-diol;ESTRADIOL HEMIHYDRATE;phosphate de polyestradiol;ESTRADIOL C-14;Estradiol Cypionate;NCGC00015422-02;estradiol phosphate polymer;polyestradiol phosphate;Estrogen Analogs;estradiolum;Receptor, Estradio;11-(((4-(5,10,15-triphenylporphyrin-20-yl)phenyl)carbonylamino)butanoyloxy)estradiol;Fosfato de poliestradiol;CENESTIN;ethinyl estradiol glucuronide;17alpha estradiol;estradiol 7 alpha-decamethylene-poly(alanyllysine)-sepharose;ESTROGENS, CONJUGATED SYNTHETIC B;ESTROGENS, CONJUGATED SYNTHETIC A;ESTRA-1,3,5(10)-TRIENE-3,17.BETA.-DIOL;Estra-1,3,5(10)-triene-3,17-diol (17beta)-;CIPLUS_148846;E2-BSA-FITC;estradiol 6-O-carboxymethyloxime-bovine serum albumin-fluorescein isothiocyanate;Analogs, Estroge;E2-6CMO-BSA-FITC;EADPALA;(17.BETA.)-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL;estradiol lipoidal derivative;17-beta-Estradiol;Estradiol Acetate;SYNTHETIC CONJUGATED ESTROGENS, A;b-Estradiol;NCGC00161666-02;SYNTHETIC CONJUGATED ESTROGENS, B;estradiol 7 alpha-decamethylene-poly(alanyl-lysine)agarose;17A-ESTRADIOL;Estrogen Analogues;NCGC00094671-01;NCGC00094671-02;LS-137;ERTK;(17.BETA.)-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL HEMIHYDRATE;E2-HC-BSA-FITC;estradiol 7 alpha-decamethylene agarose;3,17alpha-Dihydroxy-1,3,5(10)-estratriene;Antagonists, Estradio;ethinyl estradiol sulfonate;1,3,5-Estratriene-3,17beta-diol;ERalpha;CIPLUS_148536;estradiol ruthenocenecarboxylate;alfatradiolum;tetraphenylporphyrin-C11-estradiol conjugate;alpha-Estradiol;estradiol 7 alpha-trimethylene-poly(alanyllysine)-sepharose;estradiol?cypionate;Estrace;ESTRADIOL H-2;Estradiol Antagonists;17-alpha-estradiol 17-N-acetylglucosaminide;Receptor alpha, Estrogen;BETA-ESTRADIOL;17beta-Estradiol-16,16,17-d3;Estra-1,3,5(10)-triene-3,17-diol (17beta)-, homopolymer;Receptor alpha, Estradio;Estradiol-17 beta:NAD(P)+ 17-oxidoreductase;SR-90067V;Pharmacia brand of polyestradiol phosphate;POLYESTRADIOL PHOSPHATE;Estrogen Receptor alpha;Estradiol-17 beta;Estrogen Receptor 1;estradiol nitrate;CIPLUS_210703;CIPLUS_210705;Estradiol hemihydrate;11beta-bromoacetamidopentoxyphenylE2 estradiol;Dihydrofolliculin;polyestradiol;estradiol-bovine serum albumin;ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (17.BETA.)-;CIPLUS_153888;estradiol;ETHINYL ESTRADIOL H-3;CIPLUS_209199;ESTRA-1,3,5(10)-TRIENE-3,17.BETA.-DIOL HEMIHYDRATE;ETHINYL ESTRADIOL BETADEX;norelgestromin-ethinyl estradiol combination patch;LE(2);Analogues, Estroge;ESTROGENS, CONJUGATED;Estradiolum;17ALPHA-ESTRADIOL;?-Estradiol;3,17beta-Dihydroxy-1,3,5(10)-estratriene;Estradiol Congeners;alpha, Estradiol Recepto;E(2)-3D(6) cpd;estradiol 12-bovine serum albumin;Estradiol Receptor;Phosphate de polyestradiol;ethynyl estradiol glucuronide;AB08007607-01;ESTRADIOL GLUCONATE;estradiol receptor tyrosine kinase;ESTRADIOL;11beta-bromoacetamidoethoxyphenylE2 estradiol;1,3,5(10)-Estratriene-2,4-d2-3,17beta-diol;estradiol 17-hemisuccinate-bovine serum albumin-fluorescein isothiocyanate;HS_562;HS_561;CIPLUS_731672;NCGC_Prestw-441;ENJUVIA;estradiol valerate-dienogest;Estradiol;Estradurine;Estrogen Receptors alpha;ESTRADIOL-17-HEPTANOATE H-3;Estradiol Dehydrogenases;Estra-1,3,5(10)-triene-3,17 diol (17-beta)-, polymer with phosporic acid;EADMA;estradiol (E(2))-Asp-hexapeptide conjugate;Estradiol 17 Propionate;Epiestradiol;beta-Estradiol hemihydrate;ESTRAPEL;NCGC00016218-01;3,17-beta-dihydroxyestra-1,3,5(10)-triene;Estrodiolum;NCGC00091544-09;estradiol 17-acetylglucosaminide;Evra;Wyeth brand of polyestradiol phosphate;medroxyprogesterone?acetate?+?estradiol?cypionate;beta-Estradiol-d2;Ortho Evra;NCGC00091544-02;17B-ESTRAIOL;LS-64736;NCGC00091544-07;Polyestradiol phosphate;NCGC00091544-08;NCGC00091544-05;NCGC00091544-06;ETHINYL ESTRADIOL ",VOXZDWNPVJITMN,Estrogen Receptor (ER) Agonist,ESR1
NCGC00346610-01,CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O,Pantothenic acid (pantothenate),,GHOKWGTUZJEAQD,Vitamin,
NCGC00023509-14,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)\C=C2\C=C/[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12,LOVASTATIN,,PCZOHLXUXFIOCF,HMG-CoA Reductase Inhibitor,HMGCR
NCGC00016014-08,OC1=C(O)C=C(C=C1)\C=C(/C#N)C(=O)NCC2=CC=CC=C2,,"Tyrphostin-AG-490;NCGC00024576-04;NCGC00024576-05;NCGC00024576-02;2-Cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-2-propenamide;NCGC00024576-03;tyrphostin B42;NCGC00024576-01;AG-490;tyrphostin AG-490;Tyrphostin AG 490;2-Cyano-3-(3,4-dihydroxyphenyl)-N-(benzyl)-2-propenamide;AG 490;alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide;NCGC00016014-01;AG490;2-propenamide;Tyrphostin B42;",TUCIOBMMDDOEMM,Jak2/3 Inhibitor,JAK2
NCGC00346487-01,C[N]1C=C(CNCC2CCN(CC2)C3=NC=C(C=N3)C(=O)NO)C4=CC=CC=C14,JNJ-26481585,,PAWIYAYFNXQGAP,HDAC1 Inhibitor,HDAC1
NCGC00346556-01,CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCC2=C1C=CC=C2,Semagacestat (LY450139),,PKXWXXPNHIWQHW,g-Secretase Inhibitor,NOTCH1
NCGC00346955-01,COC1=CC(=CC=C1NC(=O)C2=CC3=C(C=CC=C3)[N]2C)C4=N[N](C5CCC(CC5)N6CCN(CC6)C(C)=O)C7=NC=NC(=C47)N,A-770041,,ZMNWFTYYYCSSTF,Lck Kinase Inhibitors,LCK
NCGC00346830-01,NC\1=N\C(=O)N(\C=C1F)[C@H]2C[C@H](O)[C@@H](CO)O2,NSC-48006,,IDYKCXHJJGMAEV,DNA Methyltransferase (DNMT) Inhibitor,DNMT1
NCGC00346694-01,CCN1C[C@H](C)[N]2C(=C(O)C3=C2\C(=N/N(CC4=CC=C(F)C(=C4)Cl)C3=O)C(=O)NC)C1=O,MK-2048,,JSRREMIKIHJGAA,HIV Integrase Inhibitors,
NCGC00161414-02,CN1[C@H]2CC[C@@H]1CC(C2)OC(=O)C3=C[NH]C4=CC=CC=C34,,TROPISETRON,ZNRGQMMCGHDTEI,5-HT3 Antagonists,HTR3A
NCGC00015724-14,OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1,,NIFLUMIC ACID,JZFPYUNJRRFVQU,Cyclooxygenase-2 Inhibitor,PTGS2
NCGC00162249-04,CC(C)C1=CC=C2[N](CC3=CC=C(Cl)C=C3)C(=C(SC(C)(C)C)C2=C1)CC(C)(C)C([O-])=O,,,QAOAOVKBIIKRNL,5-lipoxygenase-activating (FLAP) inhibitor,ALOX5AP
NCGC00169145-02,OC[C@H]1O[C@@H](OCCC2=CC=C(O)C=C2)[C@H](O)[C@@H](O)[C@@H]1O,Salidroside(Rhodioloside),,ILRCGYURZSFMEG,beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors,APP
NCGC00015026-14,CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,ATROPINE SULFATE,,RKUNBYITZUJHSG,M1 Muscarinic acetylcholine receptor Antagonists,CHRM1
NCGC00167441-03,CCCN[C@H]1CCC2=C(C1)SC(=N2)N,Pramipexole (Mirapex),,FASDKYOPVNHBLU,Dopamine D3 Antagonist,DRD3
NCGC00037850-05,CC1=CC(=C(C)[N]1C2=CC=CC=C2)C3=NN=C4CCCCC[N]34,,,SGHSEHOWYLRAPR,HPGD Inhibitor,HPGD
NCGC00159456-06,CN1CCN(CC1)CC2=CC=C(C=C2)C(=O)NC3=CC=C(C)C(=C3)NC4=NC=CC(=N4)C5=CC=CN=C5,Imatinib;GGP-57148B;Gleevec;STI-571,STI571;Imatinib mesilate;IMATINIB;CIPLUS_700313;Imatinib Mesilate;4-(4-(4-METHYL-1-PIPERAZINYL)METHYL)-N-(4-METHYL-3-((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINO)-PHENYL)BENZAMIDE MESYLATE;CIPLUS_670910;Imatinib mesylate;HS_649;imatinib;CPG-57148B;Glivec;Imatinib base;Genpharm brand of imatinib mesylate;IMATINIB MESILATE;Gleevec;CGP-57148;CGP 57148;imatinib mesylate;Imatinib;IMATINIB MESYLATE;CGP57148B;STI 571;imatinibum;Imatinib base(IMA-3);Novartis brand of imatinib mesylate;STI-571;,KTUFNOKKBVMGRW,Bcr-Abl Inhibitor,ABL1
NCGC00165902-02,CN1CCN(CC1)C(=O)C2=C(C)[NH]C(=C2C)\C=C3/C(=O)NC4=CC=C(C=C34)[S+]([O-])(=O)N(C)C5=CC(=CC=C5)Cl,SU11274,,PGKXHYVUCJQWPU,HGFR (MET; c-Met) Inhibitor,MET
NCGC00165815-05,CCOC(=O)N1CCN(CC1)[N+](/[O-])=N/OC2=C(C=C(C=C2)[N+]([O-])=O)[N+]([O-])=O,JS-K,,DNJRNBYZLPKSHV,nitric oxide donors,
NCGC00179341-02,C1=CC=C2C(=C1)C4=C(N2C)CCC(CN3C(C)=NC=C3)C4=O,Ondansetron,"LS-51879;Ondansetron hydrochloride;CIPLUS_3827701;LS-51878;1,2,3,9-TETRAHYDRO-9-METHYL-3-((2-METHYLIMIDAZOL-1-YL)METHYL)CARBAZOLE-4-ONE HYDROCHLORIDE DIHYDRATE, DL-;Ondansetron, (S)-Isomer;LS-171880;ONDANSETRON HCL;LS-172305;CIPLUS_196240;ONDANSETRON HCl;LS-178427;LS-178426;Zofran;NCGC_Prestw-1058;HS_1542;HS_1541;Ondansetron;4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-;Ondansetron Monohydrochloride;ONDANSETRON HYDROCHLORIDE DIHYDRATE;CIPLUS_210769;Ondansetron Hcl;9-METHYL-3-((2-METHYL-1H-IMIDAZOL-1-YL)METHYL)-1,2,3,9-TETRAHYDRO-4H-CARBAZOL-4-ONE HYDROCHLORIDE DIHYDRATE;Ondansetron, (+,-)-Isomer;Zofran ODT;ondansetronum;1,2,3,4-Tetrahydro-9-methyl-3-(2-methyl-1H-imidazol-1-ylmethyl)carbazol-4-one;ONDANSETRON HYDROCHLORIDE;Ondansetron, (R)-Isomer;Ondansetron hydrochloride dihydrate;CIPLUS_194568;ONDANSETRON;Ondansetron Hydrochloride Di;NCGC00163170-01;Ondansetron Monohydrochloride Dihydrate;HS_1037;NCGC00016968-01;GR-38032F;4H-CARBAZOL-4-ONE, 1,2,3,9-TETRAHYDRO-9-METHYL-3-((2-METHYL-1H-IMIDAZOL-1-YL)METHYL)-, MONOHYDROCHLORIDE, DIHYDRATE;Methoxamine HCl;ONDANSETERON HYDROCHLORIDE;ondansetrone;Ondansetron HCl;Ondansetron Hydrochloride;",FELGMEQIXOGIFQ,5-HT3 Antagonists,HTR3A
NCGC00263195-01,CN1CCN(CC1)C(C)(C)C#CC2=C(NC(=O)C=C)C=C3C(=NC=NC3=C2)NC4=CC(=C(F)C=C4)Cl,AV-412;MP-412,,ZAJXXUDARPGGOC,EGFR (HER1; erbB1) inhibitor,EGFR
NCGC00095486-03,CC(C)C(C)/C=C/C(C)C1CCC2\C3=C\C=C/4CC(O)CCC4(C)C3CCC12C,ERGOSTEROL,,DNVPQKQSNYMLRS,Sterol (fungal cell wall),
NCGC00163489-04,CC(C)=CC[C@@H](O)C/1=C/C(=O)C2=C(O)C=CC(=C2C1=O)O,Shikonin,,NEZONWMXZKDMKF,Drugs Acting on Chemokine Receptors,CCR5
NCGC00274030-01,CCN1CCN(CC1)C2=CC=C(NC3=CC(=NC=N3)N(C)C(=O)NC4=C(Cl)C(=CC(=C4Cl)OC)OC)C=C2,NVP-BGJ398,,QADPYRIHXKWUSV,FGFR 1/2/3/4 inhibitor,
NCGC00165889-02,CC1=NC(=CC=C1)C2=C(N=C([NH]2)C(C)(C)C)C3=CC4=C(OCO4)C=C3,SB-505124,,WGZOTBUYUFBEPZ,TGF-bR1 (ALK4/5) Inhibitor,
NCGC00346627-01,CN1CCCN(CC1)C2=CC=C3C(=O)\C(=C/4SC5=C(C=CC=C5)N4C3=N2)C(=O)NCC6=CN=C(C)C=N6,CX-5461,,XGPBJCHFROADCK,RNA Polymerase Inhibitor,POLR2A
NCGC00263174-01,CC(C)[C@@H](N(CCCN)C(=O)C1=CC=C(C)C=C1)C/2=N/C3=CC(=CC=C3C(=O)N2CC4=CC=CC=C4)Cl,Ispinesib;CK-0238273/SB-715992,,QJZRFPJCWMNVAV,Kinesin-Like Spindle Protein Inhibitor,KIF11
NCGC00263169-01,CC(C)(C)C1=C(/C=C/2NC(=O)\C(NC2=O)=C\C3=CC=CC=C3)N=C[NH]1,Plinabulin,,UNRCMCRRFYFGFX,Tubulin polymerization inhibitor,TUBB
NCGC00263152-02,CN1CCN(CC1)CC2=CC=C(NC(=O)C3=CC(=C(C)C=C3)C#CC4=CN=C5C=CC=N[N]45)C=C2C(F)(F)F,Ponatinib (AP24534),,PHXJVRSECIGDHY,FGFR Inhibitor,
NCGC00345447-02,C[N]1C=NC(=C2N=CN=C12)N,3-Methyladenine,,FSASIHFSFGAIJM,PI3K Inhibitor,PIK3CA
NCGC00263544-02,C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,Dexrazoxane Hydrochloride,,BMKDZUISNHGIBY,DNA Topoisomerase II Inhibitors,TOP2A
NCGC00068236-08,COC1=C(N2CCNC(C)C2)C(=CC3=C1N(\C=C(C(O)=O)/C3=O)C4CC4)F,GATIFLOXACIN,,XUBOMFCQGDBHNK,DNA Topoisomerase IV Inhibitors,TOP2B
NCGC00263183-01,CN1CCN(CC1)C2=CC=C(NC3=NC=C4C(=O)N(CC=C)N(C5=CC=CC(=N5)C(C)(C)O)C4=N3)C=C2,MK-1775,,BKWJAKQVGHWELA,Wee1 Kinase Inhibitor,WEE1
NCGC00185756-01,[Na+].[Na+].ClCCN(CCCl)C(=O)Oc3cc4CC[C@@H]1[C@H](CC[C@]2(C)[C@H](CC[C@@H]12)OP([O-])([O-])=O)c4cc3,Estramustine phosphate sodium,,ADFOJJHRTBFFOF,DNA Alkylating Agent,
NCGC00263235-01,CC(C)OC1=CC=C(OC2=CC=C(C=C2)C(C)NC(C)=O)C=C1,ACC1 BMS,,VZPUSWFWIJXJDY,Acetyl-CoA carboxylase inhibitor,ACACA
NCGC00346944-01,C[C@@H](N)C1=CC=C(C=C1)C(=O)NC2=C3C=C[NH]C3=NC=C2,Y-39983 dihydrochloride,,JTVBXQAYBIJXRP,ROCK Inhibitor,ROCK1
NCGC00165727-02,O=C1NC2=CC=CC=C2N1C3CCN(CC3)CC4=CC=C(C=C4)C5=C(N=C6C=C7[NH]C=NC7=CC6=N5)C8=CC=CC=C8,AKT inhibitor VIII,,BIWGYFZAEWGBAL,AKT 1/2 Inhibitor,AKT1
NCGC00187481-04,CN1C(=O)N(C2=CC=C(C=C2)C(C)(C)C#N)C3=C4C=C(C=CC4=NC=C13)C5=CC6=C(C=CC=C6)N=C5,BEZ235;NVP-BEZ-235,,JOGKUKXHTYWRGZ,mTOR inhibitor,MTOR
NCGC00346883-01,CC(=O)O\N=C1\C(NC2=CC=CC=C12)=C3/C(=O)NC4=C3C=CC(=C4)Br,BIO-acetoxime,,MENDIXKFTXYTHJ,GSK-3 inhibitor,GSK3B
NCGC00346511-01,COC1=CC(=C(\C=C\[S+]([O-])(=O)CC2=CC=C(OC)C(=C2)NCC(=O)O[Na])C(=C1)OC)OC,ON-01910,,HJYORJBPHBUKBI,Polo-like Kinase-1 (Plk-1) Inhibitor,PLK1
NCGC00177986-04,CCN1\C=C(C(O)=O)/C(=O)C2=C1C=C(N3CCN(C)CC3)C(=C2)F,Pefloxacin mesylate,,FHFYDNQZQSQIAI,Antibacterial,
NCGC00095055-03,CCC(C1CCC(C)C(O1)C(C)C(O)C(C)C(=O)C(CC)C2OC\3(O[C@]4(CC[C@@](C)(O4)C5CC[C@@](O)(CC)C(C)O5)C(O)\C=C3)C(C)CC2C)C([O-])=O,"SALINOMYCIN, SODIUM",,KQXDHUJYNAXLNZ,Anticoccidial/Antibacterial,WNT1
NCGC00167767-03,O=C(N1CCC(CC1)N2CCCC2)C3=CC=C(NC4=NC=CC(=N4)C5=CC6=C(S5)C=CC=C6)C=C3,IKK 16,,BWZJBXAPRCVCKQ,"IKK1, IKK-2, IKK complex inhibitor",IKBKB
NCGC00015225-03,COC1=C(OC)C2=C[N+](=C3C(=C2C=C1)C=CC4=CC5=C(OCO5)C=C34)C,Chelerythrine chloride;MP-0922/NSC-646662,"NCGC00162102-03;NCGC00162102-02;Chelerythrine hydrochloride;NCGC00015225-01;NCGC00162102-04;chelerythrine sulfate;CIPLUS_214574;1,2-Dimethoxy-N-methyl(1,3)benzodioxolo(5,6-c)phenanthridinium chloride;LS-174464;chelerythrine chloride;chelerythrine;CIPLUS_723475;NCGC00162102-01;CHELERYTHRINE;NCGC00093703-01;1,2-dimethoxy-12-methyl(1,3)benzodioxolo(5,6-c)phenanthridinium;LS-52942;Chelerythrine chloride;1,2-Dimethoxy-12-methyl[1,3]benzodioxolo[5,6-c]phenanthridinium chloride;CIPLUS_3884937;chelerythrine hydroxide;LS-175425;LS-175067;",LLEJIEBFSOEYIV,Bcl-xL inhibitor,BCL2L1
NCGC00017363-10,C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC2CC(=O)NC(=O)C2,CYCLOHEXIMIDE,,YPHMISFOHDHNIV,Glycogen Synthase Kinase 3 beta (GSK-3beta; tau Protein Kinase I) Inhibitor,GSK3B
NCGC00186528-04,C[N]1C2=C(SC(=C2)[S+](C)[O-])C\3=C1C(=O)N(CC4=CC(=CC=C4)N)\N=C3,NCGC00186528,,ZWKJWVSEDISQIS,PKM2 activator,PKM2
NCGC00015819-11,CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC2=CC=CC=C2,Propafenone,PROPAFENONE,JWHAUXFOSRPERK,anti-arrythmia drug,
NCGC00161641-04,COC/1=C/[C@@H]2[C@@H]3CC4=C(C(=C(OC)C=C4)O)[C@]2(CCN3C)CC1=O,Sinomenine (Cucoline),,INYYVPJSBIVGPH,Antiinflammatory opioid,
NCGC00263016-01,CCCCCN(CCC12CC3CC(CC(C3)C1)C2)C(=O)NCCCC4=CC=NC=C4,DE-096,,AIUJHENHBJHHMY,TRPV4 Antagonist,TRPV4
NCGC00263239-02,COCCNCCC[N]1C2=NC=NC(=C2C(=C1C(=O)CF)C3=CC=C(C)C=C3)N,FMK,,UPTQGXMIZXGVSC,MAPKAP-K1 (RSK; p90Rsk) Inhibitor,RPS6KA1
NCGC00025155-01,,Omacetaxine mepesuccinate,"HOMOHARRINGTONINE HYDROCHLORIDE;HOMOHARRINGTONINE;Homoharringtonine;LS-52751;Ceflatonin;CIPLUS_214595;homoharringtonine;4'-METHYL-2'R-HYDROXY-2'-(4-HYDROXY-4-METHYLPENTYL)-BUTANEDIOATE CHLORIDE, 3R;homoharringtonine, 3H-labeled, (3(R))-isomer;NCGC00025155-01;",HYFHYPWGAURHIV,Alkaloid,
NCGC00163620-02,CC1(C)CCC[C@@]2(C)[C@H]1CC[C@@]3(C)OC(=O)C[C@H]23,Sclareolide (Norambreinolide),,IMKJGXCIJJXALX,sesquiterpene natural product,
NCGC00015054-06,NC1=C(CCCC3)C3=NC2=C1C=CC=C2,Tacrine,"LS-1191;NCGC00093554-02;9-AMINO-1,2,3,4-TETRAHYDROACRIDINE;TACRINE;Tetrahydroaminacrine hydrochloride hydrate;NCGC00093554-01;Tacrine hydrochloride;TACRINE HYDROCHLORIDE;JB-8211;Tetrahydroaminacrin;9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE;NCGC00017035-01;9-Acridinamine, 1,2,3,4-tetrahydro-;CIPLUS_158828;tacrine;tacrinum;Cognex;Tacrinum;Tacrine;NCGC_Prestw-329;Tetrahydroaminoacridine Monohydrate;Tacrina;THA hydrochloride;NCGC00024908-01;9-Amino-1,2,3,4-tetrahydroacridine hydrochloride;NCGC00024908-05;NCGC00024908-04;1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8);AB02509363-01;NCGC00015054-01;THA hydrochloride hydrate;LS-926;Tacrine hydrochloride hydrate;9-Amino-1,2,3,4-tetrahydroacridine hydrochloride hydrate;CI-970;CIPLUS_152668;1,2,3,4-TETRAHYDRO-5-AMINOACRIDINE HYDROCHLORIDE;",YLJREFDVOIBQDA,Acetylcholinesterase Inhibitors,ACHE
NCGC00016246-12,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1,Chlorhexidine,,GHXZTYHSJHQHIJ,MMP Inhibitor,MMP1
NCGC00015144-04,NC1=NC(=C2N=C[NH]C2=N1)OCC3=CC=CC=C3,O6-benzylguanine,,KRWMERLEINMZFT,O6-Alkylguanine-DNA Alkyltransferase (MGMT) Inhibitors,MGMT
NCGC00181345-01,O=C([C@H]3N[C@H]([C@](OCC)=O)CCC2=CC=CC=C2)N(CC(O)=O)C[C@H](SC3)[C@@]1=CC=CS1.Cl,Temocapril hydrochloride,"LS-150463;CIPLUS_213546;LS-150462;CIPLUS_213547;Temocaprilum;1,4-Thiazepine-4(5H)-acetic acid, 6-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-, monohydrochloride, (2S-(2alpha,6beta(R*)))-;TEMOCAPRIL HYDROCHLORIDE;Acecol;TEMOCAPRIL;CS 622;temocaprilum;Temocapril Hydrochloride;TEMOCAPRIL HYCROCHLORIDE;alpha-((2S,6R)-6-((1S)-1-ethoxycarbonyl-3-phenylpropyl)amino-5-oxo-2-(2-thienyl)perhydro-1,4-thiazepin-4-yl)acetic acid.HCl;CS622;Temocapril;Temocapril hydrochloride;temocapril;A-(6((S)-1-ETHOXYCARBONYL-3-PHENYLPROPYL)AMINO-5-OXO-2-(2-THIENYL)PERHYDRO-1,4-THIAZEPIN-4-YL)ACETIC ACID(2S,6R)HYDROCHLORIDE;temocapril hydrochloride;CS-622;",FIQOFIRCTOWDOW,Angiotensin-I Converting Enzyme Inhibitor,ACE
NCGC00164561-03,CC(=O)N[C@@H]1[C@@H](NC(N)=N)\C=C(/O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O,Zanamivir (Relenza),,ARAIBEBZBOPLMB,Neuraminidase (Sialidase) Inhibitors,
NCGC00263155-01,ONC(=O)/C=C/C1=CC(=CC=C1)[S+]([O-])(=O)NC2=CC=CC=C2,Belinostat,,ZYHQUMIRDYCAMN,Histone Deacetylase (HDAC) 1/2 Inhibitor,HDAC1
NCGC00263137-01,CNC(=O)C1=CC=C(C=C1F)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(C=C4)C#N)C(F)(F)F,RD-162;NC-53,,JPQFGMYHKSKKGW,Androgen Receptor Antagonist,AR
NCGC00346894-01,C/C=C/C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C,PSC 833,,YJDYDFNKCBANTM,P-Glycoprotein (MDR-1; ABCB1) Inhibitors,
NCGC00095838-03,CN[S+]([O-])(=O)CC1=CC=C2[NH]C=C(CCN(C)C)C2=C1,SUMATRIPTAN,,VUKRFPJOONBESE,5-HT1B Agonist,HTR1B
NCGC00263230-01,COC1=CC=CC=C1C2=CC=CC(=C2)C/3=C(O)/C4=CC(=C(Cl)C=C4NC3=O)C#N,FASN MRK,,PSQCGDAJJBYDRJ,Fatty acid synthase inhibitor,FAS
NCGC00164566-02,O[C@H](C[C@H](O)\C=C\C1=C(C2=CC=C(F)C=C2)C3=C(C=CC=C3)N=C1C4CC4)CC([O-])=O,,"ITAVASTATIN CALCIUM;bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt;CIPLUS_709111;Livalo;NK-104;LS-74595;Pitavastatin;Itavastatin;P-872441;P 872441;PITAVASTATIN CALCIUM;CIPLUS_3816026;pitavastatin;itavastatin;pitavastatinum;nisvastatin;NCGC00164566-02;NK 104;Pitavastatin Calcium;7-(2-CYCLOPROPYL-4-(4-FLUOROPHENYL)-3-QUINOLIN-YL)-3,5-DIHYDROXY-6-HEPTENOIC ACID CALCIUM, E-, 3R,5S,6E;ITAVASTATIN Ca;Pitavastatin calcium;NCGC00164566-01;",VGYFMXBACGZSIL,HMG-CoA Reductase Inhibitor,HMGCR
NCGC00189393-03,FC1=C(C=C(NC(=O)NC2=NN=C(S2)C3=CC=NC=C3)C=C1)C(F)(F)F,NCGC00189393-02,,WMCOYUSJXXCHFH,BLM inhibitor,BLM
NCGC00093704-11,CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,CYCLOSPORINE,,PMATZTZNYRCHOR,immunosuppressant,
NCGC00263175-01,CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)C2=CC=CC=C2,Tosedostat;BB-76163/CHR-2797,,FWFGIHPGRQZWIW,Aminopeptidase N Inhibitor,ANPEP
NCGC00168108-02,CN(C)CC1=CC=C(C=C1)C2=NC3=CC=CC4=C3[N]2CCNC4=O,AG-14361;TBI-361???,,SEKJSSBJKFLZIT,PARP-1 Inhibitor,PARP1
NCGC00346971-01,CCOC(=O)N1CCN(CC1)[N+](/[O-])=N/OC2=C(C=C(C(=C2)O\N=[N+]([O-])\N3CCN(CC3)C(=O)OCC)[N+]([O-])=O)[N+]([O-])=O,Double JS-K,,PLJOHHDIEPULOP,nitric oxide donors,
NCGC00168759-04,OC(=O)C1=CC=CC(=C1)C2=NOC(=N2)C3=CC=CC=C3F,,,OOUGLTULBSNHNF,CFTR-G542X nonsense allele inhibitor,CFTR
NCGC00263114-01,COC1=CC=C2[C@@H]([C@@H](CCC2=C1)CN(C)CC(O)=O)C3=CC=CC=C3,SCH-900435;Org-25935,,UEBBYLJZCHTLEG,Glycine Transporter 1 (GlyT-1) Inhibitor,SLC6A9
NCGC00018193-06,FC(F)(F)C(C=C1)=CC=C1/C(CCCCOC)=N/OCCN,Fluvoxamine,"NCGC00021870-05;Fluvoxamina;NCGC00021870-04;CIPLUS_682604;NCGC00093897-01;NCGC00021870-02;Fluvoxamine;Fluvoxamine maleate;NCGC00015431-02;FLUVOXAMINE;CIPLUS_181936;LS-101999;fluvoxaminum;FLUVOXAMINE MALEATE;DU-23000;1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime, (E)-;Fluvoxamine, (Z)-Isomer;luvox;(E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone-O-(2-aminoethyl)oxime maleate;Fluvoxaminum;5-METHOXY-4'-(TRIFLUOROMETHYL)VALEROPHENONE-(E)-O-(2-AMINOETHYL)OXIME MALEATE (1:1);Luvox;CIPLUS_184080;fluvoxamine;NCGC_Prestw-995;LS-102000;NCGC00015431-01;LS-178072;",CJOFXWAVKWHTFT,5-HT Reuptake Inhibitor,HTR1A
NCGC00346968-01,CN(C)/[N](O)=N/OC1=CC(=C(C=C1[N+]([O-])=O)[N+]([O-])=O)O/N=[N+]([O-])/N2CCN(CC2)C(=O)C3=CC(=CC=C3F)C/C4=N/NC(=O)C5=CC=CC=C45,JS-65-103,,BPXMEEZAQCQENP,nitric oxide donors,
NCGC00263539-03,ClC1=CC2=C(CC(=O)N2)C=C1CCN3CCN(CC3)C4=NSC5=CC=CC=C45,Ziprasidone hydrochloride,,MVWVFYHBGMAFLY,5-HT2A Antagonists?,HTR2A
NCGC00014670-16,ClC1=CC2=C(C=C1)N(C3CCN(CCCN4C(=O)NC5=C4C=CC=C5)CC3)C(=O)N2,DOMPERIDONE,,FGXWKSZFVQUSTL,Dopamine Receptor Antagonist,DRD1
NCGC00346439-01,COC1=CC2=C(C=C1)C(CN(C)C2)C3=CC=C(Cl)C(=C3)Cl,Diclofensine,,ZJDCGVDEEHWEIG,Dopamine Transporter (DAT) Inhibitor,SLC6A3
NCGC00159453-06,CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1,Zileuton;A-64077/ABT-077,,MWLSOWXNZPKENC,5-Lipoxygenase Inhibitor,ALOX5
NCGC00263135-01,CC(C)(C)COC1=C(C=C(C=C1)[N]2C=C(C=N2)C(O)=O)C#N,Piraxostat,,AETHRPHBGJAIBT,Xanthine Oxidase Inhibitor,XDH
NCGC00263281-01,O=C(C1CC1)N2CC[C@H](C2)C[N]3C4=CC=NC=C4N=C3C5=CC=C(C=C5)C6=CC=C7OC=CC7=C6,GSK-1995010,,MXQGGBTXHJSPPG,FAS inhibitor,FAS
NCGC00095089-11,OC(C[N]1C=NC=N1)(C[N]2C=NC=N2)C3=CC=C(F)C=C3F,FLUCONAZOLE,,RFHAOTPXVQNOHP,Antifungal Agent,
NCGC00142615-03,OC1=CC([C@H](CNC)O)=CC=C1O,Epinephrine,"CIPLUS_181159;EPINEPHRINE UNDECYLENATE;NCGC00015417-01;LS-1354;LS-156;NCGC00162177-01;Adrenalin chloride;CIPLUS_758742;(-)-Epinephrine (+)-bitartrate salt;(-)-3,4-DIHYDROXY-.ALPHA.-((METHYLAMINO)METHYL)BENZYL ALCOHOL (+)-TARTRATE (1:1) SALT.;racepinefrine;Epinefrina;L-ADRENALINE;racepinefrinum;(-)-adrenaline tartrate;ADRENALINE HYDROCHLORIDE, DL-;Epinephrine bitartrate;Racepinefrina;adrenaline sulfate;(+/-)-Epinephrine;NCGC00093902-01;(+/-)-3,4-Dihydroxy-alpha-(methylaminomethyl)benzyl alcohol;(-)-Epinephrine;Adrenaline bitartrate;Benzyl alcohol, 3,4-dihydroxy-alpha-((methylamino)methyl)-, (-)-, tartrate (1:1), (+)-;L-3,4-Dihydroxy-alpha-(methylaminomethyl)benzyl alcohol D-hydrogen bitartrate salt;DL-ADRENALINE HYDROCHLORIDE;(-)-3,4-DIHYDROXY-.ALPHA.-((METHYLAMINO)METHYL)BENZYL ALCOHOL;Benzyl alcohol, 3,4-dihydroxy-alpha-((methylamino)methyl)-, (+-)-;RACEPINEPHRINE;Epinephrin;Epinephrine Hydrochloride;CIPLUS_148739;EPINEPHRINE;(?)-Adrenalin hydrochloride;CIPLUS_152179;Racepinephrine Hcl;EPINEPHRINE HYDROCHLORIDE;EPINEPHRINE BITARTRATE;LS-42883;4-((1R)-1-HYDROXY-2-(METHYLAMINO)ETHYL)BENZENE-1,2-DIOL;NCGC00094666-02;NCGC00094666-01;L-Epinephrine D-hydrogentartrate;Adrenaline-L Bitartrate;4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol;dl-Adrenaline;(R)-(-)-3,4-Dihydroxy-alpha-(methylaminomethyl)benzyl alcohol;Racepinefrinum;CIPLUS_3883737;Adrenalin;ADRENALINE BITARTRATE;RACEPINEFRINE;1,2-benzenediol, 4-(1-hydroxy-2-(methylamino)ethyl)-, hydrochloride, (r)- (9ci);LS-42887;RACEPINEPHRINE HYDROCHLORIDE;Epinephrine hydrochloride;3,4-DIHYDROXYA-((METHYLAMINO)METHYL)BENZYL ALCOHOL, L-;(+/-)-Epinephrine hydrochloride;ADRENALIN;L-Epinephrine;1,2-BENZENEDIOL, 4-(1-HYDROXY-2-(METHYLAMINO)ETHYL)-, (R)-, (R-(R*,R*))-2,3-DIHYDROXYBUTANEDIOATE (1:1) (SALT);Epinephrine Bitartrate;CIPLUS_151790;Sphygmogenin;Epinephrine;HS_544;Epinephrinum;(2R,3R)-2,3-DIHYDROXYSUCCINIC ACID - 4-((1R)-1-HYDROXY-2-(METHYLAMINO)ETHYL)BENZENE-1,2-DIOL (1:1);L-Adrenaline (+)-bitartrate salt;NCGC00142615-05;CIPLUS_148607;NCGC00142615-06;CIPLUS_748688;NCGC00142615-04;(-)-Epinephrine bitartrate;CIPLUS_148608;Benzyl alcohol, 3,4-dihydroxy-alpha-((methylamino)methyl)-, hydrochloride, (-)-;epinephrine;CIPLUS_152703;CIPLUS_152704;3,4-Dihydroxy-alpha-(methylaminomethyl)benzyl alcohol;DL-Adrenaline;Asmatane mist;CIPLUS_666031;(+/-)-Adrenalin;epinephrinum;(?)-Epinephrine hydrochloride;4-(1-Hydroxy-2-;L-Adrenaline;ADRENALINUM;(-)-Adrenalin;L-(-)-EPINEPHRINE;1,2-Benzenediol, 4-(1-hydroxy-2-(methylamino)ethyl)-, (R)-;1,2-BENZENEDIOL, 4-((1R)-1-HYDROXY-2-(METHYLAMINO)ETHYL)-;L-Adrenaline D-hydrogentartrate;NCGC00016147-01;NCGC00093916-01;NCGC_SIGMA_E1635;1,2-BENZENEDIOL, 4-(1-HYDROXY-2-(METHYLAMINO)ETHYL)-, (R)-;",UCTWMZQNUQWSLP,alpha/beta-adrenoceptor agonist,ADRA1A
NCGC00025325-03,O[C@H]1C[C@H](OCC2=CC=C(C=C2)C3=CC=CC=C3)[C@H](CC\C=C/CCC(O)=O)[C@H]1N4CCCCC4,GR-32191B,,GQGRDYWMOPRROR,Prostanoid TP Antagonist,TBXA2R
NCGC00253658-02,CN(C)[C@@H](CCOC1=CC=CC2=C1C=CC=C2)C3=CC=CC=C3,Dapoxetine hydrochloride (Priligy),,USRHYDPUVLEVMC,Serotonin Transporter (SERT) Inhibitor,SLC6A4
NCGC00015856-08,O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O.CN1CCN(CC1)CCCN2c4ccccc4Sc3ccc(Cl)cc23,Prochlorperazine dimaleate,,WIKYUJGCLQQFNW,Dopamine D2 Antagonist,DRD2
NCGC00079434-03,C[S+]([O-])(=O)N(CC(O)C[N]1C2=CC=CC=C2C3=CC=CC=C13)CC4=CC=CO4,,,OQAFDLPAPSSOHY,Cryptochrome Activator,
NCGC00346464-01,CON(C)C(=O)N1\N=C(/S[C@]1(CCCN)C2=CC=CC=C2)C3=CC(=CC=C3F)F,ARRY-520,,LLXISKGBWFTGEI,Kinesin-Like Spindle Protein Inhibitor,KIF11
NCGC00263144-02,COC1=CC(=CC=C1NC2=NC=C(Cl)C(=N2)OC3=CC(=CC=C3)NC(=O)C=C)N4CCN(C)CC4,WZ-4002,,ITTRLTNMFYIYPA,EGFR (HER1; erbB1) Inhibitor,EGFR
NCGC00263215-02,CCC(=O)N1CCN(CC1)C2=C(C=C(C=C2)N3C(=O)\C=C/C4=C3C5=CC(=CC=C5N=C4)C6=CN=C7C=CC=CC7=C6)C(F)(F)F,Torin 1,,AKCRNFFTGXBONI,mTOR inhibitor,MTOR
NCGC00346590-01,C[C@@H]1CC[C@H]2[C@@H](C)[C@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,Dihydroartemisinin (DHA),,BJDCWCLMFKKGEE,antimalarial agents,
NCGC00015950-07,OC1=C(Cl)C=C(N\C2=C(\C(=O)NC2=O)C3=C(C=CC=C3)[N+]([O-])=O)C=C1,SB 415286,,PQCXVIPXISBFPN,GSK-3 inhibitor,GSK3B
NCGC00242482-01,ClC1=CC=CC(=C1)NC(=O)NC2=NC=C(CCNC3=NC=NC4=C3SC=C4)S2,SNS-314,,FAYAUAZLLLJJGH,Aurora-A/B/C Kinase Inhibitor,AURKA
NCGC00188380-01,COC1=CC(=C(F)C(=C1N[S+]([O-])(=O)C2(CC2)C[C@H](O)CO)NC3=C(F)C=C(I)C=C3)F,RDEA-119;AR-119;BAY-86-9766,,QXLZZQSWYQRQEM,Mek 1/2 inhibitor,MAP2K1
NCGC00345781-01,OC[C@H]1O[C@H]([C@@H](F)[C@@H]1O)N2\C=C/C(=O)NC2=O,1-(2 -Deoxy-2 -fluoro-b-D-arabinofuranosyl)uracil,,UIYWFOZZIZEEKJ,DNA-Intercalating Drugs,
NCGC00094763-03,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)NC([C@@H](C)O)C(=O)N[C@H](CCN)C(=O)N[C@@H]1CCNC(=O)C(NC(=O)[C@@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O,Polymyxin B sulphate,,WQVJHHACXVLGBL,Peptide Antibiotic,
NCGC00263168-01,CC(C)CC(=O)NC1=N[NH]C2=C1CN(C(=O)C3CCN(C)CC3)C2(C)C,PHA-793887,,HUXYBQXJVXOMKX,"CDK1,2,3,4,5 Inhibitor",CDK1
NCGC00016446-12,CC1=NC=C([N]1CCO)[N+]([O-])=O,METRONIDAZOLE,,VAOCPAMSLUNLGC,Antibiotic,
NCGC00346691-01,CC1=C(CC2=CC=C(S2)C3=CC=C(F)C=C3)C=C(C=C1)[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O,Canagliflozin,,XTNGUQKDFGDXSJ,SGLT-2 inhibitor,
NCGC00263207-01,OC[C@H](CC1=CC=CC=C1)NC2=NC(=NC3=C2N=C[N]3CC4=CC=C(C=C4)C5=CC=CC=C5)OC6=CC7=C(CCC7)C=C6,QS11,,DOKZLKDGUQWMSX,ADP-ribosylation factor GTPase activating protein 1 inhibitor,ARF1
NCGC00165761-02,CC1=CC=C2N=C(NCCN)C3=NC=C(C)[N]3C2=C1,BMS345541,,PSPFQEBFYXJZEV,IKK beta inhibitor,IKBKB
NCGC00162381-03,[H][C@]12[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C1[C@@H]3OC(=O)[C@@](C)(O)[C@@]3(O)[C@H](C[C@]2(C)OC(C)=O)OC(=O)CCC,THAPSGARGIN,CIPLUS_188477;Thapsigargin;LS-176600;NCGC00162381-04;NCGC00162381-03;THAPSGARGIN;NCGC00162381-02;NCGC00094500-01;NCGC00162381-01;NCGC00016060-01;,IXFPJGBNCFXKPI,PKC Activator,PRKCA
NCGC00163633-03,COC1=C(OC)C=C(CC2NCCC3=C2C=C(OC)C(=C3)OC)C=C1,Tetrahydropapaverine hydrochloride,,YXWQTVWJNHKSCC,neurtotoxic,
NCGC00091533-11,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=CC=C34)O)[C@@H]1CC[C@@]2(O)C#C,Ethinyl Estradiol,,BFPYWIDHMRZLRN,Estrogen Receptor (ER) Agonist,ESR1
NCGC00161327-05,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2C(/CCC[C@]12C)=C/C=C3/C[C@@H](O)C[C@H](O)C3=C,Calcitriol (Rocaltrol),,GMRQFYUYWCNGIN,Vitamin D Analog,VDR
NCGC00183095-01,O=C(N)C(C3=O)=C(O)[C@@H](N(C)C)[C@]4([H])C[C@](C2=C(O)[C@]34O)([H])CC1=C(C2=O)C(O)=C(NC(CNC(C)(C)C)=O)C=C1N(C)C,Tigecycline,"Tigecycline;tigecycline;TIGECYCLINE;TetX protein, Bacillus fragilis;tigecycline 11a-hydroxylase, Bacillus fragilis;GAR-936;CL-346635;4,6-BIS(DIMETHYLAMINO)-9-((((DIMETHYLETHYL)AMINO)ACETYL)AMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-2-NAPHTHACENECARBOXAMIDE;2-NAPHTHACENECARBOXAMIDE, 4,7-BIS(DIMETHYLAMINO)-9-((((1,1-DIMETHYLETHYL)AMINO)ACETYL)AMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-, (4S,4AS,5AR,12AS)-;TBG-MINO;CIPLUS_736709;GAR 936;WAY-156936;9-(tert-butylglycylamido)minocycline;Tygacil;",FPZLLRFZJZRHSY,glycylcycline antibiotics,
NCGC00163510-03,OCC1=CC2=C(C(=C1)O)C(=O)C3=C(C=CC=C3O)C2=O,Aloe-emodin,,YDQWDHRMZQUTBA,Caspase 3 Activators,CASP3
NCGC00159438-02,O=C(O)C(CC[Se]C)N,Selenomethionine,"BUTANOIC ACID, 2-AMINO-4-(METHYLSELENO-(SUP 75)SE)-, (S)-;(S)-2-AMINO-4-(METHYLSELENYL-(SUP 75)SE)BUTYRIC ACID;Sethotope;Selenomethioninum (75 Se);Selenomethionine Hydrochloride, (S)-Isomer;Selenometionina (75 Se);Selenomethionine, (S)-Isomer;NCGC00159438-03;SELENOMETHIONINE, DL-;selenomethionine (75 Se);Butanoic acid, 2-amino-4-(methylseleno)-;SELENOMETHIONINE, SE-75;selenomethioninum (75Se);Selenomethionine, (R)-Isomer;SELENOMETHIONINE, L-;CIPLUS_208331;Seleno-DL-methionine;SELENOMETHIONINE SE 75;CIPLUS_710865;(S)-2-Amino-4-(methylseleno)butyric acid;CIPLUS_682499;CIPLUS_160576;Se 75, Selenomethionin;SELENOMETHIONINE (75 SE);Selenomethionine, (+,-)-Isomer;Selenomethionine se 75;Seleno-D, L-methionine;Selenomethionine;DL-Selenomethionine-13C1 (methyl-13C1);Seleno-L-methionine;CIPLUS_158422;SELENOMETHIONINE, L-, SE-75;",RJFAYQIBOAGBLC,dietary supplement,
NCGC00242512-01,CC\C=C/C[C@@H]1[C@H](CCC1=O)CC(=O)OC,methyl jasmonate,,GEWDNTWNSAZUDX,cytochrome c release inducer,
NCGC00161418-02,CCC1=CC=C(OCC2=C(C=CC=C2)C(=O)NC3=CC4=C(C=C3)N=C(C)C=C4N)C=C1,JTC-801,,VTGBZWHPJFMTKS,"ORL1 (OP4, NOP) Antagonists",OPRL1
NCGC00344081-02,CC1=CC=CC(=C1)NC2=NC(=CS2)C3=CC=NC=C3,STF-62247,,KATNUHQNJGNLPW,Renal cell growth inhibition,
NCGC00346712-01,COC(=O)CCC1=C(C)C2=CC3=NC(=CC4=C(C)C(=C([NH]4)C=C\5N=C(C=C1[NH]2)\C(=C5C)CCC(O)=O)C=C)\C6=C\C=C(/[C@@H](C(=O)OC)[C@@]36C)C(=O)OC,Verteporfin (Visudyne),,YTZALCGQUPRCGW,photosensitizer,
NCGC00263944-01,NC[C@H]1O[C@H](O[C@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,KANAMYCIN A SULFATE,,SBUJHOSQTJFQJX,30S Ribosomal Protein Inhibitors,
NCGC00346685-01,CCC1=C(CC(=O)N(CCOC)CCOC)C(=C(O)C=C1O)C(=O)C2=CC=C(OCCN3CCOCC3)C(=C2)OC,KW-2478,,VFUXSYAXEKYYMB,Heat Shock Protein 90 (hsp90) Inhibitor,HSP90AB1
NCGC00015619-09,C4(=C1C3=C(CCC2=C1C=CC(Cl)=C2)C=CC=N3)CCN(C(=O)OCC)CC4,Loratadine,"NCGC00023125-04;Loratadine W/Pseudo;Sch-434;NCGC00023125-06;SCH-29851;NCGC00023125-05;NCGC00023125-07;NCGC00023125-02;Sch2985;4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester;Sch 2985;Loratadine Hydrochloride;CLARITIN REDITABS;4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cycloheptal[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester;LS-178513;HS_40;HS_847;Loratadine;CIPLUS_707916;Claritin;1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester;Alavert;Wyeth Brand of Loratadine;Loratidine;Clarium;NCGC00015619-01;HS_848;HS_334;CIPLUS_192028;loratadine;WHO NO. 5864;Sch 434;loratadinum;LORATADINE;4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester;Loratadine Wyeth Bran;Sch-29851;LS-114660;8-CHLORO-6,11-DIHYDRO-11-(1-ETHOXYCARBONYL-4-PIPERIDYLIDENE)-5H-BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE;PSEUDOEPHEDRINE SULFATE;",JCCNYMKQOSZNPW,Histamine H1 Receptor Antagonists,HRH1
NCGC00183837-01,Fc1ccc(cc1)N2CCN(CC2)CCCC(=O)NC3c5ccccc5SCc4ccccc34,Monatepil,"CIPLUS_696267;AJ 2615;MONATEPIL;monatepil, (S)-isomer;monatepil, (+-) monatepil;LS-172819;LS-172817;Monatepil Maleate;monatepil maleate;LS-173001;maleate;LS-171860;11-((4-(4-(4-fluorophenyl)-1-piperazinyl)butyryl)amino)-6,11-dihydrodibenzo(b,e)thiepin maleate;1-Piperazinebutanamide, N-(6,11-dihydrodibenzo(b,e)thiepin-11-yl)-4-(4-fluorophenyl)-, (Z)-2-butenedioate (1:1);CIPLUS_3853864;MONATEPIL MALEATE;monatepil;Monatepil maleate;CIPLUS_197056;monatepil x maleate;monatepil, (R)-isomer;monatepilum;LS-173055;AJ-2615;N-(6,11-DIHYDRODIBENZO(B.E)THIEPIN-11-YL)-4-(4-FLUOROPHENYL)-1-PIPERAZINEBUTYRAMIDE MALEATE, DL-;LS-173056;",WFNRNNUZFPVBSM,Calcium Channel Blocker,
NCGC00014926-03,NC(=O)C1=C(N)[N](CC2=CC(=C(C(=C2)Cl)C(=O)C3=CC=C(Cl)C=C3)Cl)N=N1,"L-651,582",,WNRZHQBJSXRYJK,Calcium Channel Blocker,
NCGC00024547-06,OC1=C2O[C@H]3C4=C(C[C@@]5(O)[C@H]6CC(=C2[C@@]35CCN6CC7CC7)C=C1)C8=C([NH]4)[C@@H]9OC%10=C%11C(=CC=C%10O)C[C@H]%12N(CC[C@@]9%11[C@@]%12(O)C8)CC%13CC%13,nor-Binaltorphimine dihydrochloride,,APSUXPSYBJVPPS,Opioid receptor antagonist,
NCGC00346678-01,CC(C)C1=C(O)C=C(O)C(=C1)C/2=N/NC(=O)N2C3=CC4=C(C=C3)[N](C)C=C4,Ganetespib (STA-9090),,RVAQIUULWULRNW,Heat Shock Protein 90 (hsp90) Inhibitor,HSP90AB1
NCGC00346576-01,NC(=O)C1=C2[NH]C(=NC2=CC=C1)C3=CC=C(C=C3F)[C@H]4CCCN4,A-966492,,AHIVQGOUBLVTCB,PARP-1 Inhibitor,PARP1
NCGC00347936-01,[O-][S+](=O)(N1CCCCCC1)C2=CC(=CC=C2)C(=O)NC3=CC=CC(=C3)Br,,,ZRPVKNCEXWKJMU,Histone Deacetylase SIRT2 Inhibitors,SIRT2
NCGC00093354-09,NC(=O)C1=CC=CN=C1,NIACINAMIDE,,DFPAKSUCGFBDDF,Vitamin,
NCGC00346700-01,COC1=CC(=CC(=C1)NC(=O)C2=CC=C(O2)C3=CC=C(Cl)C=C3)OC,A-803467,,VHKBTPQDHDSBSP,Nav1.8 (SNS/PN3) Sodium Channel Blockers,SCN10A
NCGC00346992-01,NC1CCC(CC1)NC2=NC3=C(N=C[N]3C4=CC=CC(=C4)F)C(=N2)NC5=CC=C(C=C5)C(=O)N6CCCCC6,,,KRCOMOOXOZSNAJ,Calcium Dependent Protein Kinase (CDPK) 1 Inhibitor,
NCGC00015810-13,COC1=C(OC)C=C(CC2=C3C=C(OC)C(=CC3=CC=N2)OC)C=C1,PAPAVERINE HYDROCHLORIDE,,XQYZDYMELSJDRZ,Phosphodiesterase X (PDE10) inhibitor,PDE10A
NCGC00016611-09,CCCCOC1=CC=C(CC(=O)NO)C=C1,BUFEXAMAC,,MXJWRABVEGLYDG,non-steroidal antiinflammatory,
NCGC00346596-01,[O-][N+]12CCC[C@H]3CN4[C@H](CCCC4=O)[C@@H](CCC1)[C@@H]23,Oxymatrine (Matrine N-oxide),,XVPBINOPNYFXID,mu/kappa-Opioid Agonists,OPRM1
NCGC00346608-01,CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O,Astragaloside A,,QMNWISYXSJWHRY,treatment of degenerative bone diseases,
NCGC00015185-04,CC(CC1=CC(=C(O)C=C1)O)(NN)C(O)=O,CARBIDOPA,,TZFNLOMSOLWIDK,decarboxylase inhibitor,
NCGC00347948-01,CC1=CC=C2N=C(NC(=O)CS\C3=N\C4=C(\SCC4)C(=O)N3C5=CC=CC=C5)SC2=C1,,,WRKPZSMRWPJJDH,Porcupine (Wnt) Inhibitor,
NCGC00344623-02,O=C(N1CCC(CC1)N2CCCC2)C3=CC(=C(C=C3)C(=O)N4CCC(CC4)N5CCCC5)NC6=CC=CC=C6,,,PQOOIERVZAXHBP,L3MBTL3 methyllysine (Kme) reader domain inhibitor,
NCGC00346877-01,CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(C)C)[C@H](CSC2=CC=CS2)C(=O)NO,Batimastat,,XFILPEOLDIKJHX,MMP Inhibitor,MMP1
NCGC00253867-01,COCCCN1CCC(CC1)NC(=O)C2=CC(=C(N)C3=C2OCC3)Cl,,,ZPMNHBXQOOVQJL,5-HT4 Agonists,HTR4
NCGC00346738-01,CC(C)C[C@H](CN)CC(O)=O,Pregabalin,,AYXYPKUFHZROOJ,L-type Ca2+ channel blocker,
NCGC00163135-04,COC(=O)C/1=C(C)/N/C(=C(\C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OCCCN3CCC(CC3)(C4=CC=CC=C4)C5=CC=CC=C5)C,Niguldipine,NIGULDIPINE,SVJMLYUFVDMUHP,L-type Ca2+ channel blocker,
NCGC00178734-03,N[C@@H](CC(=O)N1CC[N]2C(=NN=C2C(F)(F)F)C1)CC3=C(F)C=C(F)C(=C3)F,SITAGLIPTIN,,MFFMDFFZMYYVKS,Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitor,DPP4
NCGC00018102-06,Fc1ccc(cc1)C(c2ccc(F)cc2)N3CCN(CC3)C/C=C/c4ccccc4,Flunarizine,"Hydrochloride, Flunarizin;flunarizinum;NCGC_Prestw-312;FLUNARIZINE DIHYDROCHLORIDE;1-[Bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)piperazine dihydrochloride;Flunarizinum;NCGC00015449-01;Flunarizine Hydrochloride;NCGC00024308-06;NCGC00015449-02;NCGC00024308-05;NCGC00024308-02;Dihydrochloride, Flunarizin;NCGC00024308-04;CIPLUS_3741150;NCGC00093920-02;R-14950;NCGC00093920-01;NCGC00093920-03;CIPLUS_3743779;LS-110464;KW-3149;Piperazine, 1-(bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)-, (E)-;Flunarizine dihydrochloride;CIPLUS_177014;Flunarizin;Flunarizine Dihydrochloride;Flunarizine hydrochloride;CIPLUS_181267;Flunarizine;Flunarizina;R1495;1-[bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)-piperazine dihydrochloride;CIPLUS_3736978;LS-110458;FLUNARIZINE HYDROCHLORIDE;Flu Narizine;FLUNARIZINE;R 1495;Sibelium;flunarizine;",SMANXXCATUTDDT,Calcium Channel Blocker,
NCGC00346555-01,COC1=CC=C(C=C1)[N]2N=C(C(N)=O)C3=C2C(=O)N(CC3)C4=CC=C(C=C4)N5CCCCC5=O,Apixaban,,QNZCBYKSOIHPEH,Coagulation Factor Xa Inhibitor,F10
NCGC00186047-02,OC1=CC=C2C=CC=CC2=C1SSC3=C4C=CC=CC4=CC=C3O,"p21-Activated Kianse Inhibitor III, IPA-3",,RFAXLXKIAKIUDT,p21-Activated Kinase 1 (PAK1) Inhibitors,PAK1
NCGC00167438-02,OC(C(=O)OC1C[C@H]2CC[C@@H](C1)[N+]23CCCC3)(C4=CC=CC=C4)C5=CC=CC=C5,Trospium chloride,,OYYDSUSKLWTMMQ,Muscarinic Antagonists,
NCGC00346581-01,C[C@H](NC1=NC(=C(F)C=C1C#N)NC2=N[NH]C(=C2)C)C3=CC=C(F)C=C3,AZ 960,,SUNXHXDJOIXABJ,Jak2/3 Inhibitor,JAK2
NCGC00015997-06,NCCS(O)(=O)=O,l-Taurine,"Aminoethylsulfonic Acid;2-ANIMOETHANESULFONIC ACID;TAURINE;CIPLUS_150971;taurinum;NCGC00024497-01;NCGC00024497-03;HS_1339;CIPLUS_658732;L-Taurine;taurine;Tauphon;AB07935405-01;Aminoethylsulfonic acid;Ethanesulfonic acid, 2-amino-;Taurine-15N;2-Aminoethanesulfonic acid;2-Amino-15N-ethanesulfonic acid;Taurine;Taurine Hydrochloride;Taurine Zinc Salt (2:1);AMINOETHYLSULFONIC ACID;Taufon;NCGC00024497-05;Taurine, Monopotassium Salt;NCGC00024497-04;ETHANESULFONIC ACID, 2-AMINO-;NCGC00015997-01;",XOAAWQZATWQOTB,amino acid antipsychotic,
NCGC00015883-08,CC/1=C(\CCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)C(=O)N/5CCCCC5=N1,,RISPERIDONE,RAPZEAPATHNIPO,Dopamine D2 Antagonist,DRD2
NCGC00159521-05,OC(C[N]1C=CN=C1)([P](O)(O)=O)[P](O)(O)=O,Zoledronic Acid (Zoledronate),,XRASPMIURGNCCH,Farnesyl Pyrophosphate Synthase Inhibitors,FDPS
NCGC00092357-04,CC(C)CC(N(C)C)C1(CCC1)C2=CC=C(Cl)C=C2,SIBUTRAMINE HYDROCHLORIDE,,UNAANXDKBXWMLN,5-HT Reuptake Inhibitor,HTR1A
NCGC00346724-01,C[C@@H]\1COC(=N1)\NC2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(OCC5=NC=CS5)C=C4)Cl,ARRY334543,,UWXSAYUXVSFDBQ,EGFR (HER1; erbB1) inhibitor,EGFR
NCGC00015785-04,[C@]12([C@]([C@@]3(CCC4[C@@]([C@@](CC1)3[H])(CCC(=O)C=4)C)[H])(CC[C@H]2C(=O)C)[H])C,Progesterone,"NCGC_Prestw-477;progesterone 20-keto-reductase;progesterone 11-alpha-hydroxylase;HS_1178;progesterone 11-succinyltyrosine methyl ester;Receptor, Progesteron;Protein, Progesterone-Bindin;pregnenolone monooxygenase;progesterone receptor A;progesterone receptor B;Progesterone Congeners;progesterone monooxygenase;oviduct progesterone receptor, Xenopus;CIPLUS_772183;progesterone 14alpha-hydroxylase;CIPLUS_3731358;mPGRMC1p, mouse;PGRMC1 protein, mouse;CIPLUS_742357;progesterone receptors B;progesterone receptors A;CIPLUS_148842;progesterone-3-(O-carboxymethyl)oxime-BSA conjugate;progesterone receptor 25-Dx protein, rat;NCGC00016253-01;HYDROXY PROGESTERONE HEXANOATE / OESTRADIOL BENZOATE / OESTRADIOL VALERATE;progesterone 11 alpha-hydroxylase;progesterone-3-bovine serum albumin;hpr6.6 protein, human;progesterone 11 alpha-monooxygenase;CIPLUS_666080;PGRMC2 protein, human;IZAg protein, human;PROGESTERONE IN INERT SILICONE ELASTOMER;7-CMPGT;progesterone 5 alpha-reductase;steroid 14-alpha-hydroxylase;CYP17A1 protein, human;Progesterone-Binding Protein;inner zone antigen, human;TMRITC-BSA progesterone;Progesterone Oil;NCGC00094770-02;11-PTME;NCGC00094770-01;progesterone-3-BSA;cytochrome P450, family 17, subfamily A, polypeptide 1, human;IZAg1 protein, human;steroid 14alpha-hydroxylase;unactive progesterone receptor, 23 kD protein, human;progesterone receptor-binding protein p48, human;Progesterone, (9 beta,10 alpha)-Isomer;progesterone 20-reductase;NCGC00022185-07;NCGC00022185-06;progesterone;NCGC00022185-05;NCGC00022185-03;6?-Methyl-17?-hydroxy-progesterone (Medroxyprogesterone);progesterone 3-(O-carboxymethyl)oxime-bovine serum albumin;progesterone 20-beta reductase;Receptors, Progesterone;steroid 11-alpha-hydroxylase;Progesterone, (13 alpha,17 alpha)-(+-)-Isomer;4-Pregnene-3,20-dione;suppression of tumorigenicity 13 protein, human;pregnenolone-17-alpha-hydroxylase;heat shock protein 90 co-chaperone protein p23, human;Pregn-4-ene-3,20-dione;PGRMC1 protein, human;Progesterona;AB07930213-01;TEBP protein, human;Progesterone;Progesterone-Binding Globulin;progesterone receptor membrane component 1 protein, rat;DETECTABLE MARKER / OESTRADIOL BENZOATE / PROGESTERONE;7-carboxymethyl progesterone;Progesterone Reductase;3 beta-Hydroxy-delta(5)-steroid:NAD+ 3-oxidoreductase;p48 protein, PR-binding;chlorpromadinone acetate;AB07944368-01;CIPLUS_669873;Progesterone: 2-hydroxypropyl-beta-cyclodextrin complex;Progesteronum;Steroid 17-alpha-Hydroxylase;Progesterone caproate (17alpha-hydroxyprogesterone);CIPLUS_3741970;PROGESTERONE;Progesterone Caproate;NCGC00015785-03;NCGC00015785-01;HYDROXY PROGESTERONE HEXANOATE;HYDROXY PROGESTERONE HEXANOATE / NANDROLONE DECANOATE / OESTRADIOL DIPROPIONATE;progesterone receptor membrane component 1 protein, human;6-hydroxyhemimaleate-progesterone;Progesterone and estrogen;Luteovis;progesterone-17 alpha-hydroxylase;progesterone-G-AP;Pregnenedione;progesteronum;progesterone receptor membrane component 1 protein, mouse;Progesterone, water-soluble;PGRMC1p, mouse;Steroid, hydrogen-donor:oxygen oxidoreductase (17 alpha-hydroxylating);(1,2,6,7-3H;dg6 protein, human;Progesterone Binding Globuli;xPR protein, Xenopus;Progesterone Binding Protei;LS-234;PREGN-4-ENE-3,20-DIONE;XPR-2 protein, Xenopus;DELTA-PREGNEN-3, 20-DIONE;progesterone 6-hemimaleate;Progesterone: HBC complex;progesterone receptor membrane component 2 protein, human;Progesterone Receptor;CIPLUS_710912;progesterone 17-alpha-hydroxylase;Crinone;pr2 protein, Xenopus;receptor A, progesterone;P-3-BSA;Hip protein, hsp70-interacting, human;ST13 protein, human;Globulin, Progesterone-Bindin;progesterone 5 beta-reductase;receptor B, progesterone;Progesterone, (17 alpha)-Isomer;hydroxyprogesterone hemisuccinate bovine serum albumin tetramethylrhodamine isothiocyanate;progesterone chlorpromadinone acetate;progesterone 11-glucuronide-alkaline phosphatase conjugate;Pgrmc1 protein, rat;pregnenolone 17-alpha-hydroxylase;CIPLUS_3817297;",RJKFOVLPORLFTN,Progestogen hormone,PGR
NCGC00262945-02,ClC1=CC=C(S1)C(=O)NCC2CN(C(=O)O2)C3=CC=C(C=C3)N4CCOCC4=O,Rivaroxaban (Xarelto),,KGFYHTZWPPHNLQ,Coagulation Factor Xa Inhibitor,F10
NCGC00015888-04,COC1C(CC2CN3CCC4=C(NC5=CC(OC)=CC=C45)C3CC2C1C(=O)OC)OC(=O)C6=CC(OC)=C(OC)C(OC)=C6,Reserpine,"CIPLUS_770802;CIPLUS_769454;RESERPINE;CIPLUS_769455;NCGC00015888-01;NCGC00091250-02;NCGC00091250-03;Serpivite;NCGC00091250-04;adelphan-esidrex;(-)-Isoreserpine;LS-178536;SALUTENSIN;CIPLUS_148558;CIPLUS_3864468;NCGC00142390-02;reserpinum;V-Serp;AB07981291-01;Nortensin;CIPLUS_697951;METHYL (3.BETA.,16.BETA.,17.ALPHA.,18.BETA.,20.ALPHA.)-11,17-DIMETHOXY-18-((3,4,5-TRIMETHOXYBENZOYL)OXY)YOHIMBAN-16-CARBOXYLATE;LS-178646;LS-178644;LS-178643;LS-178640;NCGC00016222-01;CHLOROTHIAZIDE AND RESERPINE;(3 beta,16 beta,17 alpha,18 beta,20 alpha)-11,17-dimethoxy-18-((3,4,5-trimethoxybenzoyl)oxy)yohim ban-16-carboxylic acid methyl ester, mixt. with 2,3-dihydro-1,4-phthalazinedione dihydrazone sulfate (1:1);Serpalan;Yohimban-16-carboxylic acid, 11,17-dimethoxy-18-((3,4,5-trimethoxybenzoyl)oxy)-, methyl ester, (3beta,16beta,17alpha,18beta,20alpha)-, mixt. with 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)benzoic acid;Raunervil;reserpine;Yohimban-16-carboxylic acid, 11,17-dimethoxy-18-((3,4,5-trimethoxybenzoyl)oxy)-, methyl ester, (3beta,16beta,17alpha,18beta,20alpha)-, mixt. with 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide and 1(2H)-phthalazinone hydrazone;HYDRALAZINE HYDROCHLORIDE;3,4,5-Trimethoxybenzoic acid ester;CIPLUS_3886163;raurine;CIPLUS_768968;SERPASIL-ESIDRIX #1;NCGC00095856-01;METHYL 18.BETA.-HYDROXY-11,17.ALPHA.-DIMETHOXY-3.BETA.,20.ALPHA.-YOHIMBAN-16.BETA.-CARBOXYLATE 3,4,5-TRIMETHOXYBENZOATE (ESTER).;NCGC_Prestw-875;CIPLUS_739634;Adelfan-esidrex;SERPASIL-APRESOLINE;METHYCLOTHIAZIDE;LS-178592;NCGC00094776-01;NAQUIVAL;NCGC00094776-02;CIPLUS_3886367;Yohimban-16-carboxylic acid, 11,17-dimethoxy-18-((3,4,5-trimethoxybenzoyl)oxy)-, methyl ester, (3beta,16beta,17alpha,18beta,20alpha)-;Reserpina;YOHIMBAN-16-CARBOXYLIC ACID, 11,17-DIMETHOXY-18-((3,4,5-TRIMETHOXYBENZOYL)OXY)-, METHYL ESTER, (3.BETA.,16.BETA.,17.ALPHA.,18.BETA.,20.ALPHA.)-;butiserpazide;ISORESERPINE;LS-1306;Vangarde Brand of Reserpine;Reserpine;LS-178527;caprinol;V Ser;Serpasil;Rausedil;Methyl reserpate;LS-178560;Adelphane;CHLORTHALIDONE;Apoplon;LS-178508;(3b,16b,17a,18b,20a)-11,17-Dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester;Vitarine Brand of Reserpine;LS-177572;Raupasil;CIPLUS_675383;HYDROCHLOROTHIAZIDE;Rausedyl;QUINETHAZONE;",QEVHRUUCFGRFIF,Alkaloid anitpsychotic,
NCGC00263128-01,CCN(CC)CCCCNC1=NC2=CC(=C(Cl)C=C2N=C1C3=CC=C(S3)C4=CC=CS4)Cl,PD-0220245,,MOTWHVHXEUGRAJ,CXCR1/CXCR2 Receptor Antagonist,CXCR1
NCGC00346478-02,FC1=CC(=CC=C1)COC2=CC=C(NC3=C4C=C(NC(=O)C=C)C=CC4=NC=N3)C=C2Cl,AST-1306,,MVZGYPSXNDCANY,HER2/4 (erbB2) Inhibitor,ERBB2
NCGC00179578-04,C[C@@H]1C[C@H]2[C@@H]3CC\C4=C\C(=O)\C=C/[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C5=CC=CO5)C(=O)CCl,Mometasone furoate,,WOFMFGQZHJDGCX,Corticosteroid,
NCGC00015484-06,C(CN1CCN(CCOC(C2=CC=CC=C2)C3=CC=CC=C3)CC1)CC4=CC=CC=C4,GBR 12935 dihydrochloride,,RAQPOZGWANIDQT,Dopamine Reuptake Inhibitor,
NCGC00018238-08,CCCOC1=CC=C2[NH]C(=NC2=C1)NC(=O)OC,OXIBENDAZOLE,,RAOCRURYZCVHMG,DNA Polymerase Inhibitors,
NCGC00263159-01,FC(F)(F)OC1=CC=C(NC(=O)C2=C(NCC3=CC=NC4=C3C=CC=C4)C=CS2)C=C1,OSI-930,,FGTCROZDHDSNIO,PDGFR beta inhibitor,PDGFRB
NCGC00186465-01,NC1(CCC1)c2ccc(cc2)c3nc5C=CN6C(=O)NN=C6c5cc3c4ccccc4,MK-2206;NSC-749607,,ULDXWLCXEDXJGE,PKB/Akt Inhibitor,AKT1
NCGC00262331-01,COC1=CC(=C[N]2C(=CN=C12)C3=NC(=CC=C3)NC4CNC4)Cl,,,JIGAGGIJXJGNKQ,Flt3,FLT3
NCGC00183881-01,Cl.O.O=C(O)C2=CN(c1c(OC)c(c(F)cc1C2=O)N3C[C@@H]4CCCN[C@@H]4C3)C5CC5,Moxifloxacin hydrochloride monohydrate,"BAY-12-8039;MOXIFLOXACIN HCl;HS_149;Moxifloxacin Hydrochloride;MOXIFLOXACIN HYDROCHLORIDE;Moxifloxacin hydrochloride;LS-173737;CIPLUS_730447;AVELOX;CIPLUS_678948;1-CYCLOPROPYL-7-((S,S)-2,8-DIAZABICYCLO(4.3.0)NON-8-YL)-6-FLUORO-8-METHOXY-1,4-DIHYDRO-4-OXO-3-QUINOLINE CARBOXYLIC ACID HYDROCHLORIDE;moxifloxacinum;Avelox;moxifloxacine;Moxifloxacin;MOXIFLOXACIN;NCGC00095130-02;Moxifloxacin Hcl;NCGC00095130-01;",FABPRXSRWADJSP,DNA Topoisomerase IV Inhibitors,TOP2B
NCGC00181304-01,O=C1N=C(N)C2N1C2,Imexon,"CIPLUS_210928;4-IMINO-1,3-DIAZABICYCLO(3.1.0)HEXAN-2-ONE;4-Imino-1,3-diazabicyclo[3.1.0]hexan-2-one;BM-06002;4-amino-1,3-diazabicyclo(3.1.0)hex-3-en-2-one;BM 06002;imexon;LS-176018;Imexon;4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one;IMEXON;imexonum;Imexonum;",BIXBBIPTYBJTRY,Ribonucleoside-Diphosphate Reductase Inhibitors,RRM1
NCGC00016599-05,NC/1=N/C(=O)N/C=C1F,Flucytosine (Ancobon),,XRECTZIEBJDKEO,Pyrimidine Antagonists,
NCGC00346636-01,COC(=O)NC1=CC=C(C=C1)C2=NC3=C(C=N[N]3C4CCN(CC4)CC5=CC=CN=C5)C(=N2)N6CCOCC6,WYE-687,,VDOCQQKGPJENHJ,mTOR inhibitor,MTOR
NCGC00263179-01,OCC[N]1C=C(C2=CC=C\3C(=C2)CCC3=N\O)C(=N1)C4=CC=NC=C4,AR-00341677;GDC-0879,,DEZZLWQELQORIU,Raf kinase B Inhibitor,BRAF
NCGC00263134-01,CCC1=C(N=CN=C1)N2CCN(CC2)CC3=NC4=C([NH]3)C=CC(=C4)C(F)(F)F,PF-4708671,,FBLPQCAQRNSVHB,p70 ribosomal S6 kinase (S6K1) inhibitor,RPS6KB1
NCGC00015209-12,ClCCN(CCCl)[P]1(=O)NCCCO1,Cyclophosphamide;Clafen;Cytophosphane;Cytoxan;Endoxan;Neosar;Procytox;Revimmune,,CMSMOCZEIVJLDB,BCL2/LGALS1 Expression Inhibitor,BCL2
NCGC00167740-01,CC/1=C/CC\C(=C/C2OC(=O)C(=C)C2CC1)C,,"Costus lactone;LS-71190;COSTUNOLIDE;NCGC00167740-01;costunolide;(3aS,6E,10E,11aR)-3a,4,5,8,9,11a-Hexahydro-6,10-dimethyl-3-methylene-cyclodeca[b]furan-2(3H)-one;CIPLUS_215404;Costunolide;",HRYLQFBHBWLLLL,Telomerase Inhibitor,TERT
NCGC00090691-03,OC[C@@H]1CC[C@@H](O1)[N]2C=NC3=C2\N=C/NC3=O,Didanosine,,BXZVVICBKDXVGW,Reverse Transcriptase Inhibitor,TERT
NCGC00346617-01,CC(C)[N]1C(=NC=C1C2=NC(=NC=C2)NC3=CC=C(C=C3)[S+](C)([O-])=O)C,AZD5438,,ARJWJGHFVLJPHX,CDK1/Cyclin B1 Inhibitors,
,,,,,CDK2/Cyclin E Inhibitors,CDK1
NCGC00016423-14,CC(C)C1=C(O)C(=C(C=O)C2=C1C=C(C)C(=C2O)C3=C(O)C4=C(C=O)C(=C(O)C(=C4C=C3C)C(C)C)O)O,(-)-Gossypol,,QBKSWRVVCFFDOT,Bcl-xL inhibitor,BCL2L1
NCGC00166035-02,CN[C@H]1CCC2=CC(=C(OC)C(=C2C/3=C/C=C(OC)\C(=O)/C=C13)OC)OC,,,NNJPGOLRFBJNIW,Tubulin polymerization inhibitor,TUBB
NCGC00346570-01,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)\C(=C(/N2C1=O)C(=O)OCOC(=O)C(C)(C)C)SC3CN(C3)/C4=N/CCS4,Tebipenem pivoxil (L-084),,SNUDIPVBUUXCDG,Carbapenem Antibiotic,
NCGC00178852-06,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,Tobramycin,,NLVFBUXFDBBNBW,30S Ribosomal Protein Inhibitors,
NCGC00016407-11,CC1=NN=C(N[S+]([O-])(=O)C2=CC=C(N)C=C2)S1,SULFAMETHIZOLE,,XFYCPLOQMKHGAH,Antibacterial,
NCGC00346614-01,CC1=C(C=CC=C1)N2C(=O)C3=C(C=CC=C3C)\N=C2\C[N]4N=C(C5=CC(=CC=C5)O)C6=C(N)N=CN=C46,PIK-294,,WFSLJOPRIJSOJR,PI3K Inhibitor,PIK3CA
NCGC00346626-01,ClC1=CC\2=C(NC(=O)\C(=C2N[C@@H]3CN4CCC3CC4)C5=NC6=C([NH]5)C=CC=C6)C=C1,CHIR-124,,MOVBBVMDHIRCTG,Chk1 Inhibitor,CHEK1
NCGC00262376-01,C1C[C@H](CN1)NC2=CC=CC(=N2)C3=CN=C4C=CC(=C[N]34)C5=C[NH]N=C5,,,YERJPPBISXRGBC,Flt3/IRAK Inhibitor,FLT3
NCGC00346567-01,CN1C(=O)\C(=C/C(=C1/NC2=C(F)C=C(I)C=C2)C(=O)NOCCO)C,AZD8330,,RWEVIPRMPFNTLO,MEK inhibitor,MAP2K1
NCGC00094571-07,CCN(C(=O)\C=C\C)C1=CC=CC=C1C,CROTAMITON,,DNTGGZPQPQTDQF,antipruritic,
NCGC00090774-03,CC(=O)OC1=C(C=CC=C1)C(=O)NC2=NC=C(S2)[N+]([O-])=O,,Nitazoxanide,YQNQNVDNTFHQSW,antiprotozoal agent,
NCGC00263140-01,C[C@H]1CN([C@H](C)CN1CC2=CC=C(F)C=C2)C(=O)C3=C(Cl)C=C4[N](C)C=C(C(=O)C(=O)N(C)C)C4=C3,Talmapimod,,ZMELOYOKMZBMRB,p38 MAPK Inhibitor,MAPK14
NCGC00017364-14,OC(=O)/C=C/C1=CC(=C(O)C=C1)O,CAFFEIC ACID,,QAIPRVGONGVQAS,PPAR modulator,
NCGC00246958-02,CN1CCN(CC1)C2=CC=C(C3=NO[N+](=C23)[O-])[N+]([O-])=O,NSC-207895 (XI-006),,MWFZDJLPWDCQIL,MDM4 (MDMX) Inhibitor,MDM4
NCGC00263203-02,CO[C@@H](C(=O)N1CC2=C(C1)C(=N[NH]2)NC(=O)C3=CC=C(C=C3)N4CCN(C)CC4)C5=CC=CC=C5,Danusertib;PHA-739358,,XKFTZKGMDDZMJI,Aurora-A/B/C Kinase Inhibitor,AURKA
NCGC00167531-03,CCN(C)C(=O)OC1=CC(=CC=C1)[C@H](C)N(C)C,Rivastigmine tartrate (Exelon),,XSVMFMHYUFZWBK,Acetylcholinesterase Inhibitors,ACHE
NCGC00163128-07,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,Pioglitazone HCl;AA-10090;Actos;Glustin;U-72107A;Zactos,,HYAFETHFCAUJAY,PPARgamma Agonists?,PPARG
NCGC00018296-08,CC1=CC=CC(=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4,Meclizine dihydrochloride,,OCJYIGYOJCODJL,Constitutive Androstane Receptor Agonist,NR1I3
NCGC00015970-10,C[S+]([O-])C1=CC=C(C=C1)\C=C2\C(=C(\CC(O)=O)C3=C2C=CC(=C3)F)C,SULINDAC,,MLKXDPUZXIRXEP,non-steroidal antiinflammatory,
NCGC00025330-01,CN(C)C1=CC=C(NC(=O)NC2=CC(=NC3=C2C=C(F)C=C3F)C)C=C1,SB 408124,"NCGC00025330-02;NCGC00025330-01;N-(6,8-Difluoro-2-methyl-4-quinolinyl)-N'-[4-(dimethylamino)phenyl]urea;SB-408124;SB 408124;",JTARFZSNUAGHRB,Orexin OX-1 Antagonists,HCRTR1
NCGC00186010-02,COC(=O)C/1=C/O[C@@H](O)[C@H]\2[C@@H]1C\C=C2CO,Genipin,,AZKVWQKMDGGDSV,Free Radical Scavenger,
NCGC00015889-10,OC1=CC=C(C=C1)C2=C(C(=O)C3=CC=C(OCCN4CCCCC4)C=C3)C5=C(S2)C=C(O)C=C5,RALOXIFENE HYDROCHLORIDE,,GZUITABIAKMVPG,Selective Estrogen Receptor Modulators (SERM),ESR1
NCGC00263129-01,CC(=O)C\1=C(/C)C2=CN=C(NC3=CC=C(C=N3)N4CCNCC4)N=C2N(C5CCCC5)C1=O,PD-0332991,,AHJRHEGDXFFMBM,"CDK4, 6 Inhibitor",CDK4
NCGC00018199-06,OC(=O)C1=CC(=C2C(=O)C3=C(O)C=CC=C3C(=O)C2=C1)O,,"Rhein (1,8-dihydroxy-3-carboxyl anthraquinone)",FCDLCPWAQCPTKC,component of rhubarb,
NCGC00347957-01,BrC1=CN=CC(=C1)C(=O)N2CCC(CC2)N3CCCC3,,,CQERVFFAOOUFEQ,L3MBTL3 methyllysine (Kme) reader domain inhibitor,
NCGC00345492-02,COC1=CC=C(C[N]2C=CC3=C2C=C(C=C3)C(=O)NO)C=C1,PCI-34051,,AJRGHIGYPXNABY,Histone Deacetylase 8 (HDAC8) Inhibitor,HDAC8
NCGC00021569-08,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(O)=O,ENALAPRIL MALEATE,,GBXSMTUPTTWBMN,Angiotensin-I Converting Enzyme Inhibitor,ACE
NCGC00347951-01,CC(N[C@H]1C[C@@H]1C2=CC=CC=C2)C3=CC=C4OCCOC4=C3,,,PAXGPAVOMLKKDQ,Lysine Specific Demethylase 1 (LSD1) Inhibitor,
NCGC00186028-01,CC[C@H](N1CCCC1=O)C(N)=O,Levetiracetam,,HPHUVLMMVZITSG,N-Type Calcium Channel (Ca(v) 2.2) Blockers,
NCGC00247735-02,C1NCC2CC1C3=CC4=NC=CN=C4C=C23,Varenicline tartrate,,JQSHBVHOMNKWFT,Nicotinic alpha3beta4 Agonists,CHRNA3
NCGC00242227-02,O=C(NC1=C(C#N)C2=C(CCCC2)S1)C3=C4C=CC=CC4=CC=C3,TCS JNK 5a,,WQGDQGAFSDMBLA,JNK 2/3 Inhibitor,MAPK8
NCGC00346932-01,[O-][S+](=O)(CC1CS1)C2=CC=C(OC3=CC=CC=C3)C=C2,SB-3CT,,LSONWRHLFZYHIN,"MMP-2, 9 Inhibitor",MMP2
NCGC00247879-01,CCNC(=O)C1=CC2=C(N=C(N)N=C2S1)C3=CC(=C(Cl)C=C3Cl)OCCN4CCCC4,,,WJUNQSYQHHIVFX,Heat Shock Protein 90 (hsp90) Inhibitor,HSP90AB1
NCGC00263553-02,CC(C)[N]1C=NC2=C(NCCC3=CC=C(O)C=C3)N=C(N=C12)C4=CSC5=C4C=CC=C5,StemRegenin 1,,BGFHMYJZJZLMHW,Aryl Hydrocarbon Receptor (AhR) Antagonists,AHR
NCGC00095099-04,CCCC1=N[N](C)C2=C1\N=C(/NC2=O)C3=CC(=CC=C3OCC)[S+]([O-])(=O)N4CCN(C)CC4,SILDENAFIL,,VHGLSJBUAZVCNY,Phosphodiesterase V (PDE5) inhibitor,PDE5A
NCGC00165782-02,O=C(NC1=CC=C(C=C1)/C2=N/CCN2)\C=C\C3=CC=C(\C=C\C(=O)NC4=CC=C(C=C4)C/5=N/CCN5)C=C3,GW 4869,,KDQKMUCWBRINRA,Neutral Sphingomyelinase (N-SMase) Inhibitor,NSMAF
NCGC00015958-02,O=C1C2=C(C=CC=C2)C3=N[NH]C4=CC=CC1=C34,SP 600125,"SP 600125;SP600125;NCGC00015958-01;anthra(1,9-cd)pyrazol-6(2H)-one;CIPLUS_151677;Anthrapyrazolone;NCGC00025186-05;NCGC00025186-04;SP-600125;NCGC00025186-03;NCGC00025186-02;NCGC00025186-01;1,9-Pyrazoloanthrone;",ACPOUJIDANTYHO,JNK 1/2/3 Inhibitor,MAPK8
NCGC00346465-01,CCNC(=O)NC1=CC=C(C=C1)C2=NC(=C3CCN(CC3=N2)C4COC4)N5CCOC[C@@H]5C,GDC-0349,,RGJOJUGRHPQXGF,"Pim-3 Kinase Inhibitors, mTOR",PIM3
NCGC00094575-01,Cl.CC(C)N(CCC(C1=CC=CC=C1)C2=CC(=CC=C2O)C)C(C)C,TOLTERODINE HYDROCHLORIDE,"LS-172609;Urotrol;LS-172608;tolterodine tartrate;tolterodine;Tolterodine tartrate;Detrusitol;TOLTERDINE;Detrol;HS_430;Pharmacia Spain brand of tolterodine tartrate;2-[3-[Bis(1-methylethyl)amino]-1-phenylpropy]-4-methylphenyl monohydrobromide;N,N-DIISOPROPYL-3-(2-HYDROXY-5-METHYLPHENYL)-3-PHENYLPROPYLAMINE,L- TARTRATE;NCGC00094575-01;TOLTERODINE;tolterodinum;PNU-200583E;CIPLUS_197020;Tolterodine Tartrate;PHA-686464B;Pharmacia brand of tolterodine tartrate;Tolterodinum;DETROL LA;CIPLUS_700322;TOLTERODINE HYDROCHLORIDE;TOLTERODINE TARTRATE;Tolterodina;Almirall brand of tolterodine tartrate;Unidet;Tolterodine;",OOGJQPCLVADCPB,Muscarinic M3 Antagonists,
NCGC00346440-01,CN[C@H]1CN2C(=O)NC3=C2C(=CC=C3)C1,U-95666E  ,,RKZSNTNMEFVBDT,Dopamine D2 Agonist,DRD2
NCGC00015708-17,CNCCCC12CCC(C3=CC=CC=C13)C4=C2C=CC=C4,Maprotiline hydrochloride,,QSLMDECMDJKHMQ,noradrenaline reuptake inhibitor,
NCGC00346521-01,OC(CC1=CC=CN=C1)([P](O)(O)=O)[P](O)(=O)O[Na],Risedronate sodium,,DRFDPXKCEWYIAW,Farnesyl Pyrophosphate Synthase Inhibitors,FDPS
NCGC00183001-01,Cc1ccccc1C(=O)Nc2ccc(c(C)c2)C(=O)N4CCCC(O)c3cc(Cl)ccc34,Tolvaptan,"OPC 41061;OPC-41061;7-chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine;tolvaptan;TOLVAPTAN;Tolvaptan;7-CHLORO-5-HYDROXY-1-(2-METHYL-4-(2-METHYLBENZOYLAMINO)BENZOYL)-2,3,4,5-TETRAHYDRO-1H-BENZAPINE, DL-;CIPLUS_789421;tolvaptanum;",GYHCTFXIZSNGJT,Vasopressin (AVP) V2 Antagonists,AVPR2
NCGC00346460-02,CC1=C2N=C([NH]C2=CC(=C1)N3CCOCC3)\C4=C(NC[C@@H](O)C5=CC=CC(=C5)Cl)\C=C/NC4=O,BMS-536924,,ZWVZORIKUNOTCS,IGF-1R Inhibitor,IGFR1
NCGC00241103-04,CN1CCN(CC1)CC2=CC=C(C=C2)C(=O)NC3=CC=C(C)C(=C3)NC4=NC(=CS4)C5=CC=CN=C5,Masitinib;AB-1010?,,WJEOLQLKVOPQFV,FGFR 3 Inhibitor,KIT
NCGC00016564-07,CN(C)C(=N)NC(N)=N,Metformin HCl;ADX-155;La-6023;SMP-862,,XZWYZXLIPXDOLR,AMP-Activated Protein Kinase (AMPK) Activator,PRKAA1
NCGC00093802-08,C[C@]12CC[C@H]3[C@@H](C\C=C/4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,Dehydroepiandrosterone (DHEA),,FMGSKLZLMKYGDP,Steroid hormone,
NCGC00346563-01,COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@H](O[C@H]5[C@H](O)[C@H]4O)C6=CC=CS6)C7=CC8=C(OCO8)C=C27,Teniposide (Vumon),,NRUKOCRGYNPUPR,DNA Topoisomerase II Inhibitors,TOP2A
NCGC00241099-01,CN1CCN(CCOC2=CC3=NC=NC(=C3C(=C2)OC4CCOCC4)NC5=C6OCOC6=CC=C5Cl)CC1,Saracatinib;AZD-0530,,OUKYUETWWIPKQR,cSRC inhibitor,SRC
NCGC00015061-12,N\C1=N\C2=C(N=C[N]2COCCO)C(=O)N1,ACYCLOVIR,,MKUXAQIIEYXACX,DNA Polymerase Inhibitors,
NCGC00167429-05,CN1\N=N/C2=C(N=C[N]2C1=O)C(N)=O,Temozolomide,,BPEGJWRSRHCHSN,DNA Topoisomerase II Inhibitors,TOP2A
NCGC00263098-03,COC1=CC=C(\C=C/C2=CC(=C(OC)C(=C2)OC)OC)C=C1O,Combretastatin A-4,,HVXBOLULGPECHP,Tubulin polymerization inhibitor,TUBB
NCGC00164569-03,CCCCCOC(=O)NC\1=N\C(=O)N(\C=C1F)[C@@H]2O[C@H](C)[C@@H](O)[C@H]2O,Capecitabine (Xeloda),,GAGWJHPBXLXJQN,Pyrimidine Antagonists,
NCGC00345809-01,CC(C)C1=N[N](C\2=C1C(=O)N\C(=N2)CC3=CC=C(OCCO)C=C3)C4=C(Cl)C=CC=C4Cl,Cdk/Crk Inhibitor,,RSQPNXBTPUXMQN,CDK1/2/3/7/9 inhibitor,CDK1
NCGC00242486-02,C[C@H](NC1=NC(=C(Cl)C=N1)NC2=N[NH]C(=C2)C)C3=NC=C(F)C=N3,AZD-1480,,PDOQBOJDRPLBQU,Jak1/2 inhibitor,JAK1
NCGC00181306-03,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]3(C)[C@@H]2[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)C(O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6)C(=C(/[C@@H](O)C3=O)C5(C)C)/C,,,ZDZOTLJHXYCWBA,Tubulin depolymerization inhibitor,TUBB
NCGC00347946-01,CC1=CC=CC=C1C(N(C(=O)CNC2=CC=C(C=C2)C#N)C3=CC=CC(=C3)F)C(=O)NC4CCCCC4,,,AATMNHPDEZNXEK,Isocitrate dehydrogenase inhibitor,IDH1
NCGC00238624-04,ClC1=C[NH]N=C1C\2NC(=N\C3=C2C(=O)CCC3)/NC4=NC5=CC=CC=C5O4,NCGC00238624,,ORBGGGFENULXFO,GALK inhibitor,GALK1
NCGC00177995-04,OC(=O)\C1=C\N(C2=CC=C(F)C=C2)C3=C(C=C(F)C(=C3)N4CCNCC4)C1=O,Sarafloxacin HCl,,XBHBWNFJWIASRO,Antibacterial,
NCGC00241097-01,CC(C)Oc1ccc(cc1)NC(=O)N2CCN(CC2)c5ncnc4cc(OCCCN3CCCCC3)c(OC)cc45,Tandutinib;CT-53518;MLN-0518,Tandutinib,UXXQOJXBIDBUAC,KIT inhibitor,KIT
NCGC00346677-01,NC1=NC(=CC=C1[N+]([O-])=O)NCCNC2=NC=C([N]3C=CN=C3)C(=N2)C4=CC=C(Cl)C=C4Cl,CHIR-98014,,MDZCSIDIPDZWKL,GSK-3 inhibitor,GSK3B
NCGC00161703-02,COC1=CC=CC2=C1C(=NC(=N2)C3=CC=CS3)NN4C(=O)\C=C(C)/C4=O,NCGC00161703,,GZGLPBNOIFLLRE,NF-kB/AP-1 activation inhibitor,NFKB1
NCGC00347907-01,C[C@H](N\C(NC1=CC=CC2=C1C=CC=C2)=N\C#N)C3=CC=CC=C3,A 804598,,YMEXDSVGHUELRM,P2X7 Receptor Antagonist,P2RX7
NCGC00347909-01,ClC1=C(Cl)C(=CC=C1)[N]2N=NN=C2NCC3=C(OC4=NC=CC=C4)C=CC=C3,A 839977,,GMVNBKZQJFRFAR,P2X7 Receptor Antagonist,P2RX7
NCGC00262061-02,C[N]1C=C(C2=C1C=CC=C2)\C3=C(\C(=O)NC3=O)C4=C5CC(CN)CC[N]5C6=C4C=CC=C6,Bisindoylmaleimide X    HCl salt   (Ro 31-8425),,QQKKPWJFHBFCTH,PKC inhibitor,PRKCA
NCGC00346501-01,C[C@@H](O)[C@@H](NC(=O)[C@H](C)[C@@H](O)[C@H](C)NC(=O)[C@@H](NC(=O)C1=C(C)C(=NC(=N1)[C@H](CC(N)=O)NC[C@@H](N)C(N)=O)N)C(O[C@H]2O[C@H](CO)[C@H](O)[C@@H](O)[C@H]2O[C@H]3O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]3O)C4=C[NH]C=N4)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C,Bleomycin sulfate,,OYVAGSVQBOHSSS,glycopeptide antibiotic,
NCGC00094717-05,S=C1N\C=N/C2=C1[NH]C=N2,MERCAPTOPURINE,,GLVAUDGFNGKCSF,Purine Antagonist,HPRT1
NCGC00346806-01,CC\C(C1=CC=CC=C1)=C(\C2=CC=C(O)C=C2)C3=CC=C(OCCNC)C=C3,Endoxifen,,MHJBZVSGOZTKRH,PKC inhibitor,PRKCA
NCGC00016345-09,C\C1=C\C(=O)OC2=C1C=CC(=C2)O,4-Methylumbelliferone (4-MU),,HSHNITRMYYLLCV,hyaluronic acid (HA) synthesis,
NCGC00346690-01,FC(F)(F)C1=CN=C(C=C1)N2CC[C@H](C2)NC(=O)NC3=CC=CC=C3Br,SB705498,,JYILLRHXRVTRSH,TRPV1 (Vanilloid VR1 Receptor) Agonist,TRPV1
NCGC00242511-02,CCC(O)(CC)/C=C/C=C/[C@@H](C)[C@H]1CC[C@H]2\C(CCCC12C)=C\C=C3/C[C@@H](O)C[C@H](O)C3=C,Seocalcitol;EB1089,,LVLLALCJVJNGQQ,Vitamin D Analog,VDR
NCGC00025220-03,CC(C)[C@H](CO)NC1=NC(=C2N=C[N](C(C)C)C2=N1)NC3=CC(=C(C=C3)C(O)=O)Cl,Purvalanol B,,ZKDXRFMOHZVXSG,CDK1/2/3/4/5 inhibitor,CDK1
NCGC00242458-01,NC(=O)C1CCCC2=C1[NH]C3=C2C=C(Cl)C=C3,EX-527;SEN-0014196,,FUZYTVDVLBBXDL,Histone Deacetylase SIRT1 Inhibitor,SIRT1
NCGC00263226-01,COC1=C(OC)C=C(CC/2=N/N\3C(C(C)\N=C3[C@@H](CCC4=CC=CC=C4)[C@@H](C)O)C(=O)N2)C=C1,BAY-60-7550,,OEARZJQHCLLMGS,Phosphodiesterase II (PDE2A) Inhibitor,PDE2A
NCGC00159491-05,CC(N)C12CC3CC(CC(C3)C1)C2,RIMANTADINE HYDROCHLORIDE,,UBCHPRBFMUDMNC,M2 Channel Inhibitor,
NCGC00346613-01,CC(C)(C)/[N+]([O-])=C/C1=CC=C(C=C1[S+]([O-])(=O)O[Na])[S+]([O-])(=O)O[Na],NXY-059 (Cerovive),,ZZFNASSSJJXJBJ,Free Radical Scavenger,
NCGC00250409-01,CC(C)C[C@H](NC(=O)C1=CC2=CC=CC=C2S1)C(=O)N3CCN(CC3)C(=O)[C@H](CO)N[S+]([O-])(=O)C4=CC=C(Cl)C=C4Cl,GSK-1016790A,,GAHDRVYSURNWNR,TRPV4 Agonist,TRPV4
NCGC00263884-03,CN(C)CCC1=C[NH]C2=CC=C(C[C@H]3COC(=O)N3)C=C12,Zolmitriptan (Zomig),,ULSDMUVEXKOYBU,5-HT1B Agonist,HTR1B
NCGC00159370-05,CCCCCCCCCCCCCCCCCCCCCCO,DOCOSANOL,,NOPFSRXAKWQILS,Anti-Herpes Simplex Virus Drug,
NCGC00018261-05,C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3,Perhexiline,,CYXKNKQEMFBLER,mitochondrial carnitine palmitoyltransferase-1 inhbitior,
NCGC00244257-01,O=C(NCC#N)C1=CC=C(C=C1)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4,CYT387,,ZVHNDZWQTBEVRY,Jak1/2 inhibitor,JAK1
NCGC00168085-02,O=C(CCCCCCC(NO)=O)NC1=CC=CC=C1,Vorinostat;MK-0683;SAHA;Zolinza,"CIPLUS_730694;SAHA cpd;NHNPODA;M344 compound;N-hydroxy-N'-phenyloctanediamide;Vorinostat;zolinza;VORINOSTAT;vorinostat;N-HYDROXY-N'-PHENYL-OCTANE-1,8-DIOTIC ACID DIAMIDE;SUBERANILOHYDROXAMIC ACID;Zolinza;suberoylanilide hydroxamic acid;suberanilohydroxamic acid;N-HYDROXY-N'-PHENYLOCTANEDIAMIDE;OCTANEDIAMIDE, N-HYDROXY-N'-PHENYL-;SAHA;",WAEXFXRVDQXREF,Histone Deacetylase (HDAC) 1/2/3/6 Inhibitor,HDAC1
NCGC00250389-01,CC1=C(CCOC2=CC=C(C=C2)C(O)=O)C3=CC(=CC=C3[N]1C(C4=CC=CC=C4)C5=CC=CC=C5)Cl,CDIBA,,WCJGWNYPOLQBKZ,Phospholipase C inhibitor,PLCG1
NCGC00013822-03,S1C(=C(C2=CC=NC=C2)C(=C1C3=CC=NC=C3)C4=CC=NC=C4)C5=CC=NC=C5,GANT 58,,USWLOKMMUTWFMD,Hedgehog antagonist,SHH
NCGC00346697-01,FC(F)(F)C1=NC(=NC=C1C(=O)NCC2CCOCC2)NC3=CC=C(Cl)C=C3Cl,GW-842166X,,TWQYWUXBZHPIIV,cannabinoid CB2 agonist,CNR2
NCGC00168781-01,O=C(N2[C@]3([H])C1=CC=C(OCO6)C6=C1)CN(C)C([C@]([H])2CC4=C3NC5=C4C=CC=C5)=O,Tadalafil,"6-(1,3-BENZODIOXOL-5-YL)-2,3,6,7,12,12A-HEXAHYDRO-2-METHYL-PYRAZINO(1',2';IC-351;Pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, 6-(1,3- benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)-;tadalafil;IC 351;tadalafilum;HS_316;Cialis;CIPLUS_687903;Tadalafil;1,6)PYRIDO(3,4-B)INDOLE-1,4-DIONE, 6R, TRANS;TADALAFIL;Lilly brand of tadalafil;IC351;",WOXKDUGGOYFFRN,Phosphodiesterase V (PDE5) inhibitor,PDE5A
NCGC00345836-01,FC(F)(F)C1=CC=CC(=C1)/C=C/2SC(=O)NC2=O,SMI-4a,,NGJLOFCOEOHFKQ,Pim inhibitor,PIM1
NCGC00229511-01,C[C@@H]1CCN(C[C@@H]1N(C)C2=C3C=C[NH]C3=NC=N2)C(=O)CC#N,Tofacitinib;CP-690550,,UJLAWZDWDVHWOW,Jak inhibitor,JAK1
NCGC00345790-01,C[S+]([O-])(=O)C1=C2[N](CC3=CC=C(Cl)C=C3)C4=C(CC[C@@H]4CC(O)=O)C2=CC(=C1)F,Laropiprant,,FKVDXYUOIFFOHY,prostaglandin D2 DP1 inhibitor,PTGDR
NCGC00263170-01,C[N]1N=CC=C1C2=C3C=CC=CC3=C(N=N2)N4CCC(CC4)N(C)C(=O)C5=C(C=C(F)C=C5)C(F)(F)F,LY-2940680??,,SZBGQDXLNMELTB,Smoothened (Smo) Receptor Antagonist,SMO
NCGC00253713-02,ClC1=CC(=C(C=C1)C(C[N]2C=CN=C2)OCC3=CC=C(SC4=CC=CC=C4)C=C3)Cl,Fenticonazole nitrate,,ZCJYUTQZBAIHBS,Antifungal Agent,
NCGC00345082-01,CC(C)CNC1=CC=NC(=N1)NCC2=CSC(=N2)C3=CC=CC=C3,KHS101,,DGRJOOOHPBSAHD,lineage-specific differentiation enhancer,
NCGC00263201-01,COC1=C(OCCCN2CCOCC2)C=C3N=CC=C(OC4=CC=C(C=C4F)\C5=C\N=C(\NC6=CC=C(F)C=C6)N(C)C5=O)C3=C1,AMG-51,,ONSZEUCTVQJHOZ,HGFR (MET; c-Met) Inhibitor,MET
NCGC00016418-14,COC1=C2OC(=O)\C=C/C2=CC3=C1OC=C3,METHOXSALEN,,QXKHYNVANLEOEG,Cytochrome P450 CYP1A2 Inhibitor,CYP1A2
NCGC00346584-01,C[C@@H]1CC[C@@]2(CC[C@]3(C)\C(=C/C[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O,Asiatic acid,,JXSVIVRDWWRQRT,Nitric Oxide Production Inhibitors,
NCGC00164631-03,CCN(CC)CCNC(=O)C1=C(C)[NH]C(=C1C)/C=C/2C(=O)NC3=CC=C(F)C=C23,,,WINHZLLDWRZWRT,VEGFR-1/2/3 Inhibitor,FLT1
NCGC00188690-02,CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C3CC3)C4=CC=CC=C4F)S1,Prasugrel(Effient),,DTGLZDAWLRGWQN,P2Y12 (P2T) Antagonists,P2RY12
NCGC00346618-01,COC(=O)N1CCN(CC1)CC2=CC=CC(=C2F)NC(=O)NC3=CN=C(C)C=C3,Omecamtiv mecarbil (CK-1827452),,RFUBTTPMWSKEIW,Cardiac Myosin Activators,MYH7
NCGC00346571-01,CC(C)[C@@H](N(CCCN)C(=O)C1=CC=C(C)C=C1)C/2=C(\CC3=CC=CC=C3)C(=O)C4=C(O2)C=C(Cl)C=C4,SB 743921,,PGXYIBJJCLWJST,Kinesin-Like Spindle Protein Inhibitor,KIF11
NCGC00346569-01,O=C(N1CCNCC1)C2=CC=C(C=C2)/C=C/C3=N[NH]C4=C3C=CC=C4,KW 2449,,YYLKKYCXAOBSRM,Bcr-Abl inhibitor,
NCGC00185997-03,OC1=CC(=CC=C1C2=CC=C(O2)\C=C\3SC(=O)NC3=O)F,AS-252424,,OYYVWNDMOQPMGE,PI3K gamma Inhibitor,PIK3CG
NCGC00025235-01,CN(N=O)C(=O)N[C@H]1C(O)OC(CO)[C@@H](O)[C@@H]1O,Streptozocin,"NCGC_Prestw-732;Estreptozocina;LS-957;NCGC00094786-03;NCGC00094786-02;Streptozotocine;NCGC00094786-01;STREPTOZOCIN;CIPLUS_171661;NCGC00016738-01;streptozocine;2-Deoxy-2-((methylnitrosoamino)carbonyl)amino-D-glucose;STREPTOZOTOCIN;Pharmacia Brand of Streptozocin;ZANOSAR;Streptozocin;streptozocinum;D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-;NCGC00025235-01;streptozocin;Streptozocine;Streptozotocin;2-deoxy-2-(3-methyl-3-nitrosoureido)-d-glucopyranose;STREPTOZOSIN;Streptozocinum;Zanosar;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine;",ZSJLQEPLLKMAKR,DNA Alkylating Agent,
NCGC00186009-03,FC1(F)OC2=C(O1)C=C(C=C2)\C=C\3SC(=O)NC3=O,AS-604850,,SRLVNYDXMUGOFI,PI3K gamma Inhibitor,PIK3CG
NCGC00346967-01,COC1=C(NC2=NC(=C(S2)C(=O)C3=C(Cl)C=CC=C3Cl)N)C=CC(=C1)N4CCN(C)CC4,HMSL10089,,UISRWLSAXIOCND,Calmodulin-Dependent Protein Kinase I Inhibitors,CAMKK1
NCGC00015646-04,CC1=C[NH]N=C1,FOMEPIZOLE HYDROCHLORIDE,,RIKMMFOAQPJVMX,Alcohol Dehydrogenase Inhibitor,ADH1
NCGC00015199-19,OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl,CHLORAMBUCIL,,JCKYGMPEJWAADB,DNA Alkylating Agent,
NCGC00263216-02,NC1=NC=C(C=C1)C2=CC=C3N=CC\4=C(N(C(=O)\C=C4)C5=CC(=CC=C5)C(F)(F)F)C3=C2,Torin 2,,GUXXEUUYCAYESJ,mTORC1 Inhibitor,MTOR
NCGC00241112-01,OCCC#CC1=NC(=C([N]1CCCC2=CC=CC=C2)C3=CC=NC=C3)C4=CC=C(F)C=C4,RWJ-67657,,QSUSKMBNZQHHPA,p38 MAPK Inhibitor,MAPK14
NCGC00345837-01,CC1=C(C=NC(=N1)N)C2=NC3=C(SC(=C3)C(C)(C)O)C(=N2)N4CCOCC4,GNE-490,,SFWTVVNNVHWDEE,PI3K Inhibitor,PIK3CA
NCGC00250385-02,CCOC1=C(NC2=NC=C3N(C)C(=O)C4=C(C=CC=C4)N(C)C3=N2)C=CC(=C1)N5CCC(O)CC5,XMD8-92 trifluoroacetate,,QAPAJIZPZGWAND,ERK5/BMK1 inhibitor,MAPK7
NCGC00018100-02,[O-][S+](=O)(N1CCCNCC1)C2=C3C=CN=CC3=CC=C2,Fasudil,"NCGC00024299-04;NCGC00024299-05;AT877;Fasudil hydrochloride hydrate;fasudil hydrochloride;LS-60220;fasudilum;LS-60222;CIPLUS_207923;HA 1077;1-(5-isoquinolinesulfonyl)homopiperazine;HA-1077;HA 1077 hydrochloride;1-(5-Isoquinolinylsulfonyl)homopiperazine dihydrochloride;Fasudil (HA 1077);Fasudil hydrochloride;1H-1,4-Diazepine, hexahydro-1-(5-isoquinolinylsulfonyl)-;AT-877;Fasudilum;HA-1077 dihydrochloride;AT 877;FASUDIL;1H-1,4-Diazepine, hexahydro-1-(5-isoquinolinylsulfonyl)-, monohydrochloride;fasudil;Eril-S;FASUDIL HYDROCHLORIDE HYDRATE;FASUDIL HYDROCHLORIDE;Fasudil Hydrochloride;HEXAHYDRO-1-(5-ISOQUINOLYLSULFONYL)-1H-1,4-DIAZEPINE;Fasudil Hydrochloride Hydrate;Fasudil;CIPLUS_741215;NCGC00024299-02;",NGOGFTYYXHNFQH,ROCK Inhibitor,ROCK1
NCGC00346666-01,C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)C36[C@@H](O)C(=O)O[C@H]6O[C@@]4(C(=O)O5)[C@@]12O,Ginkgolide A,,FPUXKXIZEIDQKW,GABA(A) Receptor Antagonists,GABRA1
NCGC00263142-01,OC(=O)C(=O)C1=C[N](CC2=CC=CC=C2)C3=CC=C(C=C13)C4=CC=C(OC(F)(F)F)C=C4,Tiplasinin;PAI-039,,ODXQFEWQSHNQNI,Plasminogen Activator Inhibitor (PAI-1) Inhibitor,SERPINE1
NCGC00015580-08,C1=CC=C3C(=C1)CC(=O)C4=C(C3=C2CCN(C)CC2)C=CS4,Ketotifen,"4-(1-Methyl-4-piperidylidene)-4H-benzo(4,5)cyclohepta(1,2-b)thiophen-10(9H)-one hydrogen fumarate;ketotifenum;Ketotifeno;10H-Benzo(4,5)cyclohepta(1,2-b)thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-;ketotifen fumarate ophthalmic solution;Ketotifen Maleate;CIPLUS_178306;Ketotifene;CIPLUS_178305;Ketotifen;Ketotiphene;ketotifen fumarate;NCGC00022572-05;Ketotiphen;NCGC00022572-04;4,9-Dihydro-4-(1-methyl-4-piperidylidene)-10H-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one;Ketotifen fumarate;Ketotifen fumarate salt;Ketotifen hydrogen fumarate;Fumarate, Ketotife;Ketotifen Fumarate;ketotifene;NCGC00094057-03;Zaditen;NCGC00094057-01;NCGC00094057-02;NCGC00022572-02;Zaditor;KETOTIFEN FUMARATE;Ketotifenum;LS-33820;KETOTIFEN;LS-33821;NCGC00015580-02;NCGC_Prestw-371;NCGC00015580-01;ketotifen;",ZCVMWBYGMWKGHF,Histamine H1 Receptor Antagonists,HRH1
NCGC00263019-01,COC1=C(C=CC=C1)[C@H](C2=C3C=CC=CC3=CC=C2)[C@@](C)(C#N)C(=O)N4CCC(CC4)C5=CC=CC(=C5)C(F)(F)F,WAY-204688;SIM-688,,JZPONCMNBSEYQW,NF-kappaB Activation Inhibitor,NFKB1
NCGC00025219-04,CC(C)[C@H](CO)NC1=NC(=C2N=C[N](C(C)C)C2=N1)NC3=CC(=CC=C3)Cl,Purvalanol A,,PMXCMJLOPOFPBT,CDK1/2/3/4/5 inhibitor,CDK1
NCGC00095165-05,CCCCCCNC(=O)N1\C=C(F)/C(=O)NC1=O,CARMOFUR,,AOCCBINRVIKJHY,Pyrimidine Antagonists,
NCGC00273984-03,CC[N]1C(=NC2=CN=CC(=C12)CNC3CCNCC3)C4=NON=C4N,SB-747651-A,,MBCJUIJWPYUEBX,"MSK-1,-2 Inhibitor",MAPK11
NCGC00347938-01,CCC1=CC(=CC=C1CN2CC(C2)C(O)=O)\C(C)=N\OCC3=CC=C(C4CCCCC4)C(=C3)C(F)(F)F,,,KIHYPELVXPAIDH,Lysophospholipid edg8 (S1P5) Receptor Ligands,
,,,,,Lysophospholipid edg1 (S1P1) Receptor Agonists,S1PR1
NCGC00346643-01,CO[C@H]1C[C@H](C)C\C2=C(OC)/C(=O)\C=C(\NC(=O)\C(=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(=C\[C@H](C)[C@H]1O)C)C)C2=O,Geldanamycin,,QTQAWLPCGQOSGP,Heat Shock Protein 90 (hsp90) Inhibitor,HSP90AB1
NCGC00346589-01,O[C@@H]([C@@H]1CC2CCN1C[C@@H]2C=C)C3=CC=NC4=CC=CC=C34,Cinchonidine,,KMPWYEUPVWOPIM,Alkaloid,
NCGC00092384-04,CN1CC(=O)\N=C1\NC(=O)NC2=CC(=CC=C2)Cl,Fenobam,,DWPQODZAOSWNHB,mgluR5 Antagonists,GRM5
NCGC00016530-06,COC1=CN=C(N[S+]([O-])(=O)C2=CC=C(N)C=C2)N=C1,SULFAMETER,,PGVZSIVBHMJAKA,Antibiotic,
NCGC00163431-03,CCCNC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](C(C)CC)C(=O)N2CCC[C@H]2C(=O)OC,CA-074 Me,,XGWSRLSPWIEMLQ,Cathepsin B Inhibitors,CTSB
NCGC00095188-04,COC1=C(OC)C(=NC=C1)C[S+]([O-])C2=NC3=CC(=CC=C3[NH]2)OC(F)F,PANTOPRAZOLE,,IQPSEEYGBUAQFF,H+/K+-ATPase Inhibitor,
NCGC00177979-03,CN1CCCC(CC1)N2\N=C(CC3=CC=C(Cl)C=C3)/C4=C(C=CC=C4)C2=O,AZELASTINE HYDROCHLORIDE,,MBUVEWMHONZEQD,Histamine H1 Receptor Antagonists,HRH1
NCGC00263116-01,OC1=CC=C(C[C@@H]2N3[C@H](CN(CC4=CC=CC5=C4C=CC=C5)C2=O)N(CCC3=O)C(=O)NCC6=CC=CC=C6)C=C1,ICG-001,,HQWTUOLCGKIECB,Wnt Signaling Inhibitor,WNT5A
NCGC00346719-01,C[C@]\1(CCS\C(=N1)N)C2=CC(=C(F)C=C2F)C3=CN=CN=C3,LY2811376,,MJQMRGWYPNIERM,beta-Secretase Inhibitor,BACE1
NCGC00161679-01,CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1)C=O,,NCGC00161679-02;Z-Leu-Leu-Leu-al;MG132;CIPLUS_684965;MG-132;LS-172868;benzyloxycarbonylleucyl-leucyl-leucine aldehyde;benzyloxycarbonyl-leucyl-leucyl-leucinal;,TZYWCYJVHRLUCT,Proteasome Inhibitor,PSMD1
NCGC00345056-01,COC1=CC(=CC=C1)C2=CC=C(NC(=O)/C3=C(/CCC3)C(O)=O)C(=C2)F,,,XPRDUGXOWVXZLL,Dihydroorotate Dehydrogenase (DHODH) Inhibitor,DHODH
NCGC00250404-01,C[C@@]1(CCCN1)C2=NC3=C(C=CC=C3[NH]2)C(N)=O,Veliparib;ABT-888/NSC-737664,,JNAHVYVRKWKWKQ,PARP-1/PARP-2 Inhibitor,PARP1
NCGC00016083-13,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(=C(OC)C=C2)OC)C=C1,Verapamil;E-0103?,,SGTNSNPWRIOYBX,Calcium Channel Blocker,DRD2
NCGC00182037-01,O=[C@](N[C@@H](CC2=CC=CC=C2)C(O)=O)[C@@H]1CCCN1C([C@H](C)CSC(C)=O)=O,Alacepril,N-(1-(3-(acetylthio)-2-methyl-1-oxopropyl)-L-prolyl)-L-phenylalanine;CIPLUS_214255;aracepril;alacepril;ALACEPRIL;DU-1219;Alacepril;DU 1219;cetapril;alaceprilum;LS-105750;Cetapril;,FHHHOYXPRDYHEZ,Angiotensin-I Converting Enzyme Inhibitor,ACE
NCGC00065934-06,NC(=O)N1C2=CC=CC=C2CC(=O)C3=CC=CC=C13,Oxcarbazepine,,CTRLABGOLIVAIY,Sodium channel inhibitor,
NCGC00095128-04,CCCCCCCCCCCC(CC1OC(=O)C1CCCCCC)OC(=O)C(CC(C)C)NC=O,ORLISTAT,"CIPLUS_213522;tetrahydrolipstatin;L-Leucine, N-formyl-, 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester, (2S-(2alpha(R*),3beta))-;NCGC00165856-01;HS_1517;N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester;ORLISTAT;2-deoxo-2-methylene orlistat;THLP;TETRAHYDROLIPSTATIN;(-)-Tetrahydrolipstatin;Orlistat;LS-178328;Orlipastatum;Hoffmann-La Roche brand of orlistat;orlistat;NCGC00095128-01;NCGC00095128-02;(S)-1-(((2S,3S)-3-HEXYL-4-OXO-2-OXETANYL)METHYL)DODECYL(S)-2-FORMAMIDO-4-METHYLVALERATE;orlistatum;Ro-18-0647;1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate;N-formyl-1-((3-hexyl-4-methylene-2-oxetanyl)methyl)dodecyl 2-amino-4-methylpentanoate;Roche brand of orlistat;RO-18-0647;Xenical;",AHLBNYSZXLDEJQ,Fatty acid synthase inhibitor,FAS
NCGC00345800-01,CCCN1C(=O)N(CC)C2=C([NH]C(=N2)C3=C[N](CC4=CC=CC(=C4)C(F)(F)F)N=C3)C1=O,CVT-6883,,KOYXXLLNCXWUNF,Adenosine A2B Antagonists,ADORA2B
NCGC00346566-01,FC(F)OC1=CC=C(C=C1OCC2CC2)C(=O)NC3=C(Cl)C=NC=C3Cl,Roflumilast (Daxas),,MNDBXUUTURYVHR,Phosphodiesterase IIII (PDE4) inhibitor,PDE4A
NCGC00346958-01,COC1=CC(=CC(=C1)C2=CC=C3N=CC\4=C(N(C(=O)\C=C4)C5=CC(=C(C=C5)N6CCNCC6)C(F)(F)F)C3=C2)OC,HMSL10019,,VVTHOUCIAGHQBD,Lck Kinase Inhibitors,LCK
NCGC00021301-04,O=C1C=C3[C@]([C@@]2(F)[C@@H](O)C[C@@]4(C)[C@](C[C@@]5([H])OC(C)(C)O[C@@]45[C@@](CO)=O)([H])[C@@]([H])2C[C@@H]3F)(C)C=C1,Fluocinolone acetonide,"NCGC00096005-01;6A,9A-DIFLUORO-11B,16A,17A,21-TETRAHYDROXYPREGNA-1,4-DIENE-3,20-DIONE-16,17-ACETONIDE;Fluocinolone Acetonide;Acetonide de fluocinolone;acetonide de fluocinolone;Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-;FLUOCINOLONE ACETONIDE;SQ-15392;Acetonida de fluocinolona;Fluocet;fluocinoloni acetonidum;Synalar-C;Sinalar;Fluocinolone 16,17-acetonide;Fluocinoloni acetonidum;CIPLUS_149131;6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide;6alpha-Fluorotriamcinolone acetonide;LS-118443;CIPLUS_3743853;FLUOCINOLONE;Fluocinolone acetonide 21-acetate;Synandone;6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione;Fluocinolone acetonide;",FEBLZLNTKCEFIT,Glucocorticoid steroid,
NCGC00346682-01,[O-][N+](=O)C1=C[N]2C[C@@H](COC2=N1)OCC3=CC=C(OC(F)(F)F)C=C3,PA-824,,ZLHZLMOSPGACSZ,nitric oxide donors,
NCGC00016973-03,N#CC1=CC=C(C=C1)C([N]2C=NC=N2)C3=CC=C(C=C3)C#N,Letrozole;CGS-20267;FEM-345?;Femara,,HPJKCIUCZWXJDR,Aromatase Inhibitor,CYP19A1
NCGC00095134-03,OC(CCC1C(N(C1=O)C2=CC=C(F)C=C2)C3=CC=C(O)C=C3)C4=CC=C(F)C=C4,Ezetimibe;Ezetrol;MK-0653;SCH-58235;Zetia;Zient,Simvastatin and ezetimibe;SCH-58235;ezetimibe glucuronide;Zetia;NCGC00095134-02;ezetimibe;CIPLUS_727861;Ezetimibe;NCGC00095134-01;1-(4-FLUOROPHENYL)-3(R)-(3(S)-HYDROXY-3-(4-FLUOROPHENYL)PROPYL)-4(S)-(4-HYDROXYPHENYL)-2-AZETIDINONE;EZETIMIBE;ezetimibum;HS_1532;,OLNTVTPDXPETLC,NPC1L1 Inhibitor,NPC1L1
NCGC00094419-06,CC1=CC=C(C=C1)[S+]([O-])(=O)N[C@@H](CC2=CC=CC=C2)C(=O)CCl,TPCK,,VYGZKBZYCVWKPS,Cysteine Protease Inhibitor,
NCGC00263189-01,C[N]1C=C(C=N1)C2=N[N]3C(=NN=C3C(F)(F)C4=CC=C5N=CC=CC5=C4)C=C2,JNJ-38877605,,JRWCBEOAFGHNNU,HGFR (MET; c-Met) Inhibitor,MET
NCGC00263101-01,COCC(=O)NC/C=C/C1=CC=C2N=CN=C(NC3=CC=C(OC4=CN=C(C)C=C4)C(=C3)C)C2=C1,CP-724714,,LLVZBTWPGQVVLW,HER2 (erbB2) Inhibitor,ERBB2
NCGC00015482-05,CC[N+](CC)(CC)CCOC1=CC=CC(=C1OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC,,GALLAMINE TRIETHIODIDE,OZLPUNFFCJDMJD,Muscarinic M2 Antagonists,
NCGC00016457-03,OC1=CC=C(C=C1)[C@@H]2CC(=O)C3=C(O2)C=C(O)C=C3O,NARINGENIN,,FTVWIRXFELQLPI,Cytochrome P450 CYP3A4 Inhibitor,CYP3A4
NCGC00346533-01,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C([NH]2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C([NH]5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C,BMS-790052,,FKRSSPOQAMALKA,HCV NS5A Inhibitors,
NCGC00163507-02,CCCCCCCCOC1=C(C=CC=C1)C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC,Octylonium bromide,OCTYLONIUM BROMIDE,NQHNLNLJPDMBFN,Muscarinic Antagonists,
NCGC00167982-02,COC1=C2C(=O)C3=C(C(=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@H]6CCCCO6)[C@H](C)O5)C4=C3O)C(=O)CO)O)C(=O)C2=CC=C1,,,KMSKQZKKOZQFFG,DNA Topoisomerase II Inhibitors,TOP2A
NCGC00346689-01,C[N]1C=C(C=N1)C2=N[N]3C(=CN=C3C=C2)CC4=CC=C5N=CC=CC5=C4,NVP-BVU972,,RNCNPRCUHHDYPC,HGFR (MET; c-Met) Inhibitor,MET
NCGC00263177-01,COC1=C(OCCCCCCC(=O)NO)C=C2C(=NC=NC2=C1)NC3=CC(=CC=C3)C#C,CUDC-101,,PLIVFNIUGLLCEK,EGFR (HER1; erbB1) inhibitor,EGFR
NCGC00346699-01,CC(C)(O)CC(=O)NCC[N]1C=CC2=C1C(=NC=N2)NC3=CC=C(OC4=CC=CC(=C4)C(F)(F)F)C(=C3)Cl,TAK-285,,ZYQXEVJIFYIBHZ,EGFR (HER1; erbB1) inhibitor,EGFR
NCGC00016311-16,CC1=CC=C(C=C1)N(C\C2=N\CCN2)C3=CC=CC(=C3)O,,PHENTOLAMINE,MRBDMNSDAVCSSF,alpha-Adrenoceptor Antagonists,ADRA1A
NCGC00346969-01,CCOC(=O)N1CCN(CC1)[N+](/[O-])=N/OC2=CC=C(C=C2C#N)[N+]([O-])=O,JS-59-4,,CRQUIISEMQYDFS,nitric oxide donors,
NCGC00015767-09,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C2=CC=CC=C2,OXYBUTYNIN CHLORIDE,,XIQVNETUBQGFHX,Muscarinic Antagonists,
NCGC00163411-05,CC(C)[C@]12O[C@H]1[C@@H]3O[C@@]34[C@@]5(C)CC\C6=C(COC6=O)/[C@@H]5C[C@@H]7O[C@]47[C@@H]2O,Triptolide,,DFBIRQPKNDILPW,Inhibition of RNA polymerase II?mediated transcription,POLR2A
NCGC00182713-01,Fc1ccc(cc1Cl)Nc4ncnc3cc(OCCCN2CCOCC2)c(NC(=O)C=C)cc34,Canertinib,Canertinib;PD 183805;Canertinib Dihydrochloride;canertinibum;CI-1033;CI1033;Canertinib dihydrochloride;CIPLUS_786880;PD-0183805-002B;CI 1033;PD183805;N-(4-((3-CHLORO-4-FLUOROPHENYL)AMINO)-7-(3-(4-MORPHOLINYL)PROPOXY)-6-QUINAZOLINYL)-2-PROPENAMIDE DIHYDROCHLORIDE;PD-183805;CANERTINIB DIHYDROCHLORIDE;CIPLUS_733824;,OMZCMEYTWSXEPZ,EGFR (HER1; erbB1) inhibitor,EGFR
NCGC00165736-02,NC(=O)C1=C(N)[N](C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O,Acadesine;AICAR/AR-100/SCH-900395,AICAR,RTRQQBHATOEIAF,AMP-Activated Protein Kinase (AMPK) Activator,PRKAA1
NCGC00188689-01,Clc1cc3c(cc1)Oc2ccccc2[C@@H]4CN(C)C[C@@H]34,Asenapine,Asenapine,VSWBSWWIRNCQIJ,Dopamine D1/D2 Antagonist,DRD1
NCGC00167798-02,O=C1O[Pt]2(NC3CCCCC3N2)OC1=O,,,DWAFYCQODLXJNR,DNA Alkylating Agent,
NCGC00274068-02,CCC(C)N1\N=C/N(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OC[C@H]5CO[C@@](C[N]6C=NC=N6)(O5)C7=CC=C(Cl)C=C7Cl)C=C4,Itraconazole (Sporanox),,VHVPQPYKVGDNFY,cytochrome inhibitor,
NCGC00345804-01,C[N]1C=NC2=C(F)C(=C(C=C12)C(=O)NOCCO)NC3=CC=C(Br)C=C3F,ARRY-162,,ACWZRVQXLIRSDF,Mek 1/2 inhibitor,MAP2K1
NCGC00096095-02,NC1=NC=NC2=C1N=C(Cl)[N]2[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O,,LS-174469;8-chloroadenosine;NCGC00096095-01;Kolibri-C 006;8-Chloroadenosine (8-Cl-Ado);CIPLUS_725292;,MHDPPLULTMGBSI,Telomerase Inhibitor,TERT
NCGC00168041-01,COC1=CC2=C(CC3C4CCCC[C@@]24CCN3C)C=C1,,"Dextromethorphan Hydrobromide, Monohydrate;DEXTROMETHORPHAN HYDROBROMIDE;Levometorfano;racemethorphan hydrobromide;LS-178625;Dextromethorphan hydrobromide;Levomethorphan;DEXTROMETHORPHAN;levomethorphanum;Levomethorphanum;Dextrometorfano;Dextromethorphan polistirex;3-Methoxy-17-methylmorphinan hydrobromide;Dextromethorphan, (+-)-Isomer;Morphinan, 3-methoxy-17-methyl-, (9alpha,13alpha,14alpha)-;Benylin DM;DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE;CIPLUS_153812;PHERAZINE DM;LS-176564;CIPLUS_206577;CIPLUS_206578;l-Methorphan;Racemethorphane;LS-91838;NCGC00017066-01;dextromethorphane;Dextromethorphan;CIPLUS_3859874;Racemethorphan;NCGC00162126-01;LS-175206;Dextromethorphan Hydrobromide;d-3-Methoxy-N-methylmorphinan hydrobromide;dextromethorphanum;Dextromethorphane;LS-173733;NCGC_Prestw-359;BROMFED-DM;LS-91843;Dimorlin tartrate;LS-91845;LS-91844;DEXTROMETHORPHAN POLISTIREX;LEVOMETHORPHAN;Racemethorphanum;CIPLUS_197302;Dextromethorphanum;CIPLUS_697301;NCGC00015333-01;LS-178492;d-Methorphan hydrobromide;RACEMETHORPHAN;CIPLUS_664550;(9S,13S,14S)-3-Methoxy-17-methylmorphinan hydrobromide;racemethorphanum;Racemetorfano;racemethorphane;CIPLUS_173392;Levomethorphane;levomethorphane;Dextromethorphan Hydrochloride;NCGC00093776-01;Dextromethorphan Hbr;DEXTROMETHORPHAN HYDRIODIDE;NCGC00094645-01;NCGC00094645-02;CIPLUS_778001;Dextromethorphan hydrobromide monohydrate;",MKXZASYAUGDDCJ,NMDA Antagonist,GRIN2A
NCGC00250379-03,CC1=C[NH]C(=N1)C2=C(N=C(NCCNC3=CC=C(C=N3)C#N)N=C2)C4=CC=C(Cl)C=C4Cl,CHIR-99021 (CT-99021),,AQGNHMOJWBZFQQ,GSK-3 inhibitor,GSK3B
NCGC00347910-01,CC(C)[N]1C=NC2=C(NCCCCCCNC(=O)OC(C)(C)C)N=C(NCCO)N=C12,CK59,,OXQIKGQQLYDQBM,Calmodulin-Dependent Protein Kinase II Inhibitors,CAMKK2
NCGC00016916-12,CCN1\C=C(\C(O)=O)C(=O)C2=C1C=C(N3CCNCC3)C(=C2)F,NORFLOXACIN,,OGJPXUAPXNRGGI,DNA Topoisomerase IV Inhibitors,TOP2B
NCGC00185773-02,Cl.CS[C@H]1O[C@@H]([C@H](O)[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCC)[C@H](NC(=O)[C@@H]2C[C@@H](CCC)CN2C)[C@H](C)Cl,Clindamycin palmitate hydrochloride,CLINDAMYCIN PALMITATE HYDROCHLORIDE,OYSKUZDIHNKWLV,Antibacterial,
NCGC00164591-02,[H][C@@]1(C)CC[C@@]2([H])[C@@]([H])(C)[C@@]([H])(OC)O[C@]3([H])O[C@@]4(C)CC[C@]1([H])[C@@]23OO4,Artemether,,SXYIRMFQILZOAM,antimalarial agents,
NCGC00263223-01,CN(C)CCN(C)C(=O)C1=CC=C(NC(=O)NC2=CC=C(C=C2)C3=NC4=C(C=C[N]4CC(F)(F)F)C(=N3)N5CCOCC5)C=C1,CAY10626,,GMASZVAHNYVURN,PI3Kalpha inhibitor,PIK3CA
NCGC00168110-01,CN1CCN(CC1)C2=CC(=NC(=N2)SC3=CC=C(NC(=O)C4CC4)C=C3)NC5=CC(=N[NH]5)C,Tozasertib;MK-0457;VX-680??,VX680;Vx-680;CIPLUS_3821044;VX-680;cyclopropane carboxylic acid(4-(4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-ylsulfanyl)phenyl)amide;,GCIKSSRWRFVXBI,Aurora-A/B/C Kinase Inhibitor,AURKA
NCGC00346552-01,OCC(O)CONC(=O)C1=C(NC2=CC=C(I)C=C2F)C(=C(F)C(=C1)Br)F,PD318088,,XXSSGBYXSKOLAM,Mek 1/2 inhibitor,MAP2K1
NCGC00022612-10,N[C@@H](C(=O)N[C@H]1[C@H]2SC\C(=C(/N2C1=O)C(O)=O)Cl)C3=CC=CC=C3,CEFACLOR,,QYIYFLOTGYLRGG,Cephalosporin antibiotic,
NCGC00015925-13,NC1=CC=C(C=C1)[S+]([O-])(=O)NC2=CC=N[N]2C3=CC=CC=C3,SULFAPHENAZOLE,,MAJMNCJQOUUIHD,Antibiotic,
NCGC00165721-02,CC1=CC=CC(=N1)C2=N[N](C=C2C3=CC=NC4=C3C=CC=C4)C(=S)NC5=CC=CC=C5,A 83-01,,HIJMSZGHKQPPJS,TGF-bR1 (ALK5) inhibitor,
NCGC00242493-01,CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=C[N]4C(=N3)SC5=C4C=CC(=C5)OCCN6CCOCC6,Quizartinib;AC-220/ASP-2689,,CVWXJKQAOSCOAB,KIT inhibitor,KIT
NCGC00346940-01,OCCCNC1=CC(=CC=N1)C2=NC(=NC=C2)NC3=CC=CC(=C3)Cl,CGP60474,,IYNDTACKOAXKBJ,CDK1/2 Inhibitor,CDK1
NCGC00263194-01,C[N]1C=C(C2=C1C=CC=C2)C/3=C(C(=O)NC3=O)\C4=CC(=CC(=C4)Cl)Cl,SB-216763,,UVTLOYATPTULIH,GSK-3 inhibitor,GSK3B
NCGC00094552-04,CN1CCC/N=C1/C=C/C2=CC=CS2.OC(=O)C3=CC4=CC=CC=C4C(=C3O)CC5=C(O)C(=CC6=CC=CC=C56)C(O)=O,PYRANTEL PAMOATE,,WLJNZVDCPSBLRP,antiparasitic agent,
NCGC00016408-10,NC1=CC=C(C=C1)[S+]([O-])(=O)NC2=CC=CC=N2,SULFAPYRIDINE,,GTTGUJMHVJOMHJ,Antibiotic,
NCGC00242492-02,C\C(=C/C(=O)NC1=C(C=CC=C1)C(O)=O)C2=CC3=CC=CC=C3C=C2,BIBR1532,,PGFQXGLPJUCTOI,Telomerase Inhibitor,TERT
NCGC00181796-01,C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]5CSSC[C@H](NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc4cnc3ccccc34)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(=O)N5,Octreotide,"octreotidum;Octreotide acetate;Sandostatine;SAN 201 99;Compound 201 99;L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic(2-7)-disulfide, (R-(R*,R*))-, acetate (salt);SM 20199;Octreotide;SM 201 99;Octreotide Acetate;SM 201-995;Sandoz 20199;SAN 20199;Sandoz 201 99;SMS 201 99;LS-58978;CIPLUS_192449;CIPLUS_191981;SMS 20199;SANDOSTATIN;Compound 20199;Octreotide Acetate Salt;NTOC00000206-01;OCTREOTIDE;SMS-201-995;octreotide;Sandostatin;L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2-7)-disulfide, (R-(R*,R*))-;D-PHE-CYS-PHE-D-TRP-LYS-THR-CYS-THROL ACETATE (2-7)DISULFIDE;LS-177735;SMS 201-995;OCTREOTIDE ACETATE;Compound 201-995;SAN 201-995;Sandoz 201-995;",DEQANNDTNATYII,Growth Hormone Release Inhibitors,SSTR1
NCGC00023722-07,OC[C@H]1O[C@H](C[C@@H]1O)N2\C=C(F)/C(=O)NC2=O,,"FUDR;NCGC00023722-06;2'-DEOXY-5-FLUOROURIDINE;5-FUdR;URIDINE, 2'-DEOXY-5-FLUORO;5-Fluorodeoxyuridine;FLOXURIDINE;NCGC00094992-03;NCGC00094992-02;NCGC00094992-01;CIPLUS_148580;5-Fluro-2??-Deoxyuridine;LS-160820;deoxyfluorouridine;Floxiridina;Floxuridine;2'-Deoxy-5-Fluorouridine;HS_609;floxuridine;floxuridinum;Uridine, 2'-deoxy-5-fluoro-;5 Fluorodeoxyuridin;Floxuridine (5-fluorodeoxyuridine);2'-Deoxy-5-fluorouridine;5-Fluoro-2'-deoxyuridine;5-FLUORO-2'-DEOXYURIDINE;Floxuridinum;NCGC_FLUKA_46875;",ODKNJVUHOIMIIZ,Pyrimidine Antagonists,
NCGC00162142-03,NC(=O)C1=CC=C2[NH]C=CC2=C1,SD169,,GQMYQEAXTITUAE,p38 MAPK Inhibitor,MAPK14
NCGC00094112-06,O\N=C1\C(NC2=CC=CC=C12)=C3\C(=O)NC4=CC(=CC=C34)Br,BIO,,DDLZLOKCJHBUHD,GSK-3 inhibitor,GSK3B
NCGC00346951-01,O=C1C2=CC=CC=C2[N+]3=C1C4=C(C=C3)C5=CC=CC=C5[NH]4,Fascaplysin,,WYQIPCUPNMRAKP,CDK4/6 Inhibitor,CDK4
NCGC00346628-01,[O-][S+](=O)(C1CC1)C2=CC=C(C=C2)[C@]3(C[C@H]3C4CCCCC4)C(=O)NC5=NC=C(SCCN6CCCC6)S5,LY2608204,,IUVLTDGKWVKNOC,Glucokinase activator,GCK
NCGC00018218-03,C\C1=N\N(C(=O)C1)C2=CC=CC=C2,MCI-186,"3-Methyl-1-phenyl-2-pyrazoline-5-one;edarabone;edaravone;3H-pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-;Edaravone;MCI 186;3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE (MCI-186);3-methyl-1-phenyl-2-pyrazolin-5-one;3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE;NCGC00164015-01;phenylmethylpyrazolone;Developer Z;LS-1892;MCI-186;Radicut;CIPLUS_149977;norantipyrine;NCGC00022665-05;NCGC00022665-06;AB07990273-01;NCGC00022665-02;edaravonum;1-Phenyl-3-methyl-5-pyrazolone;1-phenyl-3-methyl-5-pyrazolone;norphenazone;EDARAVONE;",QELUYTUMUWHWMC,Free Radical Scavenger,
NCGC00016480-09,OC1=CC=C(C=C1)\C2=C(O)\C(=O)C3=C(O2)C=C(O)C=C3O,Kaempferol,,IYRMWMYZSQPJKC,flavanoid,
NCGC00346734-01,OCC1OC(OC2=C(O)C=C3N(\C=C\C4=C\C(=N/C(C4)C(O)=O)C(O)=O)C(CC3=C2)C(O)=O)C(O)C(O)C1O,Betanin,,CTMLKIKAUFEMLE,treatment of lipoprotein diseases,
NCGC00263191-01,CC(C)C1=CN=C(NC(=O)[C@@H](C)C2=CC=C(NC(C)=O)C=C2)S1,PHA-690509,,NFSKEXQRNDSSAN,CDK2/Cyclin A Inhibitor,CDK2
NCGC00016268-09,OC(=O)C1=CC=CN=C1,NIACIN,,PVNIIMVLHYAWGP,Vitamin,
NCGC00178054-05,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC,"Clarithromycin (Biaxin, Klacid)",,AGOYDEPGAOXOCK,Macrolide Antibiotic,
NCGC00242489-01,CC1=CC2=C(C=C1C3(CC3)C4=CC=C(C=N4)C(O)=O)C(C)(C)CCC2(C)C,LG100268,,SLXTWXQUEZSSTJ,RXR agonist,RXRA
NCGC00013226-15,CN1CCN(CCCN2C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1,Stelazine trifluoperzine,,ZEWQUBUPAILYHI,Nav1.4 (SkM1) Sodium Channel Blockers,
,,,,,Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers,DRD2
NCGC00345792-01,OB1OCC2=CC(=CC=C12)OC3=CC=C(C=C3)C#N,AN2728,,USZAGAREISWJDP,Phosphodiesterase IIII (PDE4) inhibitor,PDE4A
NCGC00168109-01,COC1=N[N](C2=CC=C(NC(=O)CSC3=CC=CC=C3)C=C2)C(=N1)C4=CC=C5OCOC5=C4,Secin H3,,QPGYAMIHXLCFTJ,GEF inhibitor,ARHGEF1
NCGC00161408-02,ClC1=CC=C2N/C3=N/C(=O)CN3CC2=C1Cl,anagrelide;Agrelin;Agrylin;BL-4162A;BMY-26538-01;KRN-654;SPD-422;Thromboreductin;Xagrid,,OTBXOEAOVRKTNQ,Phosphodiesterase III (PDE3) inhibitor,PDE3A
NCGC00167565-01,NC(NN=C2C=C(C1=CC2=O)CC(S([O-])(=O)=O)N1C)=O.[Na+],Carbazochrome sodium sulfonate,"1H-Indole-2-sulfonic acid, 5-((aminocarbonyl)hydrazono)-2,3,5,6-tetrahydro-1-methyl-6-oxo-,monosodium salt;Adrenoxyl;carbazochrome salicylate;CIPLUS_180962;Carbazochrome sodium sulfonate;Auzei;CARBAZOCHROME SODIUM SULFONATE;Adona;Carbazochrome;Carbazochrome Sodium;Adrenosem;adrenochrome semicarbazone;adrenochrome semicarbazone sodium sulfonate;Carbzocromo sulfonato sodico;LS-83414;CIPLUS_732867;carbazochrome sulfonate de sodium;Carbazochrome sulfonate de sodium;carbazochrome sodium sulfonate;carbazochrome;Carbazochrome Sodium Sulfonate;AC-17;natrii carbazochromi sulfonas;adona trihydrate;Carbazochrome Sodium Sulfonate Anhydride;adrenochromazone;Natrii carbazochromi sulfonas;",OZCACMPSTYQSMM,Hemostatics,
NCGC00015682-02,CC1=CC=CC(=N1)C#CC2=CC=CC=C2,MPEP,CIPLUS_3820247;MPEP hydrochloride;6-Methyl-2-(phenylethynyl)pyridine hydrochloride;NCGC00015682-01;3-[3H]Methoxy-5-(pyridin-2-yl-ethynyl)pyridine;6-Methyl-2-(phenylethynyl)pyridine;NCGC00025044-01;NCGC00025044-02;NCGC00094081-01;2-METHYL-6-(PHENYLETHYNYL)PYRIDINE;NCGC00025044-03;MPEP;,NEWKHUASLBMWRE,mgluR5 Antagonists,GRM5
NCGC00346448-01,COC1=CC2=C(CN(CCC3=CC=C(NC(=O)C4=CC(=C(OC)C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)C=C3)CC2)C=C1OC,Tariquidar,,LGGHDPFKSSRQNS,P-Glycoprotein (MDR-1) Inhibitor,
NCGC00095107-10,CC1=CC=C(C=C1)[S+]([O-])(=O)NC(=O)NN2CC3CCCC3C2,GLICLAZIDE,,YITCTTXYRGIEOT,K(ATP) Channel Blockers,
NCGC00346597-01,OC[C@H]1O[C@@H](OC2=C(O)C=CC3=C2O\C=C(/C3=O)C4=CC=C(O)C=C4)[C@H](O)[C@@H](O)[C@@H]1O,Puerarin (Kakonein),,RIQBSCOBOICSFR,L-type Ca2+ channel blocker,
NCGC00165722-02,C1CNCCNCCCN(CCNC1)CC2=CC=C(CN3CCCNCCNCCCNCC3)C=C2,Plerixafor 8HCl (DB06809),,YIQPUIGJQJDJOS,Chemokine CXCR4 (SDF-1 Receptor) Antagonists,CXCR4
NCGC00181016-03,CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C3=CC=C(C=C3)C(O)=O,,,NAVMQTYZDKMPEU,Retinoid RXR Agonists?,RXRA
NCGC00183130-01,O=C(N[C@H](C(N[C@@H](CC3=CC=CC=C3)C[C@H](O)[C@@H](NC(OCC4=CN=CS4)=O)CC2=CC=CC=C2)=O)[C@@H](C)C)N(C)CC1=CSC(C(C)C)=N1,Ritonavir,"ABT 538;LS-178568;CIPLUS_726424;10-HYDROXY-2-METHYL-5-(1-METHYLETHYL)-1-(2-(1-METHYLETHYL)-4-THIAZOLYL)-3,6-DIOXO-8,11-BIS(PHENYLMETHYL)-2,4,7,12-TETRAAZATRIDECAN-13-OIC-ACID, 5-THIAZOLYLMETHYL ESTER (5S-(5R*,8R*,10R*,11R*));ABT53;538, AB;LOPINAVIR;A 84538;ritonavir;NCGC00164570-01;Thiazol-5-ylmethyl (1S,2S,4S)-1-benzyl-2-hydroxy-4-{(2S)-2-[3-(2-isopropylthiazol-4-ylmethyl)-3-methylureido]-3-methylbutyramido}-5-phenylpentylcarbamate;HS_1024;lopinavir + ritonavir (LPV/r);Norvir;RITONAVIR;Ritonavir;Kaletra;LS-148860;lopinavir?+?ritonavir?(LPV/r);ritonavirum;ABT-538;CIPLUS_197174;A-84538;KALETRA;",NCDNCNXCDXHOMX,HIV Protease Inhibitors,
NCGC00164619-04,CC(C)(C#N)C1=CC(=CC(=C1)C[N]2C=NC=N2)C(C)(C)C#N,Anastrozole,,YBBLVLTVTVSKRW,Aromatase Inhibitor,CYP19A1
NCGC00015399-15,CCC1=CC=CC2=C1[NH]C3=C2CCOC3(CC)CC(O)=O,ETODOLAC,,NNYBQONXHNTVIJ,Cyclooxygenase-2 Inhibitor,PTGS2
NCGC00249346-02,C1CCN(C1)CCOC2=C3COC/C=C/CCOC4=CC=CC(=C4)C5=NC(=NC=C5)NC(=C3)C=C2,SB1518,,HUHKVPGEFTXMJK,Jak2 inhibitor,JAK2
NCGC00345811-01,N[S+]([O-])(=O)C1=C2C(=O)C3=C(C(=CC=C3)O)C(=O)C2=CC=C1,LLL-12,,RBDFKYXSKPLXSR,STAT-3 Inhibitor,STAT3
NCGC00346585-01,CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(O)C=CC(=C2)CO)C(C)C,5-hydroxymethyl tolterodine (PNU 200577),,DUXZAXCGJSBGDW,Muscarinic M3 Antagonists,
NCGC00345829-01,CSC1=CC(=CC=C1)NC2=NC3=C(C=N2)/C=C(C(=O)N3C)/C4=C(Cl)C=CC=C4Cl,PD173955,,VAARYSWULJUGST,cSRC inhibitor,SRC
NCGC00346878-01,CC1=C[NH]C(=C1CCC(O)=O)\C=C\2C(=O)NC3=CC=CC=C23,SU 5402,,JNDVEAXZWJIOKB,FGFR 1/3 inhibitor,
NCGC00346483-01,CC1=C2[N](C=C1NC(=O)OC[C@@H]3COCCN3)N=CN=C2NC4=CC5=C(C=C4)[N](CC6=CC(=CC=C6)F)N=C5,BMS-599626 (AC480),,LUJZZYWHBDHDQX,EGFR (HER1; erbB1) Inhibitor,EGFR
NCGC00015501-07,NNC1=C2C=CC=CC2=CN=N1,Hydralazine hydrochloride,,RPTUSVTUFVMDQK,Smooth Muscle Relaxant,
NCGC00094818-08,CCC(C(CC)C1=CC=C(O)C=C1)C2=CC=C(O)C=C2,HEXESTROL,,PBBGSZCBWVPOOL,17-betahydroxysteroid dehydrogenase inhibitor,AKR1C1
NCGC00022678-07,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C4=C(O)C(=C(NC(=O)\C(=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C)C(=C4C(=C3C)O)O)\C=N\N5CCN(C)CC5,Rifampicin,,JQXXHWHPUNPDRT,DNA-Directed RNA Polymerase Inhibitor,PRKDC
NCGC00346578-01,COCCOC1=CC2=C(C=C1OCCO)C(=NC=N2)NC3=CC=CC(=C3)C#C,OSI-420 (Desmethyl Erlotinib),,KOQIAZNBAWFSQM,EGFR (HER1; erbB1) inhibitor,EGFR
NCGC00346623-01,COC1=C2C(=NC=C2C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)C4=CC=CC=C4)[NH]C=C1,BMS-806 (BMS 378806),,OKGPFTLYBPQBIX,HIV Attachment Inhibitor,
NCGC00090797-11,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@H]3[C@@H](O)C[C@@H](O[C@@H]3C)O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C/8=C/C(=O)OC8)C4,,,LTMHDMANZUZIPE,Steroid,
NCGC00249393-01,O=C(NC1=CC=C(C=C1)C2(CCCC2)C#N)C3=CC=CN=C3NCC4=CC=NC=C4,,,WPEWQEMJFLWMLV,VEGFR-2 inhibitor,FLT1
NCGC00263163-02,C[N]1C=C(C=N1)C2=N[N]3C(=NN=C3C=C2)SC4=CC5=C(C=C4)N=CC=C5,SGX-523,,BCZUAADEACICHN,HGFR (MET; c-Met) Inhibitor,MET
NCGC00015268-05,C2=CC=C(Cl)C(N=C1NCCN1)=C2Cl,Clonidine,"M-5041T;CIPLUS_182746;NCGC00015268-01;0   Clonidine Hcl;Catapres;LS-79607;2-(2,6-Dichloroanilino)-2-imidazoline hydrochloride;LS-79606;NCGC00015268-02;NCGC00093726-01;2,6-DICHLORO-N-2-IMIDAZOLIDINYLIDENEBENZENAMINE;NCGC00024734-01;HS_264;CIPLUS_163008;CIPLUS_163009;NCGC00024734-04;HS_350;clonidinum;CLONIDINE;NCGC00024734-02;NCGC00024734-03;Catarpres-TTS;Clonidine Dihydrochloride;LS-176265;Clonidine Hydrochloride;Clonidinum;Clonidina;9   Clonidine;Clonidine;CATAPRES;CLONIDINE HYDROCHLORIDE;1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-;Clonidine Monohydrobromide;NCGC_Prestw-248;clonidine;ST-155-BS;Clonidine hydrochloride;LS-172929;CATAPRESS-TTS;",GJSURZIOUXUGAL,alpha1-Adrenoceptor Agonists,ADRA1A
NCGC00015448-04,CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC1=C(C=CC=C1)C(O)=O,Salirasib;KD-032/ONO-7056,,WUILNKCFCLNXOK,mTOR Inhibitor,MTOR
NCGC00263231-01,COC1=CC=C(C=C1)C2=C(C)[NH]N=C2C3=CC=C(O)C=C3O,PDHK RIKEN,,GSBFARPNIZUMHA,Pyruvate dehydrogenase kinases inhibitor,PDK2
NCGC00179435-07,ClCCN[P]1(=O)OCCCN1CCCl,Ifosfamide,,HOMGKSMUEGBAAB,DNA Alkylating Agent,
NCGC00017254-02,C[C@H]1CCC/C=C/C2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1,Brefeldin A,"(+)-Brefeldin A;4   Brefeldin A;Decumbin;CIPLUS_705200;Ascotoxin;BREFELDIN A;LS-58416;NSC-89671;NSC 8967;NCGC00025061-01;NSC8967;NCGC00025061-03;Brefeldin- A;CIPLUS_214618;Brefeldin A;NCGC00022909-02;gamma,4-Dihydroxy-2-(6-hydroxy-1-heptenyl)-4-cyclopentanecrotonic acid lambda-lactone;Synergisidin;4H-Cyclopent(f)oxacyclotridecin-4-one,1,6,7,8,9,11a-beta,12,13,14,14a-alpha-decahydro-1-beta-13-alpha-dihydroxy-6-beta-methyl-;Cyanein;",KQNZDYYTLMIZCT,Golgi-Specific Brefeldin A-Resistance Guanine Nucleotide Exchange Factor 1 (GBF1) Inhibitors,GBF1
NCGC00017236-08,OC1=CC2=C(C(=O)\C=C(/O2)C3=CC=CC=C3)C(=C1O)O,,"5,6,7-trihydroxyflavone;5,6,7-Trihydroxyflavone;Baicalein Monohydrate;baicalein;NCGC00025282-03;NCGC00025282-02;NCGC00025282-01;Baicalein;baicalein 5,6,7-trimethyl ether;CIPLUS_206979;Baicalein 4H-1-Benzopyran-4-one,5,6,7-trihydroxy-2-phenyl-,;LS-39842;BAICALEIN;",FXNFHKRTJBSTCS,Cyp2C9 Inhibitor,CYP2C9
NCGC00346573-01,CNC(=O)CN1CCC(CC1)OC2=C(OC)C=C3N=CN=C(NC4=C(F)C(=CC=C4)Cl)C3=C2,AZD8931,,DFJSJLGUIXFDJP,HER2/3 (erbB2) Inhibitor,ERBB2
NCGC00346962-01,C[N]1C=C(C=N1)C2=CC=C3N=CC\4=C(N(C(=O)\C=C4)C5=CC6=C(CCN6C(=O)C=C)C=C5)C3=C2,HMSL10077,,RTRNJQOBEOISFQ,BTK Inhibitor,BTK
NCGC00250407-01,C[N]1C(=NC2=CC(=CC=C12)OC3=CC(=NC=C3)C4=NC(=C[NH]4)C(F)(F)F)NC5=CC=C(C=C5)C(F)(F)F,CHIR-265;RAF-265,,YABJJWZLRMPFSI,Raf kinase B/C inhibitor,BRAF
NCGC00263018-01,CC1=C[N]2C(=CN=C2C(=N1)NC3=C(F)C=C(C=C3)C(=O)N4CCNCC4)C5=C[NH]N=C5,NCGC00263018-01,,OOGMREBBHKGEMT,Brk/PTK6 inhibitor,PTK6
NCGC00181131-02,C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)\C(C)=C\C3=CSC(=N3)C,Epothilone B (EPO906),,QXRSDHAAWVKZLJ,Tubulin depolymerization inhibitor,TUBB
NCGC00160275-01,CC1=C2C(O)=CC3=C4C2=C(C(O)=C1)C(=O)C5=C4C(=C(O)C=C5O)C(=O)C3(C)C,,"geliomitsin;heliomycinum;NCGC00160275-01;resistomycin;3,5,7,10-tetrahydroxy-1,1,9-trimethyl-2H-benzo(c,d)pyrene-2,6(1H)-dione;Heliomycine;Heliomicina;RESISTOMYCIN;heliomycin;heliomycine;CIPLUS_207241;HELIOMYCIN;Heliomycin;Heliomycinum;CIPLUS_789457;",ABLACSIRCKEUOB,RNA Polymerase Inhibitor,POLR2A
NCGC00095986-02,CC[C@@]1(O)C(=O)OCC/2=C1/C=C3\N(CC4=CC5=CC(=CC=C5N=C34)O)C2=O,,CIPLUS_674440;10-Hydroxycamptothecin;10-Hydroxycamptothecin(10-HCPT);10-HYDROXY-CAMPTOTHECIN;NCGC00095986-02;NCGC00095986-01;10-HYDROXYCAMPTOTHECIN;,HAWSQZCWOQZXHI,DNA Topoisomerase I Inhibitors,TOP1
NCGC00016569-08,NCC1CCC(CC1)C(O)=O,TRANEXAMIC ACID,,GYDJEQRTZSCIOI,Tissue-Type Plasminogen Activator Inhibitor (tPA) Inhibitor,SERPINE1
NCGC00346484-01,FC(F)C1=NC2=C(C=CC=C2)[N]1C3=NC(=NC(=N3)N4CCOCC4)N5CCOCC5,ZSTK474,,HGVNLRPZOWWDKD,PI3K Inhibitor,PIK3CA
NCGC00250396-01,COC1=C(CO)C=C(C=C1)C2=CC=C3C(=N2)N=C(N=C3N4CCOCC4)N5C[C@@H](C)O[C@@H](C)C5,KU-0063794,,RFSMUFRPPYDYRD,mTORC1/2 Inhibitor,MTOR
NCGC00346530-01,OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC2=C(F)C=C(I)C=C2,AS703026,,VIUAUNHCRHHYNE,Mek 1/2 inhibitor,MAP2K1
NCGC00016526-11,COC1=C(OC)C2=C(C=C1)C=C3C4=CC5=C(OCO5)C=C4CC[N+]3=C2,BERBERINE CHLORIDE,,YBHILYKTIRIUTE,Protein Tyrosine Phosphatase (PTP) Inhibitors,PTP4A1
NCGC00263021-02,COC1=C(Cl)C=C2C(=C1NC(=O)C3=C(C)N=CC=C3)[NH]C4=C2C=CN=C4,MLN-120B,,ZNOLRTPMNMPLHY,IKK beta inhibitor,IKBKB
NCGC00346539-01,CN(C)C1=CC=C(C=C1)C2=NC3=C(N4CCN(CC4)CC(=O)NC5=NC=CS5)C(=CN=C3[NH]2)Cl,CCT129202,,QYKHWEFPFAGNEV,Aurora Kinase Inhibitor,AURKA
NCGC00346802-01,C[C@H]1CN(CCCN1[S+]([O-])(=O)C2=CC=CC3=C2C(=CN=C3)C)C(=O)CN,Glycyl-H 1152 dihydrochloride,,CMKMGFAUKPAOMG,ROCK II Inhibitor,ROCK2
NCGC00015937-02,NCCCCNCCCN,Spermidine trihydrochloride,"SPERMIDINE;NCGC00015937-01;Spermidine 0.1 M solution;NCGC00024903-03;NCGC00024903-02;NCGC00094332-02;NCGC00024903-01;NCGC00094332-01;N-(3-Aminopropyl)-1,4-diaminobutane;1,4-Butanediamine, N-(3-aminopropyl)-;N-(3-Aminopropyl)-1,4-butanediamine trihydrochloride;Spermidine;Spermidine Trihydrochloride;1,8-Diamino-4-azaoctane;Spermidine trihydrochloride;CIPLUS_152753;CIPLUS_173341;CIPLUS_180523;Spermidine phosphate salt hexahydrate;Spermidine Phosphate;Additive Screening Solution 30/Fluka kit no 78374;Spermidine-8-14C trihydrochloride;Spermidine solution;SPERMIDINE TRIHYDROCHLORIDE;Dispermidine triphosphate;",ATHGHQPFGPMSJY,Drugs Acting on NMDA Receptors,GRIN2A
NCGC00092314-04,CN1\N=C(N)/C2=C[N]([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C4=C2C1=NC=N4,API-2,,HOGVTUZUJGHKPL,PKB/Akt Inhibitor,AKT1
NCGC00347281-01,C[N]1N=C(COC2=CC=C(C=C2)N3CCN(CC3)C(C)=O)C(=C1C)C4=C5[N](CC6=CC=CN=C6)C(=C(CCCOC7=CC(=C(Cl)C(=C7)C)C)C5=CC=C4)C(O)=O,VU0483486-1,,JCGVWZYEVNBCAJ,Mcl Inhibitor,MCL1
NCGC00169864-03,C1OC2=C(O1)C=C(C=C2)[C@H]3OC[C@H]4[C@@H]3CO[C@@H]4C5=CC6=C(OCO6)C=C5,Sesamin (Fagarol),,PEYUIKBAABKQKQ,NF-kappaB Activation Inhibitor,NFKB1
NCGC00347956-01,CCCCCNC(=O)N1CCC(CN(CC2=CC=C(S2)[N+]([O-])=O)CC3=CC=C(Cl)C=C3)C1,,,PPUYOYQTTWJTIU,Rev-erb alpha agonist,NR1D1
NCGC00165811-03,OC1=C(C=C(Cl)C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F,IMD 0354,,CHILCFMQWMQVAL,IKK-2 Inhibitor,IKBKB
NCGC00347303-01,CC(C)[C@@]12C[C@@H](OC(=O)CO)[C@@](C)(O1)[C@@H]3CC[C@@H](C)[C@H]3[C@@H]2OC(=O)\C=C\C4=CC=CC=C4,,,GACOFEKSDCOVMV,PKC Activator,PRKCA
NCGC00018181-13,CCN1\C=C(\C(O)=O)C(=O)C2=CC=C(C)N=C12,NALIDIXIC ACID,,MHWLWQUZZRMNGJ,Quinoline Antibiotic,
NCGC00250412-01,CC1=C(C)C2=C(S1)[N]3C(=NN=C3[C@H](CC(=O)OC(C)(C)C)/N=C2/C4=CC=C(Cl)C=C4)C,JQ1,,DNVXATUJJDPFDM,"Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitor",BRD4
NCGC00249612-01,CC(C)C[C@H](NC(=O)CNC(=O)C1=C(Cl)C=CC(=C1)Cl)B2OC(=O)CC(CC(O)=O)(O2)C(O)=O,,,YTXSYWAKVMZICI,Proteasome Inhibitor,PSMD1
NCGC00347064-01,COC1=C2N=C(N=C(NCC3=CC=CC=C3)C2=CC=C1)[N]4C(=NC5=C4C=CC=C5)N,,,NHAMBLRUUJAFOY,p97 ATPase Inhibitor,
NCGC00090726-11,NC(=O)C1=N[N](C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O,RIBAVIRIN,,IWUCXVSUMQZMFG,Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors,IMPDH1
NCGC00179454-04,CC[C@]1(CC[C@@H](O1)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)[C@@H](OC)[C@H](C)C([O-])=O)O2)[C@@H]4O[C@H](C[C@@H]4C)[C@H]5O[C@@](O)(CO)[C@H](C)C[C@@H]5C,Monensin sodium salt (Coban),,GAOZTHIDHYLHMS,Polyether Antibiotic,
NCGC00182052-03,O=C(NC1=CC=CC=C1C2=C[N]3C(=CSC3=N2)CN4CCNCC4)C5=NC6=C(C=CC=C6)N=C5,SRT1720,,IASPBORHOMBZMY,Histone Deacetylase/SIRT1 Activator,SIRT1
NCGC00346841-01,C[C@H](NC(=O)[C@@H](O)C1=CC(=CC(=C1)F)F)C(=O)N[C@@H]2C(=O)N(C)C3=C(C=CC=C3)C4=C2C=CC=C4,LY-411575,,ULSSJYNJIZWPSB,g-Secretase Inhibitor,NOTCH1
NCGC00263197-01,CC(C)C(=O)NC1=NC=C(S1)C2=CC(=N[N]2C3=C(Cl)C=CC=C3Cl)C(F)F,BMS-5,,IVUGBSGLHRJSSP,LIMK1/LIMK2 inhibitor,LIMK1
NCGC00346557-01,OC1=CC=C(C=C1)[C@@H]2OC3=C(C=C(O)C=C3)[C@@H]4CCC[C@H]24,LY500307 (Erteberel),,XIESSJVMWNJCGZ,Estrogen Receptor (ER) beta Agonist,ESR1
NCGC00263522-02,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)\C=C/[C@]34C)[C@@H]1CC[C@@H]2C(=O)NC5=CC(=CC=C5C(F)(F)F)C(F)(F)F,Dutasteride,,JWJOTENAMICLJG,Steroid 5alpha-Reductase Inhibitors,SRD5A1
NCGC00025379-01,COC1=CC=C(CCN(C)CCCOC2=CC=C(C=C2)[S+]([O-])(=O)C3=C(C(C)C)C4=CC=CC=C4[NH]3)C=C1OC,SR 33805,SR 33805 oxalate;NCGC00025379-01;,KWAAABBJIYOBAJ,Ca2+ channel antagonist,
NCGC00015918-05,CN1CCC2(CC1)COC3=CC4=C(C=C23)N(CC4)C(=O)C5=CC=C(C=C5)C6=C(C)C=C(C=C6)C7=NOC(=N7)C,SB-224289,,ATQMRMGXINTJHV,5-HT1B Agonist,HTR1B
NCGC00344505-01,C[C@@H](NCC1=CC2=C([NH]1)C=CC=C2)C3=C4C=CC=CC4=CC=C3,Calindol,,JLPWXRZETODYFC,Calcium-Sensing Receptor (CaSR) Agonists,CASR
NCGC00015519-09,NCCC1=CC(=C(O)C=C1)O,,DOPAMINE HCl,VYFYYTLLBUKUHU,neurotransmitter,
NCGC00250390-01,CC(C)(C)OC(=O)NC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NCCCCCCC(=O)NO,ISOX,,WWGBHDIHIVGYLZ,Histone Deacetylase (HDAC) 6 Inhibitor,HDAC1
NCGC00346620-01,COC1=CC=CC(=C1)NC2=C(C=NC3=C(C)C=C(C=C23)[S+]([O-])(=O)C4=CC=CC(=C4)C(=O)N(C)C)C(N)=O,GSK256066,,AIEQMFKKQOLHNF,Phosphodiesterase IIII (PDE4) inhibitor,PDE4A
NCGC00345825-01,FC(F)C1=N[N](C(=C1)C2=CN=C(NC(=O)C3CC3)S2)C4=C(Cl)C=CC=C4Cl,BMS-3,,YBGGBHCJSAEIAS,LIMK Inhibitor,LIMK1
NCGC00263127-01,CC(C)[C@H](C[S+]([O-])(=O)C1=CC=C(C=C1)C2=CC=C(Br)C=C2)C(O)=O,PD-166793,,BTXFWURYTGXCCN,MMP-13 Inhibitor,MMP13
NCGC00015919-04,S(=O)(C)(=O)NC1=CC=C(C(O)CNC(C)C)C=C1,Sotalol,"CIPLUS_695928;mead johnson 1999;beta-cardone;LS-7704;CIPLUS_208324;LS-174288;NCGC00024899-01;Dexsotalol hydrochloride;NCGC00015919-01;CIPLUS_742713;HS_186;NCGC_Prestw-966;Sotalol Hydrochloride;LS-90249;dexsotalolum;MJ199;sotalolum;CIPLUS_162704;SOTALOL HYDROCHLORIDE;NCGC00024899-03;NCGC00024899-02;Sotalolum;Sotalol Monohydrochloride;MJ-1999;N-(4-[1-Hydroxy-2-(isopropylamino)ethyl]phenyl)methanesulfonamide hydrochloride;DEXSOTALOL;LS-175007;Monohydrochloride, Sotalo;Dexsotalol;CIPLUS_710514;(?)-Sotalol hydrochloride;Betapace (Sotalol);Dexsotalol Hydrochloride;DEXSOTALOL HYDROCHLORIDE;Betapace;NCGC_SIGMA_S0278;NCGC00016553-01;NCGC00094337-02;Hydrochloride, Sotalo;SOTALOL HYDROCHLORIDE, D-;Tolerzide;NCGC00094337-01;(+/-)-Sotalol hydrochloride;Sotalol hydrochloride;dexsotalol;SOTALOL;( )-Sotalol hydrochloride;(S)-N-(4-(1-HYDROXY-2-((1-METHYLETHYL)-AMINO)ETHYL)PHENYLMETHANESULFONAMIDE HYDROCHLORIDE, D-;HS_1289;N-[4-[1-Hydroxy-2-(isopropylamino)ethyl]phenyl]methanesulfonamide hydrochloride;Sotalol;CIPLUS_752069;Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-;sotalol;MJ 199;",JBELYSFONFSZTR,beta-Adrenoceptor Antagonists,ADRB1
NCGC00024929-01,CCN(C1=CC=CC=C1)C2=CC(=[N+](C)C(=N2)C)NC,ICI-D7288;ZD-7288?,"NCGC00024929-01;CIPLUS_700740;ICI-D2788;ICI D2788;ZENECA ZD7288;4-(N-ethyl-N-phenylamino)-1,2-dimethyl-6-(methylamino)pyrimidinium chloride;LS-172857;ZD 7288;",JABSKGQQWUDVRU,HCN [I(h)] Blockers,HCN
NCGC00250085-01,CNCC(O)C(O)C(O)C(O)CO.OC(=O)C1=CC=C(C=C1)C2=CC3=CC=CN=C3C(=N2)C4=CC5=NON=C5C=C4,NVP-ABE171,,IALXIRPKVRUJQO,Phosphodiesterase IIII (PDE4) inhibitor,PDE4A
NCGC00015892-07,O=C1N\2CCC3=C([NH]C4=C3C=CC=C4)C2=N/C5=CC=CC=C15,Rutaecarpine (Rutecarpine),,ACVGWSKVRYFWRP,Cyclooxygenase-2 Inhibitor,PTGS2
NCGC00178707-03,CCC(=O)NCC[C@@H]1CCC2=C1C3=C(OCC3)C=C2,Ramelteon (TAK-375),,YLXDSYKOBKBWJQ,Melatonin MT1/MT2 Agonist,MTNR1A
NCGC00186628-01,CCCC[N+]1(C)[C@H]2CC(C[C@@H]1[C@H]3O[C@@H]23)OC(=O)[C@H](CO)C4=CC=CC=C4,,BUTYLSCOPOLAMMONIUM Br,YBCNXCRZPWQOBR,Muscarinic acetylcholine receptor Antagonists,CHRM1
NCGC00242479-01,COC1=C(N[S+]([O-])(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4)N=CC(=N1)C,Zibotentan;ZD-4054,,SOMYEPUSNJJLPY,Endothelin ETA Receptor Antagonist,EDNRA
NCGC00164594-01,O=[C@@](OCCl)[C@](CC2)(OC(OCC)=O)[C@]1(C)[C@]2([H])[C@@](CCC3=CC4=O)([H])[C@]([C@](C)3C=C4)([H])[C@@H](O)C1,Loteprednol etabonate,"Alrex;LS-177664;LOTEPREDNOL ETABONATE;loteprednol;Lotemax;Loteprednol etabonate;loteprednol etabonate;CIPLUS_192319;NCGC00164594-01;CHLOROMETHYL 17A-ETHOXYCARBONYLOXY-11B-HYDROXYANDROSTA-1,4-DIENE-3-ONE-17B-CARBOXYLATE;chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate;CEHOAC;Loteprednol Etabonate;P-5604;",DMKSVUSAATWOCU,Corticosteroid,
NCGC00163547-02,C[C@H]([C@H](O)CCC(C)(C)O)[C@H]1CC[C@@]2(O)C/3=C/C(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C,Ecdysone,,UPEZCKBFRMILAV,Steroid prohormone,
NCGC00015697-11,OC1=CC2=C(C(=C1)O)C(=O)\C(=C(/O2)C3=CC(=C(O)C(=C3)O)O)O,,"myricetin 3-O-(2''-O-galloyl)-beta-D-glucopyranoside;myricetin 3-O-neohesperidoside;NCGC00094083-01;myricetin 7-O-glucopyranosyl-(1-6)-glucopyranoside;NCGC00094083-03;Cannabiscetin;myricetin 7-O-beta-D-glucopyranosyl-(1-6)-beta-D-glucopyranoside;3,3',4',5,5',7-Hexahydroxyflavone;myricetin 3-O-(2'',3''-di-O-galloyl)rhamnopyranoside;myricetin 3-O-(4''-acetyl)rhamnopyranoside;myricetin 3-O-(2'',3'' -di-O-galloyl)-alpha-rhamnopyranoside;myricetin 3-O-(2''-O-galloyl)-alpha-rhamnopyranoside 7-methyl ether;myricetin 7-O-rhamnopyranosyl-(1-6)-glucopyranoside;myricetin;CIPLUS_154027;m(G)-Glu;MYRICETIN;NCGC00094083-04;NCGC_Prestw-465;myricetin 7-O-alpha-L-rhamnopyranosyl-(1-6)-beta-D-glucopyranoside;myricetin 3-O-(3''-galloyl)rhamnopyranoside 7-methyl ether;3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one;myricetin-DGR;myricetin-2 cpd;NCGC00015697-02;myricetin 3-O-(2''-O-galloyl)rhamnopyranoside 7-methyl ether;Myricetin;NCGC00015697-01;myricetin-3 cpd;myricetin 3-O-(4''-acetyl)-alpha-L-rhamnopyranoside;myricetin 3-O-(3''-galloyl)-alpha-rhamnopyranoside 7-methyl ether;",IKMDFBPHZNJCSN,Cytochrome P450 CYP1A2 Inhibitor,CYP1A2
NCGC00346586-01,O[C@@H]1[C@@H](O)[C@H](O[C@@H]([C@H]1O)C(O)=O)OC2=C(O)C(=C3C(=O)\C=C(/OC3=C2)C4=CC=CC=C4)O,Baicalin,,IKIIZLYTISPENI,prolyl endopeptidase inhibitor,
NCGC00346619-01,NC1=NC=NC2=C1C(=N[N]2C3CCCC3)C4=CN=C5[NH]C=CC5=C4,PP-121,,NVRXTLZYXZNATH,PDGFR Inhibitor,PDGFRA
NCGC00346514-01,CN(C)[C@H]1CCN(C1)CC2=CC=C(C=C2C(F)(F)F)C(=O)NC3=CC=C(C)C(=C3)NC4=NC=C(C=N4)C5=CN=CN=C5,Bafetinib (INNO-406),,ZOPBZHLJXQAQON,Bcr-Abl Kinase Inhibitor,
NCGC00183875-01,Cl.Fc1cc2CC[C@@H](Oc2cc1)[C@@H](O)CNC[C@H](O)[C@@H]3CCc4cc(F)ccc4O3,rac Nebivolol hydrochloride,"nebivololum;nebivolol;Nebivolol hydrochloride;CIPLUS_213525;CIPLUS_768326;Nebivolol;A,A'-(IMINOBIS(METHYLENE))BIS(6-FLUORO-3,4-DIHYDRO-2H-1-BENZOPYRAN-2-METHANOL) HYDROCHLORIDE, DL-;NEBIVOLOL HYDROCHLORIDE;LS-178404;CIPLUS_682408;CIPLUS_767074;NEBIVOLOL;CIPLUS_767073;R-67,555;",KOHIRBRYDXPAMZ,beta1-Adrenoceptor Antagonists,ADRB1
NCGC00183867-01,O=C3C1=C(O)C=CC=C1[C@](C4=C3C(O)=CC(CO)=C4)([H])[C@@]2([H])[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2,Aloin,"Aloin- A;CIPLUS_3886516;LS-71651;Aloin;CIPLUS_158318;isobarbaloin;barbaloin, beta-D-isomer;10-beta-D-Glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)-9(10H)-anthracenone;Barbaloin;10-(1',5'-anhydroglucosyl)aloe-emodin-9-anthrone;barbaloin;NCGC00095271-01;NCGC00095271-02;LS-175805;LS-174213;barbaloin, monoglucoside;1,8-Dihydroxy-10-(beta-D-glucopyranosyl)-3-(hydroxymethyl)-9(10H)-anthracenone;ALOIN;barbaloin, (S)-isomer;LS-175526;",AFHJQYHRLPMKHU,Stimulant laxative,
NCGC00346825-01,[O-][N+](=O)C1=CC=C(NC2=CC=CC=C2C3=CC=CC=C3)C4=NON=C14,10074-G5,,KMJPYSQOCBYMCF,MYC Expression Inhibitors,MYC
NCGC00163532-01,OC[C@H]1O[C@@H](OC2=CC3=C(C=C2)C(=O)C(=CO3)C4=CC=C(O)C=C4)[C@H](O)[C@@H](O)[C@@H]1O,DAIDZIN,daidzin;DAIDZEIN GLUCOSIDE;Daidzein-7-O-beta-D-glucopyranoside;Daidzin;daidzein-7-glucoside;CIPLUS_685280;9   Daidzin;NCGC00163532-01;DAIDZIN;,KYQZWONCHDNPDP,Alcohol Dehydrogenase Inhibitor,ADH1
NCGC00015598-03,CC1(C)CC\C2=C(/O1)C3=C(C=CC=C3)C(=O)C2=O,,"BETA-LAPACHONE;LAPACHONE, beta-;NCGC00094066-03;NCGC00094066-04;LS-95515;NCGC00094066-01;NCGC00094066-02;beta-Lapachone;3,4-dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione;CIPLUS_207115;beta-lapachone;NCGC00015598-01;",QZPQTZZNNJUOLS,DNA Topoisomerase I/II Inhibitors,TOP1
NCGC00168114-03,CC1=CC=CC=C1N2\C(=N/C3=C(C(=CC=C3)C)C2=O)C[N]4C=NC5=C4N=CN=C5N,IC-87114,,GNWHRHGTIBRNSM,PI3K inhibitor,PIK3CA
NCGC00018302-08,N[S+]([O-])(=O)C1=C(Cl)C=C2NC(N[S+]([O-])(=O)C2=C1)C(Cl)Cl,TRICHLORMETHIAZIDE,,TWLBZVDPMBBKFJ,Diuretic,
NCGC00025346-01,CN1CCN2C(C1)C3=C(CC4=C2N=CC=C4)C=CC=C3,Mirtazepine,"PYRAZINO(2,1-A)PYRIDO(2,3-C)(2)BENZAZEPINE, 1,2,3,4,10,14B-HEXAHYDRO-2-METHYL-, (14BR)-, (2Z)-2-BUTENEDIOATE (1:1);S-ENANTIOMER OF MIRTAZAPINE;Celltech brand of mirtazapine;LS-127703;Mirtazanine;Norset;Mirtazepine;Remergil;CIPLUS_183976;Pyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-;ORG 3770;NCGC_SIGMA_M0443;Organon brand of mirtazapine;PYRAZINO(2,1-A)PYRIDO(2,3-C)(2)BENZAZEPINE, 1,2,3,4,10,14B-HEXAHYDRO-2-METHYL-, (14BR)-;HS_1230;(14BS)-1,2,3,4,10,14B-HEXAHYDRO-2-METHYLPYRAZINO(2,1-A)PYRIDO(2,3-C)(2)BENZAZEPINE (2Z)-BUTENEDIOATE;1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine;mirtazapine;(14BS)-2-METHYL-1,2,3,4,10,14B-HEXAHYDROPYRAZINO(2,1-A)PYRIDO(2,3-C)(2)BENZAZEPINE;Rexer;mirtazapinum;(N-methyl-11C)mirtazapine;Remeron;ORG-4419;CIPLUS_3887628;CIPLUS_3887627;Mundogen brand of mirtazapine;Mirtazapine (Remerom);MALEATE SALT OF R-ENANTIOMER OF MIRTAZAPINE;Mirtazapina;ORG-4419-2;ORG-50081;ORG-3770;Mirtazapine;PYRAZINO(2,1-A)PYRIDO(2,3-C)(2)BENZAZEPINE, 1,2,3,4,10,14B-HEXAHYDRO-2-METHYL-, (14BS)-, (2Z)-2-BUTENEDIOATE (1:1);Zispin;MALEATE SALT OF S-ENANTIOMER OF MIRTAZAPINE;PYRAZINO(2,1-A)PYRIDO(2,3-C)(2)BENZAZEPINE, 1,2,3,4,10,14B-HEXAHYDRO-2-METHYL-, (14BS)-;Mirtazapinum;(14BS)-1,2,3,4,10,14B-HEXAHYDRO-2-METHYLPYRAZINO(2,1-A)PYRIDO(2,3-C)(2)BENZAZEPINE;MIRTAZAPINE;R-ENANTIOMER OF MIRTAZAPINE;(14BR)-2-METHYL-1,2,3,4,10,14B-HEXAHYDROPYRAZINO(2,1-A)PYRIDO(2,3-C)(2)BENZAZEPINE (2Z)-BUT-2-ENEDIOATE;(14BS)-2-METHYL-1,2,3,4,10,14B-HEXAHYDROPYRAZINO(2,1-A)PYRIDO(2,3-C)(2)BENZAZEPINE (2Z)-BUT-2-ENEDIOATE;CIPLUS_10560373;1,2,3,4,10,14B-HEXAHYDRO-2-METHYLPYRAZINO(2,1-A)PYRIDO(2,3-C)(2)BENZAZEPINE;CIPLUS_3780005;Esmirtazapine maleate;6-azamianserin;HS_959;NCGC00025346-02;NCGC00025346-01;(14BR)-2-METHYL-1,2,3,4,10,14B-HEXAHYDROPYRAZINO(2,1-A)PYRIDO(2,3-C)(2)BENZAZEPINE;",RONZAEMNMFQXRA,5-HT2A/3 Antagonists?,HTR2A
NCGC00346961-01,CC1=C(NC(=O)C2=CC=NO2)C=C(C=C1)C(=O)NC3=CC(=CC(=C3)C(F)(F)F)NC(=O)C=C,HMSL10076,,UASQUKUDXJFTCO,discoidin domain receptor tyrosine kinase (DDR1),DDR1
NCGC00249391-01,C[N]1N=CC2=C1N=C(N=C2NC3=CC(=CC=C3C)C(=O)NC4=CC=CC(=C4)C(F)(F)F)C5=CC=CN=C5,,,ZCCPLJOKGAACRT,Raf kinase B/C inhibitor,BRAF
NCGC00346661-01,C/C=C(C)/C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]\1C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@H]4[C@@](C)([C@@H](O)C[C@H]5OC[C@@]45OC(C)=O)C(=O)[C@H](OC(C)=O)C(=C1C)/C2(C)C)C6=CC=CC=C6,Cephalomannine,,DBXFAPJCZABTDR,Tubulin depolymerization inhibitor,TUBB
NCGC00187906-01,OC1=CC(=CC=C1)C2=NC3=C(OC4=C3C=CC=N4)C(=N2)N5CCOCC5,PI-103,,TUVCWJQQGGETHL,"PI3Kalpha, beta, gamma Inhibitor",PIK3CA
NCGC00346882-01,C[C@H](NC(=O)C1=C(OCC2=CC=C(Cl)C=C2)C=CS1)C3=CC=CC=C3,AS 1949490,,RFZPGNRLOKVZJY,SH2 containing inositol phosphatase (SHIP) inhibitor,INPPL1
NCGC00346645-01,CC[S+]([O-])(=O)C1=CC=CC(=C1)C2=CC(=C(C)C3=C2C4=C([NH]3)N=CC(=C4)C)C(=O)NC5CCN(C)CC5,TAK-901,,RZFQUIOHJWFKEG,Aurora-A/B Inhibitor,AURKA
NCGC00092372-01,CN1C(=O)C(CC2=C[NH]C3=C2C=CC=C3)NC1=S,Necrostatin-1,necrostatin-1;Nec-1 compound;MTH-DL-Tryptophan;Necrostatin-1;NCGC00092372-02;5-(1H-indol-3-ylmethyl)-3-methyl-2-thioxo-4-Imidazolidinone;5-(indol-3-ylmethyl)-3-methyl-2-thio-Hydantoin;,TXUWMXQFNYDOEZ,RIP Kinase inhibitor,RIPK1
NCGC00159341-03,[C@@H]1(O[C@H](CS1)N\2C(\N=C(/C=C/2)N)=O)CO,Lamivudine,"lamivudine (3TC);GR-109714X;LS-2107;Lamivudine;GR109714X;zidovudine?+?lamivudine?+?nevirapine;CIPLUS_10556810;zidovudine?+?lamivudine;lamivudine triphosphate;Epivir;CIPLUS_197069;stavudine?+?lamivudine?+?nevirapine;CIPLUS_10556930;2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-;EPIVIR;AB02509316-01;LAMIVUDINE;3TC-TP;Lamivudine, (2S-cis)-Isomer;HS_546;4-AMINO-1-(2-HYDROXYMETHYL-1,3-OXATHIOLAN-5-YL)-(1H)PYRIMIDIN-2-ONE(2R,CIS);CIPLUS_215585;zidovudine + lamivudine + nevirapine;(2R, 5S) -2-(Hydroxymethyl)-5-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1,3-oxathiolane salicylate;BCH18;BCH-189;BCH 18;LAMIVUDINE W/NEVIRAPINE;LS-172904;stavudine + lamivudine + nevirapine;3TC (lamavudine);lamivudinum;zidovudine + lamivudine;2',3' Dideoxy 3' thiacytidin;lamivudine;lamivudine?(3TC);",JTEGQNOMFQHVDC,Reverse Transcriptase Inhibitor,TERT
NCGC00346436-01,COC1=CC2=NC(=NC(=C2C=C1OC)N[C@@H]3CNC[C@H]3C(C)(C)O)C4=CC(=CC=C4O)F,CCT-241533   ,,HZASIAXCPXTISQ,Checkpoint Kinase 2 (Chk2) Inhibitors,CHEK2
NCGC00163381-04,CN(C(CC1=CC=C(O[S+]([O-])(=O)C2=C3C=CN=CC3=CC=C2)C=C1)C(=O)N4CCN(CC4)C5=CC=CC=C5)[S+]([O-])(=O)C6=CC=CC7=CN=CC=C67,,,RJVLFQBBRSMWHX,Calmodulin-Dependent Protein Kinase II Inhibitors,CAMKK2
NCGC00346544-01,CN(C)CC1=CC=CC(=C1)N/C(C2=CC=CC=C2)=C/3C(=O)NC4=CC(=CC=C34)C(=O)N(C)C,BIX 02189,,HOMJAAIVTDVQJA,Mek 5 Inhibitor,MAP2K5
NCGC00166310-03,CN1CCN(CC1)C2=C3OCN(C)N4\C=C(C(O)=O)/C(=O)C(=C34)C=C2F,Marbofloxacin,,BPFYOAJNDMUVBL,Antibiotic,
NCGC00023945-13,C\C1=C\N([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,ZIDOVUDINE [AZT],,HBOMLICNUCNMMY,Reverse Transcriptase Inhibitor,TERT
NCGC00345838-01,CC(C)(O)C1=CC2=C(S1)C(=NC(=N2)C3=CN=C(N)N=C3)N4CCOCC4,GNE-493,,LEXMMFPAPDGYGZ,PI3K Inhibitor,PIK3CA
NCGC00179302-02,O=C\1NC2=C(C=CC=C2)C1=C3\NC4=C(C=CC=C4)C3=O,,,CRDNMYFJWFXOCH,CDK1/2/4/5 Inhibitor,CDK1
NCGC00345834-01,CCC1=NC(=C(S1)C2=CC(=NC=C2)NC(=O)C3=CC=CC=C3)C4=CC(=CC=C4)C,TAK-715,,HEKAIDKUDLCBRU,p38 MAPK Inhibitor,MAPK14
NCGC00345842-01,CC\1=C(C(\N=C(/N1)C2=CC(=NC=C2)Cl)C3=C(F)C=C(Cl)C=C3)/C(=O)NC4=C(F)C=C5[NH]N=CC5=C4,GSK-25,,KZYAHEIPPAPADQ,ROCK Inhibitor,ROCK1
NCGC00263566-03,[O-]C(=O)C/1=N/C(=O)NC(=O)N1,Oxonic acid potassium salt,,RYYCJUAHISIHTL,adunct antineoplastic agent,
NCGC00274061-01,C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4\C(=C(/C[C@]35C)C#N)O)[C@@H]1CC[C@@H]2O,Trilostane,,KVJXBPDAXMEYOA,Estrogen Receptor (ER) beta Modulators,ESR1
NCGC00015578-10,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C2=CC=CC=C2,KETOPROFEN,,DKYWVDODHFEZIM,non-steroidal antiinflammatory,
NCGC00347283-01,C[N]1N=C(COC2=CC=C(C=C2)N3CCN(CC3)[S+](C)([O-])=O)C(=C1C)C4=C5[N](CC6=CC=CN=C6)C(=C(CCCOC7=CC(=C(Cl)C(=C7)C)C)C5=CC=C4)C(O)=O,VU0483488-1,,FPXKBOQUQVSSFK,Mcl Inhibitor,MCL1
NCGC00092290-03,NC(\SC1=CC=C(N)C=C1)=C(C#N)/C2=CC=CC=C2C(F)(F)F,SL327,,JLOXTZFYJNCPIS,Mek 1/2 inhibitor,MAP2K1
NCGC00015840-09,OC1=CC=C(CCC(=O)C2=C(O)C=C(O)C=C2O)C=C1,PHLORETIN,,VGEREEWJJVICBM,ICAM1 Expression Inhibitors,
NCGC00016552-02,CC(=O)OC\C1=C(\[N@]2[C@@H](SC1)[C@H](N)C2=O)C(O)=O,,,HSHGZXNAXBPPDL,Cephalosporin intermediate,
NCGC00024246-13,COC1=CC=CC2=C1C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C(C)=O)C(=C3C2=O)O,DAUNORUBICIN,,STQGQHZAVUOBTE,Antineoplastic Antibiotics,
NCGC00159483-03,CCN(CCO)CCCC(C)NC1=CC=NC2=CC(=CC=C12)Cl,Hydroxychloroquine sulfate;Plaquenil???,,XXSMGPRMXLTPCZ,Autophagy Inhibitor,MAP1LC3A
NCGC00015705-04,NC(CC2(C)C1)(CC3C2)CC1(C3)C,Memantine,"NCGC00024782-01;Memantine hydrochloride;3,5-Dimethylamantadine hydrochloride;NCGC00024782-02;MEMANTINE;MEMANTINE HYDROCHLORIDE;3,5-Dimethyl-1-adamantanamine hydrochloride;LS-157051;memantinum;HS_986;Memantine;Memantinum;NCGC00016848-01;Memantine Hydrochloride;Memantina;memantine;Tricyclo(3.3.1.13,7)decan-1-amine, 3,5-dimethyl-;Memantine HCL;Merz Brand of Memantine Hydrochloride;Axura;NCGC00094186-01;CIPLUS_758735;D 14;Ebixa;NCGC00094186-02;CIPLUS_172134;Lundbeck Brand of Memantine Hydrochloride;NCGC00015705-01;1-Amino-3,5-dimethyladamantane;Namenda;NCGC_Prestw-978;Memantin;D145;1-AMINO-3,5-DIMETHYL-ADAMANTANE HYDROCHLORIDE;NCGC00024782-03;D-145;",BUGYDGFZZOZRHP,NMDA Antagonist,GRIN2A
NCGC00345832-01,OCC(=O)N1CCC(CC1)C2=N[NH]C(=C2C3=NC=NC=C3)C4=CC=C(Cl)C=C4,SD-06,,CATQHDWESBRRQA,p38 MAPK Inhibitor,MAPK14
NCGC00162288-06,CCCC(CCC)C([O-])=O,VALPROATE SODIUM,,NIJJYAXOARWZEE,GSK-3 inhibitor,GSK3B
NCGC00094374-05,CC[C@H](CO)NC1=NC(=C2N=C[N](C(C)C)C2=N1)NCC3=CC=CC=C3,Seliciclib;(R)-Roscovitine;CYC-202;NSC-701554,,BTIHMVBBUGXLCJ,"CDK 1,2,5,7,9 Inhibitor",CDK1
NCGC00346680-01,OC(=O)C[N]1N=NC(=N1)C2=CC(=NO2)N3CCC(CC3)OC4=CC(=CC=C4Br)F,MK-8245,,UJEAABFSXKCSGI,Stearoyl-CoA Desaturase Inhibitors,SCD
NCGC00346562-01,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(\N2C1=O)C(=O)OCOC(=O)C(C)(C)C)/C=C\C3=C(C)N=CS3)C4=CSC(=N4)N,Cefditoren pivoxil,,AFZFFLVORLEPPO,Cephalosporin antibiotic,
NCGC00248196-02,CC1(C)CC(O)CC(C)(C)N1[O],Tempol,,UZFMOKQJFYMBGY,Free Radical Scavenger,
NCGC00015205-07,CCC(C)N(C)C(=O)C1=NC(=C2C=CC=CC2=C1)C3=C(Cl)C=CC=C3,PK-11195,,RAVIZVQZGXBOQO,Constitutive Androstane Receptor Antagonist,NR1I3
NCGC00016797-04,CC1(C)S[C@H]2[C@H](NC(=O)[C@@H](N)C3=CC=C(O)C=C3)C(=O)[N@]2[C@H]1C(O)=O,,,LSQZJLSUYDQPKJ,beta-lactam antibiotic,
NCGC00346469-01,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)[C@@H](C)O)B(O)O,CEP18770,,SJFBTAPEPRWNKH,Proteasome Inhibitor,PSMD1
NCGC00160391-05,CC[P](CC)(CC)=[Au]S[C@@H]1OC(COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)C1OC(C)=O,Auranofin,,AUJRCFUBUPVWSZ,Thioredoxin Reductase Inhibitors,TXNRD1
NCGC00015754-15,CC1(C)NC(=O)N(C2=CC(=C(C=C2)[N+]([O-])=O)C(F)(F)F)C1=O,NILUTAMIDE,,XWXYUMMDTVBTOU,Androgen Receptor Antagonist,AR
NCGC00346736-01,C[C@]12CC[C@H]3[C@@H](CCC/4=C/C(=O)CC[C@]34C)[C@@H]1CC[C@@H]2OC(=O)CCC5CCCC5,Testosterone cypionate,,HPFVBGJFAYZEBE,Androgen Receptor Activator,AR
NCGC00178483-04,CC1(C)O[C@H]2CC(=O)OC[C@]23[C@H]4CC[C@@]5(C)[C@@H](OC(=O)[C@H]6O[C@@]56[C@]4(C)C(=O)C[C@@H]13)C7=COC=C7,Limonin,,KBDSLGBFQAGHBE,antiviral,
NCGC00090762-03,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C4=C(C(=C3C)O)C(=O)\C(=C/5NC6(CCN(CC6)CC(C)C)/N=C45)NC(=O)\C(=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C,Rifabutin,,ATEBXHFBFRCZMA,DNA-Directed RNA Polymerase Inhibitor,PRKDC
NCGC00262608-02,CN1CCN(CC1)C2=CC=C(NC3=NC=C(C)C(=N3)NC4=CC(=CC=C4)[S+]([O-])(=O)NC(C)(C)C)C=C2,TG101209,,ITOABKQCSFXXHU,Jak2 inhibitor,JAK2
NCGC00017280-22,C/C1=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)(C)CCC1,TRETINON,,SHGAZHPCJJPHSC,Retinoid RORbeta Ligand,RORB
NCGC00161290-05,CCCCC(C)(C)[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O,"16,16-Dimethyl Prostaglandin E2",,QAOBBBBDJSWHMU,prostaglandin,
NCGC00263192-02,OC(=O)C1=CC2=C(C=C1)C3=CN=CC=C3C(=N2)NC4=CC=CC(=C4)Cl,Silmitasertib;CX-4945,,MUOKSQABCJCOPU,Casein Kinase II (CK2) Inhibitor,
NCGC00017358-14,COC1=CC2=C(C=C1OC)[C@H]3[C@@H](CO2)OC4=C(C=CC5=C4C[C@@H](O5)C(C)=C)C3=O,ROTENONE,,JUVIOZPCNVVQFO,NADH-Ubiquinone Oxidoreductase (Complex I) Inhibitor,NDUFAF1
NCGC00346842-01,C[N]1C=C(C[C@@H](N)C(O)=O)C2=C1C=CC=C2,Indoximod,,ZADWXFSZEAPBJS,"Indoleamine 2,3-dioxygenase (IDO) inhibitor",IDO1
NCGC00164604-03,CC(C)[N]1C2=CC=CC=C2C(=C1\C=C\[C@H](O)C[C@H](O)CC([O-])=O)C3=CC=C(F)C=C3,Fluvastatin;SRI-62320/XU-62-320,,FJLGEFLZQAZZCD,HMG-CoA Reductase Inhibitors,HMGCR
NCGC00188863-01,CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c2c3cc(ccc3oc2CCCC)NS(C)(=O)=O,Dronedarone,Dronedarone,HADAWBYLCBLLQX,"alpha,beta-Adrenoceptor Antagonists",ADRA1A
NCGC00016210-06,CC1=C(C(=O)C2=C3C=CC=CC3=CC=C2)C4=C5N1[C@H](CN6CCOCC6)COC5=CC=C4,,,HQVHOQAKMCMIIM,Cannabinoid Receptor Agonist,CNR1
NCGC00070736-04,CC(C)C[N]1C=NC2=C(N)N=C3C=CC=CC3=C12,Imiquimod,,DOUYETYNHWVLEO,TLR 7 Receptor Antagonist,TLR7
NCGC00164590-03,C[C@]\12CCC(=O)\C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@@]5(C)[C@H]4[C@@H]6C[C@@H]6[C@@]57CCC(=O)O7,Drospirenone,,METQSPRSQINEEU,Synthetic progesterone,PGR
NCGC00274065-01,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC/5=C/C(=O)/C=C\[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,Desonide,,WBGKWQHBNHJJPZ,Corticosteroid,
NCGC00160397-01,NC1=NC(N)=NC(C2=CC(Cl)=CC=C2Cl)=N1.O=C(O)/C=C\C(O)=O,Irsogladine maleate,"LS-155294;2,4-DIAMINO-6-(2,5-DICHLOROPHENYL)-S-TRIAZINE;IRSOGLADINE;CIPLUS_210905;6-(2,5-Dichlorophenyl)-1,3,5-triazine-2,4-diamine maleate;MN-1695;NCGC00160397-02;LS-155251;Irsogladine maleate;irsogladine;irsogladinum;Irsogladine;MN 1695;Gaslon N;IRSOGLADINE MALEATE;DCPDAT;6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine;2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate;Irsogladine Maleate;CIPLUS_696248;irsogladine maleate;2,4-Diamino-6-(2,5-dichlorophenyl)-s-triazine maleate;",ATCGGEJZONJOCL,M1 Muscarinic acetylcholine receptor Antagonists,CHRM1
NCGC00345794-01,N[S+]([O-])(=O)OC[C@@H]1C[C@H](C[C@@H]1O)[N]2C=CC3=C2N=CN=C3N[C@H]4CCC5=C4C=CC=C5,MLN-4924,,WJQLJGAIUZXWJO,NEDD8-Activating Enzyme (NAE) Inhibitors,NAE1
NCGC00014352-03,CN(C)C1=C(CN2CCCN(CC3=C(C=CC=C3)N(C)C)C2C4=CC=NC=C4)C=CC=C1,GANT61,,KVQOGDQTWWCZFX,Hedgehog pathway inhibitor,SHH
NCGC00346502-01,C[C@]12CCC\3=C\4CCC(=O)\C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,Dienogest,,AZFLJNIPTRTECV,Synthetic progesterone,PGR
NCGC00025018-09,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCC4=C([NH]C5=C4C=CC=C5)[C@@H]3C[C@H]12,YOHIMBINE HYDROCHLORIDE,,BLGXFZZNTVWLAY,alpha2-Adrenoceptor Antagonists,ADRA2A
NCGC00346703-01,CCOC(=O)N1[C@H](CC)C[C@H](N(CC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C(=O)OC)C3=C1C=CC(=C3)C(F)(F)F,Torcetrapib (CP-529414),,CMSGWTNRGKRWGS,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,CETP
NCGC00263110-01,CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC=C(Cl)C(=C4)Cl)CC1)C5=CC=CC=C5,Osanetant;SR-142806,,DZOJBGLFWINFBF,Tachykinin NK3 Antagonist,TACR3
NCGC00344550-02,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC5=C(C[C@]4(C)[C@H]3CC[C@]12C)C=N[NH]5,Stanozolol,,LKAJKIOFIWVMDJ,Synthetic Steroid,
NCGC00025000-08,CC(=O)N1CCN(CC1)C2=CC=C(OC[C@H]3CO[C@@](C[N]4C=CN=C4)(O3)C5=CC=C(Cl)C=C5Cl)C=C2,,"R41,400;CIPLUS_186839;Piperazine, 1-acetyl-4-(4-((2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-, cis-;HS_776;WHO NO. 4594;NCGC00016907-01;NCGC00015577-01;NCGC_Prestw-389;R-41400;Ketoconazol;LS-110149;1-ACETYL-4-(4-(2-(2,4-DICHLOROPHENYL)-2-(1H-IMADAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZINE, CIS-;R 4140;Ketocanazole;ketoconazolum;Ketoconazolum;R41400;Nizoral;ketoconazole;KETOCONAZOLE;NCGC00025000-05;KETONAZOL;NCGC00025000-01;Ketoconazole;NCGC00025000-02;(+/-)-cis-1-Acetyl-4-(4-[(2-[2,4-dichlorophenyl]-2-[1H-imidazol-1-ylmethyl]-1,3-dioxolan-4-yl)-methoxy]phenyl)piperazine;NCGC00025000-04;cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine;cis-1-Acetyl-4-[4-[[2-(2,4-;cis-1-Acetyl-4-[4-[[2-(2,4- dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine;NCGC00094706-01;NCGC00094706-02;",XMAYWYJOQHXEEK,Aromatase Inhibitor,CYP19A1
NCGC00016447-02,C[C@@H]1O[C@@H](O[C@H]\2CC[C@]\3(C)[C@@H]4CC[C@]5(C)[C@@H](CC[C@@]5(O)[C@H]4CCC3=C2)C/6=C/OC(=O)/C=C6)[C@H](O)[C@H](O)[C@@H]1O,,"CIPLUS_168268;Proscillaridin A;Proscillaridin;Caradrin;CIPLUS_153303;3-(6-Deoxy-alpha-L-mannopyranosyloxyl)-14-hydroxybufa-4,20,22-trienolide;Ysatfabrik Brand of Proscillaridin;proscillaridinum;PROSCILLARIDIN;NCGC_Prestw-986;Scillarenin 3beta-rhamnoside;A, Proscillaridi;proscillaridine;Digitalysat;Knoll Brand of Proscillaridin;Proscilaridina;Scillase;LS-125804;Abbott Brand of Proscillaridin;Ziethen Brand of Proscillaridin;NCGC00016447-01;Sandoscill;Talusin;Rhamnoside, Scillareni;Bufa-4,20,22-trienolide, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-14-hydroxy-, (3beta)-;Proscillaridinum;Proscillaridine;",MYEJFUXQJGHEQK,Steroid,
NCGC00344764-01,OC(=O)CCCCC(CCSCC1=CC=CC=C1)SCC2=CC=CC=C2,,,ZYRLHJIMTROTBO,altered energy metabolism-directed (AEMD) compound,
NCGC00346575-01,C[N]1C(=NC2=CC(=CC=C12)C(=O)N(CCC(O)=O)C3=NC=CC=C3)CNC4=CC=C(C=C4)C(N)=N,"BIBR 953 (Dabigatran etexilate, Pradaxa)",,YBSJFWOBGCMAKL,Thrombin Inhibitors,
NCGC00346644-01,O=C(CC1=CC=C(C=N1)C2=CC=C(OCCN3CCOCC3)C=C2)NCC4=CC=CC=C4,KX2-391,,HUNGUWOZPQBXGX,Src Kinase Inhibitors,SRC
NCGC00263104-01,COC1=CC2=C(C=C1OCCCN3CCOCC3)N=CC=C2OC4=CC=C(NC(=O)C5(CC5)C(=O)NC6=CC=C(F)C=C6)C=C4F,Foretinib;EXEL-2880/GSK-089/GSK-1363089/XL-880,,CXQHYVUVSFXTMY,VEGFR-2 Inhibitor,KDR
NCGC00346304-02,OC1=CC(=CC=C1Cl)C2=C([NH]C(=N2)C3=CC=CC=C3)C4=CC=NC=C4,"L-779,450",,WXJLXRNWMLWVFB,Raf kinase C Inhibitor,BRAF
NCGC00090905-11,C[S+]([O-])(=O)OCCCCO[S+](C)([O-])=O,BUSULFAN,,COVZYZSDYWQREU,DNA Alkylating Agent,
NCGC00164574-05,COCCOC1=CC2=NC=NC(=C2C=C1OCCOC)NC3=CC=CC(=C3)C#C,Erlotinib hydrochlorid;CP-358774;NSC-718781;OSI-774;RG-1415;Ro-50-8231;Tarceva,,AAKJLRGGTJKAMG,EGFR (HER1; erbB1) inhibitor,EGFR
NCGC00346447-01,CCNC(=O)NC1=CC=C2N=CC(=NC2=N1)NC3=CC=C(C)C=C3,D-106669,,RQBRFKKFZPOBFG,PI3Kalpha inhibitor,PIK3CA
NCGC00346500-01,CN(/N=C/C1=CN=C2C=CC(=C[N]12)Br)[S+]([O-])(=O)C3=C(C)C=CC(=C3)[N+]([O-])=O,PIK-75 ,,QTHCAAFKVUWAFI,PI3K Inhibitor,PIK3CA
NCGC00345739-02,CCOC(=O)C1=C(\C(=C/N)C#N)C2=CC=C(Cl)C(=C2[N]1C)Cl,KH-CB19,,CXJCGSPAPOTTSF,"Clk1, Clk4 Inhibitor",CLK1
NCGC00346525-01,CCN1CCN(CC1)C(=O)CC2=CC=C(NC3=NC(=C(F)C=N3)NC4=CC=C(C=C4)C(=O)NC5=CC=CC=C5Cl)C=C2,Aurora A Inhibitor I,,AKSIZPIFQAYJGF,Aurora A Inhibitor,AURKA
NCGC00161419-03,COC1=C(OC)C(=CC(=C1)NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)OC,Trimetrexate,,NOYPYLRCIDNJJB,Dihydrofolate Reductase (DHFR) Inhibitors,DHFR
NCGC00345856-01,NC(=O)C1=CN=C(C2=CC=C(C=C2)C3(N)CCC3)C(=C1)C4=CC=CC=C4,AZD-26,,GIRZDHCBMNHMEH,AKT Inhibitor,AKT1
NCGC00015086-03,CC(=O)NC(CS)C(O)=O,ACETYLCYSTEINE,,PWKSKIMOESPYIA,NF-kappaB Activation Inhibitor,NFKB1
NCGC00346491-01,CCC1=C(C(=O)C(N)=O)C2=C(C=CC=C2OCC(O)=O)[N]1CC3=CC=CC=C3,Varespladib (LY315920),,BHLXTPHDSZUFHR,Secretory Phospholipase A2 (sPLA2) Inhibitors,PLA2G5
NCGC00015818-15,O=C1CN(CC2N1CCC3=C2C=CC=C3)C(=O)C4CCCCC4,PRAZIQUANTEL,,FSVJFNAIGNNGKK,antiparasitic agent,
NCGC00263233-01,NC1=CC=C(C=C1)C(=O)C2=CC3=C([NH]2)C=CC4=CC=CC=C34,IPFK2,,FRIGMYLLVAJOTF,Inducible phosphofructokinase-2 inhibitor,PFKFB2
NCGC00263171-01,C(CC1=C[NH]C2=CC=CC=C12)NC3=CC=C(NC4=CC=NC=C4)C=C3,Serdemetan;JNJ-26854165,,CEGSUKYESLWKJP,MDM2 (hdm2) Inhibitor,MDM2
NCGC00345857-01,CN1/C=C(\N=C(NC2=CC=C(C=C2)C(=O)N3CCOCC3)/C1=O)/C4=C(C)C(=CC=C4)NC(=O)C5=CC=C(C=C5)C(C)(C)C,CGI1746                    (G-182),,JIFCFQDXHMUPGP,BTK Inhibitor,BTK
NCGC00346880-01,CN(C(C)=O)C1=CC=CC(=C1)C2=CC=NC3=C(C=N[N]23)C(=O)C4=CC=CS4,Indiplon,,CBIAWPMZSFFRGN,GABAA Receptor Modulator,GABRA1
NCGC00160162-03,CN(C)CCC1=CC=C(O)C=C1,,HORDENINE,KUBCEEMXQZUPDQ,Antibiotic properties,
NCGC00346561-01,NC/1=N/C(=O)N(/C=C1F)[C@H]2CS[C@H](CO)O2,Emtricitabine (Emtriva),,XQSPYNMVSIKCOC,Reverse Transcriptase Inhibitor,TERT
NCGC00024994-01,C[C@H](CC1=CC=CC=C1)N(C)CC#C,(R)-(-)-Deprenyl hydrochloride,"NCGC_Prestw-552;NCGC00024994-01;(R)-(-)-N,alpha-Dimethyl-N-(2-propynyl)phenethylamine hydrochloride;NCGC00024994-02;LS-30156;Selegilinum;CIPLUS_776531;LS-30157;Selegiline Hydrochloride, (R,S)-Isomer;NCGC00162273-01;(-)-DEPRENYL;R(-)-N-alpha-Dimethyl-N-2-propynyl-benzeneethanamine hydrochloride;ELDEPRYL;4-fluorodeprenyl, (-)-isomer;LS-172454;CIPLUS_669845;BENZENEETHANAMINE, N,.ALPHA.-DIMETHYL-N-2-PROPYNYL-, (.ALPHA.R)-, HYDROCHLORIDE;N-METHYL-N-((1R)-1-METHYL-2-PHENYLETHYL)PROP-2-YN-1-AMINE HYDROCHLORIDE;HS_1261;R-(-)-Deprenyl hydrochloride;deprenalin;Selegiline hydrochloride;Selegiline Hydrochloride;SELEGILINE HYDROCHLORIDE;NCGC00015624-01;LS-175003;Selegiline;LS-103418;LS-175004;S(+)-Deprenyl hydrochloride;HS_1260;NCGC00016708-01;Selegiline Hcl;4-fluorodeprenyl hydrochloride, (+-)-isomer;4-fluorodeprenyl hydrochloride, (-)-isomer;NCGC00094172-01;Selegiline (Deprenyl R-(-));selegiline;HS_530;Jumex;CIPLUS_160070;Benzeneethanamine, N,Alpha-dimethyl-N-2-propynyl-(R)-;Selegilina;SELEGILINE;cpd without isomeric designation;LS-103420;Deprenyl;DEPRENYL L-;CIPLUS_169454;Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)-;LS-171874;CIPLUS_169453;DEPRENYL;N,A-DIMETHYL-N-2-PROPYNYLPHENETHYLAMINE L-;Selegiline, (R,S)-Isomer;Selegiline, (S)-Isomer;selegilinum;Eldepryl;LS-171873;(R)-(-)-Deprenyl hydrochloride;LS-171872;deprenyl;",MEZLKOACVSPNER,MAO-B Inhibitor,MAOB
NCGC00016285-08,NC1=CC=C(C=C1)[S+](N)([O-])=O,SULFANILAMIDE,,ZADLKLXOEWDVAZ,Carbonic Anhydrase Type I/II/IX Inhibitor,CA1
NCGC00346876-01,CCC(C)SSC1=NC=C[NH]1,PX 12,,BPBPYQWMFCTCNG,Thioredoxin Reductase Inhibitors,TXNRD1
NCGC00015680-14,COC1=CC2=C([NH]C=C2CCNC(C)=O)C=C1,,MELATONIN,DRLFMBDRBRZALE,Free Radical Scavengers,
,,,,,TH Expression Enhancers,
NCGC00347935-01,[O-][S+](=O)(NC1CC1)C2=CC=C(C(=C2)NC(=O)NC3=CC=CC(=C3)C(F)(F)F)C4=CSC=C4,,,IEZRQPZETYYPJR,Mutant IDH2 Inhibitor,
NCGC00186013-01,COC1=CC\2=C(C=C1)C3\C(=N2)[S+](CC4=C(C)C(=C(C)C=N4)OC)[O-][Mg]35[O-][S+](CC6=C(C)C(=C(C)C=N6)OC)C7=NC8=C(C=CC(=C8)OC)[N]57,Esomeprazole magnesium dihydrate,,MEJVBZKBQJMUAG,H+/K+-ATPase Inhibitor,
NCGC00346669-01,CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=CC=C4[C@@H](COC4=C3)CC(O)=O)C)OCCC[S+](C)([O-])=O,TAK-875,,AGXOCELTCOEGNN,Insulin Secretagogues,
NCGC00242477-01,CCCCOCCOC1=C(C)SC(=N1)C2=CC=C(C(O)=O)C(=C2)F,AC-261066,,HSAOETBFVAWNRP,RARbeta2 Agonist,RARB
NCGC00163424-03,CO[C@H]1C[C@H](C)C\C2=C(NCC=C)\C(=O)\C=C(NC(=O)\C(=C\C=C/[C@H](OC)[C@@H](OC(N)=O)C(=C/[C@H](C)[C@H]1O)/C)C)/C2=O,,ALLYLAMINO-17-DEMETHOXY-GELDANAMYCIN,AYUNIORJHRXIBJ,Heat Shock Protein 90 (hsp90) Inhibitor,HSP90AB1
NCGC00015060-19,C[N]1C=NC(=C1SC2=C3[NH]C=NC3=NC=N2)[N+]([O-])=O,AZATHIOPRINE,,LMEKQMALGUDUQG,immunosuppressant,
NCGC00346737-01,OC[C@H]1OC(OC2=CC3=C(C(=C2)O)C(=O)\C(=C/O3)C4=CC=C(O)C=C4)[C@H](O)[C@@H](O)[C@@H]1O,Genistin,,ZCOLJUOHXJRHDI,Lipid lowering agents,
NCGC00346529-01,C[C@H](NCC1=CC=C(OCC2=CC(=CC=C2)F)C=C1)C(N)=O,Safinamide Mesylate (FCE28073),,NEMGRZFTLSKBAP,Sodium channel inhibitor,
NCGC00346433-01,CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O,Peramivir trihydrate,,XRQDFNLINLXZLB,Neuraminidase (Sialidase) Inhibitors,
NCGC00346609-01,CN[C@H](C)[C@@H]1CC[C@@H](N)[C@H](O1)OC2[C@@H](N)C[C@@H](N)[C@H](OC3OC[C@](C)(O)C(NC)[C@H]3O)C2O,Gentamycin sulfate (Gentacycol),,CEAZRRDELHUEMR,Antibiotic,
NCGC00016806-12,COC(=O)NC1=NC2=C([NH]1)C=CC(=C2)C(=O)C3=CC=CC=C3,MEBENDAZOLE,,OPXLLQIJSORQAM,Tubulin depolymerization inhibitor,TUBB
NCGC00091109-03,COC1=C(O)C=C(CCC(=O)C2=C(O)C=C(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)C=C2O)C=C1,Neohesperidin dihydrochalcone (Nhdc),,ITVGXXMINPYUHD,synthetic sugar substitute,
NCGC00015830-07,NNCCC1=CC=CC=C1,PHENELZINE SULFATE,,RMUCZJUITONUFY,MAO Inhibitor,MAOA
NCGC00263093-01,CC1=CC=CC(=C1)\C=N\NC2=NC(=NC(=C2)N3CCOCC3)OCCC4=CC=CC=N4,Apilimod;STA-5326,,HSKAZIJJKRAJAV,IL-12 Production Inhibitor,IL2
NCGC00250406-01,C[N]1C=NC=C1[C@@](N)(C2=CC=C(Cl)C=C2)C3=CC=C4N(C)C(=O)\C=C(\C5=CC=CC(=C5)Cl)C4=C3,Tipifarnib;NSC-702818/Zarnestra,,PLHJCIYEEKOWNM,Farnesyltransferase Inhibitor,COX10
NCGC00142605-03,OC[C@H]1O[C@@H](OC2=CC=CC=C2CO)[C@H](O)[C@@H](O)[C@@H]1O,SALICIN,,NGFMICBWJRZIBI,Antiinflammatory agent,
NCGC00092344-05,CC1=CC(=CC=C1OCC(O)=O)SCC2=C(C)N=C(S2)C3=CC=C(C(=C3)F)C(F)(F)F,GW-0742;GW-610742???,,HWVNEWGKWRGSRK,PPARgamma Agonists?,PPARD
NCGC00091014-06,CC(C)(O)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F,Hydroxyflutamide,,YPQLFJODEKMJEF,Androgen Receptor Antagonist,AR
NCGC00159544-02,CC1(CN2CCC(CC2)N3C(=O)NC4=C3C=CC=C4)OCC5=CC=CC=C5[N]6C=CC=C16,Zaldaride maleate;CGS-9343B/KW-5617/Zy-17617B,,HTGCJAAPDHZCHL,Calmodulin Antagonist,CALM1
NCGC00178127-04,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(O)=O,Ramipril (Altace),,HDACQVRGBOVJII,Angiotensin-I Converting Enzyme Inhibitor,ACE
NCGC00016463-02,O=C1\C=C/C=C2/[C@H]3CNC[C@H](C3)CN12,(-)-Cytisine,"NCGC00025138-02;cystisin;NCGC00025138-01;NCGC00016463-01;1,2,3,4,5,6-Hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;CYTISINE;cytisine tetrahydrochloride, trihydrate;NCGC00095093-01;(-)-Cytisine;cytisine hydrochloride;cytisine;1,2,3,4,5,6-hexahydro-1,5-methano-8H- pyrido(1,2-a)(1,5)diazocin-8-one;CIPLUS_153486;Tabex;Tsitizin;NCGC00095093-02;citizine;cytiton;CIPLUS_180524;CIPLUS_165065;Cytisine;cytisine dihydrochloride, trihydrate;cytisine hydrochloride, hydrate;Cytisine (-);NCGC_Prestw-624;3   Cytisine;",ANJTVLIZGCUXLD,Nicotinic alpha3beta4 Partial Agonists,CHRNA3
NCGC00018248-08,CN1\C(=C(\O)C2=CC=CC=C2[S+]1([O-])=O)C(=O)NC3=NC=C(C)S3,Meloxicam (Mobic),,JJMWPUUMNOUPNB,Cyclooxygenase-1/2 Inhibitor,PTGS1
NCGC00346959-01,COC1=CC=C(N(C(=O)OC2=C(C)C=CC=C2C)C3=NC(=NC=C3)NC4=CC=C(C=C4)N5CCN(C)CC5)C(=C1)OC,HMSL10038,,NBTNHSGBRGTFJS,Lck Kinase Inhibitors,LCK
NCGC00250397-01,OC1=NC(=NC2=C1CSCC2)C3=CC=C(C=C3)C(F)(F)F,NVP-XAV-939;XAV-939?,,KLGQSVMIPOVQAX,TNKS1/TNKS2 Inhibitor,TNKS
NCGC00346441-01,ClC1=CC=C(C=C1)C23C[C@@H]4C[C@@H](CC(C4)(C2)C(=O)NCC5=CC=NC=C5)C3,ABC-294640,,CAOTVXGYTWCKQE,Sphingosine Kinase 2 (SphK2) Inhibitors,SPHK2
NCGC00263143-01,NC1=NC=NC2=C1N=C(NCC3=CC(=C(Cl)C=C3)Cl)[N]2[C@@H]4O[C@H](COCC5=CC=C(C=C5)C#N)[C@@H](O)[C@H]4O,VER-155008,,ZXGGCBQORXDVTE,Heat Shock Protein 70 (hsp70) Inhibitor,HSPA2
NCGC00161834-01,[H][C@@]12CC3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)CC(O)[C@@]4([H])[C@@]2([H])CCC5=CC(=O)C=C[C@]45C,,"budesonidum;budesonide;(11b,16a)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione;NCGC_Prestw-518;6   Budesonide;NCGC00015165-01;NCGC00015165-03;Pulmicort;Budesonidum;dexbudesonidum;budesonide sulphotransferase;NCGC00016862-01;CIPLUS_205192;CIPLUS_180950;CIPLUS_205193;Horacort;Budesonide;testosterone sulfotransferase;LS-175261;BUDESONIDE;LS-175262;NCGC00089747-02;NCGC00089747-03;Budesonido;NCGC00094860-01;NCGC00094860-02;Pregna-1,4-diene-3,20-dione,16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11beta,16alpha)-;Budesonide, (S)-Isomer;16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione;testosterone sulphotransferase;LS-7235;Budesonide, (R)-Isomer;Rhinocort;",VOVIALXJUBGFJZ,Glucocorticoid steroid,
NCGC00016023-17,C[N]1C=NC2=C1C(=O)NC(=O)N2C,THEOBROMINE,,YAPQBXQYLJRXSA,cAMP Phosphodiesterase Inhibitors,PDE4A
NCGC00346735-01,O[C@H]([C@H]1CC2CCN1C[C@@H]2C=C)C3=CC=NC4=CC=CC=C34,Cinchonine,,KMPWYEUPVWOPIM,P-Glycoprotein (MDR-1) Inhibitor,
NCGC00242499-01,NC1=NC=CC(=N1)C2=CC3=C(ON=C3C=C2)C4=CC=C(Cl)C=C4,Pim 1 inhibitor 2,,AQVFETGXIRKVAQ,Pim-1 inhibitor,PIM1
NCGC00263015-01,CN(CC(O)COC1=CC=C(Cl)C=C1)CC2=C(C)[N](CC3=C(Cl)C=CC=C3)N=C2C,NCGC00263015-01,,PDFAUYXBJDPBCE,TLR4 (LPS) inhibitor,TLR4
NCGC00345797-01,CN(C)C1=C(CC(O)=O)C(=NC(=N1)CC2=CC=C(NC(=O)C3=CC=C(C=C3)C(F)(F)F)C=C2)N(C)C,AP-761,,XEOSTBFUCNZKGS,prostaglandin D2 CRTH2 inhibitor,PTGDR2
NCGC00346531-01,CC[C@@H]\1CC[C@@H]2O[C@]3(CC[C@H](C)[C@H](C[C@@H](C)O)O3)[C@@H](C)[C@H](OC(=O)/C=C/[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@](C)(O)[C@@H](O)[C@H](C)C/C=C\C=C1)[C@@H]2C,Oligomycin A,,MNULEGDCPYONBU,ATP synthase inhibitor,
NCGC00263188-01,C[C@H](NC(=O)CC1=CC(=CC(=C1)F)F)C(=O)N[C@@H]2C(=O)N(C)C3=C(C=CC=C3)C4=C2C=CC=C4,YO-01027,,QSHGISMANBKLQL,g-Secretase Inhibitor,NOTCH1
NCGC00092385-02,COC1=CC=C(C=C1)C2=C(C(=O)C3=CC=C(C=C3)C#N)C4=CC=C(OC)C=C4O2,LY-320135,,RYNSGDFWBJWWSZ,Cannabinoid CB1 Antagonist,CNR1
NCGC00015529-18,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,Ibuprofen Lysine (NeoProfen),,HEFNNWSXXWATRW,Cyclooxygenase-1/2 Inhibitor,PTGS1
NCGC00015833-16,NC(=O)C1=CN=CC=N1,PYRAZINAMIDE,,IPEHBUMCGVEMRF,Fatty acid synthase inhibitor,FAS
NCGC00182059-02,OC(C1=C(C)N=C(C2=CC=C(OCC(C)C)C(C#N)=C2)S1)=O,Febuxostat,"TEI-6720;TEI 6720;2-(3-CYANO-4-ISOBUTOXYPHENYL)-4-METHYL-5-THIAZOLECARBOXYLIC ACID;Febuxostat;2-(3-CYANO-4-ISOBUTOXYPHENYL)-4-METHYL-1,3-THIAZOLE-5-CARBOXYLIC ACID;FEBUXOSTAT;TMS-67;5-THIAZOLECARBOXYLIC ACID, 2-(3-CYANO-4-(2-METHYLPROPOXY)PHENYL)-4-METHYL-;A-319198;febuxostat;febuxostatum;5-Thiazolecarboxylic acid, 2-(3-cyano-4-(2-methylpropoxy)phenyl)-4-methyl-;CIPLUS_710267;LS-173202;2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid;",BQSJTQLCZDPROO,Xanthine Oxidase Inhibitor,XDH
NCGC00023373-04,CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC/4=C/C(=O)/C=C\[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl,Clobetasol propionate,,CBGUOGMQLZIXBE,Corticosteroid,
NCGC00346540-01,CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(OC(=O)C(C)C)C=CC(=C2)CO)C(C)C,Fesoterodine fumarate (Toviaz),,DCCSDBARQIPTGU,Muscarinic Antagonists,
NCGC00346459-01,C[C@@H](OC1=CC2=C([NH]N=C2\C=C\C3=C[N](CCO)N=C3)C=C1)C4=C(Cl)C=NC=C4Cl,LY-2874455   ,,GKJCVYLDJWTWQU,FGFR Inhibitor,
NCGC00262929-02,CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=NC=CC=C4)[N]2C)C=C1,BIBR-1048 (Dabigatran),,KSGXQBZTULBEEQ,Thrombin Inhibitors,
NCGC00016000-10,CCN(CC)C(=S)SSC(=S)N(CC)CC,,,AUZONCFQVSMFAP,Aldehyde Dehydrogenase (ALDH2) Inhibitors,ALDH2
NCGC00346505-01,C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)\C(C)=C\C3=CSC(=N3)C,Epothilone A,,HESCAJZNRMSMJG,Tubulin depolymerization inhibitor,TUBB
NCGC00025125-20,COC/1=C/C=C2\C(=C/C1=O)[C@H](CCC3=CC(=C(OC)C(=C23)OC)OC)NC(C)=O,COLCHICINE,,IAKHMKGGTNLKSZ,Tubulin polymerization inhibitor,TUBB
NCGC00346507-01,COC1=CC=C2C(=CC=NC2=C1)OCC3=NN=C4C=CC(=N[N]34)C5=CC=CC=C5,AMG-208,,HEAIZQNMNCHNFD,HGFR (MET; c-Met) Inhibitor,MET
NCGC00346624-01,CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(N)=O)C3=CSC(=N3)C(C)(C)C,A66,,HBPXWEPKNBHKAX,PI3Kalpha inhibitor,PIK3CA
NCGC00346650-01,C[S+]([O-])(=O)N1CCC2=C(N=C(N=C12)N3CCOCC3)C4=CN=C(N)N=C4,CH5132799,,WSYVOARRIIRYRB,"PI3Kalpha, beta, gamma Inhibitor",PIK3CA
NCGC00346731-01,CC[C@]1(O)C[C@@H]2C[N@@](CCC3=C([NH]C4=CC=CC=C34)[C@@](C2)(C(=O)OC)C5=C(OC)C=C6N(C=O)[C@H]7[C@](O)([C@H](OC(C)=O)[C@]8(CC)\C=C/CN9CCC7([C@H]89)C6=C5)C(=O)OC)C1,Vinblastine,,OGWKCGZFUXNPDA,Tubulin polymerization inhibitor,TUBB
NCGC00346467-01,COC1CCC(CC1)N(C(=O)C2CCC(C)CC2)C3=C(SC(=C3)\C4=C\CCCC4)C(O)=O,VCH-916 ,,LNYKGELUODVSNS,RNA-Directed RNA Polymerase Inhibitor,
NCGC00346523-01,CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@@H](C)[C@H](O)[C@H](C)[C@H]3OC(=O)\C=C\C=C\[C@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]3C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]4(O)C[C@@H](O[C@H]5C[C@H](O)[C@H](O)[C@H](C)O5)[C@H](CC)[C@@H](C)O4,Azalomycin-B,,OSERMIPXNLXAPD,Macrolide Antibiotic,
NCGC00242054-03,CC1=NC(=CC=C1)C2=N[NH]C=C2C3=NC4=C(C=C3)N=CC=C4,RepSox,,LBPKYPYHDKKRFS,TGF-bR1 (ALK5) inhibitor,
NCGC00346941-01,COC1=C(C=C(SC2=CN=C(NC(=O)C3=CC=C(CNC(C)C(C)C)C=C3)S2)C(=C1)C)C(=O)N4CCN(CC4)C(C)=O,ITK inhibitor,,RRHONYZEMUNMJX,ITK inhibitor,ITK
NCGC00346949-01,CC(C(C)N1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,ICRF-193,,OBYGAPWKTPDTAS,DNA Topoisomerase II Inhibitors,TOP2A
NCGC00263190-02,O=C/1\C=C(/OC(=C1)/C2=C3SC4=C(SC3=CC=C2)C=CC=C4)N5CCOCC5,KU-0064;KU-55933,,XRKYMMUGXMWDAO,ATM Kinase Inhibitor,ATM
NCGC00346716-01,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(F)C(=CC=C3)N[S+]([O-])(=O)C4=C(F)C=CC=C4F,Dabrafenib (GSK2118436),,GBJBCIAJEHTKFD,Raf kinase B Inhibitor,BRAF
NCGC00347906-01,ClC1=C(Cl)C(=CC=C1)C2=NN=N[N]2CC3=CC=CN=C3,A 438079,,MMPAULQSJLVKHP,P2X7 Receptor Antagonist,P2RX7
NCGC00186024-02,CC1=NC(=CC=C1)C2=C(N=C([NH]2)C(C)(C)C)C3=CC=C4N=CC=NC4=C3,SB-525334,,DKPQHFZUICCZHF,TGF-bR1 (ALK5) inhibitor,
NCGC00159570-01,OCC1=CC=C(S1)C2=CC=C(O2)C3=CC=C(CO)S3,,,KZENBFUSKMWCJF,MDM2 (hdm2) Inhibitor,MDM2
NCGC00025100-09,CC(/O)=C(C#N)/C(=O)NC1=C(Br)C=CC(=C1)Br,LFM-A13,,UVSVTDVJQAJIFG,BTK Inhibitor,BTK
NCGC00263204-01,CC1=C(SC(=N1)N)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4,CYC-116,,GPSZYOIFQZPWEJ,Aurora-A/B/C Kinase Inhibitor,AURKA
NCGC00015790-02,COC1=CC=CC(=C1N)\C2=C\C(=O)C3=C(O2)C=CC=C3,PD 98059,"NCGC00025045-03;PD 98059;NCGC00025045-02;PD-98059;NCGC00025045-05;NCGC00025045-04;NCGC00015790-01;CIPLUS_753355;2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one;PD098059;2-(2'-amino-3'-methoxyphenyl)oxanaphthalen-4-one;PD09859;PD98059;PD 098059;PD-098059;PD 98,059;NCGC00025045-01;2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one;",QFWCYNPOPKQOKV,Mek 1/2 inhibitor,MAP2K1
NCGC00263214-01,CC1=C(C=C([N]1CCCN2CCOCC2)C3=CC=CC=C3)C(=O)NC4=CC=CC(=C4)C(F)(F)F,HC-067047,,NCZYSQOTAYFTNM,TRPV4 Antagonist,TRPV4
NCGC00346641-01,CCN(CC)C(=O)C1=CC=C(C=C1)C/2=C/C3(CCNCC3)OC4=CC=CC(=C24)O,ADL5859 HCl,,OPIKUXLJQFYMSC,delta-Opioid Agonists,OPRD1
NCGC00346434-01,C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)\C(=C(N2C1=O)\C(O)=O)SCCNC=N,Imipenem Monohydrate,,OUXTYMOXZJQTDG,Carbapenem Antibiotic,
NCGC00345807-01,OC1=CC=C(CCNC(=O)[C@H]2O[C@@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)NCC4=CC=CC=C4)C=C1,CAA0225,,ZHZIYQUXZUTJMW,Cathepsin L Inhibitors,CTSL1
NCGC00346673-01,CNC(=O)C1=N[N](C)C2=C1C(C)(C)CC3=CN=C(NC4=CC=C(C=C4)N5CCN(C)CC5)N=C23,PHA-848125,,RXZMYLDMFYNEIM,CDK1/2/4/5 Inhibitor,CDK1
NCGC00095707-03,CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CO,SOLANESOL,,AFPLNGZPBSKHHQ,tobacco isoprenoid alcohol,
NCGC00017256-08,COC1=CC=C2CN(C)CC[C@@]34\C=C/[C@H](O)C[C@@H]3OC1=C24,Galanthamine hydrobromide,,ASUTZQLVASHGKV,Acetylcholinesterase Inhibitors,ACHE
NCGC00346895-01,CC(C)C[C@@H](N)[C@H](O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O,Amastatin,,QFAADIRHLBXJJS,cytosolic leucine aminopeptidase inhibitor,LAP3
NCGC00346707-01,NC(=O)N1CCC(CC1)CC(=O)N2CCC(CC2)[C@H]3C4=C(CCC5=C3C(=CC(=C5)Cl)Br)C=C(Br)C=N4,Lonafarnib (SCH66336),,DHMTURDWPRKSOA,Farnesyltransferase Inhibitor,COX10
NCGC00346840-01,OCC1=CC=C(C=C1)[C@@H]2C[C@H](CSC3=NC(=C(O3)C4=CC=CC=C4)C5=CC=CC=C5)O[C@@H](O2)C6=CC=C(NC(=O)CCCCCCC(=O)NO)C=C6,Tubacin,,BHUZLJOUHMBZQY,Histone Deacetylase (HDAC) 6 Inhibitor,HDAC6
NCGC00015870-16,OC1=CC2=C(C(=C1)O)C(=O)\C(=C(/O2)C3=CC(=C(O)C=C3)O)O,Quercetine;Meletin;Sophoretin,"flavonol 3-OMT;quercetin HMGGlc;quercetin 3-O-glucopyranoside;quercetin 3-XR;QUERCETIN: 3,3',4',5,6-PENTA-HYDROXY-FLAVONE;quercetin 3-(6-malonylglucoside);quercetin 3-O-rhamnopyranosyl-1-6-O-(glucopyranosyl-1-3-O-rhamnopyranosyl-1-2)-O-galactopyranoside;flavonol 3-O-methyltransferase;quercetin 3,7-dimethyl ether 3'-O--rhamnopyranosyl-1-2-rhamnopyranosyl-1-6-glucopyranoside;quercetin 3-acetyl-7,3',4'-trisulphate;Q-M-beta-D-G;5,7-dihydroxy-3-(beta-D-glucopyranosyl-(1-2)-beta-D-glucopyranosyl-(1-2)-beta-D-glucopyranosyl)-2-(3,4-dihydroxyphenyl)-4H-1-benzopyran-4-one (quercetin 3-sophorotrioside);Q-RR cpd;quercetin 3,7-dimethyl ether 3'-neohesperidoside;NCGC00015870-01;quercetin 3,7-dimethyl ether 3'-(6(G)-rhamnosylneohesperidoside);CIPLUS_3730360;quercetin-3-methyl ether;2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one dihydrate;Quercetin hydrate;quercetin-3-O-alpha-L-arabinopyranosyl-(1-6)-(2''-O-(E)-p-coumaroyl)-beta-D-galactopyranoside;quercetin 3-O-(2-trans-caffeoyl)-alpha-L-arabinopyranosyl-(1-2)-beta-D-glucopyranoside;quercetin pentaacetate;quercetin 3-O-beta-D-glucopyranoside;quercetin 3-RhaGlcGal;4H-1-BENZOPYRAN-4-ONE, 2-(3,4-DIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-, DIHYDRATE;quercetin 3-O-alpha-L-(3-feruloylrhamnopyranosyl)(1-->6)-(alpha-L-rhamnopyra nosyl(1-->2))-beta-D-galactopyranoside;CIPLUS_151474;Quercetin;quercetin 7-O-beta-glucopyranoside;quercetinase;quercetin 3-O-rhamnopyranosyl-1-6-glucopyranosyl-1-6-galactopyranoside;quercetin digal-Gal;NCGC00017056-01;4H-1-BENZOPYRAN-4-ONE, 2-(3,4-DIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-;Q-A-CGP;quercetin 3-arabinopyranoside;quercetin 3-O-arabinopyranosyl-(1-6)-(2''-O-(E)-p-coumaroyl)-glucopyranoside;quercetin-3-O-alpha-L-rhamnopyranosyl-(1-2)-alpha-L-rhamnopyranoside;quercetin 4'-O-beta-glucopyranoside;quercetin 3-O-beta-glucopyranoside;quercetin 3-(3''-0-acetyl)alpha-L-arabinofuranoside;quercetin 4'-O-glucopyranoside;quercetin 3'-methoxy-4'-O-glucopyranoside;NCGC_Prestw-507;CIPLUS_3744549;quercetin 3-acetyl-7,3',4'-trisulfate;3,3',4',5,7-PENTAHYDROXYFLAVONE,3', 4',5,7-TETRAHYDROXYFLAVON-3-OL DIHYDRATE;quercetin 3,7,3',4'-tetrasulfate;quercetin 3-methyl ether 7-O-arabinofuranosyl(1-6)-glucopyranoside;Q3MG cpd;quercetin 3-(2,3,4-triacetylarabinopyranosyl-1-6-galactoside);quercetin 3-O-fGalp;2-(3,4-DIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-4H-CHROMEN-4-ONE DIHYDRATE;quercetin 3-O-6''-(3-hydroxy-3-methylglutaryl)-beta-D-glucopyranoside;4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-;quercetin-ATS;quercetin 3-O-rhamnopyranosyl-(1-2)-rhamnopyranoside;quercetin 3-(6-feruloyl-glucopyranosyl)-(1-2)-arabinopyranoside-7-O-glucopyranoside;quercetin 3,7-dimethyl ether 3'-O-rhamnopyranosyl-1-glucopyranoside;quercetin 2,3-dioxygenase;NCGC00025016-01;flavonol 3-sulfotransferase;2-(3,4-DIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-4H-CHROMEN-4-ONE;quercetin 3-sophorotrioside;quercetin 3-O-(2''-O-rhamnosyl-6''-O-malonyl)-glucoside;quercetin 3,7,3',4'-tetrasulphate;NCGC00025016-03;NCGC00025016-02;quercetin 3-3AcAra-Gal;quercetin 3,4'-di-O-beta-D-glucopyranoside;QFG-AG;tamarixetin 3-O-neohesperidoside;amurenoside A;amurenoside B;quercetin 3-O-alpha-L-(2-feruloylrhamnopyranosyl)(1-->6)-(alpha-L-rhamnopyra nosyl(1-->2))-beta-D-galactopyranoside;QUERCETIN;moricandin;Quercetine dihydrate;Quercetin dihydrate;miquelianin;quercetin 3-O-xylosyl-1-2-rhamnoside;quercetin 3-O-(6-feruloyl-beta-glucopyranosyl)-(1-2)-beta-arabinopyranoside-7-O-beta-glucopyranoside;quercetin 3-O-6''-(3-hydroxy-3-methylglutaryl)glucopyranoside;quercetin 3-O-(2''-O-alpha-rhamnosyl-6''-O-malonyl)-beta-glucoside;quercetin 4'-methyl ether;Q-3-AP cpd;quercetin 3-(2(G)-rhamnosylrutinoside);quercetin RGRGal;quercetin 3-methyl ether 7-O-alpha-L-arabinofuranosyl(1-6)-beta-D-glucopyranoside;boehmerin;quercetin 3-O-methyl ether;quercetin 3-O-(2'',6''-O-digalloyl)galactopyranoside;Q-tC-L-A-D-G;quercetin 3-O-gentobioside;QUERCETIN DIHYDRATE;quercetin 3'-methoxy-4'-O-beta-D-glucopyranoside;QME-Ara-Glc;quercetin 7-O-glucopyranoside;CIPLUS_",REFJWTPEDVJJIY,flavanoid,
NCGC00347065-01,C1CCC2=C(C1)N=C(N=C2NCC3=CC=CC=C3)N4CCOC5=C4C=CC=C5,,,RMZPVQQGYVSLAP,p97 ATPase Inhibitor,
NCGC00263123-01,COC1=C(C=C(CC2SC(=O)NC2=O)C=C1)C(=O)NCC3=CC=C(C=C3)C(F)(F)F,MK-767;KRP-297,,NFFXEUUOMTXWCX,PPARalpha/gamma agonist,PPARA
NCGC00016375-10,COC1=NC(=NC(=C1)N[S+]([O-])(=O)C2=CC=C(N)C=C2)OC,SULFADIMETHOXINE,,DZMIOEPDDBGADS,Antibiotic,
NCGC00345018-01,COC1=CC=C(CC2=CC=C(NC(N)=O)C=C2)C=C1C3=CC=CC(=C3)Cl,,,RJJLUTWHJUDZFP,Phosphodiesterase IIII D (PDE4D) inhibitor,PDE4A
NCGC00015898-12,COC1=C(OC2CCCC2)C=C(C=C1)C3CNC(=O)C3,Rolipram,,HJORMJIFDVBMOB,Phosphodiesterase IIII (PDE4) inhibitor,PDE4A
NCGC00346546-01,FC1=CC(=CC(=C1)F)[C@@H]2CNC3(CCCC3)C(=O)N2CC(=O)NC4=CC=C5C[C@]6(CC5=C4)C(=O)NC7=C6C=CC=N7,MK3207 HCl,,AZAANWYREOQRFB,Calcitonin Gene-Related Peptides (CGRP) Antagonists,
NCGC00015590-07,O=C1N(C2=CC=CC=C2)C3=C(C=CC=C3)C1(CC4=CC=NC=C4)CC5=CC=NC=C5,Linopirdine dihydrochloride,,YEJCDKJIEMIWRQ,K(ATP) Channel Blockers,
NCGC00346963-01,CCN(CC)CCCCNC1=NC=C2CN(C(=O)N(C)C2=N1)C3=C(Cl)C(=CC(=C3Cl)OC)OC,HMSL10083,,NHOUHWHGHAFDOP,CSF1R (c-FMS) Inhibitor,CSF1R
NCGC00346948-01,ONC(=O)C=CC#CC1=CC(=CC=C1)N[S+]([O-])(=O)C2=CC=CC=C2,Oxamflatin,,FBYVPRGXMUGJEW,Histone Deacetylase (HDAC) Inhibitor,HDAC1
NCGC00018204-11,CCOC(=O)\C1=C\[C@]2(CC)CCCN3CCC4=C([C@H]23)[N]1C5=C4C=CC=C5,,VINPOCETINE,DDNCQMVWWZOMLN,Sodium channel inhibitor,
NCGC00263118-01,C[S+]([O-])(=O)OC1=CC=C2C(=C(OC2=C1)C(=O)C3=C(Cl)C=C(Cl)C=C3)NC(N)=O,Lirimilast;BAY-19-8004,,DMDSFIXPYFMEKI,Phosphodiesterase IIII (PDE4) inhibitor,PDE4A
NCGC00025225-02,CC(C)C1=CC=C(C[N]2C=CC3=C4C(=NC(=NC4=CC=C23)NC5CC5)N)C=C1,,,AVXQPEKZIGPIJW,PAR1 Antagonist,PAR1
NCGC00183109-02,CC(C)c1nnc(C)n1[C@H]2C[C@@H]5CC[C@H](C2)N5CC[C@H](NC(=O)C3CCC(F)(F)CC3)c4ccccc4,Maraviroc,"CIPLUS_3821051;CIPLUS_3820873;maraviroc;UK-427857;MARAVIROC;Maraviroc;4,4-difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide;UK-427,857;",GSNHKUDZZFZSJB,Chemokine CCR5 Antagonist,CCR5
NCGC00024631-01,CCOC(=O)C/1=C(O)/C(=O)N(CC2=CC=CC=C2)C1,EBPC,CIPLUS_676856;1-EBPC;EBPC;ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate;NCGC00024631-01;,IGYRPDIWSYGHMY,Aldose Reductase Inhibitor,AKR1B1
NCGC00015122-09,CC(NC(C)(C)C)C(=O)C1=CC=CC(=C1)Cl,BUPROPION,,SNPPWIUOZRMYNY,Dopamine Transporter (DAT) Inhibitor,SLC6A3
NCGC00142400-06,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Chenodeoxycholic acid,,RUDATBOHQWOJDD,Farnesoid X Receptor Agonist,
NCGC00163468-06,CO[C@@]12[C@H](COC(N)=O)C/3=C(N1C[C@@H]4N[C@H]24)/C(=O)/C(=C(N)\C3=O)C,Mitomycin C,,NWIBSHFKIJFRCO,DNA Alkylating Agent,
NCGC00179363-04,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Ursodiol (Actigal Urso),,RUDATBOHQWOJDD,Steroid,
NCGC00346605-01,OC(CC1=CC(=C(O)C=C1)O)C([O-])=O,Sodium Danshensu,,PAFLSMZLRSPALU,Pregnane X Receptor (PXR) Regulator,NR1I2
NCGC00091861-06,CN(C)/N=N/C1=C([NH]C=N1)C(N)=O,DACARBAZINE,,FDKXTQMXEQVLRF,DNA Alkylating Agent,
NCGC00263103-01,CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(=C1)N=CC(=C2NC3=CC(=C(F)C=C3)Cl)C#N,Pelitinib;EKB-569/WAY-EKB-569,,WVUNYSQLFKLYNI,EGFR (HER1; erbB1) Inhibitor,EGFR
NCGC00096075-03,COC1=CC2=C(C(=C1)O)C(=O)C3=C(C=C(C)C=C3O)C2=O,Rheochrysidin (Physcione),,FFWOKTFYGVYKIR,Protein Tyrosine Phosphatase (PTP) Inhibitors,PTP4A1
NCGC00263232-01,CN(C)C1=C(Br)C=C(C=C1)C\2NC3=C(\C4=C2C(=O)CC(C)(C)C4)C5=CC=CC=C5C=C3,GLS968,,NVFRRJQWRZFDLM,Glutaminase inhibitor,GLS
NCGC00090808-03,C[C@H]1O[C@@H](O[C@@H]\2C[C@@H]3O[C@](O)(C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)/C=C/C=C/C=C/C=C/C=C/C=C/C=C2)C[C@H](O)[C@H]3C(O)=O)[C@@H](O)[C@@H](N)[C@@H]1O,Amphotericin B (Abelcet),,APKFDSVGJQXUKY,Macrolide Antibiotic,
NCGC00263106-01,[O-]C(=O)C1=C(\C=C\C(=O)NC2=CC=CC=C2)C3=C(Cl)C=C(Cl)C=C3[NH]1,Gavestinel sodium;GV-150526A,,WZBNEZWCNKUOSM,NMDA Glycine-Site Antagonist,GRIN2A
NCGC00242598-03,C1C[N]2N=C(C3=CC=CC=N3)C(=C2C1)C4=C5C=CC(=CC5=NC=C4)OCCN6CCOCC6,LY2109761,,IHLVSLOZUHKNMQ,TGF-bR1 (ALK5) and TGFbR2 inhibitor,
NCGC00263166-01,COC\1=C\C(=N/C1=C/C2=C(C)C=C(C)[NH]2)C3=CC4=CC=CC=C4[NH]3,Obatoclax;GX-015-070,,RFTSSZJZXOSICM,Bcl-xL inhibitor,BCL2L1
NCGC00090757-05,N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O,MELPHALAN,,SGDBTWWWUNNDEQ,DNA Alkylating Agent,
NCGC00346687-01,BrC1=CN=C(NC2=CC(=CC=C2)NC(=O)N3CCCC3)N=C1NCCC4=CN=C[NH]4,BX-912,,DMMILYKXNCVKOJ,Phosphoinositide Dependent Kinase (PDK) 1 Inhibitors,PDPK1
NCGC00346638-01,NC1=CC(=CC=C1)C2=CC3=C([NH]2)N=CN=C3OC4=CC=CC(=C4)O,TWS119,,VPVLEBIVXZSOMQ,GSK-3beta Inhibitor,GSK3B
NCGC00092289-01,ClC/1=C(NCCN2CCOCC2)/C(=O)C3=C(C=CC=N3)C1=O,DA-3003-1;NSC-663284,"NCGC00092289-02;NSC-663284;NSC663284;NSC 663284;6-Chloro-7-(2-morpholin-4-yl-ethylamino)quinoline-5,8-dione;",BMKPVDQDJQWBPD,Cell Division Cycle CDC25 Phosphatase Inhibitor,CDC25
NCGC00016645-03,CN(C)[C@H]\1[C@@H]2[C@@H](O)[C@@H]\3C(=C)C4=C(C(=CC=C4)O)C(=O)C3=C(\O)[C@@]2(O)C(=O)\C(=C1O)C(N)=O,,,MHIGBKBJSQVXNH,Tetracycline Antibiotic,
NCGC00015513-09,NCCC1=C[NH]C=N1,,HISTAMINE,NTYJJOPFIAHURM,Histamine Receptor Agonist,HRH1
NCGC00346886-01,COC1=CC=C(C=C1)C(=O)CC2(O)C(=O)NC3=C(Cl)C=CC(=C23)Cl,YK 4-279,,HLXSCTYHLQHQDJ,EWS-FLI1 Inhibitors,EWSR1
NCGC00162383-02,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=CC4=CC(=C3O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@H]6C[C@](C)(N)[C@H](O)[C@H](C)O6)OC7=C(Cl)C=C(C=C7)[C@@H](O)[C@@H]8NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)C9=CC=C(O)C(=C9)C%10=C(C=C(O)C=C%10O)[C@H](NC8=O)C(O)=O)C(=C2)Cl,Vancomycin hydrochloride from Streptomyces orientalis,,MYPYJXKWCTUITO,glycopeptide antibiotic,
NCGC00166111-04,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=CC=C34)O)[C@@H]1C[C@@H](O)[C@@H]2O,Estriol,,PROQIPRRNZUXQM,Estrogen Receptor (ER) Agonist,ESR1
NCGC00346646-01,CN(C)C(=O)[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)C2=CC3=CC(=CC=C3[NH]2)Cl,CP-91149,,HINJNZFCMLSBCI,Glycogen Phosphorylase a Inhibitors,PYGL
NCGC00345841-01,CC(C)NC1=CC(=CC2=NC(=N[N]12)NC(=O)C3=CN=CC=C3)C(F)(F)F,S-99 ,,BDAJJFZKNIYDOL,Apoptosis signal-regulating kinase (ASK1/MAPKKK),MAP3K5
NCGC00016543-08,NC(=N)NC(=N)NCCC1=CC=CC=C1,PHENFORMIN HYDROCHLORIDE,,ICFJFFQQTFMIBG,antidiabetic drug,
NCGC00164588-03,CC(C)OC(=O)C(C(=O)OC(C)C)=C1S\C=C/S1,Malotilate,,YPIQVCUJEKAZCP,Liver Protein Metabolism,
NCGC00017269-06,COC1=CC=C(C=C1)C/2=C/OC3=CC(=CC=C3C2=O)O,FORMONONETIN,,HKQYGTCOTHHOMP,MAO Inhibitor,MAOA
NCGC00346474-01,C1CN(CCN1)CC2=C3C=CC=CC3=CC=C2,1-(1-Naphthylmethyl)piperazine,,HGYDREHWXXUUIS,Bacterial Efflux Pump Inhibitors,
NCGC00346588-01,CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]23C(=O)O[C@@H]4OC(=O)[C@H](O)C134,Bilobalide,,MOLPUWBMSBJXER,GABA(A) Receptor Antagonists,GABRA1
NCGC00347066-01,C(NC1=NC2=CC=CC=C2C(=N1)NCC3=CC=CC=C3)C4=CC=CC=C4,,,QAIMUUJJAJBPCL,p97 ATPase Inhibitor,
NCGC00247785-05,OC1CCC(CC1)N2\C=N/C3=C(C2=N)C(=C([N]3CC4=CC=CC=C4)C5=CC=CC=C5)C6=CC=CC=C6,,,WSMXAUJFLWRPNT,Perinuclear compartment (PNC) assembly inhibitor,
NCGC00346939-01,ClC1=CC(=CC(=C1)COC(=O)N2CCN(CC2)CCC(=O)C3=CC=C4NC(=O)OC4=C3)Cl,PF-8380,,JMSUDQYHPSNBSN,Phosphodiesterase II (ENPP2; Autotaxin) Inhibitors,PDE2A
NCGC00159509-02,N1([C@@H](C[C@H]2[C@@H]1CCCC2)C(=O)O)C([C@@H](N[C@H](C(=O)OCC)CCC)C)=O,Perindopril,"cpd with unspecified MF;S 9490-3;CIPLUS_196546;LS-82690;1-(2-((1-(ETHOXYCARBONYL)BUTYL)AMINO)-1-OXOPROPYL)OCTAHYDRO-1H-INDOLE-2-CARBOXYLIC ACID(2S-(1(R*(R*)),2A,3AB,7AB))-2-METHYL-2-PROPANAMINE;S-9490;Perindopril and diuretics;LS-82762;PERINDOPRIL;S 9490;LS-178402;CIPLUS_668001;S949;perindopril;Perindopril;(2S,3(infinity)S,7(infinity)S)-1-[(S)-N-[(S)-1-Carboxybutyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester, compound with tert-butylamine (1:1);PERINDOPRIL ERBUMINE;CIPLUS_685081;HS_6;S 949;PERINDOPRIL T-BUTYLAMINE;Pirindopril;MCN-A-2833-109;perindoprilum;Perindopril erbumine;Aceon;Perindopril Erbumine;1H-Indole-2-carboxylic acid,              1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-;NCGC00095142-01;Perstarium;Erbumine, Perindopri;NCGC00095142-02;1H-Indole-2-carboxylic acid,;",IPVQLZZIHOAWMC,Angiotensin-I Converting Enzyme Inhibitor,ACE
NCGC00024928-22,CCC(/C1=CC=CC=C1)=C(C2=CC=CC=C2)/C3=CC=C(OCCN(C)C)C=C3,Tamoxifen;ICI-46474?,,NKANXQFJJICGDU,Selective Estrogen Receptor Modulators (SERM),ER
NCGC00242498-03,NC(=O)C1=CC=C(C=C1)C2=NC(=C([NH]2)C3=NC=CC=C3)C4=CC=C5OCCOC5=C4,D 4476,,DPDZHVCKYBCJHW,Casein Kinase I (CK1) Inhibitor,CSNK1A1
NCGC00244250-02,CN(C)C1=CC=C(NC2=N[N](C(=N2)N)C(=O)C3=C(F)C=CC=C3F)C=C1,NCGC00244250-01,,ZGFGFQUPXGGIOJ,Tyk 2 inhibitor,TYK2
NCGC00346705-01,[O-][S+](F)(=O)CC1=CC=CC=C1,PMSF (Phenylmethylsulfonyl Fluoride),,YBYRMVIVWMBXKQ,Serine Protease Inhibitor,
NCGC00263117-02,CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=CC=CC=C3[NH]1,LBH-589 (Panobinostat),,FPOHNWQLNRZRFC,Histone Deacetylase (HDAC) Inhibitor,HDAC1
NCGC00016960-03,O=C1N(C(NCCC(C=C3)=CC=C3S(NC(N[C@H]2CC[C@H](C)CC2)=O)(=O)=O)=O)CC(C)=C1CC,Glimepiride,GLIMEPIRIDE;NCGC00016960-01;glimepirid;LS-136752;glimepiridum;HS_650;glimepiride;NCGC_Prestw-651;1-((P-(2-(3-ETHYL-4-METHYL-2-OXO-3-PYRROLINE-1-CARBOXAMIDO)-ETHYL)PHENYL)SULFONYL)-3(TRANS)-(4-METHYLCYCLOHEXYL)UREA;CIPLUS_193913;Glimepiride;HOE-490;Amaryl;HS_65;Glimepride;NCGC00161404-02;NCGC00161404-01;,WIGIZIANZCJQQY,K(ATP) Channel Blockers,
NCGC00165915-03,NC(=O)C1=CC(=CC=C1)C2=CC=CC(=C2)OC(=O)NC3CCCCC3,URB597,,ROFVXGGUISEHAM,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,FAAH
NCGC00160163-01,C[C@H]1C2C(CC3C4CC=C5CC(O)CCC5(C)C4CCC23C)O[C@]16CC[C@@H](C)CO6,,"(25R)-5-Spirosten-3beta-ol;CIPLUS_153822;NCGC00160163-01;CIPLUS_3729552;Yamogenin;CIPLUS_737995;CIPLUS_679130;DIOSGENIN;sarsasapogenone;sarsasapogenone, (5alpha-25R)-isomer;NCGC00095204-01;CIPLUS_676820;Diosgenin;3beta-Hydroxy-5-spirostene;Spirost-5-en-3-ol, (3beta,25R)-;NCGC00095204-02;",WQLVFSAGQJTQCK,Cyclooxygenase up-regulator,PTGS2
NCGC00346933-01,CN(C)[S+]([O-])(=O)C1=CC2=C(NC(=O)C2=CC3=CC4=C(CCCC4)[NH]3)C=C1,SU6656,,HMBBZHLKUKXFRH,Lyn Kinase Inhibitor,LCK
NCGC00347945-01,COC1=CC=C(C=C1)[N]2C(=C(C3=C2C=C(O)C=C3)[N+]([O-])=O)C,,,VVZNWYXIOADGSW,DYRK Inhibitor,DYRK1A
NCGC00346486-01,CN(C)CC1=C(OC2=CC=CC=C12)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO,PCI-24781,,MAUCONCHVWBMHK,HDAC Inhibitor,HDAC1
NCGC00164637-04,CN1C(=O)/C=C(/NCCN(CCO)CCCC2=CC=C(C=C2)[N+]([O-])=O)N(C)C1=O,Nifekalant,,OEBPANQZQGQPHF,K(ATP) Channel Blockers,
NCGC00244256-02,C[C@@]12O[C@@H](C[C@]1(O)CO)[N]3C4=C(C=CC=C4)C5=C6C(=O)NCC6=C7C8=C(C=CC=C8)[N]2C7=C35,Lestaurtinib;CEP-701;KT-5555;SPM-924,,UIARLYUEJFELEN,Jak/Tyk/Flt inhibitor,JAK1
NCGC00018176-04,C[C@]12CCC3C(CCC4=C3C=CC(=C4)O)C1CCC2=O,ESTRONE,,DNXHEGUUPJUMQT,Steroid hormone,
NCGC00263694-01,OC(=O)C1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C3=CC=CC=C3,,,SLUINPGXGFUMLL,chondrocyte differentiation initiator,
NCGC00263084-02,CNC1CCC(CC1)N(CC2=CC(=CC=C2)C3=CC=NC=C3)C(=O)C4=C(Cl)C5=C(F)C=CC(=C5S4)F,Hh-Ag1.5,,RUOUXRFGKIUTHP,Smoothened (Smo) receptor agonist,SMO
NCGC00017112-11,CC/1=C/C(=O)N(O)/C(=C1)C2CCCCC2,Ciclopirox ethanolamine,,SCKYRAXSEDYPSA,Antifungal Agent,
NCGC00346456-01,CCCN[S+]([O-])(=O)NC1=NC=NC(=C1C2=CC=C(Br)C=C2)OCCOC3=NC=C(Br)C=N3,Macitentan,,POJNQSFBIKBMQI,Endothelin ETA/ETB Receptor Antagonist,EDNRA
NCGC00017338-05,CCCCCC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@@H](NC(=O)C2=C(O)C(=CC=C2)NC=O)[C@@H](C)OC1=O,Antimycin A,,UIFFUZWRFRDZJC,Antifungal Agent,
NCGC00167472-02,CC(C)C1=CC=C2OC3=NC(=C(C=C3C(=O)C2=C1)C(O)=O)N,,,SGRYPYWGNKJSDL,Mediator Release Inhibitors,
NCGC00263139-01,CCCN1C(=O)N(CCC)C2=C([NH]C(=N2)C34C[C@@H]5CC(CC3C5)C4)C1=O,Rolofylline;HMR-4902/KW-3902/MK-7418,,PJBFVWGQFLYWCB,Adenosine A1 Antagonist,ADORA1
NCGC00188962-02,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)\C=C2\C=C/[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12,Pravastatin,,TUZYXOIXSAXUGO,HMG-CoA Reductase Inhibitor,HMGCR
NCGC00346647-01,CNC(=O)C1=C(F)C=CC=C1NC2=C3C=C[NH]C3=NC(=N2)NC4=C(OC)C=C5CCN(C(=O)CN(C)C)C5=C4,GSK1838705A,,HZTYDQRUAWIZRE,IGF-1R Inhibitor,IGFR1
NCGC00015558-06,C1=C(O)C(O)=CC(C(O)CNC(C)C)=C1,Isoproterenol,"Levisoprenalinum;NCGC00017080-01;1,2-BENZENEDIOL, 4-(1-HYDROXY-2-((1-METHYLETHYL)AMINO)ETHYL)-, HYDROCHLORIDE;4-(1-HYDROXY-2-(ISOPROPYLAMINO)ETHYL)BENZENE-1,2-DIOL SULFATE (SALT) DIHYDRATE;Medihaler-Iso;NCGC00025274-04;NCGC00025274-05;ISOPRENALINE;NCGC00025274-01;NCGC00025274-03;CIPLUS_166870;l-Isoprenaline hydrochloride;Proternol-L;CIPLUS_3841635;Proternol-S;LS-178589;CIPLUS_161156;S(+)-Isoproterenol (+)-bitartrate;Isoproterenol;Isoproterenol ALSO 123;Isopropyl noradrenaline;CIPLUS_151377;LEVISOPRENALINE;ISOPRENALINE SULFATE;ISOPROTERENOL;Isoprenaline Hcl;CIPLUS_148599;CIPLUS_157037;R(-)-Isoproterenol (+)-bitartrate;1-(3',4'-Dihydroxyphenyl)-2-isopropylaminoethanol hydrochloride;1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-;Isopreterenol sulfate;dl-Isoprenaline Hydrochloride;NCGC00094016-01;(+/-)-Isoproterenol hydrochloride;Isoprenalina;Isoprenaline Hydrochloride;Isoprenaline;LS-42874;CIPLUS_152172;CIPLUS_3730115;(-)-N-Isopropyl-L-noradrenaline hydrochloride;ISOPROTERENOL SULFATE;Isoprenaline hydrochloride;HS_765;isoprenaline;CIPLUS_152497;1,2-BENZENEDIOL, 4-(1-HYDROXY-2-((1-METHYLETHYL)AMINO)ETHYL)-;1,2-BENZENEDIOL, 4-(1-HYDROXY-2-((1-METHYLETHYL)AMINO)ETHYL)-, SULFATE (2:1) (SALT), DIHYDRATE;(+)-Isoproterenol (+)-bitartrate salt;DL-ISOPRENALINE HYDROCHLORIDE;LS-1315;LS-42866;Levisoprenalina;NCGC00016665-01;(S)-(+)-Isoproterenol,L-bitartrate;MEDIHALER-ISO;(-)-Isoproterenol (+)-bitartrate salt;l-Isoprenaline Hydrochloride;Isoproterenol HCl;Isoproterenol sulfate;Isoprenaline sulfate;Isuprel;levisoprenaline;CIPLUS_169474;Isoprenalinum;Benzyl alcohol, 3,4-dihydroxy-alpha-((isopropylamino)methyl)-, sulfate (2:1) (salt);NCGC_Prestw-1097;NCGC00094033-01;LS-176565;ISOPROTERENOL HYDROCHLORIDE;Isoprenaline Sulfate;(R)-3,4-Dihydroxy-alpha-(isopropylaminomethyl)benzyl alcohol hydrochloride;NCGC00094007-01;CIPLUS_148600;(-)-Isoprenaline hydrochloride;4-(1-HYDROXY-2-(ISOPROPYLAMINO)ETHYL)BENZENE-1,2-DIOL;(-)-Isoproterenol hydrochloride;4-(1-HYDROXY-2-(ISOPROPYLAMINO)ETHYL)BENZENE-1,2-DIOL HYDROCHLORIDE;Levisoprenaline;NCGC00015558-02;(-)-Isoprenaline (+)-bitartrate salt;NCGC00015558-01;ISOPROTERENOL SULFATE MONOHYDRATE;CIPLUS_737909;ACETYLCYSTEINE;NCGC00094061-03;NCGC00094061-02;NCGC00094061-01;CIPLUS_3730141;(?)-Isoproterenol hydrochloride;N-Isopropylnorepinephrine sulfate;N-Isopropyl-DL-noradrenaline hydrochloride;Isoproterenol hydrochloride;NCGC00016155-01;isoprenalinum;levisoprenalinum;AB07981045-01;NCGC00016155-02;3,4-dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol hydrochloride;ISOPROTERENOL SULFATE DIHYDRATE;L-ISOPRENALINE HYDROCHLORIDE;3,4-DIHYDROXY-.ALPHA.-((ISOPROPYLAMINO)METHYL)BENZYL ALCOHOL HYDROCHLORIDE;Luf-Iso;dl-Isoprenaline hydrochloride;NCGC00162220-01;CIPLUS_164968;NCGC_Prestw-911;",JWZZKOKVBUJMES,beta-Adrenoceptor Agonists,ADRB1
NCGC00016026-11,COC1=CC2=NC(=NC(=C2C=C1OC)N)N3CCN(CC3)C(=O)C4CCCO4,TERAZOSIN HYDROCHLORIDE,,VCKUSRYTPJJLNI,alpha1-Adrenoceptor Antagonists,ADRA1A
NCGC00159510-04,ClC1=CC=CC(=C1Cl)N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2,ARIPIPRAZOLE,,CEUORZQYGODEFX,5-HT1A/2A Antagonists?,HTR2A
NCGC00346582-01,FC(F)(F)C1=CC=C(\C=C\C2=NC(=CO2)COC3=CC=C(CCCC[N]4C=CN=N4)C=C3)C=C1,Mubritinib (TAK 165),,ZTFBIUXIQYRUNT,HER2 (erbB2) Inhibitor,ERBB2
NCGC00271596-04,C[C@]12CC[C@H]3[C@@H](CC(=C)\C4=C\C(=O)\C=C/[C@]34C)[C@@H]1CCC2=O,Exemestane,,BFYIZQONLCFLEV,Aromatase Inhibitor,CYP19A1
NCGC00015264-08,N2(CCCN(C)C)C1=CC(Cl)=CC=C1CCC3=C2C=CC=C3,Clomipramine,"Anafranil hydrochloride;Clomipramine Maleate (1:1);Chlomipramine Hydrochloride;HS_348;NCGC00093756-02;Clomipramine Hydrochloride;Chlorimipramine hydrochloride;NCGC_Prestw-269;Clomipraminum;clomipramine;Hydiphen;NCGC00024355-02;NCGC00024355-04;Monohydrochloride, Clomipramin;clomipraminum;CIPLUS_210664;LS-173091;g 34586;Chlorimipramine;NCGC00093756-01;LS-60386;LS-60387;Clomipramine hydrochloride;Chlomipramine;Clomipramine Monohydrochloride;CHLORIMIPRAMINE;CLOMIPRAMINE;Chloripramine;NCGC00015264-02;8   Clomipramine Hcl;Clomipramine;LS-172665;Hydrochloride, Clomipramin;NCGC00015264-01;3-chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine monohydrochloride;3-Chloro-10,11-dihydro-N,N-dimethyl-5H-dibenz;Anafranil;CIPLUS_152550;NCGC00024355-05;CLOMIPRAMINE HYDROCHLORIDE;7   Clomipramine;chlorimipramine hydrochloride;5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl-;Clomipramina;",GDLIGKIOYRNHDA,Serotonin Transporter (SERT) Inhibitor,SLC6A4
NCGC00346510-01,C[N]1C=NC(=C1)C2=CC3=NC=CC(=C3S2)OC4=CC=C(NC(=S)NC(=O)CC5=CC=CC=C5)C=C4F,MGCD-265,,UFICVEHDQUKCEA,HGFR (MET; c-Met) Inhibitor,
NCGC00346495-01,CC(NC1=CC=CC=C1)C\2=C\C(=C/N3C(=O)\C=C(/N=C23)N4CCOCC4)C,TGX-221,,CPRAGQJXBLMUEL,PI3Kbeta inhibitor,PIK3CB
NCGC00025230-01,NC(=O)C1=CC=C(C=C1)C2=NC(=C([NH]2)C3=NC=CC=C3)C4=CC5=C(OCO5)C=C4,SB-431542,"4-(5-Benzol[1,3]dioxol-5-yl-4-pyrldin-2-yl-1H-imidazol-2-yl)-benzamide hydrate;SB 431542;4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide;SB-431542;NCGC00025230-02;NCGC00025230-03;4-[4-(1,3-Benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide hydrate;NCGC00025230-01;SB 431542 hydrate;4-[4-(3,4-Methylenedioxyphenyl)-5-(2-pyridyl)-1H-imidazol-2-yl]-benzamide hydrate;SB431542;",FHYUGAJXYORMHI,TGF-bR1 (ALK5) Inhibitor,
NCGC00346542-01,CC[S+]([O-])(=O)NC1=CC=C2NC(=O)C(=C(NC3=CC=C(CN4CCCCC4)C=C3)/C5=CC=CC=C5)/C2=C1,Hesperadin,,SFMSTHBZDFQEQO,Aurora Kinase Inhibitor,AURKA
NCGC00250399-01,CCC[S+]([O-])(=O)NC1=CC=C(F)C(=C1F)C(=O)C2=C[NH]C3=NC=C(C=C23)C4=CC=C(Cl)C=C4,Vemurafenib;PLX-4032;RO-5185426;Zelboraf,,ZGCSBHDPSRPIOV,Raf kinase B Inhibitor,BRAF
NCGC00346471-01,CO[C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1CO)[N]2C3=C(C=CC=C3Cl)C4=C2C5=C(C6=C([NH]5)C(=CC=C6)Cl)C7=C4C(=O)NC7=O,Rebeccamycin,,QEHOIJJIZXRMAN,DNA Topoisomerase I Inhibitors,TOP1
NCGC00346497-01,CN1CCN(CC1)C2=CC=C(NC3=NC=C(Cl)C(=N3)SC4=CC(=CC=C4)NC(=O)C=C)C=C2,WZ8040,,KIISCIGBPUVZBF,EGFR (HER1; erbB1) Inhibitor,EGFR
NCGC00346535-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(C(C)=O)C2=C(C=CC=C2)\C=C\C\3=C\C=[N](=O)\C=C3,HMN-214,,OCKHRKSTDPOHEN,Polo-like Kinase-1 (Plk-1) Inhibitor,PLK1
NCGC00163505-03,COC1=CC=C2[N](CCCN(C)C)C=C(C2=C1)C/3=C(/C(=O)NC3=O)C4=C[NH]C5=C4C=CC=C5,Go 6983,,LLJJDLHGZUOMQP,PKC inhibitor,PRKCA
NCGC00263094-01,CC1=CSC(=C1)C2=NN=C(NC3=CC=C(OC4=C(C=CC=N4)C5=CC=NC(=N5)N)C=C3)C6=C2C=CC=C6,AMG-900,,IVUGFMLRJOCGAS,Aurora-A/B/C Kinase Inhibitor,AURKA
NCGC00271415-02,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(=C4C(=C(NC(=O)\C(=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C)C5=C(N=C6C=C(C)C=C[N]56)C4=C3C2=O)O)O,Rifaximin (Xifaxan),,NZCRJKRKKOLAOJ,Pregnane X Receptor (PXR) Agonist,NR1I2
NCGC00346653-01,C[N]1C=C(C=N1)C2=C3N=C([C@H]4CCCNC4)C(=C(N)[N]3N=C2)Br,SCH 900776,,GMIZZEXBPRLVIV,Chk1 Inhibitor,CHEK1
NCGC00159574-02,COC1=C(OCCCN2CCOCC2)C=C3N=CN=C(NC4=CC=C(NC(=O)C5=CC=CC=C5)C=C4)C3=C1,ZM 44739,,OGNYUTNQZVRGMN,Aurora-A/B Inhibitor,AURKA
NCGC00159326-02,O[C@H](C)[C@@H](N[C@]([C@@H]2C[C@@H](CCC)CN2C)=O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1.Cl,Lincomycin hydrochloride,"LS-174148;D-erythro-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-(1-methyl-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-, monohydrochloride, trans-alpha-;Lincomycin hydrochloride monohydrate;CIPLUS_206644;lincomycinum;LINCOMYCIN;CIPLUS_152245;Lincomycinum;CIPLUS_213710;Lincomicina;LS-174532;LINCOMYCIN HYDROCHLORIDE MONOHYDRATE;NCGC00016545-01;NCGC00094710-01;NCGC00094710-02;LS-173630;LS-173651;Lincolcina;Lincomycin Hydrochloride;Lincomycin HCL;Lincomycin, (2S-cis)-Isomer;lincomycine;LS-98136;NCGC_Prestw-302;Lincomycin Monohydrochloride, (L-threo)-Isomer;LINCOMYCIN HYDROCHLORIDE;Lincomycin;Lincomycin hydrochloride;D-ERYTHRO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE, METHYL 6,8-DIDEOXY-6-(((1-METHYL-4-PROPYL-2-PYRROLIDINYL)CARBONYL)AMINO)-1-THIO-, MONOHYDROCHLORIDE, MONOHYDRATE, (2S-TRANS)-;Lincomycine;LS-174366;Lincocin;lincomycin, hydrochloride hydrate;LS-98138;Lincomycin, (L-threo)-Isomer;LS-98137;Lincomycin Monohydrochloride, (2S-cis)-Isomer;D-erythro-alpha-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, (2S-trans)-;",OJMMVQQUTAEWLP,Antibiotic,
NCGC00262398-03,CC1=CC=C(C=C1)[S+]([O-])(=O)NC2=C(C=CC(=C2)Cl)C(=O)NC3=NC(=CS3)C4=CC=CC=C4,,,PSCUSXNRFKYVKO,USP2 inhibitor,USP2
NCGC00263165-01,CNC(=O)C1=CC=C(C)C(=C1)N2C(=C/C(=C(/Br)C2=O)OCC3=C(F)C=C(F)C=C3)\C,PH-797804,,KCAJXIDMCNPGHZ,p38 MAPK Inhibitor,MAPK14
NCGC00179673-04,OC[C@H]1O[C@H](C[C@@H]1O)N2\C=C(\I)C(=O)NC2=O,Idoxuridine,,XQFRJNBWHJMXHO,Anti-Herpes Simplex Virus Drug,
NCGC00024379-04,[H][C@@]2(C[C@@H]3[C@@H](CC)CN4[C@@](C(C=C(OC)C(OC)=C5)=C5CC4)([H])C3)C1=CC(OC)=C(OC)C=C1CCN2,Emetine,"Emetan, 6',7',10,11-tetramethoxy-;NCGC_Prestw-570;Emetine;Emetine Dihydrochloride;Emetine hydrochloride;Amebicide;Hydrochloride, Emetin;CIPLUS_775096;LS-1183;CIPLUS_3860793;CIPLUS_153465;CIPLUS_152634;EMETINUM;NCGC00093874-01;CIPLUS_742096;Emetine Hydrochloride;NCGC00024379-05;CIPLUS_3856131;NCGC00094664-02;LS-40213;EMETINE HYDROCHLORIDE;NCGC00094664-01;(+)-Emetine dihydrochloride hydrate;NCGC00015404-01;Emetine dihydrochloride;NCGC00016428-01;Emetine dihydrochloride hydrate;CIPLUS_3870676;EMETINE;Dihydrochloride, Emetin;CIPLUS_778335;CIPLUS_3866705;",AUVVAXYIELKVAI,antiprotozoal agent,
NCGC00165799-02,CCC(=O)NC[C@H](CC1=CC=C(OCCC2=C(C)OC(=N2)C3=CC=CC=C3)C=C1)N\C(C)=C/C(=O)C4=CC=C(C=C4)C(F)(F)F,GW 6471,,TYEFSRMOUXWTDN,PPARalpha Antagonist,PPARA
NCGC00346881-01,COCC1(CO)N2CCC(CC2)C1=O,PRIMA-1MET,,BGBNULCRKBVAKL,p53-dependent reactivation of massive apoptosis,TP53
NCGC00178520-05,CN(CC1=C(N)C(=CC(=C1)Br)Br)C2CCCCC2,Bromhexine HCl,,OJGDCBLYJGHCIH,Mucolytic Agent,
NCGC00095460-06,OC1=CC2=C(C=C1O)C3C4=C(OCC3(O)C2)C(=C(O)C=C4)O,HAEMATOXYLIN,,WZUVPPKBWHMQCE,Iron Chelator,
NCGC00016229-13,CCC\C1=C\C(=O)NC(=S)N1,PROPYLTHIOURACIL,,KNAHARQHSZJURB,thyroperoxidase inhibitor,TPO
NCGC00095003-06,OC1=CC2=C(SC(=O)O2)C=C1,Tioxolone,,SLYPOVJCSQHITR,Carbonic Anhydrase Type I Inhibitor,CA1
NCGC00185774-01,O=C1SCCC1NC(=O)CSCC(=O)O,Erdosteine,,QGFORSXNKQLDNO,Mucolytic Agent,
NCGC00346637-01,CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)[S+](C)([O-])=O)C(F)(F)F)C(=O)NC3(CC3)C#N,Odanacatib (MK 0822),,ZHOHXXHIZFSSNS,Cathepsin K Inhibitors,CTSK
NCGC00246387-02,CCOC(=O)C1=C(CSC2=CC=CC=C2)[N](C)C3=CC(=C(O)C(=C13)CN(C)C)Br,Arbidol HCl,,KCFYEAOKVJSACF,antiinfluenza drug,
NCGC00263621-02,CCNC(=O)C[C@@H]1\N=C(C2=CC=C(Cl)C=C2)/C3=C(C=CC(=C3)OC)[N]4C(=NN=C14)C,,,AAAQFGUYHFJNHI,"Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitor",BRD4
NCGC00165873-02,ClC1=CC2=C([NH]C3=C2C=CN=C3)C(=C1)NC(=O)C4=CC=CN=C4,PS-1145;MLN-1145,,JZRMBDHPALEPDM,IKK-2 (IKK-beta) Inhibitor,IKBKB
NCGC00164296-03,OC(=O)CCCC1=C[NH]C2=CC=CC=C12,3-Indolebutyric acid (IBA),,JTEDVYBZBROSJT,plant hormone,
NCGC00015439-06,C1=C(F)C=C2C(=C1)N3C(CN(C)C2=O)=C(C(=O)OCC)N=C3,Flumazenil,"Hoffman La Roche Brand of Flumazeni;HS_613;FLUMAZENIL;flumazenilum;Anexate;flumazenil;Lanexat;NCGC00015439-01;4H-Imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylic acid, 8-fluoro-5,6-dihydro-5-methyl-6-oxo-, ethyl ester;CIPLUS_191889;NCGC00025116-02;NCGC00025116-01;NCGC00025116-04;NCGC00025116-05;Flumazenil;LS-77778;Roche Brand of Flumazenil;Ro- 15-1788;Hoffman-La Roche Brand of Flumazenil;Ro 15178;RO-15-1788;ETHYL 8-FLUORO-5,6-DIHYDRO-5-METHYL-6-OXO-4H-IMIDAZO(1,5-A)(1,4)BENZODIAZEPINE-3-CARBOXYLATE;Ro 15-1788;Romazicon;Ro 15 178;",OFBIFZUFASYYRE,GABA(A) BZ Site Receptor Antagonists,GABRA1
NCGC00263202-01,FC1=CC(=CC(=C1CN2CCOCC2)F)C3=C4N=C(C=NC4=CC=C3)C5=C[N](N=C5)C6CCNCC6,NVP-BSK805,,IBPVXAOOVUAOKJ,Jak2 inhibitor,JAK2
NCGC00173359-06,COC1=C(OC)C2=C(CC3N(CCC4=C3C=C5OCOC5=C4)C2)C=C1,Canadine,,VZTUIEROBZXUFA,K+/ATP Signaling Inhibitor,
NCGC00346665-01,CN1[C@H]2CC(O)C[C@@H]1[C@H]3O[C@@H]23,Scopine,,FIMXSEMBHGTNKT,Alkaloid,
NCGC00163246-01,C\C=C1/C2CC3=C(C=CC(=O)N3)C1(N)CC(C)=C2,"HUPERZINE A, (-)","Hemispheric Specialization;Cortex, Cerebra;CIPLUS_705035;Embolism, Cerebra;Middle Cerebral Artery;Vein, Thalamostriat;huperzine A;Veins, Cerebra;Arterial Circle, Cerebra;Veins, Thalamostriat;Cerebral Cortice;Embolus, Brai;Anterior Cerebral Artery;LS-90742;Anterior Cerebral Arterie;Cortex Decortication, Cerebra;Cerebral Cortex;KIMPUKAN A;Middle Cerebral Arterie;Peduncles, Cerebra;Cerebral Ventriculography;Toxoplasmosis, Intracrania;Helminthiasis, Cerebra;Vein, Sylvia;Toxoplasmosis, Cerebral;Cortex Decortications, Cerebra;Posterior Cerebral Arterie;Decortication, Cerebra;Monro Forame;Angiographies, Cerebra;Aqueducts, Cerebra;Brain Emboli;HUPERZINE A, (-);LS-178164;Brain Embolu;Galen Vei;(-)-Huperzine A;Huperzine A;Embolus, Cerebra;(-)-Selagine;Cerebral Ventricles;Arteries, Posterior Cerebra;Midbrain;Huperizne;Veins, Basa;huperzine a;Cerebral Ventriculographie;Aqueduct, Cerebra;Peduncle, Cerebra;Cerebral Veins;Arteries, Middle Cerebra;huperzine A, (5alpha,9beta,11Z)-(-)-isomer;Cerebral Arteries;Central Nervous System Toxoplasmosis;Cerebral Arteries, Middl;Willis Circl;Ventriculographies, Cerebra;Circle of Willis;Cerebral Arteries, Anterio;Basal Vein;Specialization, Hemispheri;5-AMINO-11-ETHYLIDENE-5,6,9,10-TETRAHYDRO-7-METHYL-5,9-METHANOCYCLOOCTA(B)PYRIDIN-2(1H)-ONE, 5R,9R,11E;HUPERZINE A, L-;Mesencephalon;Cerebral Emboli;Veins, Pia;Thalamostriate Vein;Cerebral Cortex Decortication;Cerebral Arteries, Posterio;Emboli, Brai;NCGC00095342-01;Vein, Basa;(+/-)-Selagine;Cerebral Embolu;Toxoplasmoses, Cerebra;NCGC00163246-01;Vein, Cerebra;NCGC00163246-02;Decortications, Cerebra;Intracranial Embolism;Emboli, Cerebra;HUPERZINE A;Cerebral Vei;Ventricle, Cerebra;Cerebral Ventricl;Artery, Cerebra;(+/-)-Huperzine A;Posterior Cerebral Artery;Cortices, Cerebra;SELAGINE;Dominances, Cerebra;Central Nervous System Helminthiasis;Vein, Pia;Cerebral Decortication;Reil Insul;Decortications, Cerebral Corte;ISOSELAGINE;Arteries, Cerebra;Artery, Anterior Cerebra;Cerebral Aqueduct;Ventricles, Cerebra;Sylvius Aqueduc;Cerebral Peduncle;Cerebral Arter;Arteries, Anterior Cerebra;Pial Vein;Artery, Middle Cerebra;fordine;CIPLUS_685576;Dominance, Cerebral;Artery, Posterior Cerebra;Cerebral Angiography;Cerebral Angiographie;Circle, Willis;",ZRJBHWIHUMBLCN,Acetylcholinesterase Inhibitors,ACHE
NCGC00186035-04,[O-][N+](=O)C1=CC=CC(=C1)C(=O)NC2=NC3=CC=CC=C3[N]2CCN4CCOCC4,IRAK-1-4 Inhibitor I,,QTCFYQHZJIIHBS,IRAK Inhibitor,IRAK1
NCGC00344630-01,C[C@@]12OC(=O)[C@@]1(NC(=O)[C@@H]2CCCl)[C@@H](O)[C@H]\3CCC\C=C3,Marizomib/Salinosporamide A,,NGWSFRIPKNWYAO,Proteasome Inhibitor,PSMD1
NCGC00160530-03,CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)C2=CC=CC=C2)C3=CC=CC=C3,TOREMIPHENE CITRATE,,XFCLJVABOIYOMF,Selective Estrogen Receptor Modulators (SERM),ESR1
NCGC00181002-02,C[C@@H](NCCCC1=CC=CC(=C1)C(F)(F)F)C2=CC=CC3=CC=CC=C23,Cinacalcet,,VDHAWDNDOKGFTD,Calcium-Sensing Receptor (CaSR) Agonists,CASR
NCGC00163650-02,C[C@H]1COC/2=C1/C(=O)C(=O)C3=C4CCCC(C)(C)C4=CC=C23,CRYPTOTANSHINONE,,GVKKJJOMQCNPGB,STAT-3 Inhibitor,STAT3
NCGC00181786-03,CN[S+]([O-])(=O)CCC1=CC=C2[NH]C=C(C3CCN(C)CC3)C2=C1,Naratriptan hydrochloride,,DISCIPFLLHHREU,5-HT1B Agonist,HTR1B
NCGC00095135-04,CN(C)CCC1=C[NH]C2=CC=C(C[S+]([O-])(=O)N3CCCC3)C=C12,ALMOTRIPTAN,,WKEMJKQOLOHJLZ,5-HT1B Agonist,HTR1B
NCGC00167525-03,CCOC(=O)C1=CC=C(N=C1)C#CC2=CC=C3SCCC(C)(C)C3=C2,Tazarotene (Avage),,OGQICQVSFDPSEI,Retinoid RAR Agonists?,RARB
NCGC00346966-01,O=C(NC1=N[NH]C2=CC(=CC=C12)C3=CC(=CC=C3)C(=O)NC4CC4)C5CC5,HMSL10088,,WBLZCNIEEVRRTG,Receptor-interacting serine/threonine-protein kinase 1 (RIPK1),RIPK1
NCGC00241411-01,CC(C)(C)C(=O)OC1=CC2=C(C=C1)[N](CCCO)C(=N2)NC(=O)C3=CC=CC(=C3)[N+]([O-])=O,NCGC00241411-01,,CEAYRKIZESVQSN,IRAK Inhibitor,IRAK1
NCGC00345818-01,CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N2CC[C@H]2C(=O)N(C)C3=CC=C(C=C3)\C(N)=N\O,Ximelagatran,,YKKFPCDGRUDPJE,Thrombin Inhibitors,
NCGC00092381-03,NC1=C2C(=NC=N1)N=C(C=C2C3=CC(=CC=C3)Br)C4=CN=C(C=C4)N5CCOCC5,ABT-702,,RQCXKDWOCUJWQZ,Adenosine Kinase Inhibitor,ADK
NCGC00347950-01,CC1=NC=CC(=C1)C2=NC=C(CC(=O)NC3=NC=C(C=C3)C4=NC=CN=C4)C=C2C,,,XXYGTCZJJLTAGH,Porcupine (Wnt) Inhibitor,
NCGC00346702-01,CNC(=O)C1=CC=C(C=C1F)C2=N[N]3C(=CN=C3N=C2)CC4=CC=C5N=CC=CC5=C4,INCB28060,,LIOLIMKSCNQPLV,HGFR (MET; c-Met) Inhibitor,MET
NCGC00024717-01,COC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O,N(G)-Nitro-L-arginine methyl ester hydrochloride,D-NAME;Nomega-Nitro-D-arginine methyl ester hydrochloride;NCGC00024717-02;NCGC00024717-01;N(G)-Nitro-L-arginine methyl ester hydrochloride;NCGC00024717-04;NCGC00024717-03;L-NAME;CIPLUS_741880;N-NITRO-ARGININE METHYL ESTER;Nomega-Nitro-L-arginine methyl ester hydrochloride;H-Arg(NO2)-OMe.HCl;NG-Nitro-D-arginine methyl ester hydrochloride;CIPLUS_180795;NG-Nitroarginine Methyl Ester;NCGC00094176-01;NG-Nitro-L-arginine methyl ester hydrochloride;CIPLUS_711444;NCGC00015745-01;L-NAME hydrochloride;Nitro-L-Arginine Methyl Ester Hydrochloride;,KCWZGJVSDFYRIX,Nitric Oxide Synthase Inhibitors,NOS3
NCGC00023037-06,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@@H]([C@@H]4OC(C)=O)[N+]5(C)CCCCC5)[C@@]2(C)C[C@@H]1[N+]6(C)CCCCC6,,PANCURONIUM Br,GVEAYVLWDAFXET,Steroid non-depolarizing blocker,
NCGC00181000-03,CCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1,Suplatast tosylate,,DYZJXZOQQRXDLE,Mediator Release Inhibitors,
NCGC00346476-01,CCOC(=O)[C@@H](N)CC1=CC=C(C=C1)C2=NC(=NC(=C2)O[C@H](C3=CC=C(Cl)C=C3[N]4C=CC(=N4)C)C(F)(F)F)N.OC(=O)CNC(=O)C5=CC=CC=C5,LX-1606,,MDSQOJYHHZBZKA,5-HT Release Inhibitor,
NCGC00346671-01,COC1=CC(=C(C=C1C2=CC=C(C=C2CN3[C@@H](C)[C@H](OC3=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C)F,Anacetrapib (MK-0859),,MZZLGJHLQGUVPN,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,CETP
NCGC00345848-01,COC1=CC=C2C(=CC=NC2=C1)OC3=CC=C(NC(=O)\C4=C(C)\N(CC(C)(C)O)N(C4=O)C5=CC=CC=C5)C=C3F,AMG-1,,UYMSIPINLJNNOU,HGFR (MET; c-Met) Inhibitor,MET
NCGC00346970-01,CNC1=CC=C(C=C1)C(=O)OC2=C(C=C(C(=C2)O\N=[N](/O)N(C)C)[N+]([O-])=O)C#N,YK-72,,WFMYSHLMGAETCU,nitric oxide donors,
NCGC00179649-07,C[C@]12C[C@H](O)[C@H]3[C@@H](CC\C4=C\C(=O)\C=C/[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,Prednisolone (Hydroretrocortine),,OIGNJSKKLXVSLS,Glucocorticoid steroid,
NCGC00346741-01,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC2=CC(=CC=C2)C(F)(F)F,Travoprost (Travatan),,MKPLKVHSHYCHOC,Prostanoid TP Agonist,TBXA2R
NCGC00344549-02,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)OC[C@]4(C)[C@H]3CC[C@]12C,Oxandrolone,,QSLJIVKCVHQPLV,Synthetic Steroid,
NCGC00015278-14,CCCC(C)(COC(N)=O)COC(=O)NC(C)C,CARISOPRODOL,,OFZCIYFFPZCNJE,Muscle relaxant,
NCGC00264052-01,C[C@H](CCC(O)=O)[C@H]1CCC2C3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)C3CC[C@]12C,alpha-HYDROXYDEOXYCHOLIC ACID,,DGABKXLVXPYZII,Antimetabolite,
NCGC00015649-05,COC1=NC(=NC(=C1N\C2=N\CCN2)Cl)C,Moxonidine hydrochloride,,WPNJAUFVNXKLIM,Imidazoline I1 Receptor Agonists,NISCH
NCGC00345796-01,CC1=NC2=C(C=C(C=C2[N]1CC3=CC=CC(=C3C)C(F)(F)F)N4CCOCC4)C(O)=O,GSK-2636771,,XTKLTGBKIDQGQL,PI3Kbeta inhibitor,PIK3CB
NCGC00346704-01,CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6)/C(=C(/[C@@H](OC)C(=O)[C@]13C)C5(C)C)C,Cabazitaxel (Jevtana),,BMQGVNUXMIRLCK,Tubulin depolymerization inhibitor,TUBB
NCGC00263109-02,CC(C)C(=O)N1CCN(CC1)CC2=C(C)C3=NC(=NC(=C3S2)N4CCOCC4)C5=CN=C(N)N=C5,GDC-0980,,GCUUKUTYMNHSJY,mTOR inhibitor,MTOR
NCGC00242507-01,CO[C@@H]1C[C@@H](CC[C@H]1OCCO)C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)/[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C/C=C\C=C(C)/[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC,Everolimus;Afinitor;NVP-RAD-001,,HKVAMNSJSFKALM,mTOR inhibitor,MTOR
NCGC00188866-01,FC(F)(F)C1=CC=C2C(SCCCCCO\C3=C\O\C(CN4CCOCC4)=C/C3=O)=CC=NC2=C1,,,MIDUFIRTIFUTQA,Rac1 inhibitor,RAC1
NCGC00253767-01,C\C1=C\N([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2F)C(=O)NC1=O,Clevudine,,GBBJCSTXCAQSSJ,Reverse Transcriptase Inhibitor,TERT
NCGC00025035-05,C[S+]([O-])C1=CC=C(C=C1)C2=NC(=C([NH]2)C3=CC=NC=C3)C4=CC=C(F)C=C4,SB-203580,,CDMGBJANTYXAIV,p38 MAPK Inhibitor,MAPK14
NCGC00346481-01,CO[C@@H]1C[C@@H](CC[C@H]1O[P](C)(C)=O)C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(C)/[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC,Deforolimus (Ridaforolimus),,BUROJSBIWGDYCN,mTOR inhibitor,MTOR
NCGC00346652-01,CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1C3=C2C=CC(=C3)NC4=NC(=C(C=N4)C(F)(F)F)NC5CCC5,PF-03814735,,RYYNGWLOYLRZLK,Aurora Kinase Inhibitor,AURKA
NCGC00093706-05,CC/1=C(/N2[C@H](SC1)[C@H](NC(=O)C(N)C3=CC=CC=C3)C2=O)C(O)=O,CEPHALEXIN,,ZAIPMKNFIOOWCQ,Cephalosporin antibiotic,
NCGC00016855-11,COC(=O)NC1=NC2=C([NH]1)C=CC(=C2)SC3=CC=CC=C3,FENBENDAZOLE,,HDDSHPAODJUKPD,antiparasitic agent,
NCGC00016643-10,CC1=CC2=C(O1)C(=C3OC(=O)\C=C(C)/C3=C2)C,Trioxsalen,,FMHHVULEAZTJMA,phototherapy treatment of skin disorders,
NCGC00250388-01,NC(CO)(CO)CCC1=C(Cl)C=C(SC2=CC(=CC=C2)OCC3=CC=CC=C3)C=C1,KRP 203;KNF-299,,IINUNQPYJGJCJI,S1P1/3/4 agonist,S1PR1
NCGC00166281-02,COC1=CC2=C(C=C1)N=CC=C2[C@@H](O)[C@@H]3CC4CCN3C[C@@H]4C=C,,,LOUPRKONTZGTKE,antimalarial agents,
NCGC00182554-02,CN1CCC2=C(C1)C3=C(C=CC(C)=C3)N2CCC4=CN=C(C)C=C4,,"LS-133645;2,3,4,5-tetrahydro-2,8-dimethyl-5-(2-(6-methyl-3-pyridyl)-ethyl)-1H-pyrid(4,3b)indole;CIPLUS_774236;dimebon;dimebone;1H-Pyrido(4,3-b)indole, 2,3,4,5-tetrahydro-2,8-dimethyl-5-(2-(6-methyl-3-pyridyl)ethyl)-;dimebolin;",JNODQFNWMXFMEV,NMDA Antagonist,GRIN2A
NCGC00273985-03,CCN1CCC(CC1)[N]2C=C(CNC3=CC(=C4N=CC(=C(NC5=CC=C(F)C(=C5)Cl)C4=C3)C#N)Cl)N=N2,Wyeth Cot inhibitor-2,,PHNZIIMWDVXPGG,Tpl-2/Cot (MAP3K8) Kinase Inhibitor,MAP3K8
NCGC00346804-01,CC1=CC=CC=C1C(=O)C2=CC=C(NC3=C(N)C=C(Br)C=C3)C=C2Cl,EO 1428,,HDCLCHNAEZNGNV,p38 MAPK Inhibitor,MAPK14
NCGC00186037-01,CCCCCN(C)CCC(O)([P](O)(O)=O)[P](O)([O-])=O,Ibandronate sodium,,MPBVHIBUJCELCL,Treatment of Osteoporosis,
NCGC00016410-18,[NH]1C2=C(C=CC=C2)N=C1C3=CSC=N3,THIABENDAZOLE,,WJCNZQLZVWNLKY,antiparasitic agent,
NCGC00017156-01,O.O.CCN1CCN(C(=O)N[C@H](C(=O)N[C@H]2[C@@H]3SC\C(=C(/N3C2=O)C(O)=O)CSC4=NN=N[N]4C)C5=CC=C(O)C=C5)C(=O)C1=O,,"C??fobis;CEFOPERAZONE SODIUM;Pfizer Brand of Cefoperazone Sodium;Cefoperazone Sodium;sulperazon;T 155;NCGC00094952-02;NCGC00094952-01;Cefoperazono;Cefoperazonum;cefoperazonum;CEFOPERAZONE;T-1551;Cefobid;T1551;cefoperazone;Cefoperazone;Prestwick-05A08;Cefoperazone sodium salt;sodium cefoperazone;cefobid;CIPLUS_184436;Sodium Salt, Cefoperazon;CIPLUS_184435;5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-(6alpha,7beta(R*)))-;Cefoperazone Sodium Salt;Sodium, Cefoperazon;CIPLUS_706816;LS-150056;Salt, Cefoperazone Sodiu;CEFOPERAZOLE SODIUM;LS-150057;NCGC00017156-01;4   Cefoperazone Sodium;Cefoperazone sodium;Farmasierra Brand of Cefoperazone Sodium;sulperazone;Cefoperazon;",GCFBRXLSHGKWDP,Cephalosporin antibiotic,
NCGC00263555-02,FC1=CC=C(CNC2=C3C=C(F)C=CC3=NC=N2)C=C1,Spautin-1,,AWIVHRPYFSSVOG,Ubiquitin Specific Peptidase (USP10/13) Inhibitors,USP10
NCGC00344515-02,ClC1=CC2=C(C=C1)C(=CC=N2)N3CCN(CCCN4CCN(CC4)C5=C6C=CC(=CC6=NC=C5)Cl)CC3,Piperaquine,,UCRHFBCYFMIWHC,antimalarial agents,
NCGC00346693-01,CCCCOC1=C2C=N[NH]C2=NC=C1C(=O)C3=C(F)C=C(C)C=C3F,BMS-265246,,SCFMWQIQBVZOQR,CDK1/2 Inhibitor,CDK1
NCGC00015480-13,CC(C)(SC1=CC=C(CCN(CCCCC2CCCCC2)C(=O)NC3CCCCC3)C=C1)C(O)=O,,,PKNYXWMTHFMHKD,PPARalpha Agonist,PPARA
NCGC00344506-01,CC(/CCC\1=C(/C)CCCC1(C)C)=C\CC\C2=C\CC(OC2O)\C3=C\C(=O)OC3O,Manoalide,,FGJIDQWRRLDGDB,Calcium Channel Blocker,
NCGC00346715-01,[O-][N+](=O)C1=NC=C[NH]1,Azomycin (2-Nitroimidazole),,YZEUHQHUFTYLPH,Antibiotic,
NCGC00015316-06,NCCCC(N)(C(F)F)C(O)=O,Eflornithine Hydrochloride,,VLCYCQAOQCDTCN,Ornithine Decarboxylase Inhibitors,ODC1
NCGC00015608-04,O=C(C(C3=CC=CC=C3)(C4=CC=CC=C4)CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)N(C)C,Loperamide,"Loperamide Hcl;Loperamide Hydrochloride;R-18553;LOPERAMIDE HYDROCHLORIDE;4-(4-CHLOROPHENYL)-4-HYDROXY-N,N-DIMETHYL-A,A-DIPHENYL-1-PIPERIDINEBUTANAMIDE;HS_736;NCGC_Prestw-144;Loperamide hydrochloride;Loperamidum;1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl-;LS-114352;LS-114353;CIPLUS_213659;HS_841;R 1855;NCGC00094059-03;NCGC00094059-02;CIPLUS_181471;NCGC00094059-01;4-(p-Chlorophenyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl-1-piperidinebutyramide hydrochloride;R1855;imodium;NCGC00015608-01;NCGC00016828-01;NCGC00024818-02;NCGC00024818-01;NCGC00024818-04;NCGC00024818-03;Hydrochloride, Loperamid;LS-178564;loperamide;Monohydrochloride, Loperamid;Loperamide Monohydrochloride;Loperamide;Loperamida;loperamidum;SIMETHICONE;Imodium;LOPERAMIDE;",RDOIQAHITMMDAJ,mu-Opioid Antagonists,OPRM1
NCGC00262642-02,C[C@H](NC(=O)/C(=C/C1=NC(=CC=C1)Br)C#N)C2=CC=CC=C2,WP1066,,VFUAJMPDXIRPKO,STAT-3/5 Inhibitor,STAT3
NCGC00346701-01,CCN(C(=O)C/1=C(O)/C2=C(C=CC=C2Cl)N(C)C1=O)C3=CC=CC=C3,Laquinimod (ABR-215062),,GKWPCEFFIHSJOE,Immunomodulators,
NCGC00015452-19,CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F,FLUTAMIDE,,MKXKFYHWDHIYRV,Androgen Receptor Antagonist,AR
NCGC00344510-02,CC(C)(CC1=CC=C2C=CC=CC2=C1)NC[C@@H](O)COC3=C(C#N)C(=CC=C3)Cl,NPS-2143 (SB262470),,PZUJQWHTIRWCID,Calcium-Sensing Receptor (CaSR) Antagonists,CASR
NCGC00181349-01,N#CC1=C(N(CC([O-])=O)CC([O-])=O)SC(C([O-])=O)=C1CC([O-])=O.[Sr+2].[Sr+2].O.O.O.O.O.O.O,Strontium ranelate heptahydrate,Ranelic acid;CIPLUS_3857870;RANELIC ACID;S-12911;Strontium Ranelate;S 12911;S12911;S12911-0;protelos;S12911-2;acide ranelique;S12911-5;acidum ranelicum;strontium ranelate;3-(3-cyano-4-carboxymethyl-5-carboxy-2-thienyl)-3-azapentanedioic distrontium salt;,DJSXNILVACEBLP,Calcium-Sensing Receptor (CaSR) Agonists,CASR
NCGC00346568-01,CC(C)C1=NOC(=N1)N2CCC(CC2)COC3=CN=C(C=C3)C4=CC=C(C=C4)[S+](C)([O-])=O,GSK1292263,,AYJRTVVIBJSSKN,"Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Agonists",GPR119
NCGC00163169-02,CN1CCC(CC1)=C2C3=C(CCC4=C2C=CC=C4)SC=C3,,PIZOTIFEN MALATE,FIADGNVRKBPQEU,Antimigraine drugs,
NCGC00346875-01,C[C@@H](N(C1=CC(=CC=C1F)F)[S+]([O-])(=O)C2=CC=C(Cl)C=C2)C3=CC=C(F)C=C3CCCC(O)=O,BMS 299897,,CWXDOAGXKIYPRR,g-Secretase Inhibitor,NOTCH1
NCGC00262829-02,COC1=CC=C(C=C1)[S+]([O-])(=O)NC2=CC(=C(O)C3=C2C=CC=C3)C4=C(O)C=CC5=C4C=CC=C5,C-188-9,,CROIZKLZMVFOFK,STAT3 Expression Inhibitors,STAT3
NCGC00347944-01,CNC1=NC(=NC=C1Cl)NC2=CC=C(C=C2OC)C(=O)N3CCOCC3,,,YEVOZZZLKJKCCD,Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors,LRRK2
NCGC00345786-01,CN1CCC2=C(C1)[N](CC3=CC=C(C=C3)C(=O)NO)C4=CC=CC=C24,Compound 7,,JVELXRPQMVXDDP,Histone Deacetylase (HDAC) 6 Inhibitor,HDAC6
NCGC00346655-01,CC#CC[N]1C(=NC2=C1C(=O)N(CC3=NC4=CC=CC=C4C(=N3)C)C(=O)N2C)N5CCC[C@@H](N)C5,Linagliptin (BI-1356),,LTXREWYXXSTFRX,Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitor,DPP4
NCGC00015601-03,CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)C3=CC=C(F)C=C3)C4=C1C=CC=C4,"LY-310,762 hydrochloride",,KDXISMANFPJVJY,5-HT1D Receptor Antagonist,HTR1D
NCGC00094580-05,O=C1N\C=N/C2=C1C=N[NH]2,ALLOPURINOL,,OFCNXPDARWKPPY,Xanthine Oxidase Inhibitor,XDH
NCGC00092364-05,ClC1=CC=C(C=C1)C(=O)N[C@H]2CN3CCC2CC3,PNU 282987,,WECKJONDRAUFDD,Nicotinic alpha7 Agonists,CHRNA7
NCGC00185053-01,O=C(OCC#CCSC1=NN=C(O1)C2=CC=CC3=CC=CC=C23)C4=CC5=C(S4)C=CC=C5,,,DEFCRCHSGYRKLO,15-Lipoxygenase Inhibitor,ALOX15
NCGC00159461-03,[H][C@@](O)(CN(CC(C)C)[S+]([O-])(=O)C1=CC=C(N)C=C1)[C@]([H])(CC2=CC=CC=C2)NC(=O)O[C@@]3([H])CCOC3,,"AMPRENAVIR MESYLATE;(3S)-TETRAHYDROFURAN-3-YL ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(ISOBUTYL)AMINO)-1-BENZYL-2-HYDROXYPROPYL)CARBAMATE;8   Amprenavir;CIPLUS_206962;GlaxoSmithKline brand of amprenavir;141W94;CARBAMIC ACID, ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-, (3S)-TETRAHYDRO-3-FURANYL ESTER;LS-173559;AMPRENAVIR;TETRAHYDRO-3-FURYL-N-((1S,2R)-3-(4-AMINO-N-ISOBUTYLBENZENESULFAMIDO)-1-BENZYL-2-HYDROXYPROPYL)CARBAMATE(3S);141W94 MESYLATE;tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate;Glaxo Wellcome brand of amprenavir;Amprenavir;VX 478;(3S)-Tetrahydrofuran-3-yl(1S,2R)-3-[(4-aminophenylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate;Agenerase;VX-478;Vertex VX478;amprenavirum;TETRAHYDRO-3-FURYL-N-((1S,2R)-3-(4-AMINO-N-ISOBUTYLBENZENESULFAMIDO)-1-BENZYL-2-HYDROXYPROPYL)CARBAMATE MESYLATE (3S);TETRAHYDRO-3-FURYL-N-((1S,2R)-3-(4-AMINO-N-ISOBUTYLBENZENESULFAM  IDO)-1-BENZYL-2-HYDROXYPROPYL)CARBAMATE(3S);amprenavir;",JRIYBJCXJSHIOL,HIV Protease Inhibitors,
NCGC00263225-01,CCOC(CN1C(=O)[C@](CC(=O)NC2=CC=C(C)C=C2)(NC(=O)NC3=CC=C(C)C=C3)C4=CC=CC=C14)OCC,AG-041R,,KOLPMNSDISYEBU,gastrin/CCKB receptor antagonist,CCK-B
NCGC00346642-01,CC1=C(C(=C([NH]1)/C=C/2C(=O)NC3=C2C=C(C=C3)[S+]([O-])(=O)CC4=C(Cl)C=CC=C4Cl)C)C(=O)N5CCC[C@@H]5CN6CCCC6,PHA-665752,,OFEDSDGPRABWEB,HGFR (MET; c-Met) Inhibitor,MET
NCGC00016740-19,COC1=CC2=NC(=NC(=C2C=C1OC)N)N3CCN(CC3)C(=O)C4=CC=CO4,PRAZOSIN HYDROCHLORIDE,,IENZQIKPVFGBNW,alpha1-Adrenoceptor Antagonists,ADRA1A
NCGC00250400-01,C[C@@H](OC1=C(N)N=CC(=C1)C2=C[N](N=C2)C3CCNCC3)C4=C(Cl)C(=CC=C4Cl)F,Crizotinib;PF-02341066;PF-2341066;Xalkori,,KTEIFNKAUNYNJU,HGFR (MET; c-Met) Inhibitor,MET
NCGC00016035-12,ClC1=CC(=CC=C1)N2CCN(CCCN3\N=C4\C=C/C=C\N4C3=O)CC2,TRAZODONE HYDROCHLORIDE,,PHLBKPHSAVXXEF,alpha2-Adrenoceptor Antagonists,ADRA2A
NCGC00015418-08,CCC1(C)CC(=O)NC1=O,ETHOSUXIMIDE,,HAPOVYFOVVWLRS,anti-epileptic drug,
NCGC00346829-01,CCO[P](=O)(OCC)C(C)NC(=O)N(CCCl)N=O,Fotemustine,,YAKWPXVTIGTRJH,DNA Alkylating Agent,
NCGC00250373-01,OC1=C(C=CC=C1)C2=CC=C(C=C2)C3=CSC4=C3C(=C(/C#N)C(=O)N4)/O,A-769662,,CTESJDQKVOEUOY,AMP-Activated Protein Kinase (AMPK) Activator,PRKAA1
NCGC00249390-01,COC1=C(OC)C=C2C(=CC=NC2=C1)OC3=CC=C(NC(=O)NC4=NOC(=C4)C)C(=C3)Cl,Tivozanib;ASP-4130/AV-951/KRN-951,,SPMVMDHWKHCIDT,VEGFR-1/2/3 Inhibitor,FLT1
NCGC00274064-01,CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC/4=C/C(=O)/C=C\[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO,Betamethasone valerate,,SNHRLVCMMWUAJD,Glucocorticoid steroid,
NCGC00346513-01,CN(C)CCN1C(=O)C2=C3C(=CC=C2)C=C(N)C=C3C1=O,Amonafide,,UPALIKSFLSVKIS,DNA Topoisomerase II Inhibitors,TOP2A
NCGC00183844-01,N[C@H]2CN(CC12CC1)c3c(F)cc4c(c3Cl)[N@@](C=C(C4=O)C(=O)O)C5C[C@H]5F,Sitafloxacin,"DU-6859A;Sitafloxacin Hydrate;sitafloxacin;sitafloxacinum;SITAFLOXACIN;CIPLUS_215256;Sitafloxacin;3-Quinolinecarboxylic acid, 7-(7-amino-5-azaspiro(2.4)hept-5-yl)-8-chloro-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-4-oxo-, (1R-(1alpha(S*),2alpha))-;SITAFLOXACIN SESQUIHYDRATE;sitafloxacine;CIPLUS_3818295;",PNUZDKCDAWUEGK,DNA Topoisomerase IV Inhibitors,TOP2B
NCGC00094994-06,OC(C1CCCCN1)C2=C3C=CC=C(C3=NC(=C2)C(F)(F)F)C(F)(F)F,MEFLOQUINE,,XEEQGYMUWCZPDN,antimalarial agents,
NCGC00346717-01,CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(N)=O)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,BYL719,,STUWGJZDJHPWGZ,PI3K alpha Inhibitor,PIK3CA
NCGC00187912-03,NC1=C2C(=NC=N1)[N](N=C2C3=CC=C(OC4=CC=CC=C4)C=C3)[C@@H]5CCCN(C5)C(=O)C=C,PCI-32765,,XYFPWWZEPKGCCK,Btk/Lck/Lyn inhibitor,BTK
NCGC00263151-01,NC1=NC(=N[N]1C(=O)C2=C(F)C=CC=C2F)NC3=CC=C(C=C3)[S+](N)([O-])=O,JNJ-7706621,,QSOTYADLORZYRZ,Aurora Kinase Inhibitor,AURKA
NCGC00263091-01,ClC1=C(C(=O)NC2=C[NH]N=C2C(=O)NC3CCNCC3)C(=CC=C1)Cl,AT-7519,,OVPNQJVDAFNBDN,CDK 1 & 2 inhibitor,CDK1
NCGC00015092-09,NCCCCCC(O)=O,AMINOCAPROIC ACID,,SLXKOJJOQWFEFD,Plasminogen Activator Inhibitor (PAI-1) Inhibitor,SERPINE1
NCGC00346723-01,O=C1NCCC2=C1C=C([NH]2)C3=CC=NC=C3,PHA-767491,,DKXHSOUZPMHNIZ,Cell Division Cycle 7-Related Protein Kinase (CDC7) Inhibitors,CDC7
NCGC00242495-01,CN(C1=NC=CC=C1CNC2=NC(=NC=C2C(F)(F)F)NC3=CC=C4NC(=O)CC4=C3)[S+](C)([O-])=O,PF-431396;PF-562271,,LLJJBDHTRHQGQA,Focal Adhesion Kinase (FAK) Inhibitor,PTK2
NCGC00344999-01,C[C@H](NCC1=CC=C2[N](CCC3=CC=CC=C3)C(=NC2=C1)NC(=O)C4=CC=C(S4)C5=C[NH]N=C5)C(C)(C)C,,,HSWJAIQNVQEPDV,ITK inhibitor,ITK
NCGC00081778-04,CCOC(=O)C(C)OC1=CC=CC2=C1\C=C/N(CC(=O)NC3=CC=C4OCCOC4=C3)C2=O,SID 7969543,,KWMBIIQCLUIHDI,SF1 (NR5A1) Receptor Antagonist,NR5A1
NCGC00346598-01,O[C@@H]1C\C(=C/C(O)C1O)C(O)=O,Shikimic acid (Shikimate),,JXOHGGNKMLTUBP,plant biochemical intermediate,
NCGC00095157-06,COC(=O)NC1=NC2=CC=C(C=C2[NH]1)[S+]([O-])C3=CC=CC=C3,OXFENDAZOLE,,BEZZFPOZAYTVHN,antiparasitic agent,
NCGC00182084-01,Nc1cc(c(cc1S(=O)(N)=O)S(N)(=O)=O)C(/Cl)=C(/Cl)Cl,Clorsulon,,BJYAIGPIFCCBOU,antiparasitic agent,
NCGC00253740-01,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1,Ertosamide,,VPPJLAIAVCUEMN,NMDA Glycine-Site Antagonist,GRIN2A
NCGC00090903-09,OC(=O)C1=CC(=CC=C1O)/N=N/C2=CC=C(C=C2)[S+]([O-])(=O)NC3=NC=CC=C3,Sulfasalazine;Azulfidine,,IQINTIBZAZDLHS,NFKB Activation Inhibitors,NFKB1
NCGC00263238-01,C[C@H]([C@H]1C\C(=C(CO)/C(=O)O1)C)[C@H]2CC[C@H]3[C@@H]4C[C@H]5O[C@]56[C@@H](O)\C=C/C(=O)[C@]6(C)[C@H]4CC[C@]23C,Withaferin A;NSC-101088,,DBRXOUCRJQVYJQ,NF-kappaB Activation Inhibitor,NFKB1
NCGC00167485-02,C[C@H](O)[C@H]1[C@@H]2[C@H](C)C(=C(\N2C1=O)C(O)=O)/S[C@@H]3CN[C@H](CN[S+](N)([O-])=O)C3,Doripenem Hydrate,,UWUMWJWVLCQLMD,Carbapenem Antibiotic,
NCGC00345816-01,CC(C)C[C@H](CC(O)=O)C(=O)N[C@@H](CC1=C[NH]C2=C1C=CC=C2)C(=O)N[C@@H](C)C3=CC=CC=C3,GM-1489,,BLPWNGOQQLJQOL,MMP Inhibitor,MMP1
NCGC00164385-04,CCN(CC)CCOC1=CC=C(C=C1)\C(=C(/Cl)C2=CC=CC=C2)C3=CC=CC=C3,CLOMIPHENE CITRATE,,GKIRPKYJQBWNGO,Selective Estrogen Receptor Modulators (SERM),ESR1
NCGC00346896-01,CC1(CCCCCCC1)N2CCC(CC2)[N]3C4=C(C=CC=C4)N=C3[C@@H]5CCCNC5,MCOPPB,,CYYNMPPFEJPBJD,"ORL1 (OP4, NOP) Agonists",OPRL1
NCGC00263531-03,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC=C(N3CCOCC3)C(=C2)F,Linezolid (Zyvox),,TYZROVQLWOKYKF,50S Ribosomal Protein Inhibitors,
NCGC00015603-07,CCN1\C=C(C(O)=O)/C(=O)C2=C1C(=C(N3CCNC(C)C3)C(=C2)F)F,LOMEFLOXACIN HYDROCHLORIDE,,ZEKZLJVOYLTDKK,Quinoline Antibiotic,
NCGC00015207-11,O=C1CCC2=C(N1)C=CC(=C2)OCCCCC3=NN=N[N]3C4CCCCC4,CILOSTAZOL,,RRGUKTPIGVIEKM,Phosphodiesterase III (PDE3) Inhibitor,PDE3A
NCGC00344513-01,CCN1C(=O)N([C@@H]2CCN(CC3CCCCCCC3)C[C@H]2CO)C4=CC=CC=C14,J113397,,MBGVUMXBUGIIBQ,"ORL1 (OP4, NOP) Antagonists",OPRL1
NCGC00263141-01,OC1=CC=C2C=CC=CC2=C1/C=N/[S+]([O-])(=O)C3=CC=CS3,STF-083010,,LBDFMBIFLKOAGE,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,ERN1
NCGC00015437-16,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(Cl)C=C2,FENOFIBRATE,,YMTINGFKWWXKFG,PPARalpha Agonist,PPARA
NCGC00263228-01,CCC(=O)N[C@H]1CC[C@@H](C1)C(=O)N(C)C2=CC=C(C=C2)C3=NC4=C(O3)C=CC=C4,FASN BI,,YNFDIGJKJPNFFD,Fatty acid synthase inhibitor,FAS
NCGC00090752-08,C\C1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)NC2=CC=C(O)C=C2)C(C)(C)CCC1,Fenretinide;McN-R-1967;NSC-374551;ST-602;SYT-101,"4-HPR;NCGC00090752-03;NCGC00090752-06;NCGC00090752-05;NCGC00090752-08;LS-177208;fenretinidum;NCGC00090752-07;MCN-R-1967;MCNR196;CIPLUS_186933;4-HYDROXYPHENYLRETINAMIDE;Retinamide;NCGC00015516-01;4 Hydroxyphenylretinamid;Fenretinide, 13-cis-Isomer;N-(4-Hydroxyphenyl)retinamide;4-Hydroxyphenylretinamide;Fenretinide;Retinoic acid p-hydroxyanilide;CIPLUS_728212;fenretinide;LS-282;N-(4-Hydroxyphenyl)-trans-Retinamide;Retinamide, N-(4-hydroxyphenyl)-;Fenretinimide;13-cis-Isomer Fenretinid;MCN R 196;4-Hydroxyphenyl retinamide;Fenretinide, 13 cis Isome;N-(4-HYDROXYPHENYL)RETINAMIDE;FENRETINIDE;AB02540517-01;",AKJHMTWEGVYYSE,RARbeta/gamma Agonist,RARB
NCGC00018117-23,CN1C(=O)N(C)C2=C([NH]C=N2)C1=O,THEOPHYLLINE,,ZFXYFBGIUFBOJW,Adenosine Receptor Antagonist,ADORA1
NCGC00348107-01,CC1CCN(CC1)C2=CC(=CC=C2NC(=O)C3=CC(=C[NH]3)C#N)N4CCN(C)CC4,CSF1R (c-FMS) Inhibitor,,DXPSQKSTVIVZLV,CSF1R (c-FMS) Inhibitor,CSF1R
NCGC00091019-08,C[C@@H]1C[C@H]2[C@@H]3CCC\4=C\C(=O)\C=C/[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Dexamethasone,,UREBDLICKHMUKA,Antiinflammatory,NR3C1
NCGC00015718-06,OC(COC3=CC=CC4=C3C=CC=C4)CN(CC2)CCN2C(C=CC=C1)=C1OC,Naftopidil,naftopidilum;NAFTOPIDIL;CIPLUS_210903;LS-112431;(+-)-1-(4-(2-methoxyphenyl)piperazinyl)-3-(1-naphthyloxy)propan-2-ol;NCGC00016882-01;1-(4-(2-methoxyphenyl)-1-piperazinyl)-3-(1-naphthyloxy)-2-propanol;NCGC00094247-01;NCGC00024672-03;Naftopidil dihydrochloride;NCGC00024672-04;4-(2-Methoxyphenyl)-alpha-[(1-naphthalenyloxy)methyl]-1-piperazineethanol dihydrochloride;NAFTOPIDIL DIHYDROCHLORIDE;KT-611;NCGC_Prestw-975;Naftopidil;Flivas;NCGC00024672-01;KT-611 dihydrochloride;NCGC00015718-01;naftopidil;,HRRBJVNMSRJFHQ,alpha1-Adrenoceptor Antagonists,ADRA1A
NCGC00017223-03,C[C@@H]1CC[C@@]2(CC[C@]3(C)\C(=C/C[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O,,,WCGUUGGRBIKTOS,STAT-3 Inhibitor,STAT3
NCGC00021191-05,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC/4=C/C(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C,,"cortisone acetate;NCGC00021191-03;NCGC00015228-01;6   Cortisone Acetate;CIPLUS_148520;Cortisone 21-acetate;Cortone acetate;PREGN-4-ENE-3,11,20-TRIONE, 21-(ACETYLOXY)-17-HYDROXY-;cortisyl;NCGC00094631-01;NCGC00021191-06;NCGC00094631-02;17-HYDROXY-3,11,20-TRIOXOPREGN-4-EN-21-YL ACETATE;21-Acetoxy-4-pregnen-17alpha-ol-3,11,20-trione;17,21-DIHYDROXYPREGN-4-ENE-3,11,20-TRIONE 21-ACETATE;CORTISONE ACETATE;Cortisone acetate;LS-55003;4-Pregnene-17alpha,21-diol-3,11,20-trione 21-acetate;17alpha,21-Dihydroxy-4-pregnene-3,11,20-trione 21-acetate;Cortisone Acetate;",ITRJWOMZKQRYTA,Glucocorticoid steroid,
NCGC00016103-06,OCC1=CC=C(O1)C2=N[N](CC3=CC=CC=C3)C4=C2C=CC=C4,,LS-173463;YC 1;CIPLUS_709283;NCGC00094472-03;NCGC00094472-02;YC-1;NCGC00016103-01;NCGC00094472-01;3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole;3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole;,OQQVFCKUDYMWGV,Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors,HIF1A
NCGC00250374-01,CC1(C)C[N]2C(=C(C3=CC=C(Cl)C=C3)C(=C2C1)C4=CC=CC=C4)CC(O)=O,Licofelone;ML-3000,,UAWXGRJVZSAUSZ,5-Lipoxygenase Inhibitor,ALOX5
NCGC00263185-01,COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C3C(=NC=NC3=C1)NC4=CC(=C(F)C=C4)Cl,Dacomitinib;PF-00299804/PF-299,,LVXJQMNHJWSHET,EGFR (HER1; erbB1) inhibitor,EGFR
NCGC00346684-01,CC(C)(C)C1=C(O)C(=CC(=C1)C=C(C#N)C#N)Br,AG-1024 ,,ABBADGFSRBWENF,EGFR (HER1; erbB1) Inhibitor,EGFR
NCGC00015110-12,CCC1(CCC(=O)NC1=O)C2=CC=C(N)C=C2,Aminoglutethimide (Cytadren),,ROBVIMPUHSLWNV,Aromatase Inhibitor,CYP19A1
NCGC00022398-06,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]3[C@@H]4C[C@H](F)C/5=C/C(=O)/C=C\[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]23C,Fluocinonide (Vanos),,WJOHZNCJWYWUJD,Glucocorticoid steroid,
NCGC00090766-08,C[C@]12CC(=O)[C@H]3[C@@H](CC\C4=C\C(=O)\C=C/[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,Prednisone (Adasone),,XOFYZVNMUHMLCC,Glucocorticoid steroid,
NCGC00025072-01,CCCN1CCO[C@H]2[C@H]1COC3=CC=C(O)C=C23,PD 128907 hydrochloride,"3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol, (-)-isomer;NCGC00094286-02;3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol, (+)-isomer;NCGC00094286-01;PD 128907 hydrochloride;PBPO;(+)-PD 128,907 hydrochloride;PD 128907;(+/-)-PD 128,907 hydrochloride;(+)-PD 128907;LS-172576;3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol;PBTO;LS-39833;S(+)-(4aR,10bR)-3,4,4a,10b-;R(-)-PD 128,908 hydrochloride;PD 125,530;NCGC00025072-02;NCGC00015788-01;(?)-PD 128,907 hydrochloride;NCGC00015788-02;NCGC00025072-03;CIPLUS_692068;NCGC00025072-01;(+)-(4ar,10br)-3,4,4a,10b-tetrahydro-4-propyl-2h,5h-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol;NCGC00025072-04;S(+)-(4aR,10bR)-3,4,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano-[4,3-b]-1,4-oxazin-9-ol hydrochloride;NCGC00025072-05;S(+)-(4aR,10bR)-3,4,4a,10b- Tetrahydro-4-propyl-2H,5H-[1]benzopyrano-[4,3-b]-1,4-oxazin-9-ol hydrochloride;(+)-(4aR,10bR)-3,4,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol hydrochloride;R(-)-(4aS,10bS)-3,4,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano-[4,3-b]-1,4-oxazin-9-ol;PD 128,907;trans-(+/-)-3,4,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol hydrochloride;PD-128907;S(+)-PD 128,907 hydrochloride;",YOILXOMTHPUMRG,Dopamine D2/D3 Agonist,DRD2
NCGC00347942-01,ClC1=CC=C(C(=C1)Cl)C(=O)C(/C#N)=C2\NC(=O)C3=C(N2)C=C(Cl)C=C3,,,JKKSCGHDRHRWOQ,AAA+ ATPase Motor Cytoplasmic Dynein Inhibitor,
NCGC00247624-02,CC1=COC2=C1C(=O)C(=O)C3=C4C=CC=C(C)C4=CC=C23,Tanshinone I,,AIGAZQPHXLWMOJ,TNF-alpha Production Inhibitors,TNF
NCGC00095597-02,C[C@@]1(CO)C(O)CC[C@]2(C)C(C/C=C/3C(O)COC3=O)C(=C)CCC12,,,BOJKULTULYSRAS,TNF-alpha Production Inhibitor,TNF
NCGC00179504-06,COC1=C(O)C(=CC(=C1)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]4O)C6=C2C=C7OCOC7=C6)OC,Etoposide (VP-16),,VJJPUSNTGOMMGY,DNA Topoisomerase II Inhibitors,TOP2A
NCGC00346536-01,CC(=O)NC1=NC(=C(S1)C2=CC(=C(Cl)C=C2)[S+]([O-])(=O)NCCO)C,PIK-93,,JEZNPTVWRSCEJC,PI3K Inhibitor,PIK3CA
NCGC00167488-03,CNC(=O)C1=CC(=CC=N1)OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2,Sorafenib;BAY-43-0006;BAY-54-9085;Nexavar,"4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate;4-(4-(((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)CARBAMOYL)AMINO)PHENOXY)-N-METHYLPYRIDINE-2-CARBOXAMIDE;BAY-439006;sorafenibum;2-PYRIDINECARBOXAMIDE, 4-(4-((((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)AMINO)CARBONYL)AMINO)PHENOXY)-N-METHYL-, MONO(4-METHYLBENZENESULFONATE);Sorafenib base;BAY 43-9006;4-(4-(3-(4-CHLORO-3-TRIFLUOROMETHYL-PHENYL)-UREIDO)-PHENOXY)-PYRIDINE-2-CARBOXYLIC ACID-4-METHYLBENZENESULFONATE;Nexavar;4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N2-METHYLPYRIDINE-2-CARBOXAMIDE 4-METHYLBENZENESULFONATE;SORAFENIB;BAY-43-9006 TOSYLATE;Sorafenib Tosilate;BAY-439006 TOSYLATE;4-(4-(3-(4-CHLORO-3-TRIFLUOROMETHYL-PHENYL)-UREIDO)-PHENOXY)-PYRIDINE-2-CARBOXYLIC ACID;2-PYRIDINECARBOXAMIDE, 4-(4-((((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)AMINO)CARBONYL)AMINO)PHENOXY)-N-METHYL-;4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N(SUP 2)-METHYLPYRIDINE-2-CARBOXAMIDE;sorafenib;CIPLUS_789424;sorafenib tosylate;SORAFENIB TOSYLATE;Sorafenib tosylate;Sorafenib;4-(4-(((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)CARBAMOYL)AMINO)PHENOXY)-N-METHYLPYRIDINE-2-CARBOXAMIDE 4-METHYLBENZENESULFONATE;",MLDQJTXFUGDVEO,VEGFR-1/2/3 Inhibitor,FLT1
NCGC00263138-01,CNC(=O)C1=CC(=CC=N1)OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C(=C2)F,Regorafenib;BAY-73-4506,,FNHKPVJBJVTLMP,VEGFR-2 Inhibitor,KDR
NCGC00253909-01,CC1=CC(=CC=C1)NC2=C(C=NC(=N2)N[C@@H]3CCCC[C@@H]3N)C(N)=O,PRT-060318;PRT-318?,,NZNTWOVDIXCHHS,Syk Kinase inhibitor,SYK
NCGC00188344-05,CC1(C)CCC(=C(CN2CCN(CC2)C3=CC=C(C=C3)C(=O)N[S+]([O-])(=O)C4=CC(=C(N[C@H](CCN5CCOCC5)CSC6=CC=CC=C6)C=C4)[S+]([O-])(=O)C(F)(F)F)\C1)/C7=CC=C(Cl)C=C7,ABT-263 (Navitoclax),,QNERGCCCLASWNA,Bcl-xL inhibitor,BCL2L1
NCGC00346659-01,COC1=CC=C(C=N1)C/2=C/C3=C(C)N=C(N)N=C3N(C4CCC(CC4)OCCO)C2=O,PF-04691502,,XDLYKKIQACFMJG,PI3K Inhibitor,PIK3CA
NCGC00182051-02,COC1=CC(=CC(=C1OC)OC)NC2=NC=C(F)C(=N2)NC3=NC4=C(OC(C)(C)C(=O)N4)C=C3,R406;NSC-742317,,NHHQJBCNYHBUSI,Syk Kinase inhibitor,SYK
NCGC00189074-01,O=C(NOCC1CC1)c3ccc(F)c(F)c3Nc2ccc(I)cc2Cl,C.I. 1040,CI-1040 (PD184352),GFMMXOIFOQCCGU,MEK inhibitor,MAP2K1
NCGC00179501-05,COC1=C(O)C=C(C=C1)[C@@H]2CC(=O)C3=C(O2)C=C(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)C=C3O,Methyl-Hesperidin,,QUQPHWDTPGMPEX,Free Radical Scavenger,
NCGC00167978-02,CO\N=C(C(=O)N[C@H]1[C@H]2SC\C(=C(/N2C1=O)C(O)=O)CSC(=O)C3=CC=CO3)/C4=CSC(=N4)N,Ceftiofur hydrochloride ,,ZBHXIWJRIFEVQY,Cephalosporin antibiotic,
NCGC00242514-01,COCC[N]1C(=[N+](CC2=NC=CN=C2)C3=C1C(=O)C4=CC=CC=C4C3=O)C,YM155,,CJZJWYDXFXAJPQ,Survivin inhibitor,BIRC5
NCGC00242485-01,NC/1=N/C(=O)C2=C([NH]C=C2CCC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1,Pemetrexed disodium;Alimta;LY-231514?,,WBXPDJSOTKVWSJ,thymidylate synthase inhibitor,TYMS
NCGC00015256-13,CCN(CC)CCCC(C)NC1=CC=NC2=C1C=CC(=C2)Cl,Chloroquine (CQ),,WHTVZRBIWZFKQO,antimalarial agents,
NCGC00250386-02,IC1=C(NCCCNC(=O)C2=CC=CS2)N=C(NC3=CC(=CC=C3)NC(=O)N4CCCC4)N=C1,BX-795,,VAVXGGRQQJZYBL,IKK-epsilon Inhibitor,IKBKE
NCGC00346515-01,CC(O)[C@@H]1[C@H]2[C@@H](C)\C(=C(/N2C1=O)C([O-])=O)SC3C[N]4N=CC=[N+]4C3,Biapenem,,RLAPFAKXSAUMLW,Carbapenem Antibiotic,
NCGC00090705-11,NC/1=N/C(=O)N(/C=C1)[C@H]2CC[C@@H](CO)O2,,,WREGKURFCTUGRC,Reverse Transcriptase Inhibitor,TERT
NCGC00162409-03,CO[C@H]1\C=C/C=C(/C)C[C@H](C)[C@H](O)[C@H](C)\C=C(C)/C=C(/OC)C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@@]2(O)C[C@@H](O)[C@H](C)[C@H](O2)C(C)C,Bafilomycin A1,,XDHNQDDQEHDUTM,Vacuolar H+ ATPase (V-ATPase) Inhibitors,
NCGC00090749-11,CCC(/C1=CC=C(O)C=C1)=C(/CC)C2=CC=C(O)C=C2,DIETHYLSTILBESTROL,,RGLYKWWBQGJZGM,Estrogen Receptor (ER) Agonist,ESR1
NCGC00250384-01,CN1CCN(CC1)C2=CC(=C(Cl)C=N2)C(=O)NC3=CC=C4CCC5=C([N](N=C5C(N)=O)C6=CC=C(F)C=C6)C4=C3,PHA-408,,ZLEZHGHFWIHCGU,IKK-beta Inhibitor,IKBKB
NCGC00242476-02,CC(C)(C)OC(=O)CN(CC1=CC=C(S1)[N+]([O-])=O)CC2=CC=C(Cl)C=C2,GSK-4112;SR-6452??,,WYSLOKHVFKLWOU,Rev-erb alpha agonist,NR1D1
NCGC00345852-01,CC(C)C1=C2N=C(N[C@@H](CO)[C@H](O)CO)C=C(NCC3=CC=CC=C3)[N]2N=C1,BS194,,KRIWIRSMQRQYJG,CDK1/2/5/9 inhibitor,CDK1
NCGC00095694-05,COC1=C(CC=C(C)C)C2=C(\C=C/C(=O)O2)C=C1,Osthol,,MBRLOUHOWLUMFF,GABAA Receptor Modulator,GABRA1
NCGC00183361-01,[Na+].O=C([O-])[C@@H]3N4C(=O)[C@@H](NC(=O)c2c(C)onc2c1ccccc1)[C@H]4SC3(C)C,Oxacillin sodium salt,"Oxacillinum;LS-176967;CIPLUS_166228;Sodium, Oxacilli;Methylphenylisoxazolyl Penicilli;oxacillinum;LS-149809;Oxacillin sodium;Oxacillin Sodium;LS-149729;OXACILLIN SODIUM MONOHYDRATE;Oxacillin sodium salt;CIPLUS_698490;4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(((5-methyl-3-phenyl-4-isoxazolyl)carbonyl)amino)-7-oxo-, (2S-(2alpha,5alpha,6beta))-;Prostaphlin;LS-149810;Oxacillin;4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-, mixt. with (2S-(2alpha,5alpha,6beta))-3,3-dimethyl-6-(((5-methyl-3-phenyl-4-isoxazolyl)carbonyl)amino)-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid;Ampicillin-oxacillin mixture;NCGC00094746-01;OXACILLIN SODIUM, ANHYDROUS;NCGC00094746-02;Bactocill;OXACILLIN SODIUM;broadcillin;Oxacillin, Monosodium Salt, Monohydrate;Oxacillin, Monosodium Salt, Anhydrous;oxacilline;OXACILLIN;Oxacillin sodium salt monohydrate;ampiox;CIPLUS_206647;Oxacillin, Sodiu;CIPLUS_149104;Oxacilina;Oxacilline;",UWYHMGVUTGAWSP,beta-lactam antibiotic,
NCGC00241036-02,OC(=O)C1=CC=C(O)C2=NC=C(C=C12)N3CCOCC3,NCGC00241036-01,,XYBGOSXCBPMITI,JMJ inhibitor,JARID2
NCGC00347955-01,C[C@H](NC(=O)C1=CC2=C(C=C1)[N](CC3=CC=C(C=C3)C4=CC=CC=C4C(O)=O)C(=C2C)C)C5=CC=C(C=C5)[N+]([O-])=O,,,IIJDFXNUWZTHIM,PPARgamma Modulator,PPARG
NCGC00345854-01,CN1CCN(CC1)C2=CC=CC(=C2)NC3=N[N]4C=CC=C(C5=CC=C(C=C5)[S+](C)([O-])=O)C4=N3,CEP-33779,,JDYXQKQKYOTVMI,Jak2 inhibitor,JAK2
NCGC00346522-01,OC(=O)[C@@H]1CCC[C@H]1C(=O)C2=CC=C(C=C2)C3=CC=C(NC(=O)NC4=CC=CC=C4)C=C3,A 922500,,BOZRFEQDOFSZBV,Diacylglycerol Acyltransferase Type 1 (DGAT-1) Inhibitors,DGAT1
NCGC00016899-04,COC1=C(OC2CCCC2)C=C(C=C1)[C@@H]3CNC(=O)C3,(S)-(-)-Rolipram,"rolipram;Rolipram;4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone;ROLIPRAM;4-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL)-2-PYRROLIDINONE;CIPLUS_10549490;CIPLUS_736201;ZK- 62711;CIPLUS_184002;(R)-(+)-Rolipram;Pyrrolidone, 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-;NCGC_Prestw-924;NCGC00089796-07;ZK6271;NCGC00089796-06;NCGC00089796-05;ZK 62711;NCGC00089796-02;NCGC00024862-01;rolipramum;NCGC00024862-03;NCGC00024862-02;LS-138709;NCGC00016899-01;ZK-62711;NCGC00015898-01;(S)-(-)-Rolipram;ZK 6271;",HJORMJIFDVBMOB,Phosphodiesterase IIII (PDE4) inhibitor,PDE4A
NCGC00270540-03,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,Miglitol (Glyset),,IBAQFPQHRJAVAV,alpha-Glucosidase Inhibitors,GAA
NCGC00263096-01,NC(=O)C1=CC(=C(I)C=C1)[N+]([O-])=O,Iniparib,,MDOJTZQKHMAPBK,PARP-1 Inhibitor,PARP1
NCGC00346733-01,C[C@]12CC[C@H]3[C@@H](CCC/4=C/C(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,Testosterone,,MUMGGOZAMZWBJJ,Androgen Receptor Agonist,AR
NCGC00167493-04,COC(=O)C\1=C(C)\N\C(=C(/C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OCCN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5)C,Manidipine,,ANEBWFXPVPTEET,Calcium Channel Blocker,
NCGC00168774-01,C#CCN[C@H]2C1=CC=CC=C1CC2.O=S(O)(C)=O,Rasagiline mesylate,"rasagiline;(S)-2,3-Dihydro-N-methyl-N-2-propynyl-1H-inden-1-amine;Azilect;CIPLUS_3857871;TVP-1012;1H-INDEN-1-AMINE, 2,3-DIHYDRO-N-2-PROPYNYL-, (1R)-;AGN 1135;2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride;TVP 101;N-2-propynyl-1-indanamine;Rasagiline mesylate;(R)-2,3-Dihydro-N-2-propynyl-1H-inden-1-amine;RASAGILINE;CIPLUS_3882444;rasagilinum;LS-173388;AGN-1135;RASAGILINE MESYLATE;N-PROPARGYL-1(R)-AMINOINDAN MESYLATE;TVP-101;N-propargyl-1-aminoindan mesylate;1H-INDEN-1-AMINE, 2,3-DIHYDRO-N-2-PROPYNYL-, (1R)-, METHANESULFONATE (1:1);CIPLUS_698847;rasagiline hydrochloride;",RUOKEQAAGRXIBM,MAO-B Inhibitor,MAOB
NCGC00161670-06,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O,Pepstatin A,,FAXGPCHRFPCXOO,Aspartyl Protease Inhibitor,
NCGC00263199-02,CNC1=NC(=CC=N1)C2=CC=CN=C2OC3=CC(=CC=C3C)C(=O)NC4=CC=CC(=C4)C(F)(F)F,AMG-Tie2-1,,ZVIWALRWYYSHSU,Tie-2 inhibitor,TEK
NCGC00345845-01,CC1=C(NC2=CC=CC(=C2)[S+]([O-])(=O)NC(C)(C)C)N=C(NC3=CC(=CC=C3)CN4CCOCC4)N=C1,TG-89,,PYMXUXUJJDVXOM,Jak2 inhibitor,JAK2
NCGC00249613-03,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,Carfilzomib (PR-171),,BLMPQMFVWMYDKT,Proteasome Inhibitor,PSMD1
NCGC00347937-01,CC1=CC=C(C=C1)\C2=N\C3=CC=C(Cl)C=C3OC2,,,MVOZLTFXYGHZPM,RARalpha Antagonist,RARA
NCGC00025012-02,COC1=CC=C(C=C1)C(=O)C2=C(C)[N](CCN3CCOCC3)C4=C2C=CC(=C4)I,AM 630,,JHOTYHDSLIUKCJ,cannabinoid CB2 antagonist,CNR2
NCGC00160396-02,COC1=CC=C(C=C1)C(=O)C2=C(C)[N](CCN3CCOCC3)C4=CC=CC=C24,Pravadoline;Win-48098,PRAVADOLINE,MEUQWHZOUDZXHH,COX inhibitor and?cannabinoid (CB)?agonist,
NCGC00015735-12,OC1=C(C=C(Cl)C=C1)C(=O)NC2=C(Cl)C=C(C=C2)[N+]([O-])=O,NICLOSAMIDE,,RJMUSRYZPJIFPJ,STAT-3 Inhibitor,STAT3
NCGC00263162-02,CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@@H]1C(=O)NC2=CC=CC=C2C3=C1C=CC=C3,RO4929097,,OJPLJFIFUQPSJR,g-Secretase Inhibitor,NOTCH1
NCGC00242478-02,CO[C@H]1C[C@H](C)C\C2=C(/NCCN(C)C)C(=O)\C=C(\NC(=O)\C(=C/C=C\[C@H](OC)[C@@H](OC(N)=O)\C(=C/[C@H](C)[C@H]1O)C)C)C2=O,Alvespimycin hydrochloride;17-DMAG/BMS-826476/NSC-707545,,KUFRQPKVAWMTJO,Heat Shock Protein 90 (hsp90) Inhibitor,HSP90AB1
NCGC00346443-01,CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](CC(=O)[C@@H](NC(=O)C2=NOC(=C2)C)C(C)C)CC3=CC=C(F)C=C3,AG-7088 (Rupintrivir),,CAYJBRBGZBCZKO,HRV 3C Protease Inhibitors,
NCGC00095152-07,COC1=CC2=C(C=C1OC)C(=NC(=N2)N(C)CCCNC(=O)C3CCCO3)N,ALFLUZOSIN,,WNMJYKCGWZFFKR,alpha1-Adrenoceptor Antagonists,ADRA1A
NCGC00346708-01,C1CCN2C[C@H]3C[C@H](\C=C/4CCCN[C@@H]34)[C@H]2C1,Aloperine,,SKOLRLSBMUGVOY,Mediator Release Inhibitors,
NCGC00162225-05,C1CN\2C[C@@H](\N=C2S1)C3=CC=CC=C3,LEVAMISOLE HYDROCHLORIDE,,HLFSDGLLUJUHTE,Nicotinic Receptor Agonist,CHRNA3
NCGC00165770-03,COC1=CC=C(NC2=NC(=CC=N2)NCCO)C=C1,Cardiogenol C hydrochloride,,LKBSMPFEKIBRGC,cardiomyocytes differentiation initiator,
NCGC00183873-01,Cl.CN4[C@@H]1CCC[C@H]4C[C@H](C1)NC(=O)c3nn(C)c2ccccc23,Granisetron hydrochloride,"GRANISETRON HCl;BRL 43694A;GRANISETRON HYDROCHLORIDE;Granisetron hydrochloride;Kytril;granisetronum;BRL-43694A;GRANISETRON;CIPLUS_196698;1H-Indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-azabicyclo(3.3.1)non-3-yl)-, endo-;granisetron;GRANISETRON BASE;Granisetronum;LS-172104;522PA;Granisetron HCL;Granisetron Hydrochloride;Granisetron;CIPLUS_207230;LS-81436;ENDO-N-(9-METHYL-9-AZABICYCLO(3.3.1)NON-3-YL)-1-METHYL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE;",MFWNKCLOYSRHCJ,5-HT3 Antagonists,HTR3A
NCGC00263090-01,COC1=C(NC2=NC=C3N(C)C(=O)N(C4CCCC4)C3=N2)C=CC(=C1)OC5CCN(C)CC5,AZ-3146,,YUKWVHPTFRQHMF,monopolar spindle 1 (Mps1)?kinase inhibitor,TTK
NCGC00346651-01,NCC/1=C/NC(=S)N1[C@H]2CCC3=C(F)C=C(F)C=C3C2,Nepicastat hydrochloride,,YZZVIKDAOTXDEB,Dopamine beta-monooxygenase Inhibitor,
NCGC00346664-01,C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]4(COC(=O)C5=CC=CC=C5)[C@H]3C[C@]24O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O,Paeoniflorin,,YKRGDOXKVOZESV,neuromuscular blocker,
NCGC00164634-01,OC(C=C2)=C(C(O)=O)C=C2/N=N/C1=CC=C(C(NCCC(O)=O)=O)C=C1,Balsalazide,"Colazal;balsalzide Disodium;BALSALAZIDE DISODIUM DIHYDRATE;BSA-5;BALSALAZIDE DISODIUM;COLAZAL;DISODIUM 5-((E)-(4-(((2-CARBOXYLATOETHYL)AMINO)CARBONYL)PHENYL)DIAZENYL)-2-HYDROXYBENZOATE DIHYDRATE;CIPLUS_669636;CIPLUS_192139;5-(carboxyethylcarbamoyl-4-phenylazo)salicylic acid;Balsalazide;Balsalzide Disodium Dihydrate;LS-36369;Benzoic acid, 5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, (E)-;Balsalazide Disodium;(e)-5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid;NCGC00164634-01;Shire brand of balsalazide disodium;Balsalazide disodium;balsalazidum;BX661A;5-(4-(2-CARBOXYETHYLCARBAMOYL)PHENYLAZO)SALICYLIC ACID DISODIUM DIHYDRATE;HS_357;balsalazide;CIPLUS_700323;BENZOIC ACID, 5-((4-(((2-CARBOXYETHYL)AMINO)CARBONYL)PHENYL)AZO)-2-HYDROXY-;Benzoic acid, 5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, disodium salt;balsalazide disodium;5-((4-((2-CARBOXYETHYL)CARBAMOYL)PHENYL)DIAZENYL)-2-HYDROXYBENZOIC ACID;CIPLUS_685263;BX 661A;BENZOIC ACID, 5-((1E)-(4-(((2-CARBOXYETHYL)AMINO)CARBONYL)PHENYL)AZO)-2-HYDROXY-, DISODIUM SALT, DIHYDRATE;BALSALAZIDE;Colazide;Salix brand of balsalazide disodium;5-((E)-(4-(((2-CARBOXYETHYL)AMINO)CARBONYL)PHENYL)AZO)-2-HYDROXYBENZOIC ACID DISODIUM SALT DIHYDRATE;Balsalazide sodium;LS-173383;",IPOKCKJONYRRHP,agents for IBS and constipation,
NCGC00346631-01,CNC(=O)C1=CC=C2C=C(C=CC2=C1)C3(O)CC[N]4C=NC=C34,TAK-700 (Orteronel),,OZPFIJIOIVJZMN,Androgen Biosynthesis Inhibitor,
NCGC00263126-01,COC1=C(OC)C=C(CCN2CCN(CCCC3=CC=CC=C3)CC2)C=C1,Cutamesine hydrochloride;AGY-94806/SA-4503,,UVSWWUWQVAQPJR,sigma1 Receptor Agonist,SIGMAR1
NCGC00017352-23,OC1=CC=C(C=C1)/C=C/C2=CC(=CC(=C2)O)O,RESVERATROL,,LUKBXSAWLPMMSZ,Cyclooxygenase-2 Inhibitor,PTGS2
NCGC00018257-07,COC1=C(OCC(O)COC(N)=O)C=CC=C1,METHOCARBAMOL,,GNXFOGHNGIVQEH,Muscle relaxant,
NCGC00346718-01,COCCOC1=CC=C2[N](C=NC2=C1)C3=NC4=C(C=CC=C4C=C3)N5CCC(N)CC5,CP 673451,,DEEOXSOLTLIWMG,PDGFR beta inhibitor,PDGFRB
NCGC00091009-05,O=C2C=C3[C@@](CC2)(C)[C@]1([H])[C@](CC3)([H])[C@@](CC4)([H])[C@]([C@@]4(C)O)(C)CC1,17-Methyltestosterone,METHYLTESTOSTERONE,GCKMFJBGXUYNAG,Aromatase Inhibitor,CYP19A1
NCGC00183105-01,O=C2[C@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@](O)([C@](CCCC)(F)F)O[C@@]([H])1C2,Lubiprostone,"PROSTAN-1-OIC ACID, 16,16-DIFLUORO-11-HYDROXY-9,15-DIOXO-, (11.ALPHA.)-;CIPLUS_735350;LUBIPROSTONE;SPI-0211;Lubiprostone;RU-0211;Amitiza;7-((2R,4AR,5R,7AR)-2-(1,1-DIFLUOROPENTYL)-2-HYDROXY-6-OXOOCTAHYDROCYCLOPENTA(B)PYRAN-5-YL)HEPTANOIC ACID;lubiprostone;RU 0211;CYCLOPENTA(B)PYRAN-5-HEPTANOIC ACID, 2-(1,1-DIFLUOROPENTYL)OCTAHYDRO-2-HYDROXY-6-OXO-, (2R,4AR,5R,7AR)-;SPI 0211;(11.ALPHA.,15R)-16,16-DIFLUORO-15-HYDROXY-9-OXO-11,15-EPOXYPROSTAN-1-OIC ACID;RU0211;SPI0211;7-((1R,3R,6R,7R)-3-(1,1-DIFLUOROPENTYL)-3-HYDROXY-2-OXABICYCLO(4.3.0)NONANE-8-ONE-7-YL)HEPTANOIC ACID, L-;",WGFOBBZOWHGYQH,ClC-2 Channel Activators,CLCN2
NCGC00022819-03,CC([N@@+]1([C@@H]2C[C@H](OC(C(C3=CC=CC=C3)CO)=O)C[C@@H]1CC2)C)C.[Br-].O,Ipratropium bromide,"CIPLUS_183666;Bronchodual;Iprafen;ALBUTEROL SULFATE;Duovent;ipratropii bromidum;CIPLUS_691838;LS-178539;itrop;NCGC_Prestw-575;IPRATROPIUM BROMIDE MONOHYDRATE;CIPLUS_3846295;IPRATROPIUM CATION;NCGC00094701-02;NCGC00094701-01;Ipratropii bromidum;Ipratropium bromide;Ipratroprium bromide;LS-176560;NCGC00024735-01;Atropine isopropyl bromide;Berodual;8-AZONIABICYCLO(3.2.1)OCTANE, 3-(3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-8-METHYL-8-(1-METHYLETHYL)-, (3-ENDO,8-SYN);IPRATROPIUM BROMIDE;bromure d'ipratropium;LS-157867;NCGC00016761-01;Bromure d'ipratropium;Bromuro de ipratropio;NCGC00163226-01;IPRATROPIUM;IPRATROPIUM BROMIDE, ANHYDROUS;LS-172279;Ipratropium;Atrovent;Ipratropium Bromide;CIPLUS_173129;Ipratropium bromide monohydrate;fenoterol-ipratropium IK6;8-Azoniabicyclo(3.2.1)octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, (endo,syn)-(+-)-;",OEXHQOGQTVQTAT,Muscarinic Antagonists,
NCGC00263148-02,C[C@]\12CC[C@H](O)CC1=C/C[C@@H]3[C@@H]2CC[C@@]\4(C)[C@H]3C\C=C4C5=CN=CC=C5,Abiraterone (CB-7598),,GZOSMCIZMLWJML,Androgen Biosynthesis Inhibitor,AR
NCGC00241107-03,COC1=C(Cl)C=C(Cl)C(=C1)NC2=C(C=NC3=C2C=C(OC)C(=C3)OCCCN4CCN(C)CC4)C#N,Bosutinib,,UBPYILGKFZZVDX,Bcr-Abl inhibitor,ABL1
NCGC00250410-01,OC(=O)C1=C(C=C(C=C1)C2=C[NH]C3=NC=C(C=C23)C4=CC=CC=C4)C5CCCC5,,,WVSBGSNVCDAMCF,serum- and glucocorticoid-regulated kinases (SGK1 and SGK2) inhibitor,SGK1
NCGC00346839-01,NC1=C2C=CC=CC2=NC=N1,4-Quinazolinamine,,DRYRBWIFRVMRPV,EGFR (HER1; erbB1) Inhibitor,EGFR
NCGC00187482-03,C[S+]([O-])(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=CC=CC5=C4C=N[NH]5)N6CCOCC6,GDC-0941;RG-7321,,RXZDIRTXSZYFFC,PI3K Inhibitor,PIK3CA
NCGC00189073-02,C[N]1C=NC2=C1C=C(C(=O)NOCCO)C(=C2F)NC3=CC=C(Br)C=C3Cl,Selumetinib,,CYOHGALHFOKKQC,Mek1/2 inibitor,MAP2K1
NCGC00187911-02,CCC[S+]([O-])(=O)NC1=CC=C(F)C(=C1F)C(=O)C2=C[NH]C3=NC=C(Cl)C=C23,PLX-4720,,JEUYKWKOFRCNHM,Raf kinase B Inhibitor,BRAF
NCGC00346551-01,NC1=C2C(=O)N(C3CCC(=O)NC3=O)C(=O)C2=CC=C1,Pomalidomide,,UVSMNLNDYGZFPF,TNF-alpha Production Inhibitor,TNF
NCGC00346457-01,COC1=C(OCCCN2CCOCC2)C=CC\3=C1/N=C(/NC(=O)C4=CN=C(N)N=C4)N5CC/N=C35,BAY-80-6946,,PZBCKZWLPGJMAO,PI3K alpha/delta Inhibitor,PIK3CA
NCGC00346634-01,C1CN(CCO1)C2=NC(=NC3=C2C=N[N]3C4CCN(CC4)CC5=CC=CN=C5)C6=CC7=C([NH]C=C7)C=C6,WAY-600,,FPEIJQLXFHKLJV,mTOR inhibitor,MTOR
NCGC00015609-05,OC(=O)C1=N[N](CC2=C(Cl)C=C(Cl)C=C2)C3=C1C=CC=C3,Lonidamine;AF-1890/KN-228/TH-070,"1-(2,4-Dichlorobenzyl)-1H-indazole-3-carboxylic acid;1-(2,4-DICHLOROPHENYL)-1H-INDAZOL-3-CARBOXYLIC ACID;NCGC00015609-01;AF 1890;NCGC00025244-03;1H-Indazole-3-carboxylic acid, 1-((2,4-dichlorophenyl)methyl)-;1-(2,4-dichlorobenzyl)indazole-3-carboxylic acid;lonidaminum;lonidamine;NCGC00095232-01;LS-7474;Diclondazolic acid;Lonidamina;LONIDAMINE;SK-31154;CIPLUS_180562;Lonidaminum;Lonidamine;diclondazolic acid;NCGC00025244-02;NCGC00025244-01;",WDRYRZXSPDWGEB,hexokinase inactivator,HK1
NCGC00246187-02,COC1=NC2=C(NC3=CC(=C(O)C(=C3)CN4CCCC4)CN5CCCC5)C6=CC=C(Cl)C=C6N=C2C=C1,Pyronaridine,,DJUFPMUQJKWIJB,antimalarial agents,
NCGC00163409-05,CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O,Betulinic acid,,QGJZLNKBHJESQX,Caspase 3/8 Activators,CASP3
NCGC00274038-01,NC(=O)NC1=C(SC(=C1)C2=CC=C(CN3CCOCC3)C=C2)C(N)=O,AZ-TAK1 Inhibitor,,MOWJKFWTFZWXHW,TGF-beta Activated Kinase (TAK1) inhibitor,MAP3K7
NCGC00017159-08,COC1=CC(=CC=C1O)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(O)C=C2)OC,,,VFLDPWHFBUODDF,NF-kappaB Activation Inhibitor,NFKB1
NCGC00347905-01,OCCNCCNC1=NC2=CC=CC(=C2C=C1)NC(=O)CC34CC5CC(CC(C5)C3)C4,AZ 10606120,,FQMZXMVHHKXGTM,P2X7 Receptor Antagonist,P2RX7
NCGC00250391-01,CN(C)C(=O)C1=CC=C(C=C1)[S+]([O-])(=O)C2=CC=C(NC(=O)[C@@](C)(O)C(F)(F)F)C(=C2)Cl,AZD-7545,,UCVMFSWTCMCDJS,Pyruvate Dehydrogenase Kinase 2 Inhibitor,PDK2
NCGC00250387-02,CCN1CCN(CC1)CC(=O)NC2=CC=C(C3=C2C4=C(S3)C=CC=C4)C5=C6O\C(=C/C(=O)C6=CC=C5)N7CCOCC7,KU 0060648,,AATCBLYHOUOCTO,DNA-Dependent Protein Kinase (DNA-PK) Inhibitor,PRKDC
NCGC00095145-01,C[C@]12C3CCC(O3)[C@]1(C)C(=O)OC2=O,CANTHARIDIN,"NCGC00025212-01;Cantharidin;NCGC00093710-01;CIPLUS_148768;Hexahydro-3a,7a-dimethyl-4,7-epoxyisobenzofuran-1,3-dione;NCGC00093710-03;NCGC00093710-04;LS-98756;NCGC00016247-01;NCGC00095145-01;NCGC00015266-01;NCGC_Prestw-885;4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-3a,7a-dimethyl-, (3aalpha,4beta,7beta,7aalpha)-;7a-Dimethylhexahydro-3a,4,7-epoxyisobenzofuran;Cantharidine;CIPLUS_10554194;Cantharidin:4,7-Epoxyisobenzofuran-1,3-dione,hexahydro-3a,7a- dimethyl-, (3a,4,7,7a)-,;CANTHARIDIN;3a,7a-Dimethylhexahydro-4,7-epoxyisobenzofuran-1,3-dione;",DHZBEENLJMYSHQ,PP-1 Inhibitors,
,,,,,PP-2A Inhibitors,PPP1CA
NCGC00094889-05,COC1=CC(=CC=C1O)/C=C/C(O)=O,FERULIC ACID,,KSEBMYQBYZTDHS,Free Radical Scavenger,
NCGC00182047-02,NC1=C2N=C[N]([C@@H]3O[C@H](CO[P](O)(O)=O)[C@@H](O)[C@@H]3O)C2=NC(=N1)F,FLUDARABINE PHOSPHATE,,GIUYCYHIANZCFB,Purine Antagonist,
NCGC00159518-04,COCCCOC1=CC=NC(=C1C)C[S+]([O-])C2=NC3=CC=CC=C3[N-]2,RABEPRAZOLE SODIUM,,KNWNQAWYVGYXNR,H+/K+-ATPase Inhibitor,
NCGC00262545-02,C[C@H](CNC(=O)CC[C@]\1(C)[C@@H](CC(N)=O)[C@H]2\N=C1\C(=C3/N=C(/C=C4\N=C(\C(=C/5[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N5[Co+]C#N)C)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)C(C)(C)[C@@H]3CCC(N)=O)C)O[P]([O-])(=O)O[C@H]6[C@@H](O)[C@H](O[C@@H]6CO)[N]7C=NC8=C7C=C(C)C(=C8)C,Vitamin B12,,RMRCNWBMXRMIRW,Vitamin,
NCGC00095348-07,C(C1=C[NH]C2=C1C=CC=C2)C3=C[NH]C4=C3C=CC=C4,"3,3'-DIINDOLYLMETHANE",,VFTRKSBEFQDZKX,Androgen Receptor Antagonist,AR
NCGC00263112-01,C[C@@H](OC1=C(SC(=C1)[N]2C=NC3=C2C=C(CN4CCN(C)CC4)C=C3)C(N)=O)C5=CC=CC=C5C(F)(F)F,GSK-461364A,,ZHJGWYRLJUCMRT,Polo-like Kinase-1 (Plk-1) Inhibitor,PLK1
NCGC00024667-13,C[C@](N)(CC1=CC(=C(O)C=C1)O)C(O)=O,METHYLDOPA,,CJCSPKMFHVPWAR,DOPA decarboxylase inhibitor,DDC
NCGC00015389-08,C1(C(C)C)=CC=CC(C(C)C)=C1O,Propofol,"HS_1197;AB08007493-01;Propofol (2,6-diisopropylphenol);LS-996;2,6-Diisopropylphenol;Propofol;propofol HP-beta-CD;Diprivan;NCGC00015389-01;2,6-DIISOPROPYLPHENOL;ici 35868;NCGC00015389-02;propofol;Propofol(2,6-Diisopropylphenol);propofolum;NCGC00091538-06;NCGC00091538-03;NCGC00091538-02;PROPOFOL;NCGC00091538-05;NCGC00091538-04;DIPRIVAN;propofol hydroxypropyl-beta-cyclodextrin;2,6-Bis(Isopropyl)-phenol;NCGC_Prestw-931;CIPLUS_159631;Phenol, 2,6-bis(1-methylethyl)-;Dipravan;",OLBCVFGFOZPWHH,TRPV1 (Vanilloid VR1 Receptor) Agonist,TRPV1
NCGC00346604-01,O[C@@H]1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC(=C(O)C(=C3)O)O,Dihydromyricetin (Ampeloptin),,KJXSIXMJHKAJOD,GABA(A) BZ Site Receptor Modulator,GABRA1
NCGC00343773-01,CN(C)C1=CC=C2C=C(C=CC2=C1)C(=O)N[C@@H](CCCNC(=N)CCl)C(=O)NCC3=CC=CC=C3,,,LJJCYRVBDASIDX,Peptidylarginine Deiminase (PAD) Inhibitors,PADI1
NCGC00346630-01,C[N]1C=C(C2=CC=NC=C2)C(=N1)C3=CC=C(OCC4=NC5=CC=CC=C5C=C4)C=C3,PF-2545920,,AZEXWHKOMMASPA,Phosphodiesterase PDE10A Inhibitors,PDE10A
NCGC00015443-06,C2=C(OCC(F)(F)F)C=CC(OCC(F)(F)F)=C2C(=O)NCC1CCCCN1,Flecainide,"N-(2-Piperidylmethyl)-2,5-bis-(2,2,2-trifluoroethoxy)benzamide acetate;flecainidum;N-(PIPERIDIN-2-YLMETHYL)-2,5-BIS(2,2,2-TRIFLUOROETHOXY)BENZAMIDE;NCGC_Prestw-735;NCGC00093934-01;Flecainide, (S)-Isomer;Flecainide Monoacetate, (S)-Isomer;Flecainidum;Tambocor;Flecainide acetate;Flecainida;Flecainide;flecainide;FLECAINIDE;CIPLUS_181804;Flecainide acetate salt;CIPLUS_181803;NCGC00016874-01;LS-27388;BENZAMIDE, N-(2-PIPERIDINYLMETHYL)-2,5-BIS(2,2,2-TRIFLUOROETHOXY)-;Flecainide Acetate;LS-7398;N-(2-PIPERIDYLMETHYL)-2,5-BIS(2,2,2-TRIFLUOROETHOXY)BENZAMIDE;(+-)-flecainide;NCGC00025175-05;flecainide acetate;NCGC00025175-04;LS-178416;NCGC00025175-03;Flecainide Monoacetate, (R)-Isomer;LS-178415;FLECAINIDE ACETATE;LS-178418;NCGC00025175-01;Flecainide, (R)-Isomer;LS-178417;NCGC00015443-01;N-(2-Piperidylmethyl)-2,5-bis-(2,2,2-trifluoroethoxy)benzamide acetate salt;Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-;",DJBNUMBKLMJRSA,Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers,SCN5A
NCGC00181765-01,O=C(NC3=C4C(C(C=C(C5=NN=NN5)O4)=O)=CC=C3)C(C=C2)=CC=C2OCCCCC1=CC=CC=C1,Pranlukast,"Benzamide, N-(4-oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl)-4-(4-phenylbutoxy)-,hemihydrate;CIPLUS_692058;RS 411;Pranlukast;pranlukast;Pranlukast Hydrate;ONO 1078;8-(4 (4-phenylbutoxy)benzoyl)amino-2-(tetrazol-5'-yl)-4-oxo-4H-1-benzopyran;pranlukastum;SB 205312;LS-27327;PRANLUKAST;ONO-RS-411;ONO-1078;ONO-RS 411;",UAJUXJSXCLUTNU,Leukotriene CysLT1/2 (LTD4) Antagonist,CYSLTR1
NCGC00182077-02,O=C(O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C2=NOCOCCOC)[C@H](C)[C@@H](O[C@H]3C[C@](OC)(C)[C@@H](O)[C@H](C)O3)[C@H](C)[C@H]([C@@](O)(C)C[C@H]2C)O[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1,Roxithromycin,"Erythromycin 9-(-O-[2-methoxyethoxy]methyloxime);NCGC00095038-02;NCGC00095038-01;roxithromycinum;Rulide;LS-64684;NCGC_Prestw-854;NCGC00016942-01;Erythromycin, 9-(O-((2-methoxyethoxy)methyl)oxime), (9E)-;ERYTHROMYCIN A, 9-(O-(2-METHOXYETHOXYMETHYL)-OXIME);RU-28965;Roxithromycin;roxithromycine;ROXITHROMYCIN;CIPLUS_192099;",RXZBMPWDPOLZGW,Macrolide Antibiotic,
NCGC00015226-11,ClC(Cl)C(C1=CC=C(Cl)C=C1)C2=C(Cl)C=CC=C2,MITOTANE,,JWBOIMRXGHLCPP,Antineoplastic Agent,
NCGC00346663-01,OC[C@H]1O[C@@H](O[C@@H]2O\C=C(/[C@H]3C\C=C(CO)/[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O,Geniposidic acid,,ZJDOESGVOWAULF,radioprotectant,
NCGC00185990-05,OC(=O)C1CC[N]2C1=CC=C2C(=O)C3=CC=CC=C3,KETOROLAC TROMETHAMINE,,OZWKMVRBQXNZKK,non-steroidal antiinflammatory,
NCGC00167453-02,CCC(C)(OC1=CC=C(C=C1)C2(CCCCC2)C3=CC=C(OC(C)(CC)C(O)=O)C=C3)C(O)=O,Clinofibrate,,BMOVQUBVGICXQN,treatment of lipoprotein diseases,
NCGC00244253-01,N#CC[C@H](C1CCCC1)[N]2C=C(C=N2)C3=NC=NC4=C3C=C[NH]4,Ruxolitinib;INCB-18424?;Jakafi,,HFNKQEVNSGCOJV,Jak1/2 inhibitor,JAK1
NCGC00346633-01,CC1(C)CC(=O)C2=C(C1)[N](N=C2C(F)(F)F)C3=CC(=C(C=C3)C(N)=O)NC4CCC(O)CC4,SNX-2112,,ZFVRYNYOPQZKDG,Heat Shock Protein 90 (hsp90) Inhibitor,HSP90AB1
NCGC00241455-01,CC1=CC(=CC=C1OCC(O)=O)SCC2=C(C)N=C(S2)C3=CC=C(C=C3)C(F)(F)F,GW-501516;501516;GSK-516,,YDBLKRPLXZNVNB,PPARdelta Agonist,PPARD
NCGC00167520-03,COC1=CC=C(C=C1OC2CCCC2)C3(CCC(CC3)C(O)=O)C#N,Cilomilast (SB-207499),,CFBUZOUXXHZCFB,Phosphodiesterase IIII (PDE4) inhibitor,PDE4A
NCGC00188399-03,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1, FTY720,,KKGQTZUTZRNORY,Sphingosine Kinase 1 (SphK1) Inhibitors,SPHK1
NCGC00161410-02,CCC1=C(O)C=C(O)C(=C1)C2=NNC(C)=C2C3=CC4=C(OCCO4)C=C3,CCT-018159,,OWPMENVYXDJDOW,Heat Shock Protein 90 (hsp90) Inhibitor,HSP90AB1
NCGC00087387-03,CC1=CC(=CC=C1OCCCC(=O)NO)Cl,,,JHSXDAWGLCZYSM,Histone Deacetylase (HDAC) 3/6/8 Inhibitor,HDAC6
NCGC00015834-11,C2(=O)C(C1=CC=CC=C1)(CC)C(=O)NCN2,Primidone,"Primidonum;LS-48;4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-;CIPLUS_173378;PRIMIDONE;Mysoline;CIPLUS_3742305;Primidone (primaclone);AB02911409-01;primidonum;5-Ethyl-5-phenylhexahydropyrimidine-4,6-dione;NCGC00023254-02;NCGC00015834-01;NCGC00023254-08;HS_1163;NCGC00023254-09;nci-c56360;Primidone;NCGC00016377-01;NCGC00023254-05;NCGC00023254-06;NCGC00023254-07;Primidona;primidone;Primaclone;2-Desoxyphenobarbital;HS_977;NCGC00023254-10;NCGC_Prestw-933;",DQMZLTXERSFNPB,anticonvulsant agent,
NCGC00165740-04,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=C(C=CC=C3)N(CC(O)=O)C2=O,Benzapril,,XPCFTKFZXHTYIP,Angiotensin-I Converting Enzyme Inhibitor,ACE
NCGC00346470-01,CC(C)N[C@@H]1CCN2C(=O)NC3=CC=CC(=C23)[C@H]1O,Zilpaterol,,ZSTCZWJCLIRCOJ,beta1-Adrenoceptor Antagonists,ADRB1
NCGC00091062-07,N[C@@H](CC1=C[NH]C2=CC=C(O)C=C12)C(O)=O,,5-HYDROXY-L-TRYPTOPHAN,LDCYZAJDBXYCGN,Serotonin modulator,
NCGC00167739-03,CC(C)C1=C(COC2=CC=C(\C=C\C3=CC=CC(=C3)C(O)=O)C(=C2)Cl)C(=NO1)C4=C(Cl)C=CC=C4Cl,GW 4064,,BYTNEISLBIENSA,Farnesoid X Receptor Agonist,
NCGC00024563-02,Clc1cc(c2OCC(=O)N(C)c2c1)C(=O)NC4CN3CCC4CC3,Azasetron hydrochloride,"CIPLUS_756591;Y 25130;Azasetron Hcl;Azasetron;N-(1-AZABICYCLO[2.2.2]OCT-3-YL)-6-CHLORO-4-METHYL-3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZINE-8-CARBOXAMIDE HYDROCHLORIDE;Y-25130;CIPLUS_765891;AZASETRON;NCGC00024563-02;Azasetron HCl;NCGC00024563-01;AZASETRON HYDROCHLORIDE;Nazasetron;LS-172550;2H-1,4-Benzoxazine-8-carboxamide, N-1-azabicyclo(2.2.2)oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo-, monohydrochloride;LS-172551;azasetronum;Serotone;N-(1-azabicyclo(2.2.2)oct-3-yl)-6-chloro-4-methyl-3-oxo-3,4 -dihydro-2H-1,4-benzoxazine-8-carboxamide hydrochloride;azasetron;azasetron, (+-)-isomer;Azasetron hydrochloride;Y-25130 hydrochloride;LS-41695;Azasetron Hydrochloride;CIPLUS_691950;",WUKZPHOXUVCQOR,5-HT3 Antagonists,HTR3A
NCGC00263102-01,CCC[C@H](NC(=O)\C(=C\C1=NC(=CC=C1)Br)C#N)C2=CC=CC=C2,Degrasyn;WP-1130,,LIDOPKHSVQTSJY,Jak2 Inhibitor,JAK2
NCGC00188429-01,O=C(O)C(=O)Nc1cccc(c1)c2nnnn2,Acitazanolast,Acitazanolast,VWQZJJZGISNFOE,Mediator Release Inhibitors,
NCGC00345801-01,CN(C)C1=C(CC(O)=O)C(=NC(=N1)CC2=CC=C(NC(=O)C3=CC=C4C=CC=CC4=C3)C=C2)Cl,AP-768,,CUNNBJJEJUDKNN,prostaglandin D2 CRTH2 inhibitor,PTGDR2
NCGC00263131-01,FC(F)(F)C1=CN=C(OC2=CC(=CC=C2)CC3CCN(CC3)C(=O)NC4=CC=CN=C4)C=C1,PF-3845,,NBOJHRYUGLRASX,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,FAAH
NCGC00263172-01,CNC(=O)C1=CC(=CC=N1)OC2=CC(=C(NC(=O)NC3=CC(=N[N]3C4=CC5=C(C=C4)N=CC=C5)C(C)(C)C)C=C2)F,DCC-2036,,WVXNSAVVKYZVOE,Bcr-Abl Inhibitor,ABL1
NCGC00168773-01,O[C@@H]([C@@H](NC(O[C@H]2CO[C@@]3([H])OCC[C@@]23[H])=O)CC1=CC=CC=C1)CN(S(=O)(C4=CC=C(C=C4)N)=O)CC(C)C,Darunavir,"Prezista;TMC 114;CARBAMIC ACID, ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-, (3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ESTER, COMPD. WITH ETHANOL (1:1);DARUNAVIR ETHANOLATE;Darunavir ethanolate;(3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(ISOBUTYL)AMINO)-1-BENZYL-2-HYDROXYPROPYL)CARBAMATE;darunavir ethanolate;DARUNAVIR;darunavir;darunavirum;((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-CARBAMIC ACID (3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ESTER;CARBAMIC ACID, ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-, (3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ESTER;Darunavir;((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)- CARBAMIC ACID (3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ESTER MONOETHANOLATE;CIPLUS_3882432;CIPLUS_786894;TMC-114;(3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester;UIC94017;Darunavirum;UIC-94017;TMC114;(3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(ISOBUTYL)AMINO)-1-BENZYL-2-HYDROXYPROPYL)CARBAMATE - ETHANOL (1:1);",MZWRXITVDVSVFP,HIV Protease Inhibitors,
NCGC00263100-01,NC(=O)C1=C(NC(=O)NCCCCN2CCCC2)SN=C1OCC3=C(F)C=C(Br)C=C3F,OSI-632;CP-547632,,HXHAJRMTJXHJJZ,VEGFR-2 Inhibitor,KDR
NCGC00015656-06,C1=CC=C2C(=C1)C4N(C3=C(C2)C=CC=C3)CCN(C)C4,Mianserin,"NCGC00024926-03;NCGC00024926-04;LS-61197;Mianserin;LS-61198;MIANSERIN HYDROCHLORIDE;NCGC_Prestw-99;CIPLUS_174235;1,2,3,4,10,14b-Hexahydro-2-methyl-dibenzo[c,f]pyrazino[1,2-a]azepine hydrochloride;Mianserine Hcl;Tolvon;NCGC00024926-01;Mianserin Hydrochloride;Mianserine hydrochloride;Mianserinum;mianserinum;NCGC00016753-01;Mianserin Monohydrochloride;Monohydrochloride, Mianseri;mianserine;CIPLUS_731806;Mianserin Hcl;Mianserin hydrochloride;Lerivon;Tetramide;CIPLUS_731713;Mianserina;Bolvidon;Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-;MIANSERIN;Mianserine;Hydrochloride, Mianseri;CIPLUS_210674;NCGC00094086-01;NCGC00094086-02;NCGC00015656-01;1,2,3,4,10,14b-Hexahydro-2-methyldibenzo[c,f]pyryzino[1,2-a]azepine hydrochloride;Org GB 94;",UEQUQVLFIPOEMF,5-HT2A Antagonists?,HTR2A
NCGC00167971-03,C[N+]1(C)[C@@H]2CC(C[C@H]1[C@@H]3O[C@H]23)OC(=O)C(O)(C4=CC=CS4)C5=CC=CS5,,,LERNTVKEWCAPOY,Muscarinic M3 Antagonists,
NCGC00161927-03,COC1=C(O)C(=CC(=C1)[C@H]2C3C(COC3=O)[C@H](O)C4=C2C=C5OCOC5=C4)OC,4'-DEMETHYLEPIPODOPHYLLOTOXIN,,YVCVYCSAAZQOJI,Antimitotic Agent,TUBB
NCGC00167431-02,CO[C@H]1/C=C/O[C@@]2(C)OC3=C(C2=O)C4=C(C(=C3C)O)C(=C(NC(=O)\C(=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C)C(=C4O)\C=N/N5CCN(CC5)C6CCCC6)O,,,WDZCUPBHRAEYDL,DNA-Directed RNA Polymerase Inhibitor,PRKDC
NCGC00346545-01,CCC[C@@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C3=NC=CN=C3)C4CCCCC4)C(C)(C)C)C(=O)C(=O)NC5CC5,Telaprevir (VX-950),,BBAWEDCPNXPBQM,HCV NS3 NS4A Protease Inhibitor,
NCGC00346836-01,CNC1=NC(=CC(=N1)C2=CC3=C(C=C2)C(=N[NH]3)N)N4C[C@H](CC[C@H]4C)C(=O)NC5CCCCC5,GSK-2334470,,QLPHOXTXAKOFMU,Phosphoinositide Dependent Kinase (PDK) 1 Inhibitors,PDPK1
NCGC00015966-03,CCN1CCCC1CNC(=O)C2=C(OC)C=CC(=C2)[S+](N)([O-])=O,(RS)-(+/-)-Sulpiride,"levosulpiride;(+/-)-SULPIRIDE;(RS)-SULPIRIDE;Levosulpirida;Levosulpiride;CIPLUS_3887438;levopraid;Dogmatyl;CIPLUS_733121;CIPLUS_733263;NCGC00024853-05;NCGC00024853-04;CIPLUS_733264;NCGC00024853-01;(+/-)-Sulpiride;(+/-)-5-(Aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide;NCGC00024853-03;NCGC00024853-02;RV-12309;levosulpiridum;CIPLUS_3735833;CIPLUS_170031;NCGC00095915-01;N-(((S)-1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide;CIPLUS_769487;S(-)-SULPIRIDE;Sulpiride (+/-)-;Levosulpiridum;sulpiride;(RS)-Sulpiride;Sulpiridum;NCGC00016718-01;NCGC00024852-04;NCGC00024852-03;Sulpiride;NCGC00024852-05;CIPLUS_3744325;LS-20059;NCGC00024852-02;NCGC00024852-01;CIPLUS_174055;(?)-Sulpiride;NCGC_Prestw-56;Sulpirida;(+/-)-N-1-(Ethylpyrrolidin-2-ylmethyl)-2-methoxy-5-sulfamoylbenzamide;(?)-5-(Aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide;(S)-5-Aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide;Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-, mixt. with aluminum oxide hydrate;LS-20058;sulpiridum;LEVOSULPIRIDE;(S)-(-)-Sulpiride;Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-;SULPIRIDE;sursumid;CIPLUS_727813;(-)-Sulpiride;dogmagel;NCGC00015966-02;NCGC00015966-01;(-)-5-Aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide;",BGRJTUBHPOOWDU,Dopamine D2 Antagonist,DRD2
NCGC00164336-05,N[C@@H](CC1=CC(=C(OC2=CC(=C(O)C(=C2)I)I)C(=C1)I)I)C(O)=O,LEVOTHYROXINE,,XUIIKFGFIJCVMT,synthetic hormone,
NCGC00346660-01,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]3(C)[C@@H]2[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](O)/C(=C(/[C@@H](O)C3=O)C5(C)C)C,10-DAB (10-Deacetylbaccatin),,YWLXLRUDGLRYDR,antineoplastic intermediate,
NCGC00346681-01,COC1=CC=C(C=N1)C2=CC=C3N=CC4=C(N(C(=O)N4C)C5=CC=C(N6CCNCC6)C(=C5)C(F)(F)F)C3=C2,NVP-BGT226,,BMMXYEBLEBULND,PI3K Inhibitor,PIK3CA
NCGC00347068-01,CC1(C)CC2=C(CO1)SC(=C2C(O)=O)NC(=S)NC(=O)C3=CC=CC=C3,,,ATSWBWHRHAQVFM,Rab7 GTPase inhibitor,
NCGC00241982-03,CC[N]1C2=C(C=NC(=C2)OC3=CC(=CC=C3)NC(=O)C4=CC=C(OCCN5CCOCC5)C=C4)N=C1C6=NON=C6N,GSK-269962A,,YOVNFNXUCOWYSG,"ROCK 1, ROCK 2 Inhibitor",ROCK1
NCGC00015647-03,COC(=O)NC1=NC2=C([NH]1)C=CC(=C2)C(=O)C3=CC=CS3,Nocodazole,"NSC 23815;Oncodazole;[5-(2-Thienylcarbonyl)-1H-benzimidazol-2-yl]-carbamic acid methyl ester;Nocodazole;NCGC00025058-04;NCGC00025058-07;Methyl [5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]carbamate;NCGC00025058-06;nocodazolum;Carbamic acid, (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl)-, methyl ester;NCGC00015647-01;Nocodazol;NCGC00015647-02;R-17934;Methyl N-(5-thenoyl-2-benzimidazolyl)carbamate;R17934;NCGC00025058-03;NCGC00025058-02;NOCODAZOLE;NCGC00025058-01;NSC-238159;CIPLUS_177419;nocodazole;NCGC_Prestw-100;NSC23815;R 1793;LS-1178;R 17934;Nocodazolum;",KYRVNWMVYQXFEU,Tubulin depolymerization inhibitor,TUBB
NCGC00184994-03,NC/1=N/C(=O)N(C[C@@H](CO)OC[P](O)(O)=O)/C=C1,Cidofovir (Vistide),,VWFCHDSQECPREK,DNA Polymerase Inhibitors,
NCGC00345840-01,CCN(CC)CCNC(=O)C1=CC=C2N=C(C3=CC=CC=C3)C(=NC2=C1)C4=CC=C(CN5CCC(CC5)N6C(=O)NC7=CC=CC=C67)C=C4,Merck-22-6,,HBCHTLGWXPVWDF,AKT Inhibitor,AKT1
NCGC00346595-01,CC1(C)CC[C@H](O)[C@]23CO[C@](O)([C@@H](O)[C@H]12)[C@@]45[C@H](O)[C@@H](CCC34)C(=C)C5=O,Oridonin (Isodonol),,SDHTXBWLVGWJFT,"Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators",NFE2L3
NCGC00165844-02,NC1=NC(=C(N=O)C(=N1)OCC2CCCCC2)N,NU6027,,DGWXOLHKVGDQLN,CDK1/2 Inhibitor,CDK1
NCGC00263178-01,CN1CCN(CC1)C2=NC(=NC(=C2)NC3=N[NH]C(=C3)C)\C=C\C4=CC=CC=C4,ENMD-981693;ENMD-2076,,BLQYVHBZHAISJM,Aurora-A Inhibitor,AURKA
NCGC00242487-01,CC1=CN=C(NC2=CC=C(F)C=C2Cl)N=C1C3=C[NH]C(=C3)C(=O)N[C@H](CO)C4=CC=CC(=C4)Cl,NCGC00242487,,WUTVMXLIGHTZJC,ERK inhibitor,MAPK7
NCGC00095161-04,OC(=O)C(CC/1=C/C(=O)NC2=CC=CC=C12)NC(=O)C3=CC=C(Cl)C=C3,REBAMIPIDE,,ALLWOAVDORUJLA,Free Radical Scavenger,
NCGC00025288-03,COC1=CC2=C(C=C1OC)[C@H]3[C@@H](CO2)OC4=C(C=CC5=C4\C=C/C(C)(C)O5)C3=O,Deguelin,,ORDAZKGHSNRHTD,PI3K Inhibitor,PIK3CA
NCGC00238453-01,COC1=CC(=CC=C1NC2=NC(NC3=C(C=CC=C3)[S+]([O-])(=O)C(C)C)=C(Cl)C=N2)N4CCC(CC4)N5CCN(C)CC5,TAE-684;NVP-TAE684?,,ZOYYVMFYDNXREZ,Anaplastic Lymphoma Kinase (ALK) Inhibitor,ALK
NCGC00346654-01,CC(C)[N]1N=C(C2=CC3=C(OC(=N3)N)C=C2)C4=C(N)N=CN=C14,INK 128,,GYLDXIAOMVERTK,mTORC1/2 inhibitor,MTOR
NCGC00263124-01,COC1=CC=C(C(=C1)OC(C)C)C/2=N/[C@@H]([C@@H](N2C(=O)N3CCNC(=O)C3)C4=CC=C(Cl)C=C4)C5=CC=C(Cl)C=C5,Nutlin-3,,BDUHCSBCVGXTJM,HDM2/HDMX inhibitor,MDM2
NCGC00183677-03,COC1=CC(=C2C(=O)O[C@@H](C)C\C=C/C(=O)[C@@H](O)[C@@H](O)CC3OC3C2=C1)O,Hypothemycin,,SSNQAUBBJYCSMY,Mek 1/2 inhibitor,MAP2K1
NCGC00262689-01,CC1=C(C=CC=C1)C(N(C(=O)C[N]2C=NC3=CC=CC=C23)C4=CC=CC(=C4)F)C(=O)NC5CCCC5,NCGC00262689,,GZLNOSRHZLTDMT,Isocitrate dehydrogenase inhibitor,IDH1
NCGC00185916-06,NC1=CC(=CC=C1)[S+]([O-])(=O)N2CCCN(CC2)[S+]([O-])(=O)C3=CC4=C(OCCO4)C=C3,,,GMHIOMMKSMSRLY,PKM2 activator,PKM2
NCGC00263087-01,CC[C@H]1N(C(C)C)C2=NC(=NC=C2N(C)C1=O)NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6,Volasertib;BI-6727,,SXNJFOWDRLKDSF,Polo-like Kinase-1 (Plk-1) Inhibitor,PLK1
NCGC00016533-14,CC1=CC(=NO1)N[S+]([O-])(=O)C2=CC=C(N)C=C2,SULFAMETHOXAZOLE,,SYKXFWLRKXLPKQ,Antibiotic,
NCGC00346709-01,CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@H]1CC[C@@]2(O)C/3=C/C(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C,20-Hydroxyecdysone,,NKDFYOWSKOHCCO,reduces expression of cPEPCK,
NCGC00167977-03,CC(O)(C[S+]([O-])(=O)C1=CC=C(F)C=C1)C(=O)NC2=CC=C(C#N)C(=C2)C(F)(F)F,Bicalutamide;Casodex;ICI-176334,,CMPOAZJLBGOPQD,Androgen Receptor Antagonist,AR
NCGC00346827-01,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)[N]3C4=C(C=CC=C4)C5=C6[C@H](O)NC(=O)C6=C7C8=C(C=CC=C8)[N]2C7=C35,UCN-01,,PBCZSGKMGDDXIJ,CDK1/2/4/6,CDK1
NCGC00024359-06,CC(C)(S)[C@@H](N)C(O)=O,PENICILLAMINE,,VVNCNSJFMMFHPL,Copper Chelator,
NCGC00090686-10,NC(=O)N/N=C/C1=CC=C(O1)[N+]([O-])=O,NITROFURAZONE,,IAIWVQXQOWNYOU,Antibiotic,
NCGC00090851-09,NC/1=N/C(=O)N(/C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O,5-Azacitidine,,NMUSYJAQQFHJEW,DNA Methyltransferase (DNMT) Inhibitor,DNMT1
NCGC00263136-03,CCCCC1=NC2=CC(=CC=C2[N]1CCN(CC)CC)/C=C/C(=O)NO,Pracinostat,,JHDKZFFAIZKUCU,Histone Deacetylase (HDAC) 1/2 Inhibitor,HDAC1
NCGC00263219-01,COC1=C2NC3=C(C=CC=C3C(=O)NC4=CC=C(CCN5CCC6=C(C5)C=C(OC)C(=C6)OC)C=C4)C(=O)C2=CC=C1,Elacridar,,OSFCMRGOZNQUSW,P-Glycoprotein (MDR-1) Inhibitor,
NCGC00015089-08,ClC1=C(N=C(C(C(NC(N)=N)=O)=N1)N)N,Amiloride,"NCGC00093608-02;NCGC00093608-03;Amiloride hydrochloride dihydrate;NCGC00093608-01;AMILORIDE;Pyrazinecarboxamide, N-amidino-3,5-diamino-6-chloro-, monohydrochloride;NCGC00015089-01;NCGC00024443-02;N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride;Amiloridum;CIPLUS_210665;Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-;LS-1094;Midamor;Amiloride hydrochloride hydrate;LS-173667;AMILORIDE HYDROCHLORIDE;Amiloride hydrochloride;Amilorida;Amiloride HCl;HS_70;Amiloride;AB07980947-01;amiloridum;AMILORIDE HCL;NCGC00017086-01;CIPLUS_160621;CIPLUS_159487;amiloride;NCGC00024443-05;NCGC_Prestw-7;NCGC00024443-06;NCGC00024443-07;LS-984;",XSDQTOBWRPYKKA,Epithelial Sodium Channels (ENaC) Blocker,SCNN1D
NCGC00015917-07,C[N]1C=CC2=CC3=C(CCN3C(=O)NC4=CC=CN=C4)C=C12,SB 206553 hydrochloride,,QJQORSLQNXDVGE,5-HT1A Receptor Partial Agonist,HTR1A
NCGC00016752-02,CCC[C@H]1C[C@@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@@H]2O[C@@H](SC)[C@@H](O)[C@@H](O)[C@H]2O,Clindamycin hydrochloride,,KDLRVYVGXIQJDK,Antibacterial,
NCGC00095158-05,CC(O)C[N]1C(=NC=C1[N+]([O-])=O)C,SECNIDAZOLE,,KPQZUUQMTUIKBP,antiprotozoal agent,
NCGC00346640-01,CC1(C)CC(=O)C2=C(C1)[N](N=C2C(F)(F)F)C3=CC=C(C(N)=O)C(=C3)NC4CCC(CC4)OC(=O)CN,PF-04929113 (SNX-5422),,AVDSOVJPJZVBTC,Heat Shock Protein 90 (hsp90) Inhibitor,HSP90AB1
NCGC00263220-02,C\C=C1/NC(=O)[C@H]2CSSCC\C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,Romidepsin;FK-228/NSC-630176,,OHRURASPPZQGQM,Histone Deacetylase (HDAC) Inhibitor,HDAC1
NCGC00346438-01,CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=CC(=C2O)NC(=O)C(=C\C=C/[C@H](OC)[C@@H](OC(N)=O)C(=C\[C@H](C)[C@H]1O)/C)/C)O,Retaspimycin HCl,,OAKGNIRUXAZDQF,Heat Shock Protein 90 (hsp90) Inhibitor,HSP90AB1
NCGC00263227-01,NC1=C(N2CCOCC2)C(=NC(=N1)C3=N[N](CC4=C(F)C=CC=C4)C5=NC=CC=C35)N,BAY-41-8543,,AQYFUZRYBJBAGZ,Guanylate Cyclase Activator,GUCY1A2
NCGC00160391-02,CC[P](CC)(CC)=[Au]S[C@@H]1OC(COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)C1OC(C)=O,,AURANOFIN,AUJRCFUBUPVWSZ,Thioredoxin Reductase Inhibitors,TXNRD1
NCGC00347285-01,COCCOC1=N[N](C2=CC=C(NC(=O)CCl)C=C2)C(=N1)C3=CC=C(Cl)C(=C3)Cl,MI-2,,TWJGQZBSEMDPQP,mucosa associated lymphoid tissue lymphoma translocation 1 (MALT1) Inhibitor,
NCGC00346807-01,COC1=C(NC2=NC=C3N(C)C(=O)C4=C(C=CC=C4)N(C)C3=N2)C=CC(=C1)C(=O)N5CCC(CC5)N6CCN(C)CC6,LRRK2-IN-1,,IWMCPJZTADUIFX,Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors,LRRK2
NCGC00263606-03,CN1CCC2=C(C1)C3=C(C=CC=C3)[N]2CC4=CC=C(C=C4)C(=O)NO,Tubastatin A hydrochloride,,GOVYBPLHWIEHEJ,Histone Deacetylase (HDAC) 6 Inhibitor,HDAC6
NCGC00238451-01,FC1=C(C=C(C\C2=N\NC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5,Olaparib;AZD-2281/KU-0059436,,FDLYAMZZIXQODN,PARP-1/PARP-2 Inhibitor,PARP1
NCGC00093560-06,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)\C=C/[C@]4(C)[C@H]3CC[C@]12C,Finasteride,,DBEPLOCGEIEOCV,Androgen Receptor Antagonist,AR
NCGC00160217-02,O=C1\C=C/C[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34,Sophocarpine,,AAGFPTSOPGCENQ,HERG Inhibitor,KCNH2
NCGC00163683-02,CSCC[C@@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC2=CC=C(O)C=C2)C(O)=O,Metenkephalin,,YFGBQHOOROIVKG,Opioid growth factor,
NCGC00346826-01,COCCOC(=O)C/1=C(C)/NC/2=C(C1C3=CC=CC(=C3)O)/C(=O)CC(C2)C4=C(OC)C=CC=C4,HPI-1,,ZXSWZQSYZYMZKS,Smoothened (Smo) Receptor Antagonist,SMO
NCGC00345173-01,CCNC(=O)C[C@H]1/N=C(/C2=CC=C(Cl)C=C2)C3=CC(=CC=C3[N]4C(=NN=C14)C)OC,,,AAAQFGUYHFJNHI,None,
NCGC00090504-10,OC1=CC=C(C=C1)/C=C/C(=O)C2=C(O)C=C(O)C=C2,ISOLIQUIRITIGENIN,,DXDRHHKMWQZJHT,Histone Deacetylase/SIRT1 Activator,SIRT1
NCGC00244252-01,CC1=C(NC2=CC(=CC=C2)[S+]([O-])(=O)NC(C)(C)C)N=C(NC3=CC=C(OCCN4CCCC4)C=C3)N=C1,TG-101348,,YLJQCJUARYFIQY,multi-kinase,JAK2
NCGC00025355-11,FC1=CC=C(C=C1)[C@@H]2CCNC[C@H]2COC3=CC=C4OCOC4=C3,PAROXETINE HYDROCHLORIDE,,AHOUBRCZNHFOSL,5-HT Reuptake Inhibitor,HTR1A
NCGC00021336-09,[O-]C(=O)CC1=CC=CC=C1NC2=C(Cl)C=CC=C2Cl,Diclofenac,,DCOPUUMXTXDBNB,Cyclooxygenase-1/2/3 Inhibitor,PTGS1
NCGC00015300-05,FC1=CC=C(C(OCCN4CCN(CC4)CCCC3=CC=CC=C3)C2=CC=C(F)C=C2)C=C1.Cl.Cl,GBR 12909 dihydrochloride,NCGC00024581-02;NCGC00024581-03;Vanoxerine;NCGC00024581-01;Vanoxerina;GBR-12909;GBR-12909 dihydrochloride;NCGC00093862-01;GBR 12969 dihydrochloride;1-[2-[bis(4-Fluorophenyl)methoxy]ethyl]-4-[3-phenylpropyl]piperazine dihydrochloride;1-(2 (bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine dihydrochloride;1-(2 (bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine;1-((DI-4-FLUORO-PHENYL)METHOXY-ETHYL)-4-(3-PHENYLPROPYL)PIPERAZINE;vanoxerine;I 893;CIPLUS_211021;NCGC_Prestw-386;CIPLUS_682378;GBR 12909;vanoxeamine;NCGC00015300-02;NCGC00015300-01;I-893;vanoxerinum;GBR 12909 dihydrochloride;1-(2-[bis(4-Fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine dihydrochloride;Vanoxerinum;VANOXERINE;,NAUWTFJOPJWYOT,Dopamine Reuptake Inhibitor,
NCGC00167811-03,OC(=O)CCC1=CC=C(NCC2=CC=CC(=C2)OC3=CC=CC=C3)C=C1,GW-9508,,DGENZVKCTGIDRZ,Free Fatty Acid Receptor 1 Agonist,FFAR1
NCGC00164559-04,CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C3=CC=CS3,DULOXETINE HYDROCHLORIDE,,ZEUITGRIYCTCEM,Serotonin Transporter (SERT) Inhibitor,SLC6A4
NCGC00263222-01,CC1(C)OC/2=C(\[C@H](NCC3=CC=CC=C3)[C@@H]1O)C(=O)C4=CC=CC=C4C2=O,CAY10581,,WKHJQIQDQXGUOD,"Indoleamine 2,3-dioxygenase (IDO) inhibitor",IDO1
NCGC00166413-03,C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)N[S+]([O-])(=O)C2=CC=CC3=C2NCC(C)C3,Argatroban,,CNTULEDKWPCJCH,Thrombin Inhibitors,
NCGC00165875-03,COC1=C2CCCC(CCCN3CCN(CC3)C4CCCCC4)C2=CC=C1,,,PHRCDWVPTULQMT,sigma1/2 Receptor Agonist,SIGMAR1
NCGC00263161-01,OCC[N]1C=C(C=N1)C2=CN=C3N=N[N](CC4=CC=C5N=CC=CC5=C4)C3=N2,PF-04217903,,PDMUGYOXRHVNMO,HGFR (MET; c-Met) Inhibitor,MET
NCGC00167832-04,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C4=CC=CC=C4[NH]3)C=CC=C1,Carvedilol,,OGHNVEJMJSYVRP,beta1-Adrenoceptor Antagonists,ADRB1
NCGC00164553-03,NC1=NC(=NC2=C1N=C[N]2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3F)Cl,,,WDDPHFBMKLOVOX,DNA Polymerase Inhibitors,
NCGC00345824-01,FC1=CC=C(C=C1)N2/C=C\C=C(C(=O)NC3=CC=C(OC4=C5C=C[NH]C5=NC=C4)C(=C3)F)/C2=O,BMS-2,,OBSFXHDOLBYWRJ,HGFR (MET; c-Met) Inhibitor,MET
NCGC00015871-07,[H]C(O)(C1=CC=NC2=CC=C(OC)C=C12)[C@@]3([H])CC4CCN3C[C@]4([H])C=C,,,LOUPRKONTZGTKE,Cytochrome P450 CYP2D6 Inhibitors,CYP2D6
NCGC00346945-01,COC1=CC=C(C=C1OC)C2=CC3=NC=C[N]3C(=N2)NC4=NC=CC=C4C(N)=O,BAY 61-3606 (dihydrochloride),,JWQOJVOKBAAAAR,Syk Kinase inhibitor,SYK
NCGC00346824-01,CCOC(=O)C(=O)CBr,3-Bromopyruvate,,VICYTAYPKBLQFB,Hexokinase 2 Inhibitors,HK2
NCGC00263234-01,CCCCC1=CC=C(N[S+]([O-])(=O)C2=CC=C(C)C(=C2)C(=O)N3CCN(CC3)C4=CC=CC(=C4C)C)C=C1,IDH-001,,BFKJDNZMRAJJSM,Isocitrate dehydrogenase inhibitor,IDH1
NCGC00346946-01,CC1=CC=C(NC2=NC=NC(=C2)C3=CC=CC(=C3)N4C(=O)C5=C(C=CC=C5)C4=O)C=C1N[S+](C)([O-])=O,CDK9 inhibitor,,RQJWQWGHVBUDEH,CDK 9 Inhibitor,CDK9
NCGC00186046-02,CCN(CC)CCN1C(=O)\C(=N/C2=CC=CC=C12)CC3=CC=C(OC)C=C3,Caroverine hydrochloride,,MSPRUJDUTKRMLM,AMPA Antagonist,
NCGC00346509-01,O=C1NC(=O)/C(S1)=C/C2=CC=C3N=CC=C(C4=CC=NC=C4)C3=C2,GSK1059615,,QDITZBLZQQZVEE,PI3Kalpha inhibitor,PIK3CA
NCGC00345783-01,COC[C@H]1OC(=O)C2=COC3=C2[C@@]1(C)\C4=C(\[C@@H]5CC[C@H](O)[C@@]5(C)C[C@H]4OC(C)=O)C3=O,17?-hydroxy Wortmannin,,XLJORQYAOTYVQS,PI3K Inhibitor,PIK3CA
NCGC00025329-02,COC1=NC(=CC=N1)C2=C(N=C[N]2C3CCC(O)CC3)C4=CC=C(F)C=C4,SB 239063,,ZQUSFAUAYSEREK,p38 MAPK Inhibitor,MAPK14
NCGC00346952-01,CCNC1=NC(=NC(=C1)NC2CCC(O)CC2)NC3=CC=C4[N](CC5=CC=CC=C5)C=CC4=C3,Cdk4/6 Inhibitor IV,,YVXCDLCJCIDFHE,CDK4/6 Inhibitor,CDK4
NCGC00263089-02,CCN(CCO)CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=N[NH]C(=C3)CC(=O)NC4=CC(=CC=C4)F,AZD-1152-HQPA,,QYZOGCMHVIGURT,Aurora-A/B Inhibitor,AURKA
NCGC00346930-01,CC\1=C/C=C\C=[N]1[Pt](N)(Cl)Cl,Picoplatin,,SAVHJPPSRMPTLD,DNA Alkylating Agent,
NCGC00094792-06,NC/1=N/C2=C([NH]C=N2)C(=S)N1,THIOGUANINE,,WYWHKKSPHMUBEB,Purine Antagonist,
NCGC00346503-01,CCCCCCCCCCCCCCCCCCO[P]([O--])(=O)OC1CC[N+](C)(C)CC1,Perifosine,,LHJQEUOALPPIHG,PI3K kinase activator,PIK3CA
NCGC00346541-01,COC1=CC(=CC(=C1)NC2=NC3=CC=CC=C3N=C2N[S+]([O-])(=O)C4=CC=C(NC(=O)C5=CC=C(C)C(=C5)OC)C=C4)OC,XL765,,KMIWOICBVVQOIM,mTORC1/2 inhibitor,MTOR
NCGC00016384-14,CC1=NOC(=C1C)N[S+]([O-])(=O)C2=CC=C(N)C=C2,SULFISOXAZOLE,,ZFHZOWBJESYXNS,Antibiotic,
NCGC00159460-02,O[C@H](CN1CCN(CC4=CC=CN=C4)C[C@H]1[C@@](NC(C)(C)C)=O)C[C@@H](CC5=CC=CC=C5)C(N[C@@H]2[C@H](O)CC3=C2C=CC=C3)=O.O=S(O)(O)=O,Indinavir sulfate,"Indinavir;Indinavir, Sulfate (1:1);L735,52;LS-102243;MK 63;INDINAVIR;CIPLUS_197177;indinavirum;INDINAVIR ANHYDROUS;L-735 524;Indinavir sulfate;(2R,4S)-2-Benzyl-5-[2-(tert-butylcarbamoyl)-4-(3-pyridylmethyl)piperazin-1-yl]-4-hydroxy-N-[(1S,2R)-2-hydroxyindan-1-yl]valeramide;Indinavir sulphate;Indivanir Sulfate;Indinavir Sulfate Ethanolate;(.ALPHA.R,.GAMMA.S,2S)-.ALPHA.-BENZYL-2-(TERT-BUTYLCARBAMOYL)-.GAMMA.-HYDROXY-N-((1S,2R)-2-HYDROXY-1-INDANYL)-4-(3-PYRIDYLMETHYL)-1-PIPERAZINEVALERAMIDE;L 735 52;[1(1 S ,2 R ),5( S )]-2,3,5-trideoxy- N -(2,3-dihydro-2-hydroxy-1 H -inden-1-yl)-5-[2-[ [(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinyl-methyl)-1-piperazinyl] -2  -(phenylmethyl)-D- erythro -pentonamide sulfate (1:1) salt;Sulfate, Indinavi;L-735,524;D-ERYTHRO-PENTONAMIDE, 2,3,5-TRIDEOXY-N-(2,3-DIHYDRO-2-HYDROXY-1H-INDEN-1-YL)-5-(2-(((1,1-DIMETHYLETHYL)AMINO)CARBONYL)-4-(3-PYRIDINYLMETHYL)-1-PIPERAZINYL)-2-(PHENYLMETHYL)-, MONOHYDRATE, (1(1S,2R),5(S))-;LS-173708;CIPLUS_197165;Indinavir sulfate ethanolate;CIPLUS_682337;L 735,52;INDINAVIR SULFATE;Crixivan;INDINAVIR SULFATE ETHANOLATE;D-ERYTHRO-PENTONAMIDE, 2,3,5-TRIDEOXY-N-(2,3-DIHYDRO-2-HYDROXY-1H-INDEN-1-YL)-5-(2-(((1,1-DIMETHYLETHYL)AMINO)CARBONYL)-4-(3-PYRIDINYLMETHYL)-1-PIPERAZINYL)-2-(PHENYLMETHYL)-, (1(1S,2R),5(S))-;MK63;indinavir;INDINAVIR SULPHATE;HS_378;MK-639;Indinavir Sulfate;(.ALPHA.R,.GAMMA.S,2S)-.ALPHA.-BENZYL-2-(TERT-BUTYLCARBAMOYL)-.GAMMA.-HYDROXY-N-((1S,2R)-2-HYDROXY-1-INDANYL)-4-(3-PYRIDYLMETHYL)-1-PIPERAZINEVALERAMIDE MONOHYDRATE;L735 52;mk639;LS-173382;",CBVCZFGXHXORBI,HIV Protease Inhibitors,
NCGC00345791-01,COC1=CC(=CC=C1NC2=NC=NC(=N2)NC3=CC=CC=C3[S+]([O-])(=O)C(C)C)N4CCC(CC4)N5CCN(C)CC5,ASP-3026,,NYTBHLBEYLIGQD,Anaplastic Lymphoma Kinase (ALK) Inhibitor,ALK
NCGC00346632-01,COC1=CC=C(F)C(=C1C(=O)C2=C(N)N=C(NC3CCN(CC3)[S+](C)([O-])=O)N=C2)F,R547,,VZYAVWNUJRPGON,CDK1/2/4 Inhibitor,CDK1
NCGC00347952-01,CC(=N/NC(=S)N1CCC1)\C2=NC=CC=C2,,,XDHBUMNIQRLHGO,Mutant p53 Activator,
NCGC00015429-08,C1=CC=CC=C1C(COC(N)=O)COC(N)=O,Felbamate,"Essex brand of felbamate;2-Phenyl-1,3-propanediol dicarbamate;Schering brand of felbamate;Wallace brand 2 of felbamate;LS-120706;2-PHENYL-1,3-PROPANEDIOL DICARBAMATE;Schering-Plough brand of felbamate;Felbamyl;ADD-03055;NCGC00023092-06;NCGC00023092-05;NCGC00023092-04;NCGC00023092-02;felbamatum;Felbatol;PHENAMATE;2-phenyl-1,3-propanediol dicarbamate;NCGC00015429-01;felbamate;HS_584;W-554;CIPLUS_174913;Felbamate;FELBAMATE;WHO NO. 5686;Taloxa;Wallace brand 1 of felbamate;",WKGXYQFOCVYPAC,GABAA Receptor Modulator,GABRA1
NCGC00095124-06,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C3=CC=CC=N3,ROSIGLITAZONE,,YASAKCUCGLMORW,PPARgamma Agonists?,PPARG
NCGC00017369-10,COC1=CC=C(C=C1)C/2=C/OC3=C(C(=CC(=C3)O)O)C2=O,Biochanin A (4-Methylgenistein),,WUADCCWRTIWANL,flavanoid,
NCGC00263111-01,[O-][S+](=O)(CCNC(=O)C1=CC=C(Cl)C=C1)C2=NC=C(C=C2)C(F)(F)F,GSK-3787,,DIWFBNCEABPYPW,PPARdelta Antagonist,PPARD
NCGC00346838-01,COC1=CC(=CC=C1O)C[C@@H](CO)[C@H](CO)CC2=CC(=C(O)C=C2)OC,Secoisolariciresinol,,PUETUDUXMCLALY,phenylpropanoid,
NCGC00142483-02,NC\1=N\C(=O)N(\C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O,Cytidine,,UHDGCWIWMRVCDJ,nucleoside,
NCGC00016936-03,C[C@H]1[C@H](NC(=O)\C(=N\OC(C)(C)C(O)=O)C2=CSC(=N2)N)C(=O)N1[S+](O)([O-])=O,AZTREONAM,,MNINXOFOQTVYHD,beta-lactam antibiotic,
NCGC00263527-02,CN[C@@H]1[C@@H](O)[C@H](OC[C@]1(C)O)O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](N)C[C@H]2NC(=O)[C@@H](O)CN,Isepamicin Sulphate,,UDIIBEDMEYAVNG,30S Ribosomal Protein Inhibitors,
NCGC00015034-02,NC(=O)C1=CC(=CC=C1)N,3-Aminobenzamide,"3-Aminobenzamide;meta-aminobenzamide;3-aminobenzamide;NCGC00024792-01;LS-25343;benzamide, 3-amino-;3-AB cpd;m-Aminobenzamide;NCGC00015034-01;CIPLUS_207084;3-AB;Aminobenzamide (3-ABA) [3-aminobenzamide (3-ABA)];NCGC00024792-02;3-AMINOBENZAMIDE;3-ABA;NCGC00024792-04;Benzamide, m-amino-;NCGC00024792-05;",GSCPDZHWVNUUFI,PARP Inhibitor,PARP1
NCGC00345799-01,COC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@@]3(C)CO3,Oprozomib,,SWZXEVABPLUDIO,Proteasome Inhibitor,PSMD1
NCGC00024427-03,OC1=CC=C2C[C@H]3N(CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O)CC6CC6,,NALTREXONE HCl,DQCKKXVULJGBQN,mu-Opioid Antagonists,OPRM1
NCGC00092284-03,OC(=O)C1=CC2=CC=C(C=C2C=C1)C3=CC=C(O)C(=C3)C45CC6CC(CC(C6)C4)C5,CD 437,,LDGIHZJOIQSHPB,RARgamma Agonist,RARG
NCGC00182058-03,O[C@H]3C[C@H](O)C/C(C3=C)=C/C=C1CCC[C@]2(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@]/12[H],Doxercalciferol;TSA-840,1alpha-hydroxyvitamin D2;1A-HYDROXYVITAMIN D2;DOXERCALCIFEROL;doxercalciferolum;doxacalciferol;1 alpha-hydroxyergocalciferol;doxercalciferol;Hectorol;HECTOROL;Bone Care brand of 1 alpha-hydroxyergocalciferol;1alpha-OHD2;1A-HYDROXYERGOCALCIFEROL;CIPLUS_700330;Draxis brand of 1 alpha-hydroxyergocalciferol;1alpha(OH)2D2;,DAQLPCKTVQWADC,Vitamin D Analog,VDR
NCGC00015252-13,CN1CCC(CC1)=C2C3=C(C=CC=C3)\C=C/C4=C2C=CC=C4,CYPROHEPTADINE HYDROCHLORIDE,,JJCFRYNCJDLXIK,Histamine H1 Receptor Antagonists,HRH1
NCGC00183808-06,CN(C)CCCNC(=O)C1=CC=C(C=C1)C2=CC3=CC=CN=C3C(=C2)O,,,QDBVSOZTVKXUES,JMJ inhibitor,JARID2
NCGC00164789-05,C[C@]12CC[C@H]3[C@@H]([C@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)CC4=CC(=CC=C34)O)[C@@H]1CC[C@@H]2O,Fulvestrant (Faslodex),,VWUXBMIQPBEWFH,Estrogen Receptor Antagonist,ESR1
NCGC00250382-01,C[C@H]1CN(C[C@@H](C)O1)C2=NC=C(NC(=O)C3=C(C)C(=CC=C3)C4=CC=C(OC(F)(F)F)C=C4)C=C2,NVP-LDE-225;Erismodegib;LDE-225,,VZZJRYRQSPEMTK,Smo Receptor Antagonist,SMO
NCGC00091281-07,CN(C)NC(=O)CCC(O)=O,,,NOQGZXFMHARMLW,KDM2/7 Histone Demethylases Inhibitor,
NCGC00346739-01,CCOC(=O)NC1=CC=C(NCC2=CC=C(F)C=C2)C=C1N,Retigabine,,PCOBBVZJEWWZFR,Voltage-Gated K(V) 7 (KCNQ) Channel Activator,KCNQ1
NCGC00015385-12,OCCN(CCO)C1=NC(N4CCCCC4)=C2C(C(N3CCCCC3)=NC(N(CCO)CCO)=N2)=N1,Dipyridamole,"NCGC00023914-04;dipyridamole;NCGC00023914-05;NCGC00023914-06;NCGC00023914-02;TX-3301;Ethanol, 2,2',2'',2'''-((4,8-di-1-piperidinylpyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis-;NCGC_Prestw-142;2,2',2'',2'''-((4,8-DIPIPERIDINOPYRIMIDO(5,4-D)PYRIMIDINE-2,6-DIYL)DINITRILO)TETRAETHANOL;NCGC00023914-08;NCGC00023914-09;DIPYRIDAMOLE;CIPLUS_10555947;LS-178622;CIPLUS_713654;TX 3301;LS-66732;Persantine;AGGRENOX;CIPLUS_3742249;Dipyridamolum;Prandiol;NCGC00015385-01;NCGC00015385-02;CIPLUS_148864;dipyridamolum;ETHANOL, 2,2',2'',2'''-((4,8-DI-1-PIPERIDINYLPYRIMIDO(5,4-D)PYRIMIDINE-2,6-DIYL)DINITRILO)TETRAKIS-;HS_1101;2,2',2'',2'''-((4,8-DIPIPERIDIN-1-YLPYRIMIDO(5,4-D)PYRIMIDINE-2,6-DIYL)DINITRILO)TETRAETHANOL;HS_483;Dipyridamole;Asasantin;Dipiridamol;",IZEKFCXSFNUWAM,Phosphodiesterase III/V (PDE5) inhibitor,PDE5A
NCGC00346885-01,CN1CCN(CC1)C2=NC(=C(C=N2)C3=CC(=CC(=C3Cl)Cl)Cl)N,Sipatrigine,,PDOCBJADCWMDGL,Nav1.2 (Brain Type II) Sodium Channel Blockers,SCN2A
NCGC00016759-03,COC1=CC2=CC=C(C=C2C=C1)[C@H](C)C(O)=O,NAPROXEN(+),,CMWTZPSULFXXJA,Cyclooxygenase-1/2 Inhibitor,PTGS2
NCGC00263085-01,CC1=CC(=CC=N1)C2=CC=C(CC(=O)NC3=CC=C(C=C3)C4=CC=CN=C4)C=C2,Wnt-C59,,KHZOJCQBHJUJFY,Wnt signaling modulator,WNT5A
NCGC00015150-04,C[N+](C)(C)CC(O)=O,Betaine,,KWIUHFFTVRNATP,nitric oxide donors,
NCGC00018294-06,ClC1=CC=C(COC(C[N]2C=CN=C2)C3=CC=C(Cl)C=C3Cl)C(=C1)Cl,MICONAZOLE NITRATE,,BYBLEWFAAKGYCD,Aromatase Inhibitor,CYP19A1
NCGC00188864-01,CC(=O)c4ccc(OCCCN1CCC(CC1)c3noc2cc(F)ccc23)c(OC)c4,Iloperidone,Iloperidone,XMXHEBAFVSFQEX,Dopamine D2 Antagonist,DRD2
NCGC00015075-07,COC(=O)\C1=C\CCN(C)C1,,ARECOLINE HBr,HJJPJSXJAXAIPN,Muscarinic receptor Agonists,
NCGC00016245-01,CN1[C@H]2CC(C[C@@H]1[C@@H]3O[C@H]23)OC(=O)[C@@H](CO)C4=CC=CC=C4,Scopolamine hydrochloride,"Hyoscine hydrobromide;1-alpha-H,5-alpha-H-Tropan-3-alpha-ol, 6-beta,7-beta-epoxy-, (-)-tropate (ester),hydrobromide;NCGC00094781-02;AB02540553-01;LS-567;NCGC00094781-01;Scopolamine hydrobromide trihydrate;Hyoscine methyl nitrate;NCGC00094354-01;Methscopolamine nitrate;NCGC00162334-01;Scopolamine Hydrobromide;LS-144659;6.BETA.,7.BETA.-EPOXY-1.ALPHA.H,5.ALPHA.H-TROPAN-3.ALPHA.-OL (-)-TROPATE (ESTER);Scopolamine hydrobormide;Hyoscine hydrochloride;HYOSCINE HYDROBROMIDE;Scopolamine hydrochloride;TRANSDERM SCOP;(1R,2R,4S,5S,7S)-9-METHYL-3-OXA-9-AZATRICYCLO(3.3.1.02,4)NON-7-YL (2S)-3-HYDROXY-2-PHENYLPROPANOATE;NCGC00015932-01;CIPLUS_204105;CIPLUS_3727155;CIPLUS_151378;CIPLUS_148601;SCOPOLAMINE;(-)-Scopolamine hydrobromide;Scopolamine;BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)-, 9-METHYL-3-OXA-9-AZATRICYCLO(3.3.1.02,4)NON-7-YL ESTER, (7(S)-(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.))-;Transderm scop;Scopolamine hydrobromide;Benzeneacetic acid, alpha-(hydroxymethyl)-, 9-methyl-3-oxa-9-azatricyclo(3.3.1.02,4)non-7-yl ester, (7(S)-(1alpha,2beta,4beta,5alpha,7beta))-;NCGC_Prestw-877;HS_1258;(-)Scopolamine methyl nitrate;Benzeneacetic acid, Alpha-(hydroxymethyl)-, 9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl ester, [7(S)-(1Alpha,2  ,4  ,5Alpha,7  )]-;(-)-Scopolamine hydrochloride;NCGC00016245-01;AB08006200-01;SCOPOLAMINE HYDROBROMIDE;Isopto hyoscine;CIPLUS_3862368;(-)-Scopolamine hydrobromide trihydrate;Hyoscine;CIPLUS_3861971;Scopolamine methyl bromide;Scopine tropate;CIPLUS_692682;BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)-,   (1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.)-9-METHYL-3-OXA-9-   AZATRICYCLO(3.3.1.02,4)NON-7-YL ESTER, (.ALPHA.S)-;CIPLUS_206597;Scopolamine (-);Hysco;CIPLUS_755173;NCGC00024357-02;",STECJAGHUSJQJN,Muscarinic Antagonists,
NCGC00242505-01,C[C@@H]1C[C@H]2[C@@H]3\C=C(C)/C4=C/C5=C(C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO)C=N[N]5C6=CC=CC=C6,deacetyl cortivazol,,BIHIECYYKNMWLX,Glucocorticoid Receptor (GR) Agonist,
NCGC00345858-01,FC1=C(NC(=O)C2=C(Cl)C(=CC=C2)C3(CC3)C#N)C=C(OC4=NC5=C(C=C4)N=C(NC(=O)C6CC6)S5)C=C1,Takeda-6d,,MDPMAXSABUPRJI,VEGFR-2 (FLK-1/KDR) Inhibitors,FLT1
NCGC00160421-02,COC1=C(OC)C=C2C3CC(=O)C(CC(C)C)CN3CCC2=C1,Tetrabenazine,,MKJIEFSOBYUXJB,Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor,SLC18A2
NCGC00015254-12,C1(Cl)=CC=C3C(=C1)N=C(N2CCN(C)CC2)C4=C(N3)C=CC=C4,Clozapine,"NCGC_Prestw-350;Leponex;8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine;Clo-Glu;5H-Dibenzo(b,e)(1,4)diazepine, 8-chloro-11-(4-methyl-1-piperazinyl)-;8-CHLORO-11-(4-METHYL-1-PIPERAZINYL)-5H-DIBENZO(B,E)(1,4)DIAZEPINE;clozapine;NCGC00015254-01;NCGC00022902-08;NCGC00015254-02;Clozaril;clozapine N-glucuronide;NCGC00022902-09;CLOZAPINE N-OXIDE;8-Chloro-11-(4-methyl)-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine;CIPLUS_726327;NCGC00022902-04;Clozapinum;NCGC00022902-05;CLOZAPINE;NCGC00022902-06;CIPLUS_164725;N-DESMETHYL CLOZAPINE;LS-60881;NCGC00022902-02;clozapinum;Clozapina;clozapin;clozapine N(+)-glucuronide;Clozapine;",QZUDBNBUXVUHMW,Dopamine D4 Antagonist,DRD4
NCGC00263858-03,O=C1O[Pt]OC(=O)C12CCC2,Carboplatin,,ZSWVADAIGMSQBB,DNA Alkylating Agent,
NCGC00347284-01,COC1=C(OCC2C[C@@H]3CN(C)C[C@@H]3C2)C=C4N=CN=C(NC5=C(F)C(=C(Cl)C=C5)Cl)C4=C1,XL-647,,HVXKQKFEHMGHSL,EGFR (HER1; erbB1) Inhibitor,EGFR
NCGC00167507-03,C[S+]([O-])(=O)CCNCC1=CC=C(O1)C2=CC3=C(NC4=CC=C(OCC5=CC(=CC=C5)F)C(=C4)Cl)N=CN=C3C=C2,Lapatinib;GW-572016F?;Tykerb,,AFMAWJOZFIKBOB,EGFR (HER1; erbB1) inhibitor,EGFR
NCGC00159406-11,NC[C@H](O)C1=CC=C(O)C(=C1)O,NOREPINEPHRINE,,SFLSHLFXELFNJZ,alpha/beta-adrenoceptor agonist,ADRA1A
NCGC00159559-01,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]4O[C@@]45[C@@]2([H])[C@@H](CC6=CC(=O)CC[C@]56C)C(=O)OC,,"METHYL HYDROGEN 9,11A-EPOXY-17A-HYDROXY-3-OXOPREGN-4-ENE-7A,21-DICARBOXYLATE, GAMMA-LACTONE;eplerenonum;NCGC00159559-02;CGP-30083;NCGC00159559-01;CGP 30083;CIPLUS_727860;HS_747;LS-172058;Inspra;SC-66110;Pharmacia brand of eplerenone;Eplerenone;9   Eplerenone;EPLERENONE;eplerenone;epoxymexrenone;",JUKPWJGBANNWMW,Mineralocorticoid Receptor (MR) Antagonist,NR3C2
NCGC00263149-01,CCN1CCN(CC1)CC2=CC=C(C=C2)C3=CC4=C(N[C@H](C)C5=CC=CC=C5)N=CN=C4[NH]3,AEE-788,,OONFNUWBHFSNBT,EGFR (HER1; erbB1) inhibitor,EGFR
NCGC00016872-09,ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1,,TICLOPIDINE,PHWBOXQYWZNQIN,P2Y12 (P2T) Antagonists,P2RY12
NCGC00185772-01,O=S(=O)(O)O.O=C(OC)[C@@]2(C[C@H]4C[C@@](O)(CC)C[N@@](CCc1c3ccccc3nc12)C4)c5cc9c(cc5OC)N(C)[C@@H]6[C@]98CCN7CC=C[C@@](CC)([C@@H](O)[C@]6(O)C(N)=O)[C@H]78,Vindesine sulfate salt,,HHJUWIANJFBDHT,Tubulin polymerization inhibitor,TUBB
NCGC00015520-10,NC(=O)NO,HYDROXYUREA,,VSNHCAURESNICA,Ribonucleoside-Diphosphate Reductase Inhibitors,RRM1
NCGC00165966-02,O=[C@@](OC)[C@](C(N3)=C(C4)C2=C3C=CC=C2)([C@@]5=CC([C@]69[C@]8([H])[C@](C=CCN8CC9)(CC)[C@@H](OC(C)=O)[C@](O)([C@](OC)=O)[C@@]([H])6N7C)=C7C=C5OC)C[C@]1([H])C=C(CC)CN4C1.O=C(O)C(O)C(O)C(O)=O.O=C(O)C(O)C(O)C(O)=O,Vinorelbine tartrate,"3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt];Vinorelbine Base;kw-2307;VINORELBINE BITARTRATE;Vinorelbine ditartrate;C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-;VINORELBINE BITATRATE;VINORELBINE TARTRATE;7Y89;KW 2307;vinorelbine;HS_1494;LS-97534;LS-97533;vinorelbinum;VINORELBINE DITARTRATE;CIPLUS_197023;5'-nor-anhydrovinblastine;Navelbine tartrate;Navelbine;Vinorelbine bitartrate;CIPLUS_668899;VINORELBINE;5'-NOR-ANHYDROVINBLASTINE DI-(L)-TARTRATE (SALT);Vinorelbine ditartrate salt hydrate;navelbine;KW-2307;Vinorelbine Tartrate;Vinorelbine Ditartrate;Vinorelbine tartrate;Vinorelbine;5'-Noranhydrovinoblastine tartrate;3',4'-DIDEHYDRO-4'-DEOXY-C'-NORVINCALEUKOBLASTINE DITARTRATE;NCGC00165966-01;vinorelbine tartrate;",GBABOYUKABKIAF,Tubulin polymerization inhibitor,TUBB
NCGC00167503-02,CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)C5=C(O)C6=C(C=C5[C@H]1C(=O)OC)C(=O)C7=CC=CC(=C7C6=O)O,Aclacinomycin A,,USZYSDMBJDPRIF,DNA Topoisomerase II Inhibitors,TOP2A
NCGC00016994-16,CC[C@@]1(O)C(=O)OC\C2=C1\C=C\3N(CC4=C3N=C5C=CC=CC5=C4)C2=O,CAMPTOTHECIN,,VSJKWCGYPAHWDS,DNA Topoisomerase I Inhibitors,TOP1
NCGC00263154-01,C[C@@H](NC1=CC=CC=C1C(O)=O)C/2=C/C(=C\N3C(=O)/C=C(\N=C23)N4CCOCC4)C,AZD-6482,,IRTDIKMSKMREGO,PI3Kbeta inhibitor,PIK3CB
NCGC00345812-01,C\C=C(C)/C(=O)O[C@H]1C(=C/[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](\C=C(CO)/[C@@H](O)[C@]12O)C3=O)C4(C)C)\C,Ingenol 3-angelate,,VDJHFHXMUKFKET,PKC Activator,PRKCA
NCGC00346803-01,OC1=C(C=C(C2=CC=CN=C12)[S+](O)([O-])=O)\N=N\C3=CC=C4C=C(C=CC4=C3)[S+](O)([O-])=O,NSC 87877,,CVFWVWGVEAVYNI,Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitor,PTP2C
NCGC00263119-01,CN(C)C[C@@H]1CC[N]2C=C(C3C(C(=O)NC3=O)C4=C[N](CCO1)C5=C4C=CC=C5)C6=C2C=CC=C6,Ruboxistaurin mesilate;LY-333531,,DRIXYLZMWNQAEJ,PKC beta Inhibitor,PRKCB
NCGC00166294-02,C[C@H]1CN(C[C@@H](C)N1)C2=C(F)C3=C(C(=C2F)N)C(=O)\C(=C/N3C4CC4)C(O)=O,,"NCGC_FLUKA_56968;AT 4140;Esparfloxacino;Aventis Behring brand of sparfloxacin;Bertek brand of sparfloxacin;sparfloxacin;PD-131501;Sparfloxacin;Zagam;CIPLUS_196797;NCGC00166294-01;AT-4140;Sparfloxacine;PD 131501;CI-978;CI 978;LS-172156;Sparfloxacinum;sparfloxacin, cis-isomer;LS-141521;sparfloxacine;SPARFLOXACIN;CIS-5-AMINO-1-CYCLOPROPYL-7-(3,5-DIMETHYL-1-PIPERAZINYL)-6,8-DIFLUORO-1,4-DIHYDRO-4-OXO-3-QUINOLINECARBOXYLIC ACID;5-Amino-1-cyclohexyl-7-(cis-3,5-dimethylpiperazino)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid;sparfloxacinum;CIPLUS_196763;",DZZWHBIBMUVIIW,DNA Topoisomerase IV Inhibitors,TOP2B
NCGC00159541-02,N[C@H](CSC(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)C(O)=O,S-Trityl-L-cysteine,,DLMYFMLKORXJPO,Mitotic Kinesin Eg5 Inhibitor,KIF11
NCGC00015349-06,OC1=C(O)C2=C(\C=C/C(=O)O2)C=C1,DAPHNETIN,,ATEFPOUAMCWAQS,antimalarial agents,
NCGC00016306-07,N[C@@H]1CONC1=O,CYCLOSERINE,,DYDCUQKUCUHJBH,NMDA partial agonist,GRIN2A
NCGC00346683-01,NC1=CC=C(C=N1)C(=O)NC2=CC=CC(=C2)C3=NC(=C4OC5=NC=CC=C5C4=N3)N6CCOCC6,YM201636,,YBPIBGNBHHGLEB,PIKfyve Inhibitor,PIKFYVE
NCGC00262604-01,NC1=CC(=C(C=N1)C2=CC(=NC(=N2)N3CCOCC3)N4CCOCC4)C(F)(F)F,BKM-120;NVP-BKM-120,,CWHUFRVAEUJCEF,PI3Kalpha inhibitor,PIK3CA
NCGC00263236-01,CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@@H](C3=CC=CC=C3)C4=C[N](CCCCC5=CC=C(CCCC[N]6C=C(N=N6)[C@@H](NC(=O)[C@@H]7CC[C@@H]8CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N78)C9=CC=CC=C9)C=C5)N=N4,SM-164 ,,LGYDZXNSSLRFJS,cIAP1/2 and XIAP inhibitor,XIAP
NCGC00346455-01,OC1(CN(C1)C(=O)C2=CC=C(F)C(=C2NC3=CC=C(I)C=C3F)F)[C@H]4CCCCN4,GDC-0973,,BSMCAPRUBJMWDF,Mek Inhibitor,MAP2K1
NCGC00181170-03,C[N]1C(=NC2=C1C=CC(=C2)N(CCCl)CCCl)CCCC(O)=O,Bendamustine HCL ,,YTKUWDBFDASYHO,Antimetabolite,XRCC1
NCGC00022001-14,COC1=C(OC)C(=CC(=C1)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](O)C4=CC5=C(OCO5)C=C24)OC,Picropodophyllin;AXL-1717/NSC-36407,,YJGVMLPVUAXIQN,Antimitotic Agent,IGFR1
NCGC00263270-01,C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](C\C(=N\OCC=C)[C@H]3O[C@@H]4O[C@]5(C)CC[C@H]6[C@H](C)CC[C@@H]([C@H]3C)[C@@]46OO5)O[C@@H]7O[C@]8(C)CC[C@@H]1[C@@]27OO8,Diartallox;BTM-2C-dimer allyl oxime,,WGDOECSYODBCCA,artemesinin analogue,
NCGC00161634-07,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,Artemisinin,,BLUAFEHZUWYNDE,antimalarial agents,
NCGC00025207-06,CCOC(=O)C(C#N)C\1C2=CC(=CC=C2O\C(=C1C(=O)OCC)N)Br,HA14-1,,SXJDCULZDFWMJC,Bcl-2 Inhibitor,BCL2
NCGC00346615-01,COC(=O)[C@H](CCCNC(N)=N)N[S+]([O-])(=O)C1=CC=C(C)C=C1,TAME,,UNIPKIHULYSOKM,Anaphase Promoting Complex (APC) Inhibitor,ANAPC1
NCGC00347941-01,OCCNC1CCCC2=C1[NH]C3=C2C=C(C=C3)C4=CC=CC=C4,,,RXIUMAOXORBRCY,Cdc42 Inhibitor,CDC42
NCGC00263213-01,C[C@]1(CO)CN(C[C@@]1(C)CO)C2=CC(=C(Cl)C=N2)C(=O)NC3=CC=C4CCC5=C([N](N=C5C(N)=O)C6=CC=C(F)C=C6)C4=C3,PF-184,,JUOWWGNRWRLBSV,IKK-2 (IKK-beta) Inhibitor,IKBKB
NCGC00183912-01,NC1=N[NH]C2=NN=C(C=C12)C3=C4C=CC=C[N]4N=C3C5=CC=CC=C5,,,XVECMUKVOMUNLE,ERK 1/2 Inhibitor,MAPK7
NCGC00025245-01,CC1C(=O)OC2C(O)C34C5CC(C(C)(C)C)C36C(O)C(=O)OC6OC4(C(=O)O5)C12O,Ginkgolide B,"ginkgolide B;Ginkgolide B Ginkgo leaves;GinkgolideB;CIPLUS_692201;GINKGOLIDE B;BN 52063;ginkgolide B, (1beta)-isomer;BN 52021;BN-52063;BN-52021;Ginkgolide B;NCGC00025245-01;LS-178439;CIPLUS_207207;Ginkgolide A, 1-hydroxy-, (1beta)-;NCGC00163561-01;Ginkolide B;",SQOJOAFXDQDRGF,GABA(A) Receptor Antagonists,GABRA1
NCGC00166323-03,OC[C@H]1O[C@H](C[C@@H]1O)N2/C=C(C(=O)NC2=O)/C(F)(F)F,Trifluridine (Viroptic),,VSQQQLOSPVPRAZ,thymidylate synthase inhibitor,TYMS
NCGC00015615-14,CC1=C(C[S+]([O-])C2=NC3=C([NH]2)C=CC=C3)N=CC=C1OCC(F)(F)F,LANSOPRAZOLE,,MJIHNNLFOKEZEW,H+/K+-ATPase Inhibitor,
NCGC00015562-24,COC1=CC2=C(C=C1)[N](C(=C2CC(O)=O)C)C(=O)C3=CC=C(Cl)C=C3,INDOMETHACIN,,CGIGDMFJXJATDK,non-steroidal antiinflammatory,
NCGC00263099-01,COC1=C(OC)C=C2C(=C1)N=CN=C2[N]3N=C(N=C3N)C4=NC=CC=C4,CP-466722,,ILBRKJBKDGCSCB,ATM Kinase Inhibitor,ATM
NCGC00016497-08,CCC1=NC=CC(=C1)C(N)=S,ETHIONAMIDE,,AEOCXXJPGCBFJA,Cell Wall Biosynthesis Inhibitors,
NCGC00091585-03,c(ccc1C(-c(ccc2)cc2)=C(C#N)C(=O)OCC(CC)CCCC)cc1,"2-Ethylhexyl-2-cyano-3,3-diphenylacrylate","octocrilenum;UVINUL N-539;CIPLUS_165218;Octocrylene;2-ethylhexyl 2-cyano-3,3-diphenylacrylate;2-ETHYLHEXYL ESTER OF DIPHENYL METHYLIDINE CYANO ACETIC ACID;octocrylene;Octocrileno;2-Ethylhexyl 2-cyano-3,3-diphenylacrylate;2-ETHYLHEXYL 2-CYANO-3,3-DIPHENYLACRYLATE;Octocrilenum;OCTOCRYLENE;AB08080858-01;2-Ethylhexyl-2-cyano-3,3-diphenylacrylate;OCTOCRILENE;",FMJSMJQBSVNSBF,photosensitizer,
NCGC00090753-05,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,Azithromycin (AZ),,MQTOSJVFKKJCRP,50S Ribosomal Protein Inhibitors,
NCGC00347958-01,CN1CCN(CC1)CC2=CC=C(NC(=O)NC3=CC=C(OC4=CC(=NC=N4)NC(=O)C5CC5)C=C3)C=C2C(F)(F)F,,,KIKOYRNAERIVSJ,beta Cell Proliferation Inducer,
NCGC00229735-03,C[C@H]1CN(C[C@@H](C)O1)CC(=O)NC2=CC=C3SC4=C(CC3=C2)C=CC=C4\C5=C\C(=O)\C=C(/O5)N6CCOCC6,KU-60019,,SCELLOWTHJGVIC,ATM Kinase Inhibitor,ATM
NCGC00168785-02,ClC1=CC=C(C=C1)C(C#N)C2=C(Cl)C=C(C=C2Cl)N3\N=C/C(=O)NC3=O,DICLAZURIL,"2,6-Dichloro-alpha-(4-chlorophenyl)-4-[4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl]benzeneacetonitrile;Diclazuril;",ZSZFUDFOPOMEET,antiprotozoal agent,
NCGC00161599-11,CC1=C(O)C(=C2CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)OC2=C1C)C,Troglitazone,,GXPHKUHSUJUWKP,CCL2 Expression Inhibitor,CCL2
NCGC00016794-14,CC1=CC(=C(C)C=C1)OCCCC(C)(C)C(O)=O,GEMFIBROZIL,,HEMJJKBWTPKOJG,PPARalpha agonist,PPARA
NCGC00016270-10,N[C@@H](CC1=CC(=C(O)C=C1)O)C(O)=O,LEVODOPA,,WTDRDQBEARUVNC,Dopamine Precursor,
NCGC00183362-01,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)CCNC(=O)OC(C)(C)C)Cc3cnc2ccccc23,Pentagastrin,N-t-Boc-beta-Ala-Trp-Met-Asp-Phe amide;Pentagastrin;,NEYNJQRKHLUJRU,synthetic polypeptide,
NCGC00263120-01,CNC(=O)C1=CC=C(C=C1F)N2C(=S)N(C(=O)C2(C)C)C3=CC(=C(C=C3)C#N)C(F)(F)F,MDV-3100;NC-54,,WXCXUHSOUPDCQV,Androgen Receptor Antagonist,AR
NCGC00346449-01,ClC1=CC=C(CCCOC/2=N/NC(=O)C(=C2NCC3=CN=CC=C3)/Br)C=C1,Parogrelil ,,YJMYSLFFZJUXOA,Phosphodiesterase III/Va (PDE) inhibitor,PDE5A
NCGC00181343-01,O=C(N(CCC3=C4)CCCN(C[C@H]1CC2=CC(OC)=C(C=C12)OC)C)CC3=CC(OC)=C4OC.Cl,Ivabradine hydrochloride;Corlentor;Procoralan;S-16257;S-16257-2,"7,8-dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one;ivabradinum;S-16257-2;LS-28023;3-(3-((((7S)-3,4-DIMETHOXYBICYCLO(4.2.0)OCTA-1,3,5-TRIEN-7-YL)METHYL)METHYLAMINO)PROPYL)-1,3,4,5-TETRAHYDRO-7,8-DIMETHOXY-2H-3-BENZAZEPIN-2-ONE;CIPLUS_709307;S-16260-2;S 16257;S-16257;IVABRADINE;S 16260-2;CIPLUS_3851977;Ivabradine hydrochloride;S 16257-2;ivabradine;",ACRHBAYQBXXRTO,HCN [I(f)] Blockers,HCN
NCGC00094087-06,NC(=O)C1=C(O)[N](C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O,Mizoribine (Bredinin),,HZQDCMWJEBCWBR,Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors,IMPDH1
NCGC00185850-02,COC1=C(OC)C=C2C(=NC(=NC2=C1)N3CCCN(C)CC3)NC4CCN(CC4)CC5=CC=CC=C5,BIX-01294,,OSXFATOLZGZLSK,Histone-lysine N-methyltransferase EHMT2 Inhibitor,EHMT2
NCGC00345785-01,CCCCC1=NC=C([NH]1)C(/CC2=CC=C(C=C2)C(O)=O)=C(CC3=CC=CS3)/C(O)=O,Eprosartan Mesylate,,IDZXLZCISXUMHU,Angiotensin AT1 Antagonist,AGT
NCGC00095192-06,CCCCCNC(=N)N/N=C/C1=C[NH]C2=C1C=C(OC)C=C2,Tegaserod maleate,,IKBKZGMPCYNSLU,5-HT4 Partial Agonists,HTR4
NCGC00249759-02,CC(C)(O)CCC1=CC=C(OCC2=CC3=CC=CN=C3C(=C2)C4=CC=CC(=C4)OC(F)F)C=C1,NCGC00249759-01,,KDAUXYRYNLBXOV,Phosphodiesterase IIII (PDE4) inhibitor,PDE4A
NCGC00347063-01,OC1=C(O)C=C(C=C1)C2CCN(CC2)C3=CC=NC4=CC=CC=C34,,,DELSIAQBXMLIQV,M18 Aspartyl Aminopeptidase Inhibitor,
NCGC00165833-04,NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=CN=C3)C=C2)C=CC=C1,Entinostat;MS-27-275/MS-275/NSC-706995,,INVTYAOGFAGBOE,HDAC1 Inhibitor,HDAC1
NCGC00092375-02,COC1CCC(CC1)C(=O)C2=CC3=C(C=C2)N=C4OCCCC4=C3,JNJ 16259685,,QOTAQTRFJWLFCR,mgluR1 Antagonists,GRM1
NCGC00346935-01,CN1CCCN(CC1)C(=O)C2=CC(=CC=C2)C3=CC=C(O3)/C=C4/C(=O)NC5=CC=C(Cl)C=C45,CX-6258,,KGBPLKOPSFDBOX,Pim 1/2/3 Kinase Inhibitor,PIM1
NCGC00263206-02,CC1=C(C=C(C=C1)C(=O)NC2=CC=CC(=C2)C(F)(F)F)C3=CC4=CN=C(NCCN5CCOCC5)N=C4C=C3,AMG-47a,,DVRSTRMZTAPMKO,Lck Kinase Inhibitors,LCK
NCGC00263224-01,CCCCCCCCCCCCCC(=O)N[C@H](CO)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O,D-NMAPPD,,XUSDVLHKNBOGJY,ceramidase inhibitor,CERS1
NCGC00015148-07,CCCC[S+]([O-])(=N)CCC(N)C(O)=O,L-BUTHIONINE SULFOXIMINE,,WDFRNLYXRQXXFS,Glutathione synthesis inhibitor,GSS
NCGC00242497-02,C[S+]([O-])(=O)C1=CC=C(C(=C1)Cl)C(=O)NC2=CC(=C(Cl)C=C2)C3=NC=CC=C3,Vismodegib;GDC-0449/CUR-691/RG-3616,,ZXTNICMLLDOPFL,Hedgehog antagonist,SHH
NCGC00024257-07,CNC[C@H](O)C1=CC=CC(=C1)O,PHENYLEPHRINE HYDROCHLORIDE,,SONNWYBIRXJNDC,alpha1-Adrenoceptor Agonists,ADRA1A
NCGC00159360-02,F[C@]1([C@](C)2C=C3)[C@@H](O)C[C@@]([C@]([C@@](COC(CC)=O)=O)(OC(CC)=O)[C@H]4C)(C)[C@](C4)([H])[C@@]([H])1CCC2=CC3=O,Betamethasone dipropionate,"Betamethasone dipropionate;dexamethasone 17,21-dipropionate;LS-178579;Diprosone;betamethasone dipropionate;belosalik;betamethasone depot;CIPLUS_724101;diproform;vipsogal;Maxivate;SQ-13209;Rinderon-DP;CIPLUS_164510;Beloderm;CIPLUS_752143;BETAMETHASONE DIPROPIONATE;Diprofos;CIPLUS_205237;DEXAMETHASONE DIPROPIONATE;diprosone Depot;Diprosalic;CIPLUS_773182;betamethasone propionate;CIPLUS_3884620;BETAMETHASONE 17,21-DIPROPIONATE;Dexamethasone propionate;betamethasone-17,21-dipropionate;Dexamethasone dipropionate;Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11beta,16beta)-, mixt. with 5-chloro-7-iodo-8-quinolinol;CLOTRIMAZOLE;Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-alpha-methyl-,17,21-dipropionate;CIPLUS_3873517;CIPLUS_701751;LS-118473;Diprospan;LS-118474;Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, disodium salt, (11beta,16beta)-, mixt. with (11beta,16beta)-9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione;Betamethasone Dipropionate;Diprophos;CIPLUS_724139;dexamethasone dipropionate;LS-178173;Diprolene;Dexamethasone Propionate;augmented betamethasone dipropionate;Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11beta,16beta)-, mixt. with 2-hydroxybenzoic acid;",CIWBQSYVNNPZIQ,Glucocorticoid steroid,
NCGC00015208-09,OC(C(CC(O)=O)(O)CC(O)=O)=O.O=C(N1C)N(C)C(N=CN2C)=C2C1=O,"Caffeine, citrated","CIPLUS_148854;CIPLUS_206163;Theobromine, 1-methyl-;CIPLUS_735327;CIPLUS_754395;CIPLUS_206165;Elsinore pill;CIPLUS_206164;1,3,7-Trimethylxanthine;CIPLUS_768780;ACETAMINOPHEN, ASPIRIN AND CAFFEINE;CIPLUS_149163;1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl-;Anhydrous caffeine;LS-178209;CAFFEINE ANHYDROUS;1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl-, mixt. with (R-(R*,S*))-alpha-(1-(methylamino)ethyl)benzenemethanol;ataralgin;CIPLUS_206166;caffeine benzoate, sodium salt;LS-175838;CIPLUS_748815;CIPLUS_167189;Bex Powder;1,3,7-TRIMETHYL-3,7-DIHYDRO-1H-PURINE-2,6-DIONE;Vincents Powder;AB02509354-01;CIPLUS_731757;CIPLUS_164854;THEOPHYLLINE COMPOUNDED WITH CAFFEINE;2-(acetyloxy)benzoic acid, mixt. with 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione & 2-hydroxy benzamide;Caffeine citrate;3   Caffeine;CIPLUS_167217;LS-48602;CAFFEINE-CITRATE;Anhydrous Caffeine;CIPLUS_206177;Benzoic acid, 2-(acetyloxy)-, mixt. with 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione and N-(4-ethoxyphenyl)acetamide;CAFFEINE THEOPHYLLINE COMPOUND;NCGC00015208-01;LS-121085;Caffeine-trimethyl-13C3 solution;CAFFEINE AND SODIUM BENZOATE;CIPLUS_167220;Cerebyx;Caffeine benzoate sodium;Cafcit;LS-237;Caffeine-trimethyl-13C3;Mettler Toledo Calibration substance ME 18872, Caffeine;CIPLUS_213711;CIPLUS_164669;1-methylcaffeine;Caffeine;CIPLUS_709606;Caffeine, citrated;citric acid, compd. with caffeine (1:1);Annaca;MIGRENIN;CIPLUS_727854;CAFFEINE;CAFFEINUM;Migrenin;Caffeine, Anhydrous;3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione;caffeine citrate;CIPLUS_170785;LS-178504;NCGC00090699-02;1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(methyl-14C)-;ANHYDROUS CAFFEINE;1H-PURINE-2,6-DIONE, 3,7-DIHYDRO-1,3,7-TRIMETHYL-;1,3,7-TRIMETHYLXANTHINE;CIPLUS_727814;Caffeine-sodium benzoate;NCGC00090699-09;NCGC00090699-08;NCGC00090699-07;NCGC00090699-06;Caffeine and sodium benzoate;caffeine benzoate;NCGC00090699-04;NCGC00090699-03;CIPLUS_168167;Caffeine-13C3 solution;Caffeine solution;2,4-Imidazolidinedione, 5,5-diphenyl-3-((phosphonooxy)methyl)-, (SP-4-2)-;",RYYVLZVUVIJVGH,Chitinase Inhibitors,
NCGC00024868-08,CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1,BISOPROLOL FUMARATE,,VHYCDWMUTMEGQY,beta1-Adrenoceptor Antagonists,ADRB1
NCGC00017244-05,CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]3(C)[C@@H]2C(=O)\C=C/4[C@@H]5C[C@](C)(CC[C@]5(C)CC[C@@]34C)C(O)=O,Enoxolone (Glycyrrhetin),,MPDGHEJMBKOTSU,15-hydroxyprostaglandin dehydrogenase inhibitor,
NCGC00142598-05,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3C\C=C/4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,??-Sitosterol,,KZJWDPNRJALLNS,Cholesterol lowering drug,
NCGC00091455-08,CC1=CC=C(C=C1)C2=CC(=N[N]2C3=CC=C(C=C3)[S+](N)([O-])=O)C(F)(F)F,Celecoxib,,BMYBYNKYPXBISM,Cyclooxygenase-2 Inhibitor,PTGS2
NCGC00346672-01,CC1=CC(=CC=C1OC2=CC3=NC=N[N]3C=C2)NC4=C5C=C(C=CC5=NC=N4)C6=CC=C(CNCC[S+](C)([O-])=O)O6,Arry-380,,ALTZIUJSNATZSL,HER2 (erbB2) Inhibitor,ERBB2
NCGC00015955-09,OC(C1=CC=C(C(=C1)CO)O)CNC(C)(C)C,Albuterol,"Xopenex;NCGC00016736-01;2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol;NCGC00015955-02;NCGC00015955-01;ALBUTEROL SULFATE;SALBUTAMOL;Levalbuterol hydrochloride;Proventil;NCGC00024698-06;NCGC00024698-05;NCGC00024698-04;NCGC00024698-03;NCGC00024698-02;NCGC00024698-01;alpha1-[(tert-Butylamino)methyl]-4-hydroxy-1,3-benzenedimethanol hemisulfate salt;CIPLUS_3742847;salbutamol;HS_42;salbutamolum;Levalbuterol;CIPLUS_747236;Salbutamol hemisulphate;CIPLUS_754546;LS-29862;alpha-(;alpha-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha'-diol;NCGC00094370-01;LEVALBUTEROL HYDROCHLORIDE;ALBUTEROL (+/-);Albuterol Sulfate;LS-175140;CIPLUS_171517;CIPLUS_700317;Salbutamol Sulfate;CIPLUS_739438;CIPLUS_700318;Albuterol (Salbutamol);CIPLUS_180818;LS-7693;Sultanol;Salbutamol sulfate;Albuterol;SALBUTAMOL SULFATE;Asmaven sulfate;1,3-Benzenedimethanol, alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-;NCGC00024698-07;NCGC00094582-01;levosalbutamol;CIPLUS_759517;Salbutamolum;CIPLUS_755105;Albuterol hemisulfate;NCGC_Prestw-198;LEVOSALBUTAMOL;levosalbutamolum;Salbutamol hemisulfate salt;Salbutamol;ALBUTEROL;Levalbuterol Hydrochloride;Hydrochloride, Levalbutero;Albuterol sulfate;Ventolin;ALBUTEROL HYDROCHLORIDE, R-;R-albuterol hydrochloride;Salbutamol hemisulfate;",NDAUXUAQIAJITI,beta2-Adrenoceptor Agonists,ADRB2
NCGC00346453-01,C[C@]1(CCCN1C2=N[N]3C=CC=C3C(=N2)NC4=N[NH]C(=C4)C5CC5)C(=O)NC6=CN=C(F)C=C6,BMS-754807,,LQVXSNNAFNGRAH,IGF-1R Inhibitor,IGFR1
NCGC00263160-01,C[C@@H](O)COC1=C[N]2N=CN=C(OC3=C(F)C4=C([NH]C(=C4)C)C=C3)C2=C1C,Brivanib;BMS-540215,,WCWUXEGQKLTGDX,"VEGFR-2,3/FGFR1,2,3 Inhibitor",KDR
NCGC00179596-04,ClC1=CC=C(CCC(C[N]2C=CN=C2)SC3=C(Cl)C=CC=C3Cl)C=C1,Butoconazole nitrate,,SWLMUYACZKCSHZ,Antifungal Agent,
NCGC00163125-07,CC(=O)[C@H]1CC[C@H]2[C@@H]3C/C=C4/C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,Pregnenolone,,ORNBQBCIOKFOEO,Steroid,
NCGC00015251-14,ClC1=C(C=CC=C1)C([N]2C=CN=C2)(C3=CC=CC=C3)C4=CC=CC=C4,CLOTRIMAZOLE,,VNFPBHJOKIVQEB,Lanosterol 14alpha-demethylase Inhibitors,CYP51A1
NCGC00016959-07,OC(=O)\C1=C\N(C2CC2)C3=CC(=C(F)C=C3C1=O)N4CCNCC4,CIPROFLOXACIN,,MYSWGUAQZAJSOK,DNA Topoisomerase IV Inhibitors,TOP2B
NCGC00346937-01,COC1=CC=C(\C=C/C2=CC(=C(OC)C(=C2)OC)OC)C=C1NC(=O)[C@H](N)CO,Ombrabulin,,IXWNTLSTOZFSCM,Tubulin polymerization inhibitor,TUBB
NCGC00025179-13,CC#C[C@]1(O)CC[C@H]2[C@@H]/3CCC/4=C/C(=O)CCC4=C3[C@H](C[C@]12C)C5=CC=C(C=C5)N(C)C,Mifepristone (Mifeprex),,VKHAHZOOUSRJNA,Progesterone Receptor Antagonist,PGR
NCGC00094927-01,CC1(C)OC2CC3C4CC(F)C/5=C/C(=O)/C=C\C5(C)C4C(O)CC3(C)[C@@]2(O1)C(=O)CO,FLUNISOLIDE,"FLUNISOLIDE ANYHYDROUS;CIPLUS_191465;flunisolidum;Flunisolide (anhydrous);PREGNA-1,4-DIENE-3,20-DIONE, 6-FLUORO-11,21-DIHYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))-, HYDRATE (2:1), (6.ALPHA.,11.BETA.,16.ALPHA.)-;Flunisolidum;flunisolide, (6beta,11beta,16alpha)-isomer;FLUNISOLIDE HEMIHYDRATE;6-Fluoro-11,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 16,17-acetonide;FLUNISOLIDE C-14;LS-177464;6.ALPHA.-FLUORO-11.BETA.,  16.ALPHA., 17, 21 -TETRAHYDROXYLPREGNA-1, 4-DIENE-3, 20-DIONE CYCLIC-16, 17-ACETAL WITH  ACETONE, HEMIHYDRATE;Flunisolide;NCGC00016983-01;Nasalide;Flunisolida;LS-177352;CIPLUS_659083;RS-3999;LS-118464;NCGC00094927-02;NCGC00094927-01;FLUNISOLIDE;flunisolide;(4AR,4BS,5S,6AS,6BS,9AR,10AS,10BS,12S)-12-FLUORO-6B-GLYCOLOYL-5-HYDROXY-4A,6A,8,8-TETRAMETHYL-4A,4B,5,6,6A,6B,9A,10,10A,10B,11,12-DODECAHYDRO-2H-NAPHTHO(2',1':4,5)INDENO(1,2-D)(1,3)DIOXOL-2-ONE HEMIHYDRATE;NCGC_Prestw-643;6 alpha-fluoro-11 beta,16 alpha,17,21- tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone;",XSFJVAJPIHIPKU,Corticosteroid,
NCGC00346688-01,CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C)(C)C5=C(C2=O)C6=CC=C(C=C6[NH]5)C#N,CH5424802,,KDGFLJKFZUIJMX,Anaplastic Lymphoma Kinase (ALK) Inhibitor,ALK
NCGC00015508-17,N[S+]([O-])(=O)C1=C(Cl)C=C2NCN[S+]([O-])(=O)C2=C1,HYDROCHLOROTHIAZIDE,,MEPMRFDKQYMUPK,hypertension treatment,
NCGC00345849-01,COC1=CC=C(NC2=CC(=NC(=N2)N3CCOCC3)C4=CN=C(N)N=C4)C=N1,NIBR-17,,XZTYTIOLZIKUJR,PI3K Inhibitor,PIK3CA
NCGC00094226-11,OC1=CC(=CC(=C1)/C=C/C2=CC(=C(O)C=C2)O)O,Piceatannol,,CDRPUGZCRXZLFL,Syk Kinase inhibitor,SYK
NCGC00183848-01,OC[C@H]1OCC(O1)[N@@]2C=CC(N)=NC2=O,Troxacitabine,"2R(-)-cis-HMD-cytosine;Troxacitabine;LS-173247;LS-173246;LS-173400;TROXACITABINE;BCH-4556;BCH 4556, trans-(+-)-isomer;LS-173262;2'-DEOXY-3'-OXACYTIDINE,1'S,4'S,L-;BCH 4556, cis-(+-)-isomer;BCH 4556, (2S-trans)-isomer;BCH 4556, 2R(-)-cis-isomer;LS-173106;troxacitabine;CIPLUS_728716;troxacitabinum;CIPLUS_703293;",RXRGZNYSEHTMHC,DNA Polymerase Inhibitors,
NCGC00165869-03,C1CCN(CC1)CCOC2=CC=C(C=C2)C3=C[N]4N=CC(=C4N=C3)C5=CC=NC=C5,Dorsomorphin dihydrochloride,,XHBVYDAKJHETMP,TGF-bR1 (ALK5) inhibitor,
NCGC00250395-01,COC1=CC=CC2=C1[NH]C(=C2)C3=C4[N](N=CN=C4N)C(=N3)C5CCC(CC5)C(O)=O,OSI-027,,JROFGZPOBKIAEW,mTORC1/2 Inhibitor,MTOR
NCGC00347940-01,BrC1=CC=C(C=C1)N2C(=N)S\C(=C/C3=CC=C(O3)C4=CC5=C(C=C4)C(=O)NC5=O)C2=O,,,ULBOWKXOFOTCMU,TRAIL Receptor DR5 Agonist,
NCGC00346943-01,CC(C)OC1=CC=C(C=C1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)CC2=CC=C(C=C2)C3=C[N]4C=CC=C([C@H](C)O)C4=N3,GSK-923295,,WHMXDBPHBVLYRC,Centromere Associated Protein (CENP) Inhibitors,CENPE
NCGC00162440-01,CCC(\C=C\[C@@H]1OC(=O)C=C[C@@H]1C)=C\[C@H](C)C\C=C\C(C)=C\[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C\C(O)=O,Leptomycin B,"PD 114720;PD-114,720;Leptomycin B from Streptomyces sp.;ELACTOCIN;2,10,12,16,18-Nonadecapentaenoic acid, 19-(3,6-dihydro-3-methyl-6-oxo-2H-pyran-2-yl)-17-ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-8-oxo-;former RN;elactocin;CI 940;Leptomycin B;CIPLUS_215872;NCGC00162440-01;LS-96801;leptomycin B;LS-178242;CI-940;",YACHGFWEQXFSBS,Antineoplastic Antibiotics,
NCGC00346692-01,COC1=CC=C(C=N1)C2=NC3=C(SC(=C3)CN(C)C4=NC=C(C=N4)C(=O)NO)C(=N2)N5CCOCC5,PI3K/HDAC Inhibitor I,,JOWXJLIFIIOYMS,PI3K Inhibitor,PIK3CA
NCGC00262603-01,CC[C@H](NC1=C2N=C[NH]C2=NC=N1)C/3=N/C4=C(C(=CC=C4)F)C(=O)N3C5=CC=CC=C5,CAL-101;GS-1101?,,IFSDAJWBUCMOAH,PI3Kdelta inhibitor,PIK3CD
NCGC00263088-01,CC1=NC2=CN=C3C=CC(=CC3=C2[N]1C4=CC=C(C=C4)C(C)(C)C#N)C#CC5=CN=CC=C5,BAG-956,,GVPAGJWVBUZHNQ,PI3K/PDK1 Inhibitor,PIK3CA
NCGC00346936-01,CC1=CC=C(NC(=O)NC2=CC(=CC=C2F)C(F)(F)F)C=C1NC3=CC4=C(C=C3)C(=C/C5=CC=C[NH]5)/C(=O)N4,GNF-5837,,YYDUWLSETXNJJT,Tropomyosin Related Kinase A/B/C (TrkA/B/C) inhibitor,NTRK1
NCGC00263020-01,CC(C)[N]1C=C(C2=CC=NC(=N2)NC3=C(C)C=CC(=C3)C(N)=O)C4=C1C=NC=C4,NCGC00263020-01,,TZZISDZOBASIEO,NFkappaB-inducing kinase Inhibitor,NFKB1
NCGC00015038-08,NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(=O)NC(CCC(O)=O)C(O)=O)N=C2C(=N1)N,,"Aminopterin sodium;Disodium Salt Aminopteri;CIPLUS_148719;LS-175944;Aminopterin;AMINOPTERIN SODIUM;CIPLUS_746893;LS-71807;NCGC00093553-05;AMINOPTERIN;NCGC00093553-06;4-Amino-PGA;LS-71805;Sodium, Aminopteri;0   Aminopterin Di;Aminofolic acid, 4-;NCGC00093553-01;NCGC00093553-02;NCGC00093553-03;Aminopterin, Disodium Salt;NCGC00093553-04;Aminopterinum natricum;Aminopterin Sodium;Aminopterine sodique;aminopterinum natricum;4-Aminopteroyl-L-glutamic acid;NCGC00015038-01;aminopterine sodique;L-Glutamic acid, N-(4-(((2,4-diamino-6-pteridinyl)methyl)amino)benzoyl)-;Aminopterin hydrate;CIPLUS_747865;Aminopterina sodica;CIPLUS_166708;CIPLUS_747864;4-Aminofolic acid;",TVZGACDUOSZQKY,Dihydrofolate Reductase (DHFR) Inhibitors,DHFR
NCGC00017337-15,COC1=C(O)C=CC(=C1)CNC(=O)CCCC\C=C\C(C)C,CAPSAICIN,,YKPUWZUDDOIDPM,NF-kappaB Activation Inhibitor,NFKB1
NCGC00346747-02,CC(O)(C#CC1=CC2=C(CCN2C3=NC(=NC=C3Cl)N)C=C1)C4=NC=CS4,,,OKFYOOFXVBCIIP,NFkappaB-inducing kinase Inhibitor,NFKB1
NCGC00346583-01,OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)C3=CC=CC=C3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,Amygdalin,,XUCIJNAGGSZNQT,Caspase 3 Activators,CASP3
NCGC00093926-04,C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2\C=C(F)/C(=O)NC2=O,5-fluoro-5'-deoxyuridine,,ZWAOHEXOSAUJHY,thymidylate synthase inhibitor,TYMS
NCGC00024762-05,CCN(CC)CCOC1=CC=C(CC2=CC=CC=C2)C=C1,Tesmilifene hydrochloride,,NFIXBCVWIPOYCD,Estrogen Receptor Antagonist,ESR1
NCGC00159513-02,O=C1N(C(C(O)=O)=C2C=CC)[C@@](SC2)([H])[C@@]([H])1NC([C@@H](C3=CC=C(O)C=C3)N)=O.O,Cefprozil monohydrate,"cis-Cefprozil;CEFZIL;Cefprozil;Cefzil;CIPLUS_205164;CIPLUS_193776;7-(AMINO(4-HYDROXYPHENYL)ACETYLAMINO)-8-OXO-3-(1-PROPENYL)-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, MONOHYDRATE, (6R-(3(Z),6A,7B(R*)));cefprozilum;BMY-28100-03;CEFPROZIL;CEFPROZIL MONOHYDRATE;LS-172480;Cefprozilo;Cefprozilum;Cefprozil:(6R,7R)-7-[(2R)-2-Amino-2-(4-hydroxyphenyl)acetylamino]-8-oxo-3-(1-pro-penyl)-5-thia-1-azabicylo[4.2.0]oct-2-ene-2-carboxylic acid;CIPLUS_668909;cefprozil;",WDLWHQDACQUCJR,Cephalosporin antibiotic,
NCGC00016925-10,COC1=CC2=C([NH]C(=N2)[S+]([O-])CC3=C(C)C(=C(C)C=N3)OC)C=C1,Omeprazole;AGI-010/DM-3458,,SUBDBMMJDZJVOS,ABCC3 Expression Enhancer,ABCC3
NCGC00016656-01,NC1=NC=NC2=C1N=C[N]2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O,Vidarabine,"9H-PURIN-6-AMINE, 9-.BETA.-D-ARABINOFURANOSYL-, MONOHYDRATE;9-xylosyladenine, ((9alpha)-(L))-isomer;9-alpha-Ribofuranosyladenine;Vira-A;polyriboadenosine;sandesin;CIPLUS_749319;NCGC00023673-05;CIPLUS_673570;Adenine-9-beta-D-ribofuranoside;-D-ARABINOFURANOSIDE;CIPLUS_699212;VIDARABINE MONOHYDRATE;NCGC_Prestw-768;alpha-Adenosine;polyadenosine;ARA-A;Vidarabinum;Adenocard;NCGC00015103-01;LS-15062;NCGC00023673-04;9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-;Ara-A;9-(alpha-D-Ribofuranosyl)adenine;VIDARABINE;Spongoadenosine;Adenosine;Vidarabine;9H-purin-6-amine, 9-xylofuranosyl-;Adenine riboside;9-beta-d-arabinofuranosyladenine monohydrate;6-AMINO-9-.BETA.-D-RIBOFURANOSYL-9H-PURINE;9-.BETA.-D-ARABINOFURANOSYL-9H-PURIN-6-AMINE;CIPLUS_679618;LS-15059;CIPLUS_197179;9-.BETA.-D-RIBOFURANOSYLADENINE;9H-PURIN-6-AMINE, 9-.BETA.-D-ARABINOFURANOSYL-;Adenine 9-beta-D-arabinofuranoside;xylosyladenosine;CIPLUS_738244;Adenine, 9-beta-D-arabinofuranosyl-, monohydrate;NCGC00093614-01;Adenosine-8-14C;CIPLUS_743155;9-beta-D-Arabinofuranosyladenine;NCGC00094579-02;NCGC00094579-03;vidarabinum;NCGC00094579-01;9-beta-D-Ribofuranosyladenine;NCGC00094579-04;LS-15085;9 beta-D-xylosyladenine;adenosine arabinose;NCGC00016656-01;VIDARABINE, ANHYDROUS;HS_25;ADENOSINE;CIPLUS_174304;ADENINE 9-BETA;CIPLUS_164422;CIPLUS_207362;xyloA;9 beta-D-xylofuranosyladenine;CIPLUS_3729654;9-xylosyladenine;CIPLUS_10551262;vidarabine;9-.BETA.-D-ARABINOFURANOSYLADENINE MONOHYDRATE;",OIRDTQYFTABQOQ,Anti-Herpes Simplex Virus Drug,
NCGC00346593-01,O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34,Matrine ((+)-Matrine),,ZSBXGIUJOOQZMP,kappa-Opioid Agonists,OPRK1
NCGC00263617-05,CN(C)C1=CC=C(C=C1)C(=O)NCCCCCCC(=O)NO,M344,,MXWDSZWTBOCWBK,Histone Deacetylase (HDAC) Inhibitor,HDAC1
NCGC00346884-01,CC1(C)C(N(O)C(=O)NC2=CC=C(Cl)C=C2)N(C(=O)N1CC(=O)N\N=C\C=C\C3=CC=C(O3)[N+]([O-])=O)C4=CC=C(Cl)C=C4,Eeyarestatin I,,JTUXTPWYZXWOIB,inhibitor of endoplasmic reticulum associated protein degradation,
NCGC00181754-01,OC1=CC=CC=C1C2=NC(C4=CC=CC=C4O)=NN2C3=CC=C(C(O)=O)C=C3,Deferasirox,"ICL-670A;CIPLUS_787917;BENZOIC ACID, 4-(3,5-BIS(2-HYDROXYPHENYL)-1H-1,2,4-TRIAZOL-1-YL)-;Deferasirox;4-(3,5-BIS(2-HYDROXYPHENYL)-1,2,4-TRIAZOL-1-YL)BENZOIC ACID;4-(3,5-bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid;deferasirox;ICL 670A;ICL 670;ICL670A;DEFERASIROX;Exjade;ICL670;Deferasiroxum;ICL-670;4-(3,5-BIS(2-HYDROXYPHENYL)-1H-1,2,4-TRIAZOL-1-YL)BENZOIC ACID;",BOFQWVMAQOTZIW,Iron Chelator,
NCGC00016786-14,COC1=C(C)C2=C(C(=C1C\C=C(/C)CCC(O)=O)O)C(=O)OC2,MYCOPHENOLIC ACID,,HPNSFSBZBAHARI,Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors,IMPDH1
NCGC00263146-01,CC1=NC=C(C=C1)C2=N[N](C=N2)C3=CC=C(NC4=NC=CC(=N4)C5=CC(=CC=C5)N6CCOCC6)C=C3,SR-3306,,QDMXVKKPYBGIAS,JNK 1/2/3 Inhibitor,MAPK8
NCGC00095150-07,CCCC1=NC2=C(C=C(C=C2C)C3=NC4=CC=CC=C4[N]3C)[N]1CC5=CC=C(C=C5)C6=CC=CC=C6C(O)=O,Telmisartan,,RMMXLENWKUUMAY,Angiotensin AT1 Antagonist,AGT
NCGC00263237-01,OC(C1CCN(CC1)C(=O)OC2=CC=C(C=C2)[N+]([O-])=O)(C3=CC4=C(OCO4)C=C3)C5=CC=C6OCOC6=C5,JZL-184,,SEGYOKHGGFKMCX,Monoacylglycerol lipase (MAGL) inhibitor,MGLL
NCGC00346879-01,CC1=CC=C(O1)/C=N/NC(=O)C2=C(OC3=CC=CC=C3)C=CC=C2,PNU 74654,,JJEDWBQZCRESJL,Wnt Signaling Inhibitor,WNT5A
NCGC00167751-03,COC1=CC(=C2C(=O)N(COC/3=C/C(=O)N4\C=C/C=C(OCCN5CCCCC5)\C4=N3)[S+]([O-])(=O)C2=C1)C(C)C,SSR-69071,,DRZXDZYWZSKFDL,Leukocyte Elastase Inhibitor,ELA2
NCGC00015605-10,NC1=NC(=C(N=N1)C2=CC=CC(=C2Cl)Cl)N,Lamotrigine,,PYZRQGJRPPTADH,Sodium channel inhibitor,
NCGC00253737-01,CCN1C(=O)N(CC)C2=C([N](C)C(=N2)\C=C\C3=CC=C(OC)C(=C3)OC)C1=O,Istradefylline,,IQVRBWUUXZMOPW,Adenosine A2A Agonists,ADORA2A
NCGC00247954-02,FC(F)(F)C1=CC=CC(=C1Cl)C(=O)N[C@H]([C@@H]2CCCCN2)C3=CC=CC=C3,SSR-504734,,MEZRZVWPLXVLSO,Glycine Transporter 1 (GlyT-1) Inhibitor,SLC6A9
NCGC00016092-03,COC1=C(C=CC=C1)N2CCN(CC2)CCN(C(=O)C3CCCCC3)C4=CC=CC=N4,WAY-100635 maleate,,SBPRIAGPYFYCRT,5-HT1A Receptor Antagonist,HTR1A
NCGC00013841-08,CN(C)CCC=C1C2=C(C=CC=C2)\C=C/C3=C1C=CC=C3,CYCLOBENZAPRINE HYDROCHLORIDE,,JURKNVYFZMSNLP,5-HT2A Antagonists?,HTR2A
NCGC00346960-01,OC1CCC(CC1)NC2=NC=C3N=C(NC4=C(F)C=C(F)C=C4F)[N]([C@@H]5CCOC5)C3=N2,HMSL10058,,IBGLGMOPHJQDJB,JNK Inhibitor,MAPK8
NCGC00167467-04,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@@H]([C@@H]4OC(C)=O)[N+]5(C)CCCCC5)[C@@]2(C)C[C@@H]1N6CCCCC6,Vecuronium Bromide,,BGSZAXLLHYERSY,Steroid non-depolarizing neuromuscular blocker,
NCGC00164353-03,OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CO,MANNITOL,,FBPFZTCFMRRESA,osmotic diuretic agent,
NCGC00165772-02,CCCCCCCCC1OC(=O)C(=C)C1C(O)=O,C-75,,VCWLZDVWHQVAJU,Fatty acid synthase inhibitor,FAS
NCGC00241410-01,ClC1=C[N]2C(=NC=C2C3=CC=CC(=N3)NC4CNC4)C=C1,NCGC00241410-01,,RDTAHMIMQLRAMR,IRAK Inhibitor,IRAK1
NCGC00095023-04,CC\12CCC(=O)\C=C1CCC3C2CCC4(C)C3CCC4(O)C#C,ETHISTERONE,,CHNXZKVNWQUJIB,Progestogen hormone,PGR
NCGC00185778-02,[O-][N+](=O)C1=CC(=CC=C1C(=O)C2C(=O)CCCC2=O)C(F)(F)F,Nitisinone,,OUBCNLGXQFSTLU,4-Hydroxyphenylpyruvate Dioxygenase (4HPPD) Inhibitors,HPD
NCGC00344053-01,C1CCC(CC1)[N]2C=NC3=C2N=C(OC4=CC=CC5=C4C=CC=C5)N=C3NC6=CC=C(C=C6)N7CCOCC7,Purmorphamine,,FYBHCRQFSFYWPY,lineage-specific differentiation enhancer,
NCGC00024901-03,CN(C)CCN(C)CCC1=CC=C(Cl)C(=C1)Cl,,,MGVRNMUKTZOQOW,sigma Receptor Antagonist,SIGMAR1
NCGC00253439-01,CCC1=CC(=C(OC)C=C1N2CCC(CC2)N3CCN(CC3)[S+](C)([O-])=O)NC4=NC(=CC=N4)C5=C(N=C6C=CC=C[N]56)C7=CC(=C(OC)C=C7)C(=O)NC8=C(F)C=CC=C8F,GSK-1904529A,,CFAXFDHNFUSQQA,IGF-1R Inhibitor,IGFR1
NCGC00182552-03,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,Atazanavir sulfate,,AXRYRYVKAWYZBR,HIV Protease Inhibitors,
NCGC00025195-01,OC(=O)/C=C/C1=CC=C(C[N]2C=CN=C2)C=C1,Ozagrel hydrochloride,"OZAGREL HCl;4-(1-imidazoylmethyl)cinnamic acid;3-(4-(1H-imidazol-1-ylmethyl)phenyl)-2-propenoic acid;Ozagrel Hydrochloride;OKY-046;LS-177692;(e)-3-(4-(1h-imidazol-1-ylmethyl)phenyl)-2-propenoic acid hydrochloride hydrate;OZAGREL HYDROCHLORIDE;Ozagrel;LS-123661;NCGC00025195-01;OZAGREL;2-Propenoic acid, 3-(4-(1H-imidazol-1-ylmethyl)phenyl)-, (E)-;Ozagrel sodium;Ozagrel Sodium;Ozagrel HCL;LS-177084;NCGC00016937-01;OKY 046;Ozagrel hydrochloride hydrate;OZAGREL SODIUM;Ozapen;CIPLUS_214042;CIPLUS_695802;NCGC_Prestw-979;(E)-3-[4-(Imidazol-1-ylmethyl)phenyl]propenoic acid hydrochloride hydrate;ozagrel;(E)-P-(IMIDAZOL-1-YLMETHYL)CINNAMIC ACID;ozagrel, monohydrochloride;ozagrel, monohydrochloride, (E)-isomer;Ozagrel hydrochloride;ozagrelum;",SHZKQBHERIJWAO,Thromboxane Synthase Inhibitor,TBXA2R
NCGC00015204-08,ClCCNC(=O)N(CCCl)N=O,CARMUSTINE,,DLGOEMSEDOSKAD,DNA Alkylating Agent,
NCGC00095042-08,S=[P](N1CC1)(N2CC2)N3CC3,THIOTEPA,,FOCVUCIESVLUNU,Cytochrome P450 Oxidase Inhibitor,
NCGC00015622-02,O=C1\C=C(/OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4,LY 294002 hydrochloride,"NCGC00025020-04;NCGC00025020-03;LY 294002;CIPLUS_682328;NCGC00025020-02;2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one;NCGC00025020-01;LY-294002;NCGC00094060-01;4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-;2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one hydrochloride;LY294002;2-(4-Morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride;NCGC00015622-01;LY-294,002 hydrochloride;LY 294002 hydrochloride;",CZQHHVNHHHRRDU,PI3K Inhibitor,PIK3CA
NCGC00346698-01,CNC(=O)C1=CC=CC(=C1)C2=CC=C3C(=N2)N=C(N=C3N4CCOC[C@@H]4C)N5CCOC[C@@H]5C,AZD2014,,JUSFANSTBFGBAF,mTORC1/2 inhibitor,MTOR
NCGC00345881-02,CC1=NC2=C([NH]1)C3=CC=CC=C3N(CC2)C(=O)C4=CC=C(NC(=O)C5=CC=CC=C5C6=CC=CC=C6)C=C4,Conivaptan HCl (Vaprisol),,IKENVDNFQMCRTR,Vasopressin (AVP) V1a/V2 Antagonists,AVPR1A
NCGC00018099-10,CN1C(=O)N(C)C2=C([N](CC(O)CO)C=N2)C1=O,DYPHYLLINE,,KSCFJBIXMNOVSH,Xanthine Derivative,
NCGC00242217-04,COC1=CC2=C(C=C1OC)[N](C=N2)C3=CC(=C(S3)C(N)=O)OCC4=C(C=CC=C4)C(F)(F)F,GW 843682X,,JSKUWFIZUALZLX,Polo-like Kinase-1 (Plk-1) Inhibitor,PLK1
NCGC00016017-07,COC1=CC2=NC=NC(=C2C=C1OC)NC3=CC=CC(=C3)Cl,,,GFNNBHLJANVSQV,EGFR (HER1; erbB1) inhibitor,EGFR
NCGC00181350-02,Cl.Cl.Clc1ccc(cc1)Nc4nnc(Cc2ccncc2)c3ccccc34,Vatalanib;CGP-79787D;PTK-787;PTK/ZK;ZK-222584,"CIPLUS_791590;1-PHTHALAZINAMINE, N-(4-CHLOROPHENYL)-4-(4-PYRIDINYLMETHYL)-;Vatalanib 2HCL;vatalanibum;(4-CHLOROPHENYL)-(4-PYRIDIN-4-YLMETHYLPHTHALAZIN-1-YL)AMINE SUCCINATE;VATALANIB;PTK-787;1-PHTHALAZINAMINE, N-(4-CHLOROPHENYL)-4-(4-PYRIDINYLMETHYL)-, BUTANEDIOATE (1:1);CIPLUS_728735;Vatalanib;ZK-222584;vatalanib;VATALANIB SUCCINATE;N-(4-CHLOROPHENYL)-4-(PYRIDIN-4-YLMETHYL)PHTHALAZIN-1-AMINE SUCCINATE;Vatalanib succinate;(4-CHLOROPHENYL)-(4-(4-PYRIDYLMETHYL)PHTHALAZIN-1-YL)AMMONIUM HYDROGEN SUCCINATE;N-(4-CHLOROPHENYL)-4-(PYRIDIN-4-YLMETHYL)PHTHALAZIN-1-AMINE;",YCOYDOIWSSHVCK,"VEGFR-1,2,3 Inhibitor",VEGFA
NCGC00346808-01,NC(=O)C1=CC(=CC=C1)C2=NC=NC(=C2)NC3=CC=C(OC(F)(F)F)C=C3,GNF 2,,WEVYNIUIFUYDGI,Bcr-Abl inhibitor,ABL1
NCGC00345793-01,CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC(=CC=C3)CN4/N=C(\C=C/C4=O)C5=CC(=CC=C5)C#N,EMD-1214063,,AHYMHWXQRWRBKT,HGFR (MET; c-Met) Inhibitor,MET
NCGC00249392-01,CNC(=O)C1=NC=CC(=C1)COC2=NN=C(NC3=CC=C(Cl)C=C3)C4=C2OC=C4,Telatinib;BAY-579352/BAY 57-9352,,QFCXANHHBCGMAS,"VEGFR-2,3 Inhibitor",KDR
NCGC00346548-01,CCCNC(=O)NC1=CC=C(OC2=NC=NC3=CC(=C(OC)C=C23)OC)C=C1Cl,KRN 633,,VPBYZLCHOKSGRX,VEGFR-2 inhibitor,FLT1
NCGC00347278-01,CC1=N[NH]C2=C1C=C(C=C2)C3=CN=CC(=C3)OC[C@@H](N)CC4=C[NH]C5=C4C=CC=C5,A-443654,,YWTBGJGMTBHQTM,PKB alpha/Akt1 Inhibitors,AKT1
NCGC00025103-01,CCOC(=O)C/1=C(C)/NC(=S)NC1C2=CC=CC(=C2)O,Monastrol,"4-(3-Hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro-4H-pyrimidin-5-carboxylic Acid Ethyl Ester;Monastrol;NCGC00025103-03;NCGC00025103-02;NCGC00025103-01;",LOBCDGHHHHGHFA,Kinesin-Like Spindle Protein Inhibitor,KIF11
NCGC00016612-04,COC1=NC=NC(=C1OC)N[S+]([O-])(=O)C2=CC=C(N)C=C2,Sulfadoxine,,ALDRLJHPNKNXIP,Dihydropteroate Synthase (DHPS) Inhibitors,
NCGC00346657-01,OC(=O)C1(CCC(CC1)OC2=C(F)C(=CC=C2)Cl)CC3=CC=CC(=N3)NC4=NC=CS4,MK-5108 (VX-689),,LCVIRAZGMYMNNT,Aurora A Inhibitor,AURKA
NCGC00263095-01,CN1CCN(CC1)C2=NC3=CC=CC=C3C(=N2)C4C(C(=O)NC4=O)C5=C[NH]C6=CC=CC=C56,Sotrastaurin;AEB-071,,QYMDWEPIJODSDN,PKC inhibitor,PRKCA
NCGC00346832-01,COC1=C(OC)C=C(C[C@H](C)[C@H](C)CC2=CC(=C(OC)C=C2)OC)C=C1,Terameprocol,,ORQFDHFZSMXRLM,Antimitotic Agent,
NCGC00095264-05,OC1=C2N=CC=CC2=C(Cl)C=C1Cl,CHLOROXINE,,WDFKMLRRRCGAKS,Antibacterial,
NCGC00250381-02,CC(C)OC1=CC(=N[NH]1)NC2=C(Cl)C=NC(=N2)N[C@@H](C)C3=CC=C(F)C=N3,AZ-23,,LBVKEEFIPBQIMD,Tropomyosin Related Kinases (Trk) inhibitor,NTRK1
NCGC00346721-01,CC1=C(NC(=O)CNC2=CC(=C(F)C=C2)F)C=C(CN3CCNCC3)C=C1,GW 791343 hydrochloride,,GRUWKTIRBBPZSD,P2X7 Receptor Antagonist,P2RX7
NCGC00346519-01,CC(C)CCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC2=C3OC4=CC=C(C[C@H]5NC(=O)[C@H](N)C6=CC(=C(O)C=C6)OC7=CC(=CC(=C7)O)[C@H](NC5=O)C(=O)N[C@H]8C(=O)N[C@H]9C(=O)N[C@@H]([C@H](O[C@@H]%10O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%10NC(C)=O)C%11=CC(=C(OC2=CC8=C3)C=C%11)Cl)C(=O)N[C@@H](C(O)=O)C%12=CC(=CC(=C%12C%13=C(O)C=CC9=C%13)O[C@H]%14O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]%14O)O)C=C4Cl,Teicoplanin,,FHBQKTSCJKPYIO,glycopeptide antibiotic,
NCGC00163548-02,CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)C3=NC4=CC=CC=C4N=C3)NC(=O)C5=NC6=CC=CC=C6N=C5,Echinomycin,,AUJXLBOHYWTPFV,Antineoplastic Antibiotics,
NCGC00142423-03,OC[C@H]1O[C@@H](OC2=C(C(=O)CCC3=CC=C(O)C=C3)C(=CC(=C2)O)O)[C@H](O)[C@@H](O)[C@@H]1O,PHLORIDZIN,,IOUVKUPGCMBWBT,SGLT-1/2 inhibitor,
NCGC00249389-01,C1CN(CCN1)C2=CC=C(C=C2)C3=C[N]4N=CC(=C4N=C3)C5=CC=NC6=C5C=CC=C6,LDN-193189,,CDOVNWNANFFLFJ,Activin Receptor Like Kinase 3 (ALK3; BMPR-IA) Inhibitors,BMPR1A
NCGC00262195-02,CN1C(=O)\C(=C/C2=C1N=C(NC3CCOCC3)N=C2)OC4=C(F)C=C(F)C=C4,R1487   (SY-R1487),,KKKRKRMVJRHDMG,p38 MAPK Inhibitor,MAPK14
NCGC00015191-06,C2CC(=O)N(C)C(C1=CC=C(Cl)C=C1)S2(=O)=O,Chlormezanone,"NCGC00024597-04;NCGC00024597-03;NCGC00024597-02;NCGC00024597-01;Acetamide, N-(4-hydroxyphenyl)-, mixt. with 2-(4-chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide;NCGC00015191-01;Chlormezanone;NCGC_Prestw-336;CHLORMEZANONE;Beserol;CIPLUS_149639;Clormezanona;4H-1,3-THIAZIN-4-ONE, 2-(4-CHLOROPHENYL)TETRAHYDRO-3-METHYL-, 1,1-DIOXIDE;2-(4-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide;4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide;LS-150535;Clormetazon;CIPLUS_707729;NCGC00024597-05;chlormezanonum;Lobak;Trancopal;2-(P-CHLOROPHENYL)TETRAHYDRO-3-METHYL-4H-1,3-THIAZIN-4-ONE 1,1-DIOXIDE;NCGC00016325-01;Chlormezanonum;chlormezanone;2-(4-CHLOROPHENYL)-3-METHYL-1,3-THIAZINAN-4-ONE 1,1-DIOXIDE;",WEQAYVWKMWHEJO,GABA Modulators,GABRA1
NCGC00164600-03,C[C@@H]1CC[C@H]2[C@@H](C)[C@H](O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4)OC(=O)CCC(O)=O,Artesunate,,FIHJKUPKCHIPAT,antimalarial agents,
NCGC00159337-06,FC(F)(F)C1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC3CC3,Efavirenz,,XPOQHMRABVBWPR,Reverse Transcriptase Inhibitor,TERT
NCGC00250402-01,CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1,Dapagliflozin;BMS-512148,,JVHXJTBJCFBINQ,SGLT-2 inhibitor,
NCGC00181166-01,C(S(=O)(=O)[O-])CS.[Na+],Sodium 2-mercaptoethanesulfonate,"Mesnex tabs;Mesna (2-Mercaptoethanesulfonic acid);Mesna (2-Mercaptoethane Sulfonic Acid Sodium Salt);MESNA;CIPLUS_653974;Mesnum;2-MERCAPTOETHANE SULFONATE SODIUM SALT;2-Mercaptoethanesulfonic acid solution;Sodium 2-mercaptoethanesulfonate;Ethanesulfonic acid, 2-mercapto-, monosodium salt;MESNEX;Coenzyme M;HS-CoM Na;mesna;mesnum;LS-7484;2-Mercaptoethanesulfonic acid sodium salt;Uromitexan;NCGC00094939-02;NCGC00094939-01;Mesnex;CIPLUS_172033;Mesna;Coenzyme M sodium salt;2-MERCAPTOETHANESULFONIC ACID SODIUM SALT;",KLHUOHDGOSLHED,Antineoplastic Enhancing Agents,
NCGC00016927-10,CCN1\C=C(\C(O)=O)C(=O)C2=C1N=C(N3CCNCC3)C(=C2)F,ENOXACIN,,IDYZIJYBMGIQMJ,Quinoline Antibiotic,
NCGC00167967-01,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]3N(CCCC[N]4C=NC(=C4)C5=CN=CC=C5)C(=O)O[C@]13C)OC,,"CIPLUS_3818865;RU 66647;telithromycin;NCGC00164575-01;RU-66647;Ketek;Telithromycin;HMR-3647;NCGC00095154-01;telithromycinum;HMR 3647;NCGC00095154-02;CIPLUS_215896;TULATHROMYCIN;HMR3647;11,12-DIDEOXY-3-DE((2,6-DIDEOXY-3-C-METHYL-3-O-METHYL-A-L-RIBO-HEXOPYRANOSYL)OXY)-6-O-METHYL-3-OXO-12,11-(OXOCARBONYL((4-(4-(3-PYRIDINYL)-1H-IMIDAZOL-1-YL)BUTYL)IMINO))ERYTHROMYCIN;Aventis brand of telithromycin;TELITHROMYCIN;KETEK;",LJVAJPDWBABPEJ,Ketolide antibiotic,
NCGC00015463-02,C\C1=N\N=C(\C2=CC=C(N)C=C2)C3=CC4=C(OCO4)C=C3C1,GYKI 52466 hydrochloride,"GYKI 52895;Benzenamine, 4-(8-methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)-;GYKI 52466;1-(p-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride;GYKI-52466;NCGC00025169-01;NCGC00025169-02;1-(4-Aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride;CIPLUS_682422;GYKI 52466 hydrochloride;NCGC00015463-01;NCGC00093998-01;1-(4-Aminophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine;",LFBZZHVSGAHQPP,AMPA Antagonist,
NCGC00263268-01,C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](CC(=O)[C@H]3O[C@@H]4O[C@]5(C)CC[C@H]6[C@H](C)CC[C@@H]([C@H]3C)[C@@]46OO5)O[C@@H]7O[C@]8(C)CC[C@@H]1[C@@]27OO8,BTM-2C-dimer ketone;BTM-2C-dimer ketone,,GZJIPMCINQOOAP,artemesinin analogue,
NCGC00014873-04,CN(C)CCCN\C1=C\2C(=O)N(C)C(=O)\N=C2N(C)C3=C1C=CC=C3,HLI-373989;HLI-373,,LNRUPMPQQGPSQT,MDM2 (hdm2) Inhibitor,MDM2
NCGC00181033-02,CN1C(=O)C[C@@H](NC1=O)C(=O)N[C@@H](CC2=CN=C[NH]2)C(=O)N3CCC[C@H]3C(N)=O,Taltirelin,,LQZAIAZUDWIVPM,Thyrotropin-Releasing Hormone (TRH) Analogs,TRHR
NCGC00346888-01,NC(=O)C1=NOC(=N1)[C@H](CCCC2CCCCC2)CC(=O)NO,UK 383367,,ARJCBSRIPGJMAD,Procollagen C-Endopeptidase Inhibitor,
NCGC00182965-04,OC(CCN1CCCCC1)(C2CC\3CC2\C=C3)C4=CC=CC=C4,BIPERIDEN,,YSXKPIUOCJLQIE,Anticholinergic,
NCGC00167781-07,OC(=O)COCCN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(Cl)C=C3,CETIRIZINE HYDROCHLORIDE,,ZKLPARSLTMPFCP,Histamine H1 Receptor Antagonists,HRH1
NCGC00016024-06,OC1C(OC2=C(C(=CC(=C2)O)O)C1=O)C3=CC(=C(O)C=C3)O,Taxifolin (Dihydroquercetin),,CXQWRCVTCMQVQX,flavanoid,
NCGC00186460-01,O=C(OC)[C@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5[C@@](C)(C)C(=O)C(=C[C@]5(C)C4=CC(=O)[C@@H]3[C@@H]2C[C@](C)(C)CC1)C#N,Bardoxolone methyl,,WPTTVJLTNAWYAO,NF-kappaB signaling Inhibitor,NFKB1
NCGC00016467-05,OC1=CC(O)=C2C(=O)C=C(OC2=C1)C3=CC(O)=C(O)C=C3,,"luteolin 7-diglucuronide;NCGC00016467-01;NCGC_Prestw-870;CIPLUS_153554;Luteoline;Luteolin;luteolin-7-D-apf-D-glu;luteolin 7-O-glucoside 4''-sulfate;luteolin 5-rutinoside;NCGC00142375-02;3',4',5,7-Tetrahydroxy-Flavone;luteolin 7-O-beta-D-apiofuranosyl-(1-2)-beta-D-glucopyranoside;LS-69039;luteolin 5-O-beta-rutinoside;LUTEOLIN;luteolin 8-C-rhamnoside-7-O-rhamnoside;luteolin 4'-O-glucoside;luteolin 3'-O-beta-D-glucuronide;luteolin 8-C-Rham-7-O-Rham;luteolin 7-O-(glucuronosyl-1-2-glucuronide);3',4',5,7-Tetrahydroxyflavone;luteolin 3'-glucuronide;",IQPNAANSBPBGFQ,Phosphodiesterase IIII (PDE4) inhibitor,PDE4A
NCGC00346706-01,CCCCOC1=CC=C(C=C1)C(=O)NC2=C(F)C=C(F)C=C2,VU 0357121,,AHCYOTLTLQTPSU,mgluR5 allosteric modulator,GRM5
NCGC00344511-02,CC1=C2CC[C@@H](C[C@H](O)C2=CC=C1)CN3CCC(CC3)C4=C(Cl)C=CC=C4Cl,SB 612111 hydrochloride,,OHRDCQFCAWLDBP,Opioid receptor antagonist,
NCGC00159489-04,O=[N+]([O-])c1ccc(cc1)[C@@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCC)NC(=O)C(Cl)Cl,Chloramphenicol palmitate,"chloramphenicol palmitate, monoammonium salt;Chloromycetin palmitate;Chloramphenicol Palmitate;LS-101202;chloramphenicol palmitate, diammonium salt;chloramphenicol monopalmitate;CIPLUS_154039;chloramphenicol palmitate;CHLORAMPHENICOL MONOPALMITATE (ESTER);CHLORAMPHENICOL PALMITATE;D-THREO-(-)-2,2-DICHLORO-N-(.BETA.-HYDROXY-.ALPHA.-(HYDROXYMETHYL)-P-NITROPHENETHYL)ACETAMIDE .ALPHA.-PALMITATE;Chloramphenicol palmitate;chloramphenicol palmitate, monopalmitate;CHLORAMPHENICOL MONOPALMITATE;CHLORAMPHENICOL;Chloramphenicol palmitate (ester);4   Chloramphenicol Palmitate;CHLORAMPHENICOL .ALPHA.-PALMITATE;Palmitic acid, alpha-ester with D-threo-(-)-2,2-dichloro-N-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)acetamide;HEXADECANOIC ACID, (2R,3R)-2-((DICHLOROACETYL)AMINO)-3-HYDROXY-3-(4-NITROPHENYL)PROPYL ESTER;(2R,3R)-2-((DICHLOROACETYL)AMINO)-3-HYDROXY-3-(4-NITROPHENYL)PROPYL PALMITATE;",PXKHGMGELZGJQE,Antibiotic,
NCGC00242597-01,OC23CC1C[C@@](C2)([C@@H](C(N5[C@H]4C[C@H]4C[C@H]5C#N)=O)N)CC(C3)C1,Saxagliptin,,QGJUIPDUBHWZPV,Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitor,DPP4
NCGC00346891-01,ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1,Pyroxamide,,PTJGLFIIZFVFJV,Histone Deacetylase (HDAC) Inhibitor,HDAC1
NCGC00018276-03,NC(N)=NC1=NC(=CS1)CSCCC(=N)N[S+](N)([O-])=O,,FAMOTIDINE,VZUQZRYQNIGGIH,Histamine H2 Receptor Antagonists,HRH2
NCGC00167533-03,CCCC1=NC(=C2[N]1NC(=N\C2=O)/C3=CC(=CC=C3OCC)[S+]([O-])(=O)N4CCN(CC)CC4)C,Vardenafil Hydrochloride Trihydrate (Vivanza,,WDVDQZPUKXFUEK,Phosphodiesterase V (PDE5) inhibitor,PDE5A
NCGC00263153-05,CC(C)[C@H](C(=O)NC1=CC=C(C=C1)C(=O)NO)C2=CC=CC=C2,AR-42 (HDAC-42),,LAMIXXKAWNLXOC,Histone Deacetylase (HDAC) 1/2 Inhibitor,HDAC1
NCGC00345819-01,C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(=C4)O)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O,Estetrol,,AJIPIJNNOJSSQC,Selective Estrogen Receptor Modulators (SERM),ESR1
NCGC00346732-01,C[C@@H]1CNC(=O)CC[C@]/2(C)[C@@H](CC(N)=O)[C@H]3N4C2=C(C)/C5=[N]6/C(=C\C7=[N]8\C(=C(C)/C9=[N](/[C@]3(C)[C@@](C)(CC(N)=O)[C@@H]9CCC(N)=O)[Co+]468(O)\[N]%10=C\N([C@H]%11O[C@H](CO)[C@@H](O[P]([O-])(=O)O1)[C@H]%11O)C%12=C%10C=C(C)C(=C%12)C)[C@@](C)(CC(N)=O)[C@@H]7CCC(N)=O)C(C)(C)[C@@H]5CCC(N)=O,Hydroxocobalamin,,XVXCLEXSDVMESA,Vitamin,
NCGC00018157-11,CC(C(O)=O)C1=CC=C(C(=C1)F)C2=CC=CC=C2,FLURBIPROFEN,,SYTBZMRGLBWNTM,non-steroidal antiinflammatory,
NCGC00166125-01,[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)(CNC)O,Meglumine,"MEGLUMINE ASCORBATE;CIPLUS_170809;NIACIN MEGLUMINE;NCGC_FLUKA_66930;GLUCANTIME;CIPLUS_167320;methylglucamine antimonate;THEOPHYLLINE-MEGLUMINE;MEGLUMINE;Megluminum;CIPLUS_173853;1-Deoxy-1-(methylamino)-D-galactitol;Salicylate Meglumine;CIPLUS_692154;LS-71364;N-Methyl glucamine Antimoniate;CIPLUS_3882515;N-Methylglucamine (Meglumine);NCGC00016673-01;Aventis brand of meglumine antimoniate;Glucantime;N-Methyl-D-Glucamine;NCGC_Prestw-884;1-deoxy-1- (methylamino)glucitol antimonate(V);MEGLUMINE SALICYLATE;CIPLUS_776158;N-Methyl-D-glucamine;N-methylglucamine;megluminum;meglumine salicylate;meglumine antimoniate;meglumine;MEGLUMINE ANTIMONIATE;CIPLUS_170831;CIPLUS_3853394;methylglucamine orotate;NCGC00166125-01;CIPLUS_165322;Meglumine;N-METHYLGLUCAMINE;N-methylglucamine antimonate;Meglumina;CIPLUS_206891;D-Glucitol, 1-deoxy-1-(methylamino)-;",MBBZMMPHUWSWHV,amino sugar,
NCGC00263145-01,OC1=NN=C(SC2=NC=C(S2)[N+]([O-])=O)[N]1C3=CC4=C(OCCO4)C=C3,BI-78D3,,QFRLDZGQEZCCJZ,SAPK1 (JNK) Inhibitor,MAPK8
NCGC00345815-01,CCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1)C=O,Z-Leu-Leu-Nva-H (aldehyde),,QEJRGURBLQWEOU,Proteasome Inhibitor,PSMD1
NCGC00164549-01,O=S(NC(C=C2)=CC=C2CCN(C)CCOC(C=C1)=CC=C1NS(=O)(C)=O)(C)=O,Dofetilide,"dofetilide;dofetilidum;N-(4-(2-(2-(4-(METHANESULPHONAMIDO)PHENOXY)-N-METHYLETHYLAMINO)ETHYL)PHENYL)METHANESULPHONAMIDE;CIPLUS_213557;DOFETILIDE;UK-68798;UK 68798;1-MSPMPE;1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane;Dofetilidum;LS-90151;UK-68,798;NCGC00164549-01;Tikosyn;Dofetilide;2   Dofetilide;Dofetilida;",IXTMWRCNAAVVAI,K(V)11.1 (erg1) Channel Blocker,
NCGC00182549-02,COC[C@H](N1CCN(C[C@@H]1C)C2(C)CCN(CC2)C(=O)C3=C(C)N=CN=C3C)C4=CC=C(C=C4)C(F)(F)F,Vicriviroc Malate,,CNPVJJQCETWNEU,Chemokine CCR5 Antagonist,CCR5
NCGC00015267-09,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C3=CC=C(F)C=C3,CITALOPRAM,,WSEQXVZVJXJVFP,5-HT Reuptake Inhibitor,HTR1A
NCGC00164547-06,COC1=CC(=CC=C1CC2=C[N](C)C3=CC=C(NC(=O)OC4CCCC4)C=C23)C(=O)N[S+]([O-])(=O)C5=CC=CC=C5C,Zafirlukast,,VDUNZQQNKGPZOK,Leukotriene CysLT1 (LTD4) Antagonist,CYSLTR1
NCGC00015725-16,C[S+]([O-])(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O,NIMESULIDE,,PMOPRBJLSQDYMY,Cyclooxygenase-2 Inhibitor,PTGS2
NCGC00160529-05,ClC1=C(N\C2=N\CCN2)C3=NSN=C3C=C1,Tizanidine hydrochloride,,XFYDIVBRZNQMJC,alpha2-Adrenoceptor Agonists,ADRA2A
NCGC00092310-03,O=S(C1=C(N)C=C(OC)C(C(NCC2CCCN2CC)=O)=C1)(CC)=O,Amisulpride,"CIPLUS_3859753;4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide;Amisulpride;4-AMINO-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)-5-ETHYLSULFONYL-2-METHOXYBENZAMIDE, DL-;dan 2163;SL-91.1077-00;LS-25532;CIPLUS_3859483;Amisulprida;Benzamide, 4-amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-;Amisulpridum;amisulpridum;CIPLUS_211061;Deniban;DAN-2163;amisulpride;AMISULPRIDE;",UYNLYBPIAORSSZ,Dopamine D2/D3 Antagonist,DRD2
NCGC00017324-08,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)\C=C2\C=C/[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12,SIMVASTATIN,,RYMZZMVNJRMUDD,HMG-CoA Reductase Inhibitor,HMGCR
NCGC00165880-04,C1CCC(CC1)NC2=C3N=C[NH]C3=NC(=N2)NC4=CC=C(C=C4)N5CCOCC5,Reversine,,ZFLJHSQHILSNCM,Adenosine A3 Antagonists,ADORA3
NCGC00167433-02,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N5CCOCC5)[N+]6(CCCC6)CC=C,Rocuronium bromide,,YXRDKMPIGHSVRX,Steroid non-depolarizing neuromuscular blocker,
NCGC00159346-05,CN(C\C=C\C#CC(C)(C)C)CC1=CC=CC2=C1C=CC=C2,TERBINAFINE HYDROCHLORIDE,,DOMXUEMWDBAQBQ,Fungal Squalene Monooxygenase Inhibitor,
NCGC00022735-07,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]\4(C)/C=C\C(=O)\C=C14,Methylprednisolone,,VHRSUDSXCMQTMA,Glucocorticoid steroid,
NCGC00263198-01,COC1=C(C=C2C(=CC=NC2=C1)OC3=CC(=C(NC(=O)NC4CC4)C=C3)Cl)C(N)=O,Lenvatinib;E-7080/ER-203492-00,,WOSKHXYHFSIKNG,VEGFR-1/2/3 Inhibitor,FLT1
NCGC00263229-01,CC1=NC(=NC=C1)N[S+]([O-])(=O)C2=CC=C(NC(=O)NC3=CC=C(C=C3)[S+]([O-])(=O)NC4=NC(=CC=N4)C)C=C2,GSK837149A,,BDCUADOXVKPHSZ,Fatty acid synthase inhibitor,FAS
NCGC00160428-02,ClC1=CC=C(C[N]2C=C(C(=O)C(=O)NC3=CC=NC=C3)C4=CC=CC=C24)C=C1,Indibulin,,SOLIIYNRSAWTSQ,Tubulin polymerization inhibitor,TUBB
NCGC00015693-08,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C3=C(C(=CC=C3O)O)C2=O,MITOXANTHRONE HYDROCHLORIDE,,KKZJGLLVHKMTCM,DNA Topoisomerase II Inhibitors,TOP2A
NCGC00345847-01,CCNC(=O)NC1=C(Cl)C=C(OC2=C(\C=N\OC)C(=NC=N2)N)C=C1,JNJ-38158471,,BJHCYTJNPVGSBZ,VEGFR-2 (FLK-1/KDR) Inhibitors,FLT1
NCGC00178697-05,CCC1=C2C=C(OC(=O)N3CCC(CC3)N4CCCCC4)C=CC2=NC\5=C1CN6C(=O)\C7=C(/C=C56)[C@@](O)(CC)C(=O)OC7,Irinotecan,,UWKQSNNFCGGAFS,DNA Topoisomerase I Inhibitors,TOP1
NCGC00263918-04,COC1=C2C(=O)C3=C(C(=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)C4=C3O)C(=O)CO)O)C(=O)C2=CC=C1,Epirubicin Hydrochloride,,AOJJSUZBOXZQNB,DNA Topoisomerase II Inhibitors,TOP2A
NCGC00346591-01,COC1=CC2=C(C=C1OC)[C@@H]3CC4=CC=C(OC)C(=C4CN3CC2)OC,Rotundine,,AEQDJSLRWYMAQI,5-HT Release Inhibitor,
NCGC00274067-01,CC1=CC=C(C=C1C)N2/N=C(C)\C(=N/NC3=CC=CC(=C3O)C4=CC=CC(=C4)C(O)=O)C2=O,Eltrombopag,,XDXWLKQMMKQXPV,Thrombopoietin Receptor (TpoR) Agonists,MPL
NCGC00015436-09,OCCN1CCN(CCCN2C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1,,FLUPHENAZINE 2HCl,PLDUPXSUYLZYBN,Dopamine D2 Antagonist,DRD2
NCGC00347217-01,CCC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)CN3CCN(C)CC3)C#CC4=C[N]5N=CC=C5N=C4,,,DDLPXZXBWGJRGK,discoidin domain receptor tyrosine kinase (DDR1),DDR1
NCGC00347903-01,COC1=CC(=C(OC2=CN=C(NC(CO)CO)N=C2N)C=C1I)C(C)C,Ro 51,,PAYROHWFGZADBR,P2X3/P2X2 Receptor Antagonist,P2RX3
NCGC00346488-01,OC(=O)C1=CC=C(NC2=NC3=C(C\N=C(/C4=CC(=CC=C34)Cl)C5=C(F)C=CC=C5F)C=N2)C=C1,MLN8054,,HHFBDROWDBDFBR,Aurora-A Inhibitor,AURKA
NCGC00238452-02,C[N]1C=C(C2=CC=CC=C12)\C3=C(\C(=O)NC3=O)C4=C[N](C5CCN(CC5)CC6=NC=CC=C6)C7=C4C=CC=C7,Enzastaurin;LY-317615,,AXRCEOKUDYDWLF,"PKCa, PKCb, PKCg inhbitor",PRKCA
NCGC00346805-01,CC1=N[N](C2=CC=CC=C2)C(=C1)C(=O)N3CCN(CC3)C4=CC(=CC=C4)Cl,XRP44X,,NPHPNBGYPKBDDB,Tubulin polymerization inhibitor,TUBB
NCGC00346494-01,COC1=CC=C(C=C1)[S+]([O-])(=O)NC2=C(NC3=CC=C(O)C=C3)N=CC=C2,ABT-751,,SUIIFMOTEUOZDB,Tubulin polymerization inhibitor,TUBB
NCGC00346559-01,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Erythromycin (E-Mycin),,ULGZDMOVFRHVEP,NF-kappaB Activation Inhibitor,NFKB1
NCGC00025297-01,CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1,Gabexate mesylate,"LS-35906;Gabexate monomethanesulfonate;LS-174783;gabexate;CIPLUS_179515;NCGC00025297-01;Gabexate Methanesulfonate;Gabexate;Gabexate mesilate;CIPLUS_182710;Gabexate Monomethanesulfonate, 14C-Labeled Cpd;LS-175792;Gabexato;Gabexate Mesylate;NCGC_Prestw-1008;gabexatum;Arodate;NCGC00017121-01;Gabexato mesilato (Spanish);GABEXATE MESYLATE;4-((6-((AMINOIMINOMETHYL)AMINO)-1-OXOHEXYL)OXY)-ETHYL-BENZOATE MESYLATE;Gabexatum;GABEXATE;Gabexate Mesilate;Benzoic acid, 4-((6-((aminoiminomethyl)amino)-1-oxohexyl)oxy)-, ethyl ester;Gabexate mesylate;GABEXATE MESILATE;LS-171812;",YKGYIDJEEQRWQH,NF-kappaB Activation Inhibitor,NFKB1
NCGC00344990-01,CC(C)(O)C[N]1C(=NC2=CC(=CC=C12)CN3CCOCC3)NC(=O)C4=CC=C(S4)C5=C[NH]N=C5,,,PRGUDNWYEAHEQM,ITK inhibitor,ITK
NCGC00250376-01,COC1=CC=C(C=C1)[S+]([O-])(=O)N(CCO)C2=CC=CC=C2CN(C)C(=O)\C=C\C3=CC=C(Cl)C=C3,KN-93,,NRKXVSYVDUGZGF,Calmodulin-Dependent Protein Kinase II Inhibitors,CAMKK2
NCGC00263265-01,C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](CC(C[C@H]3O[C@@H]4O[C@]5(C)CC[C@H]6[C@H](C)CC[C@@H]([C@H]3C)[C@@]46OO5)C[S+]([O-])(=O)C7=CC=C(COC(=O)N(C)C)C=C7)O[C@@H]8O[C@]9(C)CC[C@@H]1[C@@]28OO9,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2;ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,,CRSJHIRCVZDTHB,artemesinin analogue,
NCGC00092360-01,NC1=NC=NC2=C1N=C[N]2[C@@H]3O[C@H](CO)C[C@H]3O,,"3'-deoxydenosine;LS-15121;Cordycepin;NSC-63984;9-Cordyceposidoadenine;3'-deoxyadenosine;3'-Deoxyadenosine;CIPLUS_149242;cordycepin;3'-DEOXYADENOSINE, H-3;CORDYCEPIN, H-3;CIPLUS_10551396;",OFEZSBMBBKLLBJ,Purine Antagonist,
NCGC00185071-02,N/C1=N/C(=O)C/2=C(NC[C@@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)N2C=O)\N1,,"N5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid;FOLINIC ACID CALCIUM SALT;CIPLUS_148853;Levoleucovorin Calcium;CALCIUM N-(P-((((6S)-AMINO-5-FORMYL-1,4,5,6,7,8-HEXAHYDRO-4-OXO-6-PTERIDINYL)METHYL)AMINO)BENZOYL)-L-GLUTAMATE (1:1);5-Formyl-5,6,7,8-tetrahydrofolic acid calcium salt;L-Glutamic acid, N-(4-(((2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-;LS-71774;Calcium levofolinate;CALCIUM FOLINATE;L-GLUTAMIC ACID, N-(4-(((2-AMINO-5-FORMYL-1,4,5,6,7,8-HEXAHYDRO-4-OXO-6-PTERIDINYL)METHYL)AMINO)BENZOYL)-, CALCIUM SALT (1:1), (S)-;Calcium Folinate;Wellcovorin;CIPLUS_682532;CIPLUS_3741774;Calcium folinate;CIPLUS_711792;Levoleucovorin calcium;Citrovorum factor calcium salt;folinate de calcium;5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid calcium salt;Calcium Levofolinate;NCGC00094708-01;NCGC00094708-02;CIPLUS_192127;calcii folinas;Folinic acid calcium salt hydrate;leucovorin;citrovorum;N-(4-(((2-AMINO-5-FORMYL-1,4,5,6,7,8-HEXAHYDRO-4-OXO-6-PTERIDINYL)METHYL)AMINO)BENZOYL)-GLUTAMIC ACID;NCGC00017055-01;Calcii folinas;Leucovorin Calcium;Leucovorin;LEUCOVORIN CALCIUM;5-HCO-H4PteGlu;CIPLUS_158472;calcii levofolinas;Uzel;CIPLUS_756906;Folinic acid;LS-177560;HS_806;HS_805;NCGC_Prestw-738;LS-175894;Leucovorin calcium;LEVOLEUCOVORIN CALCIUM;LS-176087;Leucovorin calcium salt;Citrovorum factor;LEUCOVORIN;calcium leucovorin;Leucovorin Calcium (pentahydrate);Folinate de calcium;CIPLUS_727061;CALCIUM LEVOFOLINATE;levofolinate de calcium;Folinato calcico;Folinic acid calcium salt;",VVIAGPKUTFNRDU,Antineoplastic Enhancing Agents,
NCGC00347934-01,CC1=CC=CC=C1C(N(C(=O)C[N]2C=CN=C2C)C3=CC=CC(=C3)F)C(=O)NC4CCCCC4,,,FNYGWXSATBUBER,Mutant IDH1 Inhibitor,
NCGC00095977-03,COC1=CC=C(C(C)=O)C(=C1)O,PAEONOL,,UILPJVPSNHJFIK,Lipid Peroxidation Inhibitors,
NCGC00163127-05,COC1=C(C)C(=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(=C1)C)C,Acitretin,,IHUNBGSDBOWDMA,retinoid,
NCGC00016456-12,OC1=CC2=C(C(=C1)O)C(=O)\C=C(/O2)C3=CC=CC=C3,CHRYSIN,,RTIXKCRFFJGDFG,Antiinflammatory Drug,
NCGC00346667-01,CN1\C(=C(O)/C2=C(C=C(Cl)S2)[S+]1([O-])=O)C(=O)NC3=NC=CC=C3,Lornoxicam (Xefo),,GTASRFITTBVXRX,non-steroidal antiinflammatory,
NCGC00167773-03,NC(=O)NC1=C(C=C(S1)C2=CC=C(F)C=C2)C(N)=O,TPCA-1,,SAYGKHKXGCPTLX,IKK beta inhibitor,IKBKB
NCGC00345831-01,COC1=NC=CC(=N1)C2=C(N=C[N]2C3CCNCC3)C4=CC=C(F)C=C4,SB242235,,PDTYLGXVBIWRIM,p38 MAPK Inhibitor,MAPK14
NCGC00181011-01,O=C1C=C(O)C(Cl)=CN1,Gimeracil,"GIMERACIL;5-chloro-2,4-dihydroxypyridine;5-chloro-4-hydroxy-2(1H)-pyridinone;gimeracil;Gimeracil;1,2-Dihydro-5-chloro-4-hydroxybenzene;gimeracilum;CIPLUS_696016;",ZPLQIPFOCGIIHV,Dihydropyrimidine Dehydrogenase Inhibitor,DPYD
NCGC00160670-04,CCOC(=O)C1=C(C)[N](C)C2=CC=C(O)C=C12,Mecarbinate,,YTBNTDMBGXAOCG,antiinfluenza drug,
NCGC00016244-14,NNC(=O)C1=CC=NC=C1,ISONIAZID,,QRXWMOHMRWLFEY,Cell Wall Biosynthesis Inhibitors,
NCGC00015451-06,CCOC(=O)NC1=CC=C(NCC2=CC=C(F)C=C2)N=C1N,Flupirtine maleate,,JUUFBMODXQKSTD,Voltage-Gated K(V) 7 (KCNQ) Channel Activator,KCNQ1
NCGC00142624-04,OC[C@H]1O[C@@H](O[C@@H]2[C@@H](CO)O[C@](O)(CO)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O,LACTULOSE,,JCQLYHFGKNRPGE,synthetic sugar,
NCGC00015116-10,O=C(C1=CC=C(OC)C=C1)N(CCC2)C2=O,Aniracetam,1-(4-Methoxybenzoyl)-2-pyrrolidinone;aniracetam;NCGC00021402-02;ANIRACETAM;1-(4-methoxybenzoyl)-2-pyrrolidinone;aniracetamum;3   Aniracetam;NCGC00015116-01;NCGC00021402-05;NCGC00021402-06;NCGC00021402-07;WHO NO. 4902;NCGC00021402-08;1-ANISOYL-2-PYRROLIDINONE;CIPLUS_189751;Ro-13-5057;Ro 13-5057;1-anisoyl-2-pyrrolidinone;RO-13-5057;1-(4-METHOXYBENZOYL)-2-PYRROLIDINONE;Aniracetam;LS-138873;Aniracetamun;,ZXNRTKGTQJPIJK,neuroprotective drug,
NCGC00164617-05,COC1=CC=C(C=C1C23CC4CC(CC(C4)C2)C3)C5=CC=C6C=C(C=CC6=C5)C(O)=O,Adapalene,,LZCDAPDGXCYOEH,topical retinoid,
NCGC00095322-03,O=C(C(OC)=C1OC)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC\C=C(C)/C)=C(C)C1=O,Ubidecarenone,"Coenzyme- Q10;ubiquinone Q10;Adelir;CoQ 10;ubisemiquinone radical;Ubiquinone-10;Coenzyme Q10;ubidecarenone;Ubiquinone 50;LS-174860;ubiquinone 50;NCGC00095322-01;ubidecarenonum;Ubidecarenone;UBIDECARENONE;coenzyme Q10;2,3-dimethoxy-5-methyl-6-decaprenylbenzoquinone;0   Coenzyme Q10;coenzyme Q10, ion (1-), (all-E)-isomer;CIPLUS_206904;COENZYME Q10;coenzyme Q10, (Z,Z,Z,Z,Z,Z,E,E,E)-isomer;CIPLUS_3737186;UBIQUINONE-50;2,3-DIMETHOXY-5-METHYL-6-DECAPRENYL-1,4-BENZOQUINONE;LS-40331;UBIDECARENEONE;Q-10;ubisemiquinone;CoQ10;",ACTIUHUUMQJHFO,mitochondrial electron transport,
NCGC00186006-04,CC1=C(NC(=O)CN2CCCC2=O)C(=CC=C1)C,Nefiracetam (Translon),,NGHTXZCKLWZPGK,GABAergic Transmission Enhancer,GABRA1
NCGC00014891-03,OC(=O)[C@H](CC1=C[NH]C2=C1C=CC=C2)N3C(=O)C4=C(C=CC=C4)C3=O,RG-108;NSC-401077,,HPTXLHAHLXOAKV,DNA Methyltransferase (DNMT) Inhibitor,DNMT1
NCGC00344564-02,COC1=CC=C(C=C1O)C/2=C/C(=O)C3=C(O2)C=C(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)C=C3O,Diosmin,,GZSOSUNBTXMUFQ,Aryl Hydrocarbon Receptor (AhR) Agonists,AHR
NCGC00015335-11,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,Diphenhydramine,DIPHENHYDRAMINE HCl,ZZVUWRFHKOJYTH,Histamine H1 Receptor Antagonists,HRH1
NCGC00015173-02,OC(CN1CCN(CC1)C2=CC=CC(=C2)Cl)C(C3=CC=CC=C3)C4=CC=CC=C4,BRL 15572 hydrochloride,"BRL- 15572;NCGC00025039-03;3-(4-(3-chlorophenyl)piperazin-1-yl)-1,1-diphenyl-2-propanol;NCGC00025039-02;BRL 15572 hydrochloride;NCGC00025039-01;BRL 15572;NCGC00015173-01;BRL-15572;NCGC00093663-01;4-(3-Chlorophenyl)-alpha-(diphenylmethyl)-1-piperazineethanol hydrochloride;",QJHCTHPYUOXOGM,5-HT1D Receptor Antagonist,HTR1D
NCGC00168853-03,CC(=C)[C@@H]1CC[C@]2(C)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12,Lupeol,,MQYXUWHLBZFQQO,Steroid,
NCGC00167803-03,C[C@H](NC(=O)CC1=CC(=CC(=C1)F)F)C(=O)N[C@H](C(=O)OC(C)(C)C)C2=CC=CC=C2,DAPT,,DWJXYEABWRJFSP,g-Secretase Inhibitor,NOTCH1
NCGC00346534-01,C[N]1C=C(/C=C/C(=O)C2=CC=CC(=C2)F)C=C1\C=C\C(=O)NO,MC1568,,QRDAPCMJAOQZSU,Histone Deacetylase 2 (HDAC2) Inhibitor,HDAC2
NCGC00347286-01,CC[C@H](C)[N]1C=C(C)C2=C1C=C(C=C2C(=O)NC\C3=C(C)\C=C(\C)NC3=O)C4=CC=C(N=C4)N5CCNCC5,GSK126,,FKSFKBQGSFSOSM,EZH2 Methyltransferase Inhibitor,
NCGC00167801-01,O=C(NCCCCN1CCOCC1)C2=CC3=CC=CC=C3O2,,N-[4-(4-Morpholinyl)butyl]-2-benzofurancarboxamide hydrochloride;CL 82198 hydrochloride;NCGC00167801-01;,KUJQEQAVMNFFAO,MMP-13 Inhibitor,MMP13
NCGC00160519-02,CC1=[N+]([O-])C=C(N=C1)C(O)=O,,,DJQOOSBJCLSSEY,Niacin deravitive,
